MX2007001201A - Pyrrole derivatives as pharmaceutical agents - Google Patents

Abstract

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Description

DERIVATIVES OF PIRROL AS PHARMACEUTICAL AGENTS Field of the Invention Compounds, compositions and methods are provided to modulate the activity of the receptors and for the treatment, prevention or amelioration of one or more of the symptoms of a disease or a disorder related to the activity of the receptors.

BACKGROUND OF THE INVENTION The nuclear receptor (NR) superfamily comprises more than 150 different proteins, most of which are thought to function as transcription factors activated by ligands, which exert widely different biological responses by regulating gene expression (for a review see Di Croce et al, EMBO Jl 8: 6201-6210 (1999);); Mangelsdorf, et al Cell 83: 825-839 (1995); Perlmann, et al, Cell 90: 391-397 (1997)). Members of this family include receptors for endogenous small lipophilic molecules, such as spheroidal hormones, retinoids, vitamin D and thyroid hormone.

Classical steroid receptors include the mineralocorticoid receptor (MR) or aldosterone receptor), the estrogen receptors, ER alpha and ER beta, the androgen receptor (AR), the progesterone receptor (PR), and the receptor glucocorticoid (GR). Estrogen-related receptors (ERR) ERR1, ERR2, and ERR3 are also closely related in structure. Steroid receptors fulfill important functions in the body that are related to the transcription homeostasis of electrolyte and water balance, growth, development and wound healing, fertility, stress responses, immune function and functioning cognitive (see Assay Drug Dev. Technol., 1 (6): 843-52 (2003)). Accordingly, compounds that modulate (ie, antagonize, agonize, partially antagonize, partially agonize) the activity of nuclear steroid receptors are important pharmaceutical agents that have a specific utility in numerous methods, as well as for the treatment and prevention of a wide range of diseases and disorders modulated by the activity of nuclear steroid receptors.

Members of the nuclear steroid receptor subfamily have significant homology to each other and possess DNA and closely related ligand binding domains. Given the close similarity in the ligand binding domains of nuclear steroid receptors, it is not surprising that many natural and synthetic molecules possess the ability to modulate the activity of more than one nuclear steroid receptor. For example, the natural glucocorticoids cortisol and corticosterone are capable of modulating both the glucocorticoid receptor and the mineralocorticoid receptor under physiological conditions.

Accordingly, one approach to developing compounds that are modulators of nuclear steroid receptors is to identify a core chemical scaffold that has a common structural motif that provides the ability to bind to a nuclear steroid receptor, and which in certain embodiments possesses the ability to selectively modulate one or more of the other nuclear steroid receptors. These compounds are useful for the local or systemic treatment or prophylaxis of human and veterinary diseases, disorders and conditions that are modulated or otherwise affected by one or more nuclear steroid receptors, or in which the activity of nuclear receptors is involved. of steroids.

A well-characterized example of the classical steroid receptor subfamily that is amenable to this approach is the mineralocorticoid receptor (aldosterone receptor). The mineralocorticoid receptor plays an important role in the regulation of electrolyte balance and blood pressure in the body (Adv Physiol Educ., 26 (1): 8-20 (2002)) and its activity is modulated in vivo through of aldosterone secretion.

Traditionally it was thought that aldosterone was secreted by the glomerulosa zone of the adrenal gland in response to angiotensin II, potassium and adrenocorticotropic hormone (ACTH), and that it acted mainly on the epithelial cells of the kidney and colon to regulate the transport of sodium and of potassium More recently, it has been appreciated that aldosterone is also synthesized by endothelial cells and in vascular smooth muscle cells (VSMC), the brain, blood vessels and the myocardium where it can fulfill a paracrine or autocrine role (Ann. Acad. Sci. 970 89-100 (2002)).

Tissue specificity for aldosterone is conferred by local expression of the mineralocorticoid receptor and by the activity of 11-beta hydroxysteroid dehydrogenase type 2 (11 ~ HSD2), which acts to convert glucocorticoids cortisol and corticosterone to cortisone and 11-dehydrocorticosterone which have significantly reduced affinity for MRs (Science, 242: 583-585 (1988)).

In humans, elevated plasma aldosterone levels are usually associated with hypertension, usually mediated through the effect of the hormone on sodium retention and blood volume. Hypertension affects five million Americans, about a third of whom do not know their condition and are not receiving any treatment. Hypertension is associated with the development of cardiovascular, cardiac and renal diseases, including chronic and congestive heart failure (J. Postgrad. Med. J., 7_9: 634-642 (2003)), progressive renal failure (J.? P Soc. Ephrol., 14: 2395-2401 (2003)) and chronic renal failure and end stage (Am. J. Kid. Dis., _3J7 (4): 677-688 (2001)). Under these conditions, elevated blood pressure seems to increase and amplify the progressive decline in organ function in these diseases.

Aldosterone also has direct effects on brain, cardiac, vascular and renal tissues. In cardiac, vascular and renal tissues, the action of aldosterone can also play a significant role in the development and progress of inflammation, scarring and fibrosis (the generation of fibrotic tissue) independently of the effects on blood pressure. blood (Clin. Cardiol., 23: 724-730 (2000); Adv. Physiol. Educ, 26 (1): 8-20 (2002); Hypertension, 26: 101-111 (1995)).

In the brain, aldosterone has been linked to different cognitive dysfunctions, and aldosterone antagonists have been shown to be useful for improving cognitive function (U.S. Patent Application US2002 / 0111337), and to treat cognitive and mood dysfunctions.

In chronic heart failure (CHF), impaired cardiac function triggers a series of compensatory mechanisms, including aldosterone secretion, which ultimately leads to worsening of symptoms and reduced survival (J. Clin. Endo &Meta, 88: (6) 2376-2383 (2003)). These changes are mediated mainly by the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. The activation of RAAS results in increases in renin, angiotensin II and aldosterone. Angiontensin II acts on a vasoconstrictor, promotes the production of aldosterone and stimulates the release of norepinephrine from the sympathetic nerve terminals to increase the heart rate. Aldosterone acts by increasing the volume of blood, and therefore blood pressure, through its action of sodium retention in the kidney.

While the net effect of these factors is to restore blood pressure, increased peripheral vascular resistance also increases the load against which the heart functions. Finally, increased cardiac pressure results in cardiac remodeling, which results in pulmonary rigidity, pulmonary edema and suffocation. In addition, peripheral vasoconstriction results in reduced blood flow to the skeletal muscles that contributes to fatigue during exercise.

The treatments with current drugs for CHF concentrate on the alleviation of the symptoms of the disease, the improvement of the quality of life, the slowing down of the progress of the disease, the prevention of hospitalization, the prolongation of the active life, and the reduction of mortality. These therapeutic approaches include the use of diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), beta-adrenergic receptor blockers (beta-blockers), AT antagonists, and calcium channel blockers to suppress the damaging effects of compensatory mechanisms neuroendocrines such as the RAAS and the beta-adrenergic (sympathetic) nervous system (Postgrad. Med. J. 7_9 634-642 (2003)).

Diuretics act to reduce water retention, reduce blood pressure and can act as vasodilators to reduce circulatory resistance. ACE inhibitors and beta blockers have been shown to reduce mortality and improve symptomatic status in CHF in part by reducing levels of angiotensin II and aldosterone. However, angiotensin II and aldosterone usually return to normal levels with chronic therapy. Accordingly, angiotensin II receptor antagonists, which selectively block the angiotensin ATI receptor, and aldosterone antagonists, which selectively block the mineralocorticoid receptor, provide a significant therapeutic benefit for the treatment of CHF (Circulation, 100: 1056-1064 (1999); N. Eng. J. Med., 341 (10): 709-718 (1999)).

In addition to aldosterone and angiotensin II, calcium channels play an important role in heart failure. In both vascular and cardiac tissue, contraction of muscle cells occurs when cells are depolarized from the flow of calcium through calcium channels to the cell. Calcium channel blockers inhibit muscle contraction and promote relaxation. In vascular smooth muscle this leads to vessel dilation, reduced blood pressure (antihypertensive effect) and a reduction in the force the heart needs to pump blood. Calcium channel blockers also act on the heart to improve filling promoting cardiac muscle relaxation in diastole. However, calcium channel blockers also reduce the force of contraction during systole (negative inotropy) and consequently are frequently not the drug chosen to treat heart failure.

Hypertension is not only the main cause of the development of cardiovascular, cardiac and renal diseases, but also a risk factor for the progress of these diseases initiated by other mechanisms such as atherosclerosis, cardiovascular disease, ischemic heart disease, diabetes, diabetic nephropathy, chronic glomerulonephritis and polycystic kidney disease (J. Am. Soc. Nephrol., 1_4 j_2395-2401 (2003)).

In renal failure, as in the case of heart failure, numerous clinical trials have established that interrupting the RAAS cascade with ACE inhibitors is beneficial in limiting kidney disease (Am. J. Kid. Dis., 37 (4): 677-688 (2001) Other studies have also established that aldosterone antagonists can attenuate the proteinuria and renal damage that are generally seen in progressive kidney disease and offer another therapeutic benefit 'compared to inhibitors of ACE alone (Hypertension., 31.: 451-458 (1998)).

Many aldosterone antagonists are known. For example, spironolactone, the first approved aldosterone antagonist, has been used to block aldosterone-dependent sodium transport in the distal tubule of the kidney to reduce edema and treat essential hypertension and primary hyperaldosteronism (F. Mantero et al. Clin. Sci. Mol. Med., 45 (Suppl 1), 219s-224s (1973)). Spironolactone is also commonly used in the treatment of other hyperaldosterone-related diseases such as liver cirrhosis, renal failure and congestive heart failure (F. Saunders et al., Aldactone, Spironolactone: A Comprehensive Review, Searle, N.Y. (1978)).

However, spironolactone is not very selective for MRs compared to other steroid receptors, which include the androgen and progesterone receptors. This cross-reactivity results in unwanted side effects such as menstrual irregularity in women, and gynecomastia in men (Circulation, 107: 2512-2518 (2003)). Eplerenone is a derivative of spironolactone that is more selective for MRs than spironolactone (Nature Reviews, _2j_ 177-178 (2003)). However, eplerenone has relatively low potency for MR, induces hyperkalemia and is eliminated mainly through the kidney, which is inadequate for patients with progressive renal failure.

Accordingly, there is a need for new modulators that are useful in the prevention, treatment and amelioration of one or more of the symptoms of diseases or disorders associated with the activity of mineralocorticoid receptors. These diseases or disorders include, but are not limited to, fluid retention, edema, primary hyperaldosteronism, Crohn's syndrome, hypertension, high blood pressure, liver cirrhosis, cardiovascular disease, heart failure, heart failure. chronic, heart disease, kidney disease, chronic kidney disease, fibrosis, and cognitive dysfunction.

Extract of the invention Compounds are provided for use in pharmaceutical compositions and methods for modulating the activity of one or more nuclear steroid receptors. In one embodiment, the compounds for use in the compositions and methods provided herein have the formula (I): wherein: R1 and R2 are each independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally heteroaralkyl substituted, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, -OR9, -SR9, -N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R 4 is hydrogen, -C (0) R 9 or -S (0) 2 R 9; or R4 is | alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkyl, nitro, ~ 0R9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, ~ C (0) SR9, -C (S) SR9, -C (NR9) SR9, -S (0) t0R9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN ( R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N ( R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9) C (0) 0R10, -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N ( R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -0C (0) R10, -OC (NR9) R10, -OC (S) R10, -0C (0) 0R10, -0C (NR9) OR10, -OC (S) OR10, -0C (0) SR9, '-OC (0) N (R9) 2, -OC (NR9) N (R9) ) 2, -0C (S) N (R9) 2, -CÍOJ-R ^ -CÍOJR9, -C (0) -RX1-C (S) R9, -C (0) -R1X-C (NR9) R9, -C (0) -R11-C (0) 0R9, -C (0) -R11-C (S) 0R9, -C (0) -RX1-C (NR9) OR9, -C (0) -R11- C (0) N (R9) 2f -C (0) -R11-C (S) N (R9) 2, -C (0) -Rn-C (NR9) N (R9) 2, -C (0) -R1X-C (0) SR9, -C (0) -R- (S) SR9 and -C (0) -R11-C (NR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy., nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl , optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9j OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) fcN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S ( 0) tN (R9) C (NR9) N (R9) 2 (where t is 1 -o 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10 , -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- OC (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9 , -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R ^ -C (0) R9, -R8-C (0) -Ru-C (S) R9, -R8-C (0) -RX1-C (NR9) R9, -R8-C (0) -R -C (0) OR9, -R8 -C (0) -Ru-C (S) OR9, -R8-C (0) -R1X-C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2,. -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (0) -R11-C (NR9) N (R9) 2, -R8-C (O) -R1X- C (O) SR9, -R8-C (0) -Ru-C (S) SR9 and -R8-C (0) -R1: LC (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, where each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (0) R14, -C (S) R14, -C (NR14) R14, -C (0) 0R14, -C (S) 0R14, -C (NR1) OR 14, -C (0) N (R 14) 2, -C (S) N (R 14) 2, -C (NR 14) N (R 14) 2, -C (0) SR 14, -C (S) SR 14, - C (NR14) SR14, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -S (0) tN (R1) N = C (R1) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R8-S (0) tN (R1) C (0) N (R1) 2 (where t is 1 or 2), -R8-S (0) tN (R14) C (NR1) N (R14) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R14) C (0) OR15 , -N (R14) C (0) SR15, ~N (R14) C (NR14) SR15, -N (R14) C (S) SR15, -N (R1) C (0) N (R14) 2, - N (R14) C (NR14) N (R1) 2, -N (R1) C (S) N (R14) 2, -N (R14) S (0) tR15 (where t is 1 or 2), -0C (0) R15, -0C (NR14) R15, -0C (S) R15, -0C (0) OR15, -OC ( NR14) OR15, -0C (S) 0R15, -0C (0) SR14, -OC (0) N (R14) 2, -OC (NR14) N (R1) 2, -0C (S) N (R14) 2 , -C (0) -R16-C (0) R14, -C (0) -R16-C (S) R14, -C (0) -R16-C (NR1) R14, -C (0) -R16 -C (0) OR 14, -C (0) -R 16 -C (S) OR 14, -C (0) -R 16 -C (NR 1) OR 14, -C (0) -R 16 -C (0) N (R 14 ) 2, -C (0) -R16-C (S) N (R14) 2, -C (0) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14 , -C (0) -R16-C (S) SR14 and -C (0) -R16-C (NR14) SR14; or R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, dioxo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, oprtatically substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13 -C (0) R14, -R13 -C (S) R14, -R13-C (NR14) R14, -R13-C (O) OR14, -R13-C (S) OR14, -R13-C (NR1) OR14, -R13-C (O) N (R14) 2, -R13-C. (S) N (R14) 2, -R13-C ( NR14) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (O) tOR14 (where t is 1 or 2 ), -R13-S (O) tN (R14) 2 (where t is 1 or 2); -R13-S (0) tN (R14) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R14) 2, -R13-S (O ) tN (R14) C (O) R15 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13 -N (R14) C (O) R15, -R13-N (R14) C (0) OR15, -R13-N (R1) C (0) SR15, -R13-N (R14) C (NR14) SR15,-R13-N (R14) C (S) SR15, -R13-N (R14) C (O) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R1- N (R14) C (S) N (R1) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-OC (0) R15, -R13-OC (NR14 ) R15, -R13-OC (S) R15, -R13-OC (O) 0R15, -R13-OC (NR1) OR15, ~R13-OC (S) OR15, -R13-OC (0) SR14, -R13 -OC (0) N (R14) 2 / -R13-OC (NR14) N (R14) 2, -R13-OC (S) N (R1) 2, -R13-C (0) -R16-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (O) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R1-C (0) -R16-C (S) OR14, -R13-C (0) -R16 ~ C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) Zr -R13- C (0) -R16-C (S) N (R14) 2, -R13-C (0) -R16C (NR14) N (R1) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (O) -R16-C (NR14) SR14; wherein each R8 and R13 are independently a direct bond, an optionally substituted straight or branched alkylene rod, or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted ethercyclyl, optionally substituted heterocyclylalkyl, heteroaryl optionally substituted heteroaralkyl optionally substituted; or two R9, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl optionally substituted heteroaralkyl substituted; or two R14, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; wherein each R 11 and R 16 are independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; and as a single isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

In another aspect, the invention includes compounds of the formula (ID wherein: R2 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, heterocyclyl | optionally substituted, optionally substituted heterocyclylalkyl, -OR9, -SR9, - (R9) 2 -C (0) 0R9 or -C (0) N (R9) 2; R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; R4 is hydrogen; -C (0) R9 or -S (0) 2R9; or R4 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2 ), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C ( NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, ~ C (0) SR9, -C (S) SR9 , -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN (R9 ) N (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R9) C (0) OR10 , -N (R9) C (O) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, - N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC ( NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (0) N (R) 2 / -OC (NR9) N (R9) 2, -OC (S) N (R9) 2 , -C (O) -R -C (O) R9, -C (O) -RX1-C (S) R9, -C (O) -R1X-C (NR9) R9, -C (O) -R11 -C (O) OR9, -C (O) -Rn-C (S) OR 9, -C (O) -Ru-C (NR 9) OR 9, -C (O) -Ru-C (O) N (R 9) 2, -C (O) -Rai-C (S) N (R9) 2, -C (O) -Ru-C (NR9) N (R9) 2, -C (O) -Ru-C (O) SR9, -C (O) -R1: LC (S) SR9 and -C (O) -R1: LC (NR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl / aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, heteroaralkenyl optionally substituted, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0 ) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9 ) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8-S (O) tN ( R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (O) tN (R9) C (O) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 2), -R8-N (R9) C (O) R10 , -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) ) SR10, -R8-N (R9) C (O) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (O) tR10 (where t is 1 or '2), -R8-OC (O) R10, -R8 -OC (NR9) R10, -R8-OC (S) R10, -R8-OC (O) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (O) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (O) -R -C (O) R9, -R8-C (0) -R11-C (S) R9, -R8 -C (0) -R -C (NR9) R9, -R8-C (0) -R ^ -C (0) 0R9, -R8-C (0) -R ^ -C (S) OR9, -R8 -C (0) -Rn-C (NR9) OR9, -R8-C (O) -R -C (0) N (R9) 2, -R8-C (0) -R ^ -C (S) N (R9) 2, -R8-C (O) -RX1-C (NR9) N (R9) 2, -R8-C (0) -R ^ -C (0) SR9, -R8-C (0) -R -C (S) ) SR9 and -R8-C (0) -Rai-C (NR9) SR9; R5 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, -C (0) R9 or -S (0) 2R9; R6 is hydrogen or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CM, -C (0) R14, -C (S) R14, -C (NR1) R14, -C (0 ) 0R14, -C (S) 0R14, -C (NR14) OR14, -C (0) N (R14) 2, -C (S) N (R14) 2, -C (NR14) N (R1) 2, -C (0) SR14, -C (S) SR14, -C (NR14) SR14, -S (0) t0R14 (where t is lo 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R1) N (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N = C (R14) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R8-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -N (R14) ) C (0) R15, -N (R14) C (0) OR15, -N (R14) C (0) SR15, -N (R14) C (NR14) SR15, -N (R1) C (S) SR15 , -N (R14) C (0) N (R1) 2, -N (R14) C (NR14) N (R14) 2, -N (R1) C (S) N (R1) 2, -N (R14) ) S (O) tR15 (where t is 1 or 2), -OC (0) R15, -0C (NR1) 4) R15, -OC (S) R15, -OC (0) OR15, ~ OC (NR1) OR15, -OC (S) OR15, -OC (0) SR14, -OC (0) N (R14) 2, -OC (NR14) N (R1) 2, -OC (S) N (R14) 2, -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C ( S) R14, -R13-C (0) -R16-C (NR1) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (O) -R16-C (NR14) SR14; or R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, dioxo, optionally substituted alkyl, optionally substituted alkenyl, alkynyl optionally substituted, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, ~R13-OR14, -R1J-SRi4, -RiJ-S (0) tR (where t is 1 or 2), -RiJ-N (Ri4) 2, -R1J-CN, -R13 -C (0) R14, -R13-C (S) ) R14, -R13-C (NR14) R14, -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR14 ) N (R14) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) t0R14 (where t is 1 or 2) , -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13- S (0) tN (R14) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15, -R13-N (R14) C (0) R15, -R13 ~ N (R14) C (0) OR15, -R13-N (R14) C (0) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R14) 2, -R13-N (R14) C (NR14) N (R1) 2, -R13- N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-OC (0) R15, -R13-OC (NR1 ) R15, | -R13-0C (S) R15, -R13-0C (0) OR15, -R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-0C (0) SR14, - R13-0C (0) N (R14) 2, -R13-OC (NR1) N (R1) 2, -R13-OC (S) N (R14) 2 -R13-C (0) -R16-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13-C (O) -R16-C (S) N (R14) 2 -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (O) -R16-C (O) SR14, -R13-C (O) -R16-C (S) SR14 and -R13-C (O) ~ R16-C (NR14) SR14; wherein each R8 and R13 are independently a direct bond, an optionally substituted straight or branched alkylene chain, or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl optionally substituted heteroaralkyl substituted; or two R9, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; or two R14, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted or optionally substituted heteroaralkyl; and wherein each R 11 and R 16 are independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; as a single isomer, a mixture of isomers, or - as a racemic mixture of isomers; or as a solvate or a polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

In another aspect, the invention includes compounds of the formula (III): R1 is independently halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally heterocyclylalkyl substituted, -0R9, -SR9, - (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R4 is hydrogen; -C (0) R9 or -S (0) 2R9; or R4 is alkyl, alkenyl or alkynyl optionally substituted with one or more substituents selected from the group consisting of "halo, haloalkyl, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR 9, -C (0) N (R 9) 2, -C (S) N (R 9) 2, -C (NR 9) N (R 9) 2, -C (0) SR 9, -C (S) SR 9, - C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R) 2 (where t is 1 or 2), -S. (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (O) tN (R9) C (O) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R9) C (0) OR10 , -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, - N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (O) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (O) SR9, -OC ( 0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (O) -R1X-C (O) R9, -C (O) - R11-C (S) R9, -C (O) -R1X-C (NR9) R9, -C (O) -R1: LC (O) OR9, -C (O) -R ^ -C (S) OR9, -C (O) -Rn-C (NR9) OR9, -C (O) -R1: LC (O) N (R9) 2, -C ( O) -R11-C (S) N (R9) 2, -C (0) -Rn-C (NR9) N (R9) 2, -C (0) -R "-C (O) SR9, -C (0) -R11-C (S) SR9 and -C (0) -R- (NR9) SR9; or R4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, where each is substituted optionally with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl , optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8- C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) 0R9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) ) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 2), -R8-N (R9) ) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8- OC (NR9) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8-OC (NR9) OR10 -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (0) N (R9) 2 -R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R11-C ( 0) R9, -R8-C (0) -R ^ -C (S) R9, -R8-C (O) -R1X-C (NR9) R9, -R8-C (0) -Ru-C (0) OR9, - R8-C (0) -R ^ -C (S) OR9, -R8-C (0) -R ^ -C (NR9) OR9, -R8-C (0) -R -C (0) N (R9) 2, -R8-C (0) -R -C (S) N (R9) 2, -R8-C (0) -R11- C (NR 9) N (R 9) 2, -R 8 -C (O) -Rn-C (O) SR 9, -R 8 -C (0) -R 11 -C (S) SR 9 and -R 8 -C (O) - R11-C (NR9) SR9; R5 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, -C (O) R9 or -S (0) 2R9; R5 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) 0R9, -C (S) 0R9, - C (NR 9) OR 9, -C (0) N (R 9) 2, -C (S) N (R 9) 2, -C (NR 9) N (R 9) 2, -C (0) SR 9, -C (S ) SR9, -C (NR9) SR9, -S (0) t0R9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -S ( 0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (O) tN (R9) C (O) N (R9) 2 (where t is 1, or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R 10, -N (R 9) C (0) OR 10, -N (R 9) C (0) SR 10, -N (R 9) C (NR 9) SR 10, -N (R 9) C (S) SR 10, - N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (O) -Ru-C (O) R 9, -C (0) -R 11 -C (S) R 9, -C (0) -R 11 -C (NR 9) R 9 / -C (0) -R -C (0) OR 9 , -C (0) -R11-C (S) 0R9, -C (0) -Rn-C (MR9) OR9, -C (0) -RX1-C (0) N (R9) 2, -C (0 ) -Rn-C (S) N (R) 2, -C (0) -Ru-C (NR 9) N (R 9) 2, -C (0) -R 11 -C (0) SR 9, -C (0 ) -Rn-C (S) SR9 and -C (O) -R -C (NR9) SR9; R6 is hydrogen, alkyl or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, whereach is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR14, -SR14, -S (0) tR, 15 (where t is 1 or 2), -N (R 1) 2, ~ CN, -C (0) R 14, -C (S) R 14, -C (NR 14) R 14, -C (0) 0R14, -C (S) 0R14, -C (NR14) OR14, -C (0) N (R14) 2, -C (S) N (R1) 2, -C (NR1) N (R14) 2, -C (0) SR14, -C (S) SR14, -C (NR14) SR14, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R1) N (R1) 2 (where t is 1 or 2), -S (O) tN (R14) N = C (R14) 2, -S ( 0) tN (R14) C (0) R15 (where t is 1 or 2), -S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -N ( R14) C (0) R15, -N (R14) C (0) OR15, -N (R14) C (0) SR15, -N (R1) C (R14) SR15, -N (R1) C (S) SR15, -N (R14) C (0) N (R14) 2, -N (R1) C (NR14) N (R14) 2, -N (R14) C (S) N (R14) 2, -N (R14) S (0) tR15 (where t is 1 or 2), - 0C (0) R15, -0C (NR14) R15, -OC (S) R15, -OC (0) OR15, -OC (NR14) OR15, -OC (S) OR15, -OC (0) SR14, -OC (0) N (R14) 2, -OC (NR1) N (R14) 2, -OC (S) N (R14) 2, -C (0) -R15-C (0) R14, -C (0) -R15-C (S) R14, -C (0) -R16-C (NR14) R14, C (0) -R16-C (0) OR14, -C (0) -R16-C (S) OR14, -C (0) -R16-C (NR14) OR14, -C (0) -R16-C (0) N (R1) 2, -C (0) -R16-C (S) N (R14) 2, -C (0) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14, -C (O) -R16-C (S) SR14 and -C (0) - R16-C (NR14) SR14; or R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, whereach is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro dioxo, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl , optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (Ri) 2, -R -CN, -RI3-C (0) R, -R -C (S) R, -R -C (NR) R, -R13-C (0) OR14, -R1 3-C (S) OR14, -R13-C (NR14) OR14, -R13-C (O) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR14) N (R1) 2, -R13-C (O) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) tOR14 (where t is 1 or 2), -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) N = C (R14) 2, -R13-S (O) tN (R14) C (O) R15, -R13-N (R14) C (O) R15, -R13-N ( R14) C (0) OR15, -R13-N (R14) C (0) SR15, -R1-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (O) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R13- N (R14) C (S) N (R14) 2, -Ri3-N (R14) S (0) tR15 (where t is 1 or 2), -R13-OC (O) R15, -R13-OC (NR14 ) R15, -R13-0C (S) R15, -R13-0C (0) OR15, -R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-OC (O) SR14, -R13 -OC (O) N (R14) 2, -R13-OC (NR1) N (R14) 2, -R13-OC (S) N (R14) 2 -R13-C (O) -R16-C. ) R14, -R13-C (O) -R16-C (S) R14, -R13-C (O) -R16-C (NR14) R14, -R13C (O) -R16-C (0) OR14, -R13-C (O) -R16-C (S) OR14, -R13-C (O) -R16-C (NR14) OR14, -R13-C (O) -R16-C (O) N (R14) 2, -R13 -C (O) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (O) -R15-C (0) SR14, -R13-C (O) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; wherein each R8 and R13 are independently a direct bond, an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and heteroaralkyl; optionally substituted; or two R9, together with the nitrogen to which they are "attached, form an optionally substituted heterocyclyl, wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally cycloalkylalkyl substituted, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl, or two R14, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl, wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, aryl op tatively substituted, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 and R 16 are independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; or as a single isomer, or a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

In another aspect, the invention includes compounds of the formula (IV): R1 and R2 are each independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, -0R9, -SR9, -N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R4 is hydrogen; or R4 is alkyl, alkenyl or alkynyl, where each. one is optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, haloalkoxy, nitro, -0R9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CM, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (0) SR9, -C (S) SR9, -C (NR9) SR9, - S (0) t0R9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R) N = C (R9) 2, -S (O) tN (R9) C (O) R10 (where t is 1 or 2), -R8-S (O) tN (R9) C (O) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R9) C (0) OR10, -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N ( R9) 2, -N (R9) S (0) fcR10 (where t is 1 or 2), -OC (O) R10, -OC (NR9) R10, -0C (S) R10, -OC (0) OR10, -OC ( NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2 , -C (0) -Ru-C (0) R9, -CÍO-R ^ -CÍSJR9, -C (0) -Ru-C (NR9) R9, -C (0) -R ^ -C (0) OR9, -CÍO-R ^ -CÍSJOR9, -C (0) -Rn-C (NR9) OR9, -C (0) -R "-C (0) N (R9) 2, -C (0) -R -C (S) N (R9) 2, -C (0) -Rn-C (NR9) N (R9) 2, -C (O) -Ru-C (0) SR9, -C (0) -R1: LC (S) SR9 and -C (0) -RX1-C CNR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, cycloalkyl optionally substituted, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, heterocyclylalkenyl > optionally substituted, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2 , -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9 , -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, - R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N = C (R9) 2, -R8-S (O) tN (R9) C (O) R10 (where t is 1 or 2), -R8-S (O) tN (R9) C (O) N ( R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (O) SR10 , -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (O) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (O) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8-OC (NR9) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-OC (S) ) N (R9) 2, -R8-C (0) -R ^ -C (0) R9, -R8-C (0) -R -C (S) R9, -R8-C (0) -RX1-C (NR9) R9, - R8-C (0) -R1: LC (0) 0R9, -R8-C (0) -R1: LC (S) OR9, -R8-C (0) -R11-C (NR9) OR9, -R8- C (0) -R -C (0) (R9) 2, -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (0) -R11-C (NR9) N (R 9) 2 / -R 8 -C (0) -R -C (0) SR 9, -R 8 -C (0) -Ru-C (S) SR 9 and -R 8 -C (O) -X 1 -C ( NR9) SR9; R6 is hydrogen or optionally substituted alkyl; each R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R1) 2, -CN, -C (0) R14 -C (S) R14, -C (NR14) R14, -C (0) 0R14, -C (S) 0R14, -C (NR1) OR14 -C (0) N (R1) 2, -C (S) N (R14) 2, -C (NR14) N (R14) 2, -C (0) SR14, -C (S) SR14 -C (NR14) SR14, -S (0) tOR14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2) ), -S (0) tN (R14) N (R14) 2 (where t is 1 or 2) -S (0) tN (R14) N = C (R14) 2, -S (0) tN (R1) C (0) R15, -N (R14) C (0) R15 -N (R1) C (0) OR15, -N (R1) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15 -N (R14) C ( 0) N (R14) 2, -N (R14) C (NR14) N (R1) 2, -N (R14) C (S) N (R14) 2 -N (R1) S (0) tR15 (where t is 1 or 2), -0C (0) R15, -OC (NR14) R15 -0C (S) R15, -0C (0) 0R15, -OC (NR14 ) OR15, -0C (S) 0R15, -0C (0) SR14 -OC (0) N (R14) 2, -OC (NR14) N (R14) 2, -0C (S) N (R14) 2, - C (0) -R16-C (0) R14 -C (0) -R16-C (S) R14, -C (0) -R16-C (NR14) R14, -C (0) -R16-C ( 0) OR14 -C (0) -R1D-C (S) 0Rxq, -C (0) -R16-C (NR14) 0R14, -C (0) -R16-C (0) N (R14) 2, - C (0) -R16-C (S) N (R14) 2r -C (O) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14, -C (0 ) -R16-C (S) SR14 and -C (O) -R16-C (NR14) SR14; or each R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycldlalkyl, "aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, dioxo, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13- S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) 0R14, -R13-C (0) N (R14) 2, -R13-C ( S) N (R1) 2, -R13-C (NR14) N (R1) 2, -R13-C (0) SR14 , -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) t0R14 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R14) 2r -R13-S (0) tN (R14) C (0) R15, -R13-N (R14) C (0) R15, -R13-N (R1) C (O) 0R15, -R13-N (R14) C (0) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R14) 2, -R13-N (R14) C (NR1) N (R14) 2, -R13- N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-OC (0) R15, -R13-OC (NR14 ) R15, -R13-OC (S) R15, -R13-OC (0) OR15, -R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-OC (O) SR14, -R13 -OC (0) N (R14) 2, -R13-OC (NR14) N (R14) 2, -R13-OC (S) N (R14) 2, -R13-C (0) -R16-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (O) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (0) -R16C ( NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (O) -R16-C (NR14) SR14; wherein each R8 and R13 are independently a direct bond, an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; or two R9, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, · heteroaryl optionally substituted and optionally substituted heteroaralkyl; or two R14, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, heteroaryl optionally substituted heteroaralkyl optionally substituted; wherein each R11 and R16 are independently an optionally-substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; R 32 is independently hydrogen, halo, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; as a single isomer, a mixture of isomers, or a racemic mixture of isomers; or as a solvate or a polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

These compounds can bind to one or more nuclear steroid receptors with high affinity and modulate their activity. Generally, these compounds have an EC 50 or IC 50 of less than 10 μ ?, and in certain embodiments less than 1 μ ?, 0.5 μ ?, 250 nM, 100 n or 50 nM. In one aspect, the compounds provided herein are selective for a specific nuclear receptor, ie they are at least 10, or in another aspect, at least 100 times more potent, as measured by any of the in vitro assays described in present, at the binding to the desired nuclear steroid receptor than any other steroid receptor.

Also of interest are all pharmaceutically acceptable derivatives of the compounds disclosed herein, including, but not limited to, salts, esters, enol ethers, enol esters, solvates, hydrates, polymorphs and prodrugs of the described compounds. Another embodiment are methods of using the disclosed compounds and compositions, or pharmaceutically acceptable derivatives thereof, for the local systemic treatment or prophylaxis of human or veterinary diseases, disorders and conditions modulated or otherwise affected by one or more nuclear receptors. of spheroids, or where the activity of the spheroidal nuclear receptor is involved, which they define here.

Also provided are pharmaceutical compositions formulated for administration by an appropriate route and means containing effective concentrations of one or more of the compounds provided herein, or pharmaceutically acceptable derivatives thereof, and comprising at least one carrier vehicle, binder, diluent, disintegrating agent, lubricant, glidant, sweetening agent or pharmaceutical flavoring agent. These pharmaceutical compositions provide effective amounts for the treatment, prevention or amelioration of one or more symptoms of diseases or disorders that are modulated or otherwise affected by one or more spheroidal nuclear receptors, or where receptor activity is involved. nuclear These diseases or disorders include, but are not limited to: a) Diseases or disorders associated with an excess or lack of spheroid receptor ligands, or spheroid receptor activity, including, for example, Alzheimer's disease, Cushing, Crohn's syndrome, Turner syndrome, hormone replacement therapies, menopause, hypogonadism, somatopause, andropause, and viropause; b) Diseases or disorders related to cancer, including cancers that depend on hormones such as breast cancer (U.S. Patent No. 6,306,832), prostate cancer - (U.S. Patent No. 5,656,651), benign prostatic hyperplasia (U.S. Patent No. 5,656. -651), ovarian cancer, endometrial cancer (U.S. Patent No. 6,593,322), leukemia (U.S. Patent No. 6,696,459), and lymphoma (U.S. Patent No. 6,667,299); c) Diseases or disorders related to infertility including endometriosis, control of menstruation, dysfunctional uterine bleeding, dysmenorrhea, endometriosis, meningiomas, leiomyomas (uterine fibroids), induction of labor (US Patent No. 6,358,947, U.S. Patent No. 5,943,933) and as modulators of male and female fertility (e.g., as contraceptives or antigestational agents); e) Diseases or disorders related to metabolic syndromes that include Syndrome X, hyperglycemia, insensitivity to insulin, diabetes, obesity, storage or distribution of fat, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, hyperinsulinemia, atherosclerosis and hyperuricemia (patent U.S. Patent No. 6,699,893, U.S. Patent No. 6,680,310, U.S. Patent No. 6,593,480, U.S. Patent Application No. 2003/0028910); f) Diseases or disorders related to bone or cartilage dysfunction, including osteoporosis, weakness, decreased bone density and hypercalcemia (U.S. Patent No. 6,686,351, U.S. Patent No. 6,660,468, U.S. Patent Application No. 2002 / 0187953); g) Inflammatory diseases or disorders related to immune dysfunction, including: immunodeficiency, immunomodulation, autoimmune diseases, tissue rejection, wound healing, allergies, inflammatory bowel disease, Lupus Erythematosis, arthritis, osteoarthritis, rheumatoid arthritis, asthma and rhinitis ( U.S. Patent No. 6,699,893, U.S. Patent No. 6,380,223, U.S. Patent No. 6,716,829); h) Illness or disorders related to cognitive dysfunction, including psychosis, cognitive disorder, mood disorder, anxiety disorder, personality disorder and Parkinson's disease and Alzheimer's disease (U.S. Patent 6,620,802, U.S. Patent No. 6,734. 211); i) Diseases or disorders related to high blood pressure, including fluid retention, edema, cardiovascular disease and hypertension (U.S. Patent No. 6,608,047); j) Diseases or disorders related to cardiac disease, including ischemic heart disease, heart failure, systolic deterioration, diastolic deterioration, myocardial necrosis, pulmonary venous congestion, atrial fibrillation, myocardial infarction, myocardial fibrosis and chronic heart failure ( U.S. Patent No. 6,716,829, U.S. Patent No. 6,391,867); k) Diseases or disorders related to kidney disease, including diabetic nephropathy, chronic glomerulonephritis, polycystic kidney disease, non-diabetic nephropathy, and chronic kidney disease (U.S. Patent No. 6,716,829, U.S. Patent No. 6,391,867); 1) Diseases or disorders related to fibrosis (U.S. Patent No. 6,716,829, U.S. Patent No. 6,391,867); m) Diseases or disorders releaded with epidermal dysfunction that include acne, hirsutism, alopecia and skin atrophy; n) diseases or disorders related to muscle wasting, low muscle mass, metabolic rate and poor ratio of muscle mass to fat.

Methods of modulating the activity of one or more nuclear steroid receptors in a whole cell, tissue or organism, using the compounds and compositions provided herein, or pharmaceutically acceptable derivatives thereof are also provided. These methods also include methods of contraception, methods of regulating hair growth, methods of regulating muscle mass, methods of inducing weight loss, methods of regulating the deposition or distribution of fat, methods of stimulating metabolic rate, methods of alter the ratio of muscle mass to fat, methods of regulating the development and growth of epidermal tissue, methods of regulating cognitive function, methods of regulating electrolyte balance, methods of regulating blood pressure and methods of regulating immunological function.

Also contemplated herein are combination therapies that use one or more compounds or compositions provided herein, or pharmaceutically acceptable derivatives thereof, in combination with a wide variety of combination therapies to treat the diseases and disorders described in I presented. Therefore, the compounds and their pharmaceutically acceptable derivatives can be used in conjunction with other pharmaceutically active agents of the diseases and disorders described herein.

In one embodiment, those additional pharmaceutical agents include one or more of the following: ACE inhibitors, Angiotensin II blockers, anti-cancer agents, anticoagulants, antiarrhythmics, anti-inflammatory agents, beta-blockers, calcium channel blockers, lipid modulating agents, antagonists of cytokine, digital medicines, diuretics, endothelin blockers, erythropoietin, vasodilators, and glucose-lowering agents.

The compound and composition provided herein, or the pharmaceutically acceptable derivative thereof, may be administered simultaneously, before or after the administration of one or more of the preceding agents. Also provided are pharmaceutical compositions containing a compound provided herein and one or more of the preceding agents.

In the practice of the methods, effective amounts of the compounds or compositions containing therapeutically effective concentrations of the compounds, which are formulated for systemic administration, including parenteral, oral or intravenous administration, or for local application or administration, are administered. topical, to an individual who presents - the symptoms of the disease or disorder to be treated. The amounts are effective to improve or eliminate one or more symptoms of the diseases or disorders.

Also provided are articles of manufacture comprising a compound or composition provided herein, or a pharmaceutically acceptable derivative thereof, a packaging material, and a label indicating that the compound or composition, or the pharmaceutically acceptable derivative of they are used to modulate the activity of a spheroid nuclear receptor, or for the treatment, prevention or amelioration of one or more symptoms of diseases or disorders mediated by spheroidal nuclear receptors, or diseases or disorders in which it is involved the activity of spheroidal nuclear receptors.

Detailed Description of the invention A. Definitions? unless otherwise defined, all technical and scientific terms used herein have the same definition as commonly understood by one skilled in the art to which the present invention pertains, all patents, patent applications, published applications and other publications are incorporated as a reference in their entirety. In the event that there are several definitions for a term in the present, those that appear in this section prevail unless stated otherwise.

"Alkyl" refers to a straight or branched hydrocarbon chain radical comprising exclusively carbon and hydrogen atoms, which does not contain any unsaturation, having from one to ten carbon atoms, and which is attached to the rest of the molecule by a simple bond, for example, methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl) and the like.

"Alkenyl" refers to a straight or branched hydrocarbon chain radical comprising exclusively carbon and hydrogen atoms, which contains at least one double bond, having from two to ten carbon atoms, and which is attached to the remainder of the carbon atom. the molecule by a single bond or a double bond, for example, ethenyl, pro-l-enyl, but-l-enyl, pentyl-enyl, penta-1,4-dienyl and the like.

"Alkynyl" refers to a straight or branched hydrocarbon chain radical comprising exclusively carbon and hydrogen atoms, which contains at least one triple bond, having two to ten carbon atoms and which is attached to the remainder of the carbon atom. molecule by a single bond or a triple bond, for example, ethinyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-3-ynyl and the like.

"Alkylene" and "alkylene chain" refer to a straight or branched divalent hydrocarbon chain comprising exclusively carbon and hydrogen, which contains no unsaturation, and which has from one to eight carbon atoms, for example, methylene, ethylene , propylene, n-butylene and the like. The alkylene chain may be attached to the remainder of the molecule through any two carbons within the chain.

"Alkenylene" or "alkenylene chain" refers to a branched or straight chain unsaturated divalent radical exclusively comprising carbon and hydrogen atoms, having from one to eight carbon atoms, wherein the unsaturation is present only as double bonds and wherein the double bond may exist between any two carbon atoms in the chain, for example ethenylene, prop-1-enylene, but-2-enylene, and the like. The alkenylene chain may be attached to the remainder of the molecule through any two carbons within the chain.

"Alkoxy" refers to the radical having the formula -0R wherein R is alkyl or haloalkyl. An "optionally substituted alkoxy" refers to the radical having the formula -0R wherein R is an optionally substituted alkyl defined herein.

"Alkynylene" or "alkynylene chain" refers to a branched or straight chain unsaturated divalent radical which exclusively comprises carbon and hydrogen atoms, having from one to eight carbon atoms, wherein the unsaturation is present only as triple bonds and wherein the triple bond can exist between any two carbon atoms in the chain, for example, ethynylene, prop-1-inylene, but-2-inylene, pent-1-inylene, pent-3-inylene, and the like. The alkynylene chain may be attached to the remainder of the molecule through any two carbon atoms within the chain.

As used herein, "amidino" refers to a radical having the formula -C (= NR) (R ') R "wherein R, R' and R" are each independently hydrogen or alkyl.

"Amino" refers to a radical having the formula -NR'R "wherein R 'and R" are each independently hydrogen, alkyl or haloalkyl. An "optionally substituted amino" refers to a radical having the formula -NR 'R "wherein one or both of R' and R" are optionally substituted alkyl defined herein.

"Androgen receptor" or AR "refers to all mammalian isoforms, splice variants and polymorphisms of the nuclear receptor Representative forms include human (Genetic Bank Accession Number P10275), rat (Accession Number of Genetic Bank P15207) , mouse (Accession number of Genetic Bank P19091), and rabbit (Accession number of Genetic Bank P49699).

"Angiotensin-converting enzyme inhibitors" or "AGE inhibitors" refers to factors that act to reduce the conversion of angiotensin I to angiotensin II. A representative group of ACE inhibitors includes the following compounds: AB-103, ancovenin, benazeprilat, BRL-36378, BW-A575C, CGS-13928C, CL-242817, CV-5975, Equaten, EU-4865, E-4867, EU-5476, foroximitin, FPL 66564, FR-900456, Hoe- 065, I5B2, indolapril, ketomethylureas, KRI-1177, KRI-1230, L-681176, libenzapril, DCM, MDL-27088, MDL-27467A, moveltipril, MS-41, nicotianamine, pentopril, phenacetin, pivopril, rentiapril, RG- 5975, RG-6134, RG-6207, RGH-0399, ROO-911, RS-10085-197, RS-2039, RS 5139, RS 86127, RU-44403, S-8308, SA-291, spiraprilat, SQ- 26900, SQ-28084, SQ-28370, SQ-28940, SQ-31440, Synecor, utibapril, WF-10129, Wy-44221, Wy-44655, Y-23785, Yissum P-0154, zabicipril, Asahi Brewery AB-47 , alatriopril, BMS 182657, Asahi Chemical C-lll, Asahi Chemical C-112, Dainippon DÜ-1777, mixanpril, Prentil, zofenoprilat, 1- (- (l-carboxy-6- (4-piperidinyl). hexyl) amino ) -1-oxopropyl octahydro-lH-indole-2-carboxylic acid, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Mn Merrell Dow MDL-100240, perindoprilat and Servier S-5590, alacepril , benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat and spirapril. A group of ACE inhibitors of great interest includes the following compounds: alacepril, benazepril, captopril, cilazapril, delapril, enalapril, ehalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat and spirapril.

"Angiotensin II blockers" or "ATI antagonists" refers to factors that act to reduce the binding of angiotensin II to the Angiotensin II receptor. A group of highly interesting ATI antagonists includes the following compounds: Atacand (candesartan czlexetil), Avapro (irbesartan), Cozaar (losartan), Diovan (valsartan), Micardis (telmisartan), and Teveten (eprosartan mesylate).

"Anticancer agents" refers to antimetabolites (e.g., 5-fluoro-uracil, methotrexate, fludarabine), antimicrotubule agents (e.g., vincapervinca alkaloids such as vincristine, vinblastine, taxanes such as paclitaxel, docetaxel), alkylating agents ( for example, cyclophosphamide, melphalan, carmustine, nitrosoureas such as bischloroethylnitrosurea and hydroxyurea), platinum agents (eg, cisplatin, carboplatin, oxaliplatin, JM-216, CI-973), anthracyclines (eg, doxorubicin, daunorubicin), antitumor antibiotics (eg, mitomycin, idarubicin, adriamycin, daunomycin), topoisomerase inhibitors (eg, etoposide, camptothecins) or any other cytotoxic agent, (estramustine phosphate, prednimustine), hormones or agonists, antagonists, partial agonists or partial antagonists of hormones, and radiation treatment.

"Anticoagulants" refers to factors that act to reduce the ability of blood to clot. Examples that exist in the United States include, but are not limited to, the brands: Coumadin (warfarin), and Miradon (anisinidione).

"Antiarrhythmics" refers to factors that act to reduce abnormal heart rhythms. Examples that exist in the United States include, but are not limited to, the following brands: Betapace (sotalol), Cardizem (diltiazem), Cordarone (amiodarone), Covera (verapamil), Inderal (propranolol), Isoptin (verapamil), Pacerone (amiodarone), Ethmozine (moricizine), Lopressor (metoprolol), Mexitil (mexiletine), Norpace (disopyramide), Procanbid (procainamide), Pronestil (procainamide), Quinaglute Dura-tabs (quinidine gluconate), Quinidex Extentabs (quinidine sulfate), Rythmol ( propafenone), Tambocor (flecainide), Tenormin (atenolol), Tiazac (diltiazem), Tikosyn (dofetilide), Tonocard (tocainide), and Toprol XL (metoprolol).

"Antiinflammatory agents" refer to matrix metalloproteinase inhibitors, inhibitors of proinflammatory cytokines (eg, anti-TNF molecules, soluble TNF receptors, and IL1), non-spheroidal anti-inflammatory drugs (NSAIDs) such as prostaglandin synthase inhibitors (eg, example, choline magnesium salicylate, salicylsalicylic acid), COX-1 or COX-2 inhibitors, glucocorticoid receptor agonists such as corticosteroids, methylprednisone, prednisone or cortisone.

"Aryl" refers to a radical of the carbocyclic ring system wherein at least one of the rings is aromatic. The aryl can be fully aromatic, for example phenyl, naphthyl, anthracenyl, acenaphthylenyl, azulenyl, fluorenyl, indenyl and pyrenyl. The aryl may also contain an aromatic ring combined with a non-aromatic ring, for example acenaphene, indene and fluorene.

"Aralkyl" refers to a radical of the formula -RaRb wherein Ra is an alkyl radical defined above, substituted by Rb, an aryl radical, defined above, for example, benzyl. Both alkyl and aryl radicals may be optionally substituted as defined herein.

"Aralkoxy" refers to a radical of the formula -ORaRb wherein -RaRb is an aralkyl radical defined above. Both aralkyl and aryl radicals can optionally be substituted as defined hereinbefore.

"Atherosclerosis" refers to the process by which atherosclerotic plaques are formed within the inner lining of the arterial wall. that results in atherosclerotic cardiovascular diseases. Atherosclerotic cardiovascular diseases can be recognized and understood by physicians practicing in the relevant fields of medicine and include but are not limited to restenosis, coronary heart disease (also called arterial heart disease or ischemic heart disease), cerebrovascular disease that includes stroke ischemic, dementia due to multiple infarctions, and peripheral vessel disease, which includes intermittent claudication and erectile dysfunction.

"Beta blockers" refers to factors that act to reduce the activity of the sympathetic nervous system. Blistering beta drugs generally act to selectively block the β-adrenergic receptor, but in some cases they also block the activity of the α 1 adrenoceptor. Representative beta-blockers include the following: Acc 9369, AMO-140, acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, bevantolol, bisoprolol, bopindolol, bucumolol, bucindolol, bunitrolol, butofilolol, betaxolol, capsinolol, carazolol, CP-331684, carteolol, carvedilol, celiprolol, chloranolol, diprafenone, ersentilide, esmolol, esprolol, Fr-172516, indenolol, ISV-208, L-653328, labetalol, laniolol, levobunolol, LM-2616, levoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, S-atenolol, SB-226552 ', SR-58894A, SR-59230A, talinolol, tertatolol, tilisolol, timolol, Toprol, TZC-5665, UK-1745, xamoterol , and viskenit and YM-430. A group of Beta blockers of great interest include the following compounds: Betapace (sotalol), Blocadren (timolol), Brevibloc (esmolol), Cartrol (carteolol), Coreg (carvedilol), Corgard (nadolol), Inderal (propranolol), Inderal- LA (propranolol), Kerlone (betaxolol), Levatol (penbutolol), Lopressor (metoprolol), Normodyne (labetalol), Sectral (acebutolol), Tenormin (atenolol), Toprol-XL (metoprolol), Trandate (labetalol), Visken (pindolol) ), and Zebeta (bisoprolol).

"Calcium channel antagonists" or "calcium channel blockers" refers to factors that act to reduce the activity of the calcium channel. Examples include but are not limited to: Adalat (nifedipine), Calan (verapamil), Cardene (nicardipine), Cardizem (diltiazem), Cardizem CD (diltiazem), Cardizem SR (diltiazem), Cartia (diltiazem), Covera-HS (verapamil) , Dilacor XR (diltiazem), Diltia XT (diltiazem), DynaCirc (isradipine), Isoptin (verapamil), 'Lotrel (amlodipine), Nimotop (nimodipine), Norvasc (amlodipine), Plendil (felodipine), Procardia (nifedipine), Procardia XL (nifedipine), Sular (nisoldipyria), Teczem, Tiamate (diltiazem), Tiazac (diltiazem), Vascor (bepridil) Verelan (verapamil), aranidipine, atosiban, barnidipine, buflomedil, cilnidipine, docosahexaenoic acid, efonidipine HCL, fasudil, isradipine , lacidipine, lercanidipine, lomerizine, manidipine, nifelan, nilvadipine, nimodipine, nisoldipine, bepridil HC1. NS-7, NW-1015, SB-237376, SL-34.0829-08, terodiline, R-erapamil, bisaramyl, CAI, ipenoxazone, JTV-519, S-312d, SD-3212, tamolarizine, TA-993, vintoperol, YM-430, CHF-1521, eldipipine, nitrendipine, furnidipine, L-651582, oxodipine, ranolazine, AE-0047, azelnidipine, dotarizine, lemildipine, pranidipine, semothiadil, temiverin HC1, tenosal, vatanidipine HC1, and ziconotide. A group of calcium channel antagonists of great interest includes the following compounds: Adalat (nifedipine), Calan (verapamil), Cardene (nicardipine), Cardizem (diltiazem), Cardizem CD (diltiazem), Cardizem SR (diltiazem) Cartia (diltiazem) ), Covera-HS (verapamil), Dilacor XR (diltiazem), Diltia XT (diltiazem), DynaCirc (isradipine), Isoptin (verapamil), Lotrel (amlodipine), Nimotop (nimodipine), Norvasc (amlodipine), Plendil (felodipine) , Procardia (nifedipine), Procardia XL (nifedipine), Sular (nisoldipine), Teczem, Tiamate (diltiazem), Tiazac (diltiazem), Vascor (bepridil) Verelan (verapamil).

"Chronic heart failure" or "CHF", or alternatively "congestive heart failure", refers to a disorder in which heart failure has a left ventricular ejection fraction of 40% or less, determined on an echocardiogram or an angiography radionucleotide . "Heart failure" refers to a disorder in which the heart has a left ventricular ejection fraction greater than 40%, but less than 90%, determined on an echocardiogram or an angiographic radionucleotide.

"Cognitive dysfunction" refers to psychosis, cognitive disorder, mood disorder, anxiety disorder and personality disorder. Psychosis includes symptoms characterized by one or more of the following: impairment of behavior, inability to think coherently, inability to understand reality, false belief and abnormal sensations. Cognitive disorder includes symptoms characterized by one or more of the following: confusion, disorientation, memory disturbance, and disorganization of behavior. The mood disorder includes symptoms characterized by one or more of the following: depression, bipolar disorder, persistent mood abnormality, altered activity rhythm, sleep disturbance, and appetite disturbance. Anxiety disorder includes symptoms characterized by one or more of the following: anxiety, panic, dysphoria, obsession, irrational fear, ritualistic behavior, compulsion and pattern behavior.

"Cytokine antagonists" refers to factors that act to block the activity of cytokines such as tumor necrosis factor. Examples include, but are not limited to, Pentoxifylline and Etanercept.

"Cycloalkyl" refers to a stable monovalent monocyclic or bicyclic hydrocarbon radical comprising exclusively carbon and hydrogen atoms, having from three to ten carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decalinyl, norbornane, norbornene, adamantyl, bicyclo [2.2.2] octane and the like.

"Cycloalkylalkyl" refers to a radical of the formula -Ra¾ where Ra is an alkyl radical defined above and Rb is a cycloalkyl radical defined above. The alkyl radical and the cycloalkyl radical can be optionally substituted as defined herein.

"Diuretics" refers to factors that act to reduce blood pressure by reducing the amount of sodium and water in the body. Diuretics include thiazide diuretics, potassium-depleting diuretics, and loop-action diuretics. Examples of thiazide diuretics of great interest include the following compounds: Aquatensen (methyclothiazide), Diucardin (hydroflumetiazide), Diulo (metolazone), Diuril (chlorothiazide), Enduron (methyclothiazide), Esidrix (hydrochlorothiazide), Hydro-chlor (hydrochlorothiazide), Hydro -D (hydrochlorothiazide), HydroDIÜRIL (hydrochlorothiazide), Hydromox (quininezone), Hygroton (chlorthalidone), Metahydrin (trichlormethiazide), Microzide (hydrochlorothiazide), Mykrox (metolazone), Naqua (trichlormetiazide), Naturetin (bendroflumetiazide), Oretic (hydrochlorothiazide), Renese (polythiazide), Saluron (hydroflumethiazide), Thalitone (chlorthalidone), Trichlorex (trichlormethiazide), and Zaroxolyn (metolazone). - Examples of diuretics that dispense potassium of interest include the following compounds: Aldactone (spironolactone), Eplerenone, Dyrenium (triamterene), and Midamor (amiloride). Examples of loop action diuretics of great interest include the following compounds: Bumex (bumetanide), Demadex (torsemide), Edecrin (ethacrynic acid), Lasix (furosemide), and Myrosemide (furosemide).

"Digital medicines" refers to digoxin and related compounds. Examples of great interest include: Lanoxicaps (digoxin), Lanoxin (digoxin), Lanoxin Pediatric Elixir (digoxin), Lanoxin Injection (digoxin), and Lanoxin Pediatric Injection (digoxin).

"Dyslipidemia" refers to abnormal levels of lipoproteins in blood plasma that include reduced and / or high levels of lipoproteins (e.g., high levels of Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL), and reduced levels). of High Density Lipoprotein (HDL).

"EC5o" refers to a dosage, concentration or amount of a particular test compound that produces a dose-dependent response at 50% of the maximum expression of a particular response that is induced, evoked or potentiated with the test compound particular.

"Endothelin blockers" refers to factors that act to reduce the action of endothelin in the endothelin receptors ETA and ETB. Examples include, but are not limited to, Bosentan Acetelion (Roche), Ro-61-0612 (Roche), SB217242, SB247083, Enrasentan, (SmithKline Beecham Pharmaceuticals), TBC-11251 (Texas Biotechnology Corp., Houston, x), BMS187308 (Bristol-Myers Squibb Company, Princeton, NJ), PD-145065 (Parke-Davis &Co.), TAK-044 (Takeda), Tarasentan (Abbott), ZD-1611 (Zeneca Foot Group) and J-104132 (Banyu Pharmaceutical Co. Ltd).

"ER" or "ER family" refers to all species of ER alpha and ER beta. Representative ERa species include, but are not limited to, the rat receptor forms (Genbank Access P06211), pig (Genbank Access Q29040), and human (GenBank Access P03372). Representative species of ER ß include, but are not limited to, the rat receptor forms (Access of GenBank Q62986), mouse (Access of Genbank 008537), and human (Access of GenBank Q92731).

"ERR", "ERRs" or "ERR subfamily" refers to all ERRa, ERR and ERRy species. Representative ERRa species include, but are not limited to, the rat receptor forms (Genbank Accession XM_215174), mouse (Genbank Accession NM_007953), and human (GenBank Accession NM_004451, XM_048286) forms of the recipient. Representative ERR ß species include, without limitation the rat (Access of GenBank NM_011934), mouse (Access of Genbank NM_011934), and human (Access of GenBank NM_00452). Representative species of ERR? include, but are not limited to, the rat receptor forms (GenBank Access XM_341170), mouse (Genbank Access NM_011935), and human (GenBank Access N _001438).

As used in the presenete, "guanidino" refers to a radical having the formula -N (R) C (= NR ') NR "R'" where R, R ', R' 'and R' '' they are each independently hydrogen or alkyl.

"Fibrosis" refers to fibrotic tissue formation associated with tissue damage and scarring. Examples include, but are not limited to, cardiac fibrosis, vascular fibrosis, renal fibrosis and hepatic fibrosis.

"Reductive glucose agents" refers to factors that act to reduce, or help control plasma glucose levels, for example in diabetes, insensitivity to insulin or hyperglycemia. Examples include sulfonylureas (such as chlorpropamide, tolbutamide, acetohexamide, tolazamide, glyburide, gliclazide, glinease, glimepiride, and glipizide), biguanides (such as metformin), thiazolidinediones (such as ciglitazone, pioglitazone, troglitazone, and rosiglitazone); dehydroepiandrosterone (also called DHEA or its, conjugated sulfate ester, DHEA-S04); antiglucocorticoids; TNFa inhibitors; β-glucosidase inhibitors (such as acarbose, miglitol, and voglibose), pramlintide (a synthetic analogue of the human amylin hormone), other insulin secretagogues (such as repaglinide, gliquidone, and nateglinide) and insulin.

"Glucocorticoid receptor" or "GR" refers to all mammalian isoforms, splice variants and nuclear receptor polymorphisms. Representative forms include human (Genetic Bank Accession Number P04150), rat (Genetic Bank Accession Number P06536) and mouse (Genetic Bank Accession Number P06537).

"Halo", "halogen" or "halide" refers to F, Cl, Br or I. "Haloalkyl" refers to an alkyl group in which one or more of the hydrogen atoms is replaced by halogen. These groups include, but are not limited to, chloromethyl, trifluoromethyl, and 1-chloro-2-fluoroethyl.

"Haloalkenyl" refers to an alkenyl group in which one or more of the hydrogen atoms is replaced with halogen. These groups include, but are not limited to, l-chloro-2-fluoromethyl.

"Heart disease" or "heart disease" refers to all forms of ischemic heart disease, heart failure, systolic deterioration, diastolic deterioration, myocardial necrosis, pulmonary venous congestion, atrial fibrillation, myocardial infarction, myocardial fibrosis and Chronic heart failure "Heterocyclyl" refers to a stable 3- to 15-membered ring radical comprising carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For the purposes of this invention, the heterocyclic ring system radical may be a monocyclic, bicyclic or tricyclic or tetracyclic ring system, which may include ring-fused fused ring systems; and the nitrogen or sulfur atoms of the heterocyclic ring system radical can optionally be oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclic radical may be partially or fully saturated or aromatic. The heterocyclic ring system can be attached to the main structure in any heteroatom or carbon atom that results in the creation of a stable compound. Examples of such heterocyclic radicals include, but are not limited to: acridinyl, azepinyl, benzimidazolyl, benzolyl, benzisoxazinyl, benzo [4,6] imidazo [1, 2-a] pridinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzofuranyl, benzonaphtofuranyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahidrotienilo, benzothiadiazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzothiopyranyl, benzoxazinyl, benzoxazolyl, benzothiazolyl, ß-carbolinyl, carbazolyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dibenzofuranyl, dihidrobenzisotiazinilo, dihidrobencisoxazinilo, dihydrofuryl, dihydropyranyl, dioxolanyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrazolyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, furanyl, imidazolidinyl, imidazolinyl, imidazolyl, imidazopyridinyl, imidazothiazolyl, indazolyl, indolinyl, indolizinyl, indolyl, isobenzotetrahydrofuranyl , Isobenzotetrahydrothienyl, isobenzothienyl, isochromanyl, isocoumarinyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroindolyl, octahydroisoindolyl, oxadiazolyl, oxazolidinonyl, oxazolidinyl, oxazolopyridinyl, oxazolyl, oxiranyl, perimidinyl, phenanthridinyl, fenatrolinilo, fenarsazinilo , phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, 4-piperidonyl, pteridinyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridopyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuryl , tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, tetrazolyl, thiadiazolopyrimidinyl, thiadiazolyl, thiamorpholinyl-, thiazolidinyl, thiazolyl, thiophenyl, triazinyl, triazolyl and 1,3,5-trityanyl.

"Heteroaralkyl" refers to a radical of the formula -RaRf where Ra is an alkyl radical defined above and Rf is a heteroaryl radical defined herein. The alkyl radical and the heteroaryl radical may be optionally substituted as defined herein. "Heteroaralkoxy" refers to a radical of the ormula -ORaRf where -RaRf 'is a heteroaralkyl radical defined above. The alkyl radical and the heteroaralkyl radical may be optionally substituted as defined herein. "Heteroaryl" refers to a heterocyclyl radical defined above that is aromatic. The heteroaryl radical may be attached to the backbone at any heteroatom or carbon atom that results in the creation of a stable compound. Examples of such heteroaryl radicals include, but are not limited to: acridinyl, benzimidazolyl, benzolyl, benzisoxazinyl, benzo [4,6] imidazo [1,2-a] pyridinyl, benzofuranyl, benzonaphthaluranyl, benzothiadiazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzothiopyranyl , benzoxazinyl, benzoxazolyl, benzothiazolyl, ß-carbolinyl, Carbazolyl, cinnolinyl, dibenzofuranyl, furanyl, imidazolyl, imidazopyridinyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isobenzothienyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, naphthyridinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxazolopyridinyl, oxazolyl, oxiranyl, perimidinyl, phenanthridinyl , phenazinyl, phenazinyl, phenazinyl, phenazinyl, phenoxyzinyl, phenoxyzinyl, phenazinyl, phenazinyl, phenazinyl, pteridinyl, purinyl, pyrazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridopyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrazolyl, thiadiazolyl, thiazolyl, thiophenyl, triazinyl and triazolyl.

"Heterocyclylalkyl" refers to a radical of the formula -RaRe wherein Ra is an alkyl radical defined above and Re is a heterocyclyl radical defined herein. The alkyl radical and the heterocyclic radical may be optionally substituted as defined herein.

"Heterocyclylalkoxy" refers to a radical of the formula -ORaRe wherein -RaRe is a heterocyclylalkyl radical defined above. The alkyl radical and the heterocyclyl radical may be optionally substituted as defined herein.

"Hyperlipidemia" refers to the presence of an abnormally high level of lipids in the blood. Hyperlipidemia can appear in at least three forms: (1) · (1) hypercholesterolemia, that is, a higher elevated LDL cholesterol level than normal (2) hypertriglyceridemia, that is, a higher triglyceride level than normal and (3) ) Combined hyperlipidemia, ie a combination of hypercholesterolemia and hypertriglyceridemia. "Hypertension" 'refers to a diastolic blood pressure set at 90 mm Hg or higher, and / or, a systolic blood pressure of 140 mm Hg or more.

"IC50" refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response, such as modulation of MR transcription activity measured through any of the assays in live or in vitro described herein.

"Imine" or "imino" refers to = NR, where R is hydrogen or alkyl.

"Lipid Modulating Agents" refers to factors that act to reduce the levels of cholesterol (LDL cholesterol, total cholesterol or HDL cholesterol) and / or triglycerides in the plasma Examples include but not limited to: HMG-CoA inhibitors reductase (which include statins such as lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, and rivastatin), bile acid sequestrants (resins), nicotinic acid (niacin), and fibric acid derivatives (fibrates).

"Meta" as used in the claims refers to the position on the benzene ring that is meta with respect to the point of attachment of the benzene group to the rest of the molecule.

"Mineralocorticoid receptor" or "aldosterone receptor" or "MR" refers to all mammalian isoforms, splice variants and nuclear receptor polymorphisms, (including, the non-nuclear rapid response receptor). Representative forms include human (Genetic Bank Accession Number AAA59571, isoforms NP_000892 and P0.8235), rat (Genetic Bank Accession Number P22189), mouse (Genetic Bank Accession Number CAC86375), chicken (Bank Access Number) Genetic Q8QH12) and sheep (Accession number of Genetic Bank 99BDJ7).

"Natriuretic peptides" refers to natural or analogous forms of the natriuretic peptides that are activated in CHF as a result of ventricular and atrial wall stretching.

"Optionally substituted alkyl", "optionally substituted alkenyl" and "optionally substituted alkynyl" refer to alkyl, alkenyl and alkynyl radicals, respectively, but may be optionally substituted by one or more substituents independently selected from the group consisting of nitro, halo, azido, cyano, cycloalkyl, heteroaryl, heterocyclyl, -ORx, -N (Ry) (Rz), -SRX, -C (J) RX, -C (J) ORx, -C (J) N (Ry) (Rz) ), -C (J) SRX, -S (0) tRw (where t is 1 or 2), -OC (J) Rx, -OC (J) ORx, -OC (J) N (Ry) (Rz) , -OC (J) SRx, -N (RX) C (J) RX, -N (Rx) C (J) ORx, -N (Rx) C (J) N (Ry) (Rz), -N ( RX) C (J) SRX, -Si (Rw) 3, -N (RX) S (0) 2RW, -N (Rx) S (O) 2N (Ry) (Rz), -S (0) 2N ( Ry) (Rz), -P (0) (Rv) 2, -OP (O) (Rv) 2, -C (J) N (Rx) S (O) 2RW, -C (J) N (Rx) N (Rx) S (0) 2Rw, -C (Rx) = N (ORx), and -C (Rx) = NN (Ry) (Rz), where: Rx is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl; Rw is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; Rv is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxy, -0RX or -N (Ry) (Rz); and J is O, NRX or S.

Unless specifically stated otherwise in the specification, it is understood that substitution can occur at any carbon in the alkyl, alkenyl or alkynyl group.

"Optionally substituted aryl", "optionally substituted cycloalkyl", "optionally substituted heteroaryl" and "optionally substituted heterocyclyl" refer to aryl, cycloalkyl, heterocyclyl and heteroaryl radicals, respectively, which are optionally substituted by one or more substituents selected from the group formed by nitro, halo, haloalkyl, haloalkenyl, azido, cyano, oxo, thioxo, imino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, -Ru-ORx, -Ru -N (Ry) (Rz), -Ru-SRX, -Ru-C (J) RX, -Ru-C (J) ORx, -Ru-C (J) N (Ry) (Rz), -Ru-C (J) SRX , -Ru -S (0) tRw (where t is 1 or 2), -Ru -OC (J) Rx, -Ru -QC (J) ORx, -Ru -OC (J) N (Ry) (Rz) , -Ru-OC (J) SRX, -Ru -N (RX) C (J) RX, -Ru -N (Rx) C (J) ORx, -Ru -N (Rx) C (J) N (Ry ) (R2), -Ru -N (RX) C (J) SRX, -Ru-Si (Rw) 3, -Ru -N (R: :) S (0) 2RW, -Ru -N (Rx) S (0) 2N (Ry) (Rz), -Ru -S (0) 2N (Ry) (Rz), -Ru -P (0) (Rv) 2, - u -0P (0 ) (Rv) 2, -Ru-C (J) N (Rx) S (0) 2Rw, -Ru -C (J) N (Rx) N (Rx) S (0) 2RW, -Ru -C (R ) = N (0Rx) and -Ru -C (Rx) = NN (Ry) (Rz), where: each Ru is independently alkylene or a direct bond; each Rv is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxy, -0RX or -N (Ry) (Rz); Rw is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; each Rx is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocycle or heteroaryl; and J is 0, NRX or S.

Unless otherwise specifically stated in the specification, it is understood that substitution may occur at any atom of the cycloalkyl, heterocyclyl, aryl or heteroaryl group.

"Oxo" refers to = 0. "Ortho" as used in the claims refers to the position on the benzene ring that is ortho to the point of attachment of the benzene group to the rest of the molecule.

"Para" as used in the claims refers to the position on the benzene ring that is for with respect to the point of attachment of the benzene group to the rest of the molecule.

"Pharmaceutically acceptable derivatives" of a compound include salts, esters, enol ethers, enol esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs thereof. These derivatives can be readily prepared by those skilled in the art using known methods for that derivation. The compounds produced can be administered to animals or humans without substantial toxic effects and are pharmaceutically active or are prodrugs. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as non-limiting, N, IV'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N- benzylphenethylamine, l-para-chlorobenzyl-2-pyrrolidin-l-l-methylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris (hydroxymethyl) aminomethane; alkali metal salts, such as non-exhaustively salts of lithium, potassium and sodium; alkaline earth metal salts, such as non-exhaustively metal salts of barium, calcium and magnesium; transition metal salts such as non-exhaustive, zinc; and other metal salts, such as in the non-limiting form sodium hydrogen phosphate and disodium phosphate; and which also include salts of mineral acids, such as non-exhaustively, hydrochlorides and sulfates; and salts of organic acids such as non-exhaustively, acetates, lactates, maleates, tartrates, citrates, ascorbates, succinates, butyrates, valerate and fumarates. Pharmaceutically active esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, and heterocyclyl esters of acid groups including, but not limited to carboxylic acids, phosphoric acids, phosphinic acids, acids sulfonic acids, sulfinic acids and boronic acids. The pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of the formula C = C (OR) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl or heterocyclyl. The pharmaceutically acceptable enol esters include, but are not limited to, derivatives of the formula C = C (0C (0) R) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl or heterocyclyl.

The pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more molecules of solvent or water, or from 1 to 100, or from 1 to 10, or from 1 to 2, 3 or 4, solvent or water molecules.

"Polymorph" refers to the different forms of crystals of a compound, derived from the possibility of at least two different orderings of the molecules of the compound in the solid state. The polymorphs of a given compound have a different crystal structure but are identical in the liquid or gaseous states. The different polymorphic forms of a given substance may differ from one another with respect to one or more physical properties, such as solubility and dissociation, true density, crystal shape, compaction behavior, flow properties and / or solid state stability. .

"Prodrug" is a compound that, when administered in vivo, is metabolized by one or more steps or processes or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound. To produce a prodrug, the pharmaceutically active compound is modified such that the active compound is regenerated by metabolic processes. The prodrug can be designed to alter the metabolic stability or transport characteristics of a drug, to mask the side effects or toxicity, to improve the taste or a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and in vivo drug metabolism, those skilled in the art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, eg, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392).

"Progesterone receptor" or "PR" refers to all mammalian isoforms, splice variants and nuclear receptor polymorphisms. Representative forms include human (Accession Bank Number, P06401), and mouse (Accession Number of Genetic Bank Q63449).

"Kidney Disease" or "kidney disease" or refers to diabetic nephropathy, chronic glomerulonephritis, polycystic kidney disease, non-diabetic nephropathy and all forms of chronic kidney disease. "Chronic Kidney Disease" or "CKD" or "Kidney Failure" or "Kidney Failure" is generally characterized based on glomerular filtration rate or GFR. In general Chronic Kidney Disease is suggested when the GFR is 90 or less.

"Spheroid Receptors" or "Spheroidal Nuclear Receptors" refers to all splice variants and mammalian isoforms of nuclear steroid receptors AR (NR3C4), PR (NR3C3), ERa (NR3 1), ER (NR3A2) , GR (NR3C1), and MR (NR3C2), as well as all orphan nuclear receptors ERR1 (NR3B1), ERR2 (NR3B2), and ERR3 (NR3B3).

As used herein, "substantially pure" means sufficiently homogeneous to appear free of easy to detect impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography. performance (HPLC), mass spectrometry (MS), used by those skilled in the art to determine that purity, or sufficiently pure so that a new purification would not detectably alter the physical and chemical properties, such as enzymatic activities and biological, of the substance. ' Methods for purifying the compounds to produce essentially chemically pure compounds are known to those skilled in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers. In those cases, a new purification could increase the specific activity of the compound.

"Sulfur" refers to the radical having the formula -SR wherein R is an alkyl or haloalkyl group. An "optionally substituted sulfide" refers to the radical having the formula -SR wherein R is an optionally substituted alkyl defined herein.

"Tioxo" refers to = S.

"Vasodilators" refers to compounds that act to cause vasodilatation of blood vessels thereby increasing blood flow. The vasodilators of great interest include the following compounds: IMDUR (isosorbide mononitrate), ISMO (isosorbide mononitrate), Isordil (isosorbide dinitrate), Monoket (isosorbide mononitrate), Nitro-Dur (nitroglycerin), Nitrolingual (nitroglycerin), Nitrostat (nitroglycerin), and Sorbitrate (isosorbide dinitrate).

Unless specifically expressed otherwise, when a compound can assume alternative tautomeric, regioisomeric and / or stereoisomeric forms, it is desired that all alternative isomers fall within the scope of the present invention. For example, when a compound is described as having one or two tautomeric forms, it is desired that both tautomeric forms be within the scope of the present invention. Therefore, the compounds herein can be enantiomerically pure, or they can be. stereoisomeric or diastereoisomeric mixtures. In the case of amino acid residues, those residues may have the form of L or D. The configuration for natural amino acid residues is generally L. When the residue is not specified it is the L form. As used herein , the term "amino acid" refers to -aminoacids that are racemic, or with the configuration of D or L. The designation "d" that precedes an amino acid designation (eg, dAla, dSer, dVal, etc.) refers to to the D isomer of the amino acid. The designation "di" that precedes the designation of the amino acid (e.g., dlPrp) refers to a mixture of the L and D isomers of the amino acid. It should be understood that the qiral centers of the compounds provided herein may undergo epimerization in vivo. As such, one skilled in the art will recognize that the administration of a compound in its (R) form is equivalent, for the compounds passing through in vivo epimerization, to the administration of the compound in its (S) form.

It should also be understood that the compounds provided herein may contain chiral centers. Those chiral centers can have the (R) or (S) configuration, or they can be a mixture of them.

The (+) and (-), (R) and (S) or (D) and (L) ethically active isomers can be prepared using chiral reagents, or resolved using conventional techniques, such as. HPLC inverted phase.

When the number of any given substituent is not specified (eg, haloalkyl), there may be one or more substituents present. For example, the "haloalkyl" may include one or more thereof or different halogens.

As used herein, abbreviations for all protecting groups, amino acids and other compounds are, unless otherwise indicated, in accordance with their common use, recognized abbreviations, or the IÜPAC-IÜB Commission on Biochemical Nomenclature. (see Biochem., 1972, 11: 942-944).

AcOH Acetic acid anhydrous Acid anhydrous CDC13 Deuterochloroform conc concentrated DCM Dichloromethane DMF N, -dimethylformamide DMSO Dimethyl sulfoxide Et20 Diethyl ether EtOAc Ethyl acetate EtOH Ethanol (100%) Hex Hexanes MeOH Methanol Pd / C Palladium on activated carbon satd Saturated THF Tetrahydrofuran B. FORMULATION OF PHARMACEUTICAL COMPOSITIONS The pharmaceutical compositions provided herein contain therapeutically effective amounts of one or more of the compounds or compositions, or pharmaceutically acceptable derivatives thereof, provided herein that are useful in the prevention, treatment, or amelioration of diseases, disorders, and disorders. human and veterinary conditions mediated by, or otherwise affected by, one or more spheroidal nuclear receptors, or in which the activity of the nuclear steroid receptor is involved, as defined herein. The compounds, the compositions or pharmaceutically acceptable derivatives thereof are preferably formulated in suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained-release formulations or elixirs, for oral administration or in solutions or suspensions sterile for parenteral administration, as well as the preparation transdermal patches and dry powder inhalers. Generally the compounds described above are formulated in pharmaceutical compositions using techniques and procedures known in the art (see, for example, Ansel Introduction to Pharmaceutical Dosage Formsr Fourth Edition 1985, 126; Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975).

In pharmaceutical compositions, effective concentrations of one or more pharmaceutically acceptable compounds or derivatives thereof are mixed with at least one suitable carrier, vehicle, diluent or pharmaceutical solvent. Dosage forms or compositions containing the active ingredient in the range of 0.00% to 100% can be prepared with the remainder composed of a non-toxic carrier. The compositions contemplated may contain 0.001% -100% of the active ingredient, preferably 0.1% -85%, generally 75% -95%. In addition, the compounds can be formulated as the pharmaceutically active ingredient only in the composition or can be combined with other active ingredients.

The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect without undesirable side effects on the treated patient. The therapeutically effective concentration can be determined empirically by testing the compounds using in vitro and in vivo systems described herein and in International Patent Application Publication Nos. 99/27365 and 00/25134 and then extrapolated therefrom for dosages for humans.

The concentration of the active compound in the pharmaceutical composition depends on the rates of absorption, inactivation and excretion of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and the amount administered as well as other factors known to those skilled in the art. For example, the amount that is administered is sufficient to ameliorate one or more of the symptoms of diseases or disorders associated with the activity of nuclear receptors or in which the activity of nuclear receptors is involved, as described herein.

Generally, a therapeutically effective dosage should produce a serum concentration of the active ingredient of 0.1 ng / ml at 50-100 μg / ml. The pharmaceutical compositions should generally provide a dosage of 0.001 mg to 2000 mg of the compound per kilogram of body weight per day. The pharmaceutical dosage unit forms are prepared to provide from 1 mg to 1000 mg and preferably from 10 to 500 mg of the essential active ingredient or a combination of the essential ingredients for each unit dosage form.

The active ingredient can be administered once, or it can be divided into numerous smaller doses which must be administered at time intervals by an appropriate route, which includes the oral, parenteral, rectal, topical and local route. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and can be determined using known assay protocols or by extrapolation from in vivo or in vitro assay data. It should be noted that the concentrations and dosage values may also vary with the severity of the condition being relieved. It should be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and professional judgment of the person administering or supervising the administration of the compositions, and that the ranges of the Concentrations set forth herein are examples only and it is not desired to limit the scope or practice of the claimed compositions.

In cases in which the compounds have insufficient solubility, methods for solubilizing compounds can be used. Those methods are known to those skilled in the art and include, but are not limited to, using co-solvents, such as dimethyl sulfoxide (DMSO), using surfactants, such as TWEENS®, or aqueous sodium bicarbonate solution. Derivatives of the compounds, such as prodrugs of the compounds in the formulation of effective pharmaceutical compositions can also be used.

When mixing or adding the compound (s), the resulting mixture can be a solution, suspension, emulsion or the like. The shape of the resulting mixture depends on numerous factors, including the desired form of administration and the solubility of the compound in the carrier or vehicle selected. The effective concentration is sufficient to improve the symptoms of the disease, disorder or condition treated and can be determined empirically.

The pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions and oral solutions or suspensions, and oil and water emulsions containing suitable amounts of the compounds or pharmaceutically acceptable derivatives thereof. Pharmaceutically and therapeutically active compounds and derivatives thereof are generally formulated and administered in unit dosage forms or multiple dosage forms. The unit dosage forms as used herein refer to discrete units physically suitable for human and animal subjects and individually packaged as is known in the art. Each unit dose contains a predetermined quantity of the therapeutically active compound to produce the desired therapeutic effect, in association with the carrier, vehicle or pharmaceutical diluent. required. Examples of unit dosage forms include ampoules and syringes and individually packaged tablets or capsules. The unit dosage forms may be administered in fractions or multiples thereof. A multiple dose form is a plurality of identical unit dosage forms packaged in a single container that must be administered in the form of segregated unit doses. Examples of multiple dose forms include bottles of tablets or capsules or bottles of pints or gallons. Therefore, the multiple dose form is a multiple of unit doses that do not segregate when packaged.

Compositions for oral administration Oral pharmaceutical dosage forms are solid, gel or liquid. The solid dosage forms are tablets, capsules, granules or global powders. Types of oral tablets include tablets, chewable tablets or tablets that may have an enteric coating, a sugar coating or a film coating. The capsules can be hard or soft gelatin capsules, while the granules and powders can be provided in a non-effervescent or effervescent form with the combination of other ingredients known to those skilled in the art.

In certain embodiments, the formulations are solid dosage forms, preferably capsules or tablets. Tablets, pills, capsules, chips and the like can contain any of the following ingredients or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a slider; a sweetening agent; and a flavoring agent.

Examples of binders include microcrystalline cellulose, tragacant gum glucose solution, acacia mucilage, gelatin solution, celluloses, polyvinyl pyrrolidone, povidone, crospovidones, sucrose and starch paste. Lubricants include talc, starch, magnesium or calcium stearate, lycopodium and stearic acid. Diluents include, for example, lactose, sucrose, starch, kaolin, salt, mannitol, carboxymethylcellulose and dicalcium phosphate. Glidants include, but are not limited to, colloidal silicon dioxide. Disintegrating agents include croscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Coloring agents include, for example, any of the certified water soluble FD and C dyes, mixtures thereof and water insoluble FD and C dyes suspended on hydrated alumina. Sweetening agents include sucrose, lactose, mannitol and artificial sweetening agents such as saccharin, and any amount of spray-dried flavors. Flavoring agents include natural flavors extracted from plants such as fruits and synthetic blends of. compounds that produce a pleasant sensation, such as, in non-exhaustive form, mint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene laurel ether.

In all embodiments, the tablet and capsule formulations can be coated as known to those skilled in the art to modify or sustain the dissolution of the active ingredient. If oral administration is desired, the compound can be provided in a composition that protects it from the acid medium of the stomach. Thus, for example, they can be coated with a conventional enterically digestible coating, such as phenylsalicylate, waxes and cellulose acetate phthalate. Enteric coatings can also include fatty acids, fats, waxes, shellac, ammonia lacquer and cellulose acetate phthalates. Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate. The composition can also be formulated in combination with an antacid or other similar ingredient.

When the unit dosage form is a capsule, it may contain, in addition to the material of the preceding type, a liquid carrier such as a fatty oil. In addition, the unit dosage forms may contain different materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents. The compounds may also be administered as a component of an elixir, suspension, syrup, wafer, spray, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, colorants and flavorings. The active ingredient can also be mixed with other materials that do not prevent the desired action, or with materials that complement the desired action, such as antacids, H2 blockers and diuretics. The active ingredient is a compound or a pharmaceutically acceptable derivative thereof that is described herein.

The sugar coated tablets are > compressed tablets to which different layers of pharmaceutically acceptable substances have been applied. The tablets coated with a film are compressed tablets that have been coated with a polymer or other suitable coating. Several compressed tablets are compressed tablets made by more than one compression cycle using the pharmaceutically acceptable substances mentioned previously.

Liquid oral dosage forms include solutions, emulsions, suspensions, solutions and / or aqueous suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. The emulsions are oil in water or water in oil.

Elixirs are hydroalcoholic preparations, sweetened, transparent. The "pharmaceutically acceptable carriers used in the elixirs include solvents.The syrups are concentrated aqueous solutions of a sugar, for example, sucrose and may contain a preservative, an emulsion is a two-phase system in which a liquid is dispersed in the form of small globules in any other liquid.The pharmaceutically acceptable carriers used in the emulsions are non-aqueous liquids, emulsifying agents and preservatives.The suspensions use pharmaceutically acceptable suspending agents and preservatives.The pharmaceutically acceptable substances used in the non-effervescent granules, which must reconstituted in an oral liquid dosage form, include diluents, sweeteners and wetting agents.The pharmaceutically acceptable substances used in the effervescent granules, which must be reconstituted in an oral liquid dosage form, include organic acids and a source of carbon dioxide. The colorants and flavoring agents are used in all the preceding dosage forms.

Solvents include glycerin, sorbitol, ethyl alcohol and syrup. Examples of preservatives include glycerin, methyl and propylparaben, benzoic acid, sodium benzoate and alcohol.

Examples of non-aqueous liquids used in emulsions include mineral oil and cottonseed oil. Examples of emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, gum V and acacia. The diluents include lactose and sucrose. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as saccharin. Wetting agents include monostearate. of propylene glycol, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether. Organic acids include citric and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate. The coloring agents include any of the approved cerifified water soluble FD and C dyes and mixtures thereof. Flavoring agents include natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, for example in propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule. Those solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Patent Nos. 4,328,245; 4,409,239; and 4,410,545. For the liquid dosage form, the solution, for example, in polyethylene glycol, can be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier, for example water, to be measured for administration.

Alternatively, oral semisolid liquid formulations can be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (eg, propylene carbonate) and other similar carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsules. Other useful formulations include those set forth in U.S. Patent Nos. 28,819 and 4,358,603. In summary, these formulations include, but are not limited to, those containing a compound provided herein, a dialkylated mono or polyalkylene glycol, including, but not limited to, 1,2-dimethoxymethane, diglyme, triglyme, tetraglimethyl, dimethyl ether, polyethylene glycol 350, polyethylene glycol dimethyl ether 550, polyethylene glycol dimethyl ether 750 where 350, 550 and 750 refer to the approximate molecular weight of polyethylene glycol, and one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hoydroxyanisole (BHA), I propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, melic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates.

Other formulations include, but are not limited to, aqueous alcoholic solutions including pharmaceutically acceptable acetal. The alcohols used in these formulations are any pharmaceutically acceptable water-miscible solvent having one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol. Acétals include, but are not limited to, di (lower alkyl) acetals of lower alkyl aldehydes such as acetaldehyde diethyl acetal.

Injectables, solutions and emulsions Parenteral administration, generally characterized by injection, subcutaneously, intramuscularly or intravenously is also contemplated herein. Preparations for parenteral administration include sterile solutions for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent immediately before use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry ready insoluble products to be combined with a vehicle immediately before use and sterile emulsions. The solutions can be aqueous or non-aqueous.

In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other agents such as example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS) and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

The pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances. Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose Injection and Lactated Ringers. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents at bacteriostatic or fungistatic concentrations should be added to parenteral preparations packaged in multiple-dose containers that include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl-l-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and chloride of benzethonium. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80 (TWEEN® 80). A metal ion chelating or sequestering agent includes EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for vehicles miscible with water and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

The concentration of the pharmaceutically active compound is adjusted such that an injection provides an effective amount to produce the desired pharmacological effect. The precise dose depends on the age, weight and condition of the patient or animal as is known in the art.

Parenteral unit dose preparations are packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration must be sterile, as is known and practiced in the art.

The compound can be suspended in a micronized form or in another suitable form or it can be derivatized to produce a more soluble active product or to produce a prodrug. The shape of the resulting mixture depends on numerous factors, including the desired mode of administration and the solubility of the compound in the carrier or vehicle selected. The effective concentration is sufficient to improve the symptoms of the condition and can be determined empirically.

Lyophilized powders Freeze-dried powders are also of interest here, which can be reconstituted for administration as solutions, emulsions or other mixtures. They can also be reconstituted and formulated as solids or gels.

The sterile lyophilized powder is prepared by dissolving a compound provided herein, or a pharmaceutically acceptable derivative thereof, in a suitable solvent. The solvent may contain an excipient that improves the stability or other pharmacological component of the reconstituted powder or solution, prepared from the powder. The excipients that can be used include, but are not limited to, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent. The solvent may also contain a buffer, such as citrate, sodium or potassium phosphate or other buffer known to those skilled in the art, generally at neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those skilled in the art provides the desired formulation. In general, the resulting solution is dispensed into bottles for lyophilization. Each bottle contains a single dosage (10-1000 mg, preferably 100-500 mg) or multiple dosages of the compound. The lyophilized powder can be stored under appropriate conditions, such as at 4 ° C to room temperature.

The reconstitution of this lyophilized powder with water for injection provides a formulation for use in parenteral administration. For reconstitution, 1-50 mg, preferably 5-35 mg, more preferably 9-30 mg of the lyophilized powder, are added per mL of sterile water or other suitable carrier. The precise amount depends on the selected compound. That amount can be determined empirically.

Topical Administration Topical mixtures are prepared as described for local and systemic administration. The resulting mixture can be a solution, suspension, emulsions or the like, and are formulated as creams, ointments, emulsions, solutions,. elixirs, lotions, suspensions, solutions, pastes, foams, sprays, irrigations, sprays, suppositories, bandages, skin patches or any other formulation for topical administration.

The compounds or pharmaceutically acceptable derivatives thereof can be formulated as aerosols for topical application, for example by inhalation (see, for example, US Patent Nos. 4,044,126, 4,414,209 and 4,364,923, which describe aerosols for administration of a spheroid useful for the treatment of inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract may be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In that case, the particles of the formulation generally have diameters less than 50 microns, preferably less than 10 microns.

The compounds can be formulated for local or topical application, for example for topical application to the skin and mucous membranes, such as the eye, in the form of gels, creams, and lotions and for application to the eye or for application intracisternal or intraspinal. Topical administration is contemplated for transdermal administration and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination with other pharmaceutically active excipients can also be administered.

These solutions, particularly those intended for ophthalmic use, can be formulated as isotonic solutions at 0.01% -10%, at pH 5-7, with appropriate salts.

Sustained Release Formulations Implantation of a slow release or sustained release system, such that a constant level of dosage is maintained (see, for example, US Patent No. 3,710,795) is also contemplated herein. In summary, a compound provided herein is dispersed in a solid inner matrix, for example polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene-, polybutadiene, polyethylene. , copolymers of ethylene and vinyl acetate, silicone gums, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic powders such as acrylic and methacrylic acid ester hydrogels, collagen, cross-linked polyvinyl alcohol and partially crosslinked polyvinyl acetate crosslinked, which is surrounded by an outer polymeric membrane, for example, polyethylene, polypropylene, ethylene / propylene copolymers, ethylene / ethyl acrylate copolymers, ethylene / vinyl acetate copolymers, silicone gums, polydimethyl siloxanes, neoprene gum, chlorinated polyethylene, chloride of polyvinyl, chloride copolymers of vinyl with wine acetate, vinylidene chloride, ethylene and propylene, ionomeric polyethylene terephthalate, butyl rubber, epichlorohydrin gums, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, and ethylene copolymer / vinyl ethanol, which is insoluble in body fluids. The compound diffuses through the outer polymeric membrane in a step of controlling the rate of release. The percentage of the active compound contained in these parenteral compositions depends very much on its specific nature, as well as the activity of the compound and the needs of the subject.

Compositions for other administration routes Other routes of administration, such as transdermal patches, and rectal administration are also contemplated herein.

Transdermal patches, including iotrophoretic and electrophoretic devices, are known to those skilled in the art. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010,715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957.

The pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for the systemic effect. Rectal suppositories that are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. The pharmaceutically active substances used in rectal suppositories are bases or vehicles and agents for raising the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbocera (polyoxyethylene glycol) and appropriate mixtures of mono, di and triglycerides of fatty acids. You can also use combinations of different bases. Agents for raising the melting point of suppositories include whale sperm and wax. Rectal suppositories can be prepared by the compression method or by molding. The typical weight of a rectal suppository is 2 to 3 mg. Tablets and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.

Directed Formulations Compounds provided on the presnete, or pharmaceutically acceptable derivatives thereof, may also be formulated to be directed to a particular tissue, recipient, or other area of the subject's body to be treated. Many of the methods for directing are known to those skilled in the art. All such methods for directing are contemplated herein for use in the present compositions. For non-exhaustive examples of methods for directing, see, for example, U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071. 495, 66060.082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874.

In one embodiment, liposomal suspensions, which include liposomes directed to a tissue, such as liposomes targeted to tumors, may also be suitable as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art. For example, liposomal formulations described in U.S. Patent No. 4,522,811 can be prepared. Briefly, liposomes such as multicellular vesicles (MLV) can be formed by drying phosphatidyl choline from egg and cerebral phosphatidyl serine (molar ratio of 7: 3) inside a flask. A solution of a compound provided herein is added in saline with phosphate buffer having no divalent cations (PBS) and the flask is shaken until the lipid film is dispersed. The resulting vesicles are washed to remove the unencapsulated compound, pellets are formed by centrifugation and then resuspended in PBS.

Manufacturing Articles The compounds or pharmaceutically acceptable derivatives thereof can be packaged as articles of manufacture comprising a packaging material, a compound or composition, or a pharmaceutically acceptable derivative thereof provided herein, and a label indicating that the compound or composition, or the pharmaceutically acceptable derivative thereof, is used to modulate the activity of a spheroid nuclear receptor, or for the treatment, prevention or amelioration of one or more symptoms of a disease or disorder mediated by a spheroidal nuclear receptor, or diseases or disorders in. which is involved the activity of a nuclear spheroid receptor.

The articles of manufacture provided herein contain packaging materials. Packaging materials for use in packaging pharmaceutical products are known to those skilled in the art. See, for example, U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, tubes, inhalers, pumps, bags, bottles, containers, syringes, bottles and any suitable packaging material for a selected formulation and form of administration and treatment desired.

EMBODIMENTS OF THE INVENTION Of the different aspects of the invention set forth Summary of the Invention, certain embodiments are described An embodiment are compounds of the formula (I): wherein: R1 and R2 are each independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally heteroaralkyl substituted, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, -0R9, -SR9, -N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R3 is independently hydrogen or halo; R 4 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, - R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8 -C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, ~ R8 -C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8-S ( O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N = C (R9) 2, -R8-S (O) tN (R9) C (O) R10 (where t is 1 or 2), -R8-S (O) tN (R9) C (O) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8-N (R9) C (0) OR10, -R8 -N (R9) C (O) SR10, -R8-N (R9) C (NR9) SR10, ~ R8-N (R9) C (S) SR10, -R8-N (R9 ') C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8 ~ OC (NR9) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (0) SR9, -R8-OC (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -RX1-C (0) R9, -R8-C (0) -Ru-C (S) R9, -R8-C (O) -R- (NR9) R9, -R8-C (0) -R11-C (0) OR9, -R8 -C (0) -R11-C (S) OR9, -R8-C (0) -Rn-C (NR9) OR9, -R8-C (0) -RX1-C (0) N (R9) 2, -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (0) -Ru-C (NR9) N (R9) 2, -R8-C (O) -Rn-C (O) SR9, -R8-C (0) -R1X-C (S) SR9 and -R8-C (O) -R1: LC (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; R7 is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl , optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyloptionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2 ), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -Rx -C (0) ORiqr -R1 -C (S) OR, -R- (NR) OR, -R -C (O) N (R) 2 -R13-C (S) N (R14) 2, -R13-C (NR1 ) N (R14) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (O) tOR14 (where t is 1 or 2) , -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13- S (0) tN (R14) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R13-S (0) tN ( R14) C (NR14) (R14) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) C (0) OR15, -R13-N ( R14) C (0) SR15, -R13-N (R1) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R1) 2, -R13-N (R14) C (NR14) (R14) 2, -R13-N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) t 15 (where t is 1 or 2), -R13-OC (0) R15, -R13-0C (NR14 ) R15, -R13-0C (S) R15, -R13-0C (0) OR15, -R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-0C (0) SR14, -R13 -0C (0) N (R14) 2, -R13-OC (NR1) N (R14) 2, -R13-OC (S) N (R14) 2, -R13-C (0) -R15-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13 -C (0) -R16-C (S) N (R14) 2, -R13-C (0) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; Where each R8 and R13 are independently a direct bond, an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; where each R9 is independently selected from the group consisting of hydrogen, optionally alkyl "substituted alkenyl optionally substituted alkynyl, optionally substituted cyclo-alkyl optionally substituted cieloalquilalquilo optionally substituted aryl, optionally substituted aralkyl optionally substituted heterocyclyl optionally substituted heterocyclylalkyl optionally substituted , optionally substituted heteroaryl and optionally substituted heteroaralkyl; or two R9, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; wherein each R14 is independently selected from the group tornado hydrogen, optionally substituted alkyl, alkenyl optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl optionally substituted heterocyclyl optionally substituted heterocyclylalkyl optionally substituted heteroaryl, optionally substituted and optionally substituted heteroaralkyl; or two R14s, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl; where each R10 and R15 is independently selected from the group consisting of alkyl optionally substituted alkyl, alkenyl optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted, aralkyl optionally substituted heterocyclyl optionally substituted heterocyclylalkyl optionally substituted, heteroaryl optionally substituted and optionally substituted heteroaralkyl; wherein each R 11 is independently selected from an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; as a single isomer, or a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or a polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

Another embodiment are compounds of the formula (II): wherein: R2 is cyano, halo, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted cycloalkyl optionally, substituted cicloalquiilalquilo optionally substituted aryl, optionally substituted aralkyl optionally substituted, "optionally substituted or heteroaralkyl optionally substituted heteroaryl; R3 is hydrogen or halo;. .R4 is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alqiinilo, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, heterocyclylalkyl opt. tively, substituted heterocyclyl optionally substituted, heteroaryl optionally substituted heteroaralkyl optionally substituted heteroaralkyl optionally substituted, -R8-OR9, -R8-SR9, -R8-S (0) R 10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, ~ R8-C (O) N (R9) 2, -R8-C (S) N (R9) ) 2, · -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8- S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), ~ R8-S ( 0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- 0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-0C (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R13-C (0) R9, -R8-C (0) -R ^ -C (S) R9, -R8-C (0) -Rai-C (NR9) R9, -R8-C (0) -R1] -C (0) OR9 , -R8-C (0) -Ru-C (S) OR9, -R8-C (0) -Rn-C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) ) 2, -R8-C (0) -Ru-C (S) N (R9) 2, -R8-C (0) -RX1-C (NR9) N (R9) 2, -R8-C (0) -R -C (0) SR9, -R8-C (0) -R1X-C (S) SR9 or -R8-C (0) -R11-C (NR9) SR9; R5 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; R6 is hydrogen; R7 is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13 ~ OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R1) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (MR14) R14, -R13- C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, -R13-C (S) N (R1) 2, -R13-C (NR14) N (R14) 2, -R13-C (0) SR1, -R13-C (S) SR1, -R13-C (NR14) SR14, -R13-S (0) t0R14 (do nde t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R1) 2, -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R13 -S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R1) C (NR14) N (R14) 2 (where t is 1 or 2) and -R13-N (R14) S (0) tR15 (where t is 1 or 2); wherein each R8 and R13 are independently a straight bond or an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, alkyl, optionally substituted, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the nitrogen to which they are attached, form an optionally substituted hearocyclyl; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and heteroaralkyl optionally substituted; or wherein two R14, together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl, wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl optionally substituted, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl, and wherein each R 11 is independently an optionally substituted straight or branched alkylene chain or a straight or branched alkenyl chain optionally substituted, as a single isomer, a mixture of isomers, or as a racemic mixture of isomers, or as a solvate or polymorphism, or as a prodrug, or as a pharmaceutically acceptable salt thereof.

Another embodiment of the invention are compounds of the formula (III): wherein: R1 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl -OR9, -SR9, -N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R4 is hydrogen; -C (0) R9 or -S (0) 2R9; or R4 is alkyl, alkenyl or alkynyl optionally substituted by one or more substituents selected from the group consisting of halo, haloalkoxy, nitro, -0R9, -SR9, -S (0) tR10 (where t is 1 or 2), -N ( R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) 0R9, -C (NR9) OR9, - C (0) N (R9) 2, -C (S) N (R) 2, -C (NR9) N (R9) 2, -C (O) SR9, -C (S) SR9, -C (NR9 ) SR9, -S (0) t0R9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9) C (0) OR10 , -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, - -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -0C (0) R10, -0C (NR9) R10, -0C (S) R10, -0C (0) 0R10, -0C ( NR9) OR10, -OC (S) OR10, -0C (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -0C (S) N (R9) 2 , -C (0) -R1X-C (0) R9, -C (0) -R -C (S) R9, -C (0) -Rn-C (NR9) R9, -C (0) -RX1 -C (0) OR9, -CÍOJ-R ^ -CÍSJOR9, -C (0) -R -C (NR9) OR9, -C (0) -R1X-C (0) N (R9) 2, -C (0) -R -C ( S) N (R9) 2, -C (0) -Ru-C (NR9) N (R9) 2, -C (0) -Rn-C (0) SR9, -CÍOJ-R ^ -CÍSJSR9 and -C (0) -RU-C (NR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, heteroaralkenyl optionally substituted, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0 ) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) ) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), | -R8-N (R9) C (0) R10, -R8 ~ N (R9) C (0) OR10, -R8 ~ N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8 ~ N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8- 0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-0C (S) OR10, -R8-OC (0) SR9 , -R8-OC (0) N (R9) 2, -R8 ~ OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R1: LC (0) R9, -R8-C (0) -R ^ -C (S) RS, -R8-C (0) -Rai-C (NR9) R9, -R8-C (0) -R12-C (0) OR9, - R 8 -C (0) -R -C (S) OR 9, -R 8 -C (0) -R -C (NR 9) OR 9, -R8-C (0) -Rn-C (0) N (R9) 2, -R8-C (0) -Rn-C (S) N (R9) 2, -R8-C (0) -Rai- C (NR9) N (R9) 2, -R8-C (O) -Rn-C (O) SR9, -R8-C (0) -R1X-C (S) SR9 and -R8-C (0) - R11-C (NR9) SR9; R5 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, C (0) R9 or -S (0) 2R9; R5 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R) 2 r -C (0) SR9, -C (S) SR9, -C (NR9) SR9, -S (0) t0R9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN ( R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N ( R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9) C (0) 0R10, -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N ( R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -0C (0) R10, -0C (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (O) -R11-C (O) R 9, -C (O) -R- (S) R9, -C (O) -Rn-C (NR9) R9, -C (O) -Rn-C (O) OR9, -C (0) -R -C (S) OR 9 -C (0) -R 11 -C (NR 9) OR 9, -C (O) -R -C (O) N (R 9) < R -C (0) -R11-C (S) N (R9) 2, -C (0) -R11-C (NR9) N (R9) 2, -C (O) -Ru-C (O) SR9, -C (0) -R11-C (S) SR9 and -C (O) -Ru-C (NR9) SR9; or R5 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy , nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, optionally substituted heteroaralguiloyl , optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) .OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, - R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N ( R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C ( 0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- 0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9 , -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -Ru C (0) R9, -R8-C (0) -R -C (S) R9, -R8-C (0) -R1X-C (NR9) R9, -R8-C (0) -RX1-C (0) OR9, -rR8 -C (0) -RX1-C (S) OR9, -R8-C (0) -R ^ - (NR9) OR9, -R8-C (0) -Rlx-C (0) N (R9) 2, '-R8-C (0) -R -C (S) N (R9) 2, -R8-C (0) -Rn -C (NR) N (R9) 2, -R8-C (0) -Ru-C (0) SR9, -R8-C (0) -R11-C (S) SR9 and -R8-C (0) -Rlx-C (NR9) SR9; R6 is hydrogen, alkyl or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalguyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -C, -C (0) R14, -C (S) R14, -C (NR14) R14, -C (0 ) 0R14, -C (S) 0R14, -C (NR14) OR14, -C (0) N (R 14) 2, -C (S) N (R 1) 2, -C (NR 14) N (R 14) 2, -C (0) SR 14, -C (S) SR 14, -C ( NR14) SR14, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R1) N (R14) ) 2 (where t is 1 or 2), -S (0) tN (R14) N = C (R14) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2) , ~ S (0) tN (R1) C (0) N (R1) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R14) C (0) OR15, -N (R1) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15, -N (R14) C (0) N (R14) 2, -N (R14) C (NR1) N (R14) 2, -N (R14) C (S) N (R14) 2, -N (R14) S (0) tR15 (where t is 1 or 2), -0C (0) R15, -0C (NR14) R15, -0C (S) R15, -0C (0) 0R15, -OC ( NR1) OR15, -0C (S) 0R15, -0C (0) SR14, -OC (0) N (R14) 2, -OC (NR14) N (R14) 2, -0C (S) N (R14) 2 , -C (0) -R16-C (0) R14, -C (0) -R16-C (S) R14, -C (0) -R16-C (NR14) R14, C (0) -Ri6- C (0) OR14, -C (0) -R16-C (S) OR14, -C (0) -R16-C (NR14) OR14, -C (0) -R16-C (0) N (R14) 2, -C (0 ) -R16-C (S) N (R14) 2r -C (0) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14, -C (0) -R16 -C (S) SR14 and -C (0) -R16-C (NR14) SR14; or R7. is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of alkyl, Alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, d'ioxo, cycloalkyl optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl optionally substituted, cycloalkenyl optionally substituted aryl, optionally substituted aralkyl optionally substituted aralkenyl optionally substituted heterocyclyl optionally substituted optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR1) OR1, -R13-C (O) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR1 ) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) tOR14 (where t is 1 or 2) , -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R 13-S (0) tN (R1) N (R1) 2 (where t is 1 or 2), -R13-S (O) tN (R14) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15, -R13-N (R14) C (0) R15, -R13-N (R14) C (0) OR15, -R13-N (R14) C (0) SR15,. -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R13- N (R1) C (S) N (R1) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-OC (0) R15, -R13-0C (NR14 ) R15, -R13-0C (S) R15, -R13-0C (0) 0R15, -R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-0C (0) SR14, -R13 -0C (0) N (R14) 2, -R13-OC (NR14) N (R1) 2, ~ R13-OC (S) N (R1) 2 -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (O) -R16-C (O) N (R14) 2, -R13 -C (0) -R16 ~ C (S) N (R14) 2, -R13-C (0) -R16C (NR1) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; wherein each R8 and R13 is independently a direct bond, an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; or wherein two R9, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl optionally substituted heteroaralkyl substituted; or wherein two R14, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; and wherein each R11 and R16 are independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenyl chain; as a single isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

Another embodiment of the invention are compounds formula (III): wherein: R1 is cyano, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; R3 is hydrogen or halo; R is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, - R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10,. -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2,. -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8-0C (NR9) R10, -R8-0C (S) R10, -R8 -0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-0C (NR9) N (R9) ) 2r -R8-OC (S) N (R9) 2; -R8 ~ C (0) -R -C (0) R14, -R8-C (0) -R11-C (S) R14, -R8-C (0) -R11-C (NR14) R14, -R8 -C (O) -Ria-C (0) OR14, -R8-C (0) -R ^ -C (S) OR14, -R8-C (0) -Ru-C (NR14) OR14, -R8-C (0) -R1: L-C (0) N (R14) 2, -R8-C (0) -R1X-C (S) N (R14) 2, -R8-C (0) -Rn-C (NR14) N (R14) 2, -R8-C (0) -Rn-C (0) SR14, -R8-C (0) -Rn-C (S) SR14 and -R8-C (0) -R -C (NR14) SR14; R5 is hydrogen, -C (0) R9 or -S, (0) 2R9; or R5 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, -0R9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (0) SR9, -C (S) SR9, - C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9) C (0) OR10, -N (R9) C (0) SR10, -N (R9) C (NR9 ) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2) ,. -0C (0) R10, -OC (NR9) R10, -OC (S) R10, -0C (0) OR10, -0C (NR9) OR10, -OC (S) OR10, -0C (0) SR9, - 0C (0) N (R9) 2, -0C (NR9) N (R9) 2, -0C (S) N (R9) 2,. -C (0) -Rn-C (0) R 9, -C (0) -RU-C (S) R 9, -C (0) -R -C (NR 9) R 9, -C (0) -R1X-C (0) 0R9, -C (0) -Rxl-C (S) 0R9, -C (0) -R ^ -C (NR9) OR9, -C (0) -R1: LC (0) N (R9) 2, -C (0) -R1: LC (S) N (R9) 2, -C (0) -R -C (NR9) N ( R9) 2, -C (0) -R -C (0) SR9, -C (0) -R1: LC (S) SR9 and -C (0) -Rlx-C (NR9) SR9; or R5 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted with a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, cycloalkyl optionally substituted, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally heteroaralkenyl substituted, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (Q) R9, -R8-C (S) R9, ~ R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t .es l 'or 2), - R8-S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, · -R8-N ( R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- OC (NR9) R10, -R8-0C (S) R10, -R8-0C (0) 0R10, -R8-OC (NR9) OR10, -R8-0C (S) 0R10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -Rn-C (0) R9, -R8-C (0) -R ^ - (S) R9, -R8 -C (0) -Rn-C (NR9) R9, -R8-C (0) -R1: LC (0) 0R9, -R8-C (0) -Ria-C (S) OR9, -R8-C (0) -R ^ -C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2, -R8-C (0) -RX1-C (S) N (R9) 2, -R8-C (O) -Ru-C (NR9) N (R9) 2, ~ R8-C (0) -R1: LC (0) SR9, -R8-C (0) -RX1-C (S) SR9 and -R8-C (0) -Rn-C (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), - N (R14) 2, -CN, -C (0) R14, -C (S) R14, -C (NR1) R14, -C (0) 0R14, -C (S) 0R14, -C (NR14) OR14 , -C (0) N (R1) 2, -C (S) N (R14) 2, -C (NR14) N (R14) 2, -C (0) SR14, -C (S) SR14, -C (NR14) SR14, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N ( R14) 2 (where t is 1 or 2), -S (0) tN (R1) N = C (R1) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2 ), -R8-S (0) tN (R1) C (0) N (R14) 2 (where t is 1 or 2), -R8-S (0) tN (R1) C (NR1) N (R1) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R14) C (0) OR15 , -N (R14) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15, -N (R14) C (0) N (R14) 2, - (R14) C (NR14) N (R14) 2r - (R14) C (S) N (R14) 2, -N (R1) S (0) tR15 (where t is 1 or 2), -0C (0) R15, -0C (NR14) R15, -0C (S) R15, -0C (0) 0R15, -0C ( NR14) OR15, -0C (S) 0R15, -0C (0) SR14, -OC (0) N (R14) 2, -OC (NR14) N (R1) 2, -0C (S) N (R14) 2 , -C (0) -R16-C (0) R14, -C (0) -R15-C (S) R14, -C (0) -R15-C (NR14) R14, -C (0) -R16 -C (0) OR14, -C (0) -R16-C (S) OR14, -C (0) -R16-C (NR1) OR14, -C (0) -R16-C (0) N (R14) 2, -C (O ) -R16-C (S) N (R14) 2, -C (0) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14, ~ C (0) - R16-C (S) SR14 and -C (0) -R16-C (NR14) SR14; R6 is hydrogen; R7 is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alginyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylguil, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, ~ R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0) 0R14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR14 ) N (R1) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) t0R14 (where t is 1 or 2) , -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13- S (0) tN (R14) N = C (R14) 2, ~ R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R13-S (0) tN ( R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R1) C (NR14) N (R1) 2 (where t is 1 or 2) and - R13-N (R14) S (0) tR15 (where t is 1 or 2); wherein each R8 and R13 are independently a straight bond or an optionally substituted straight or branched alguylene chain or an optionally substituted straight or branched alkenyl chain; wherein R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and heteroaralkyl optionally substituted; or wherein two R9, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; and wherein R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; or wherein two R14, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; wherein each R10 and R15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted and optionally substituted heteroaralkyl; Y wherein each R 11 is independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; as a single isomer, a - mixture of isomers or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.

Another embodiment of the invention are compounds of the formula (IV): wherein: R1 and R2 are each independently cyano, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; R32 is hydrogen or halo; R 4 is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, - R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, ~ R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (O) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) ) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), * -R8-0C (0) R10, -R8 -OC (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-0C (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R -C (0) R9, -R8-C (0) -R11-C (S) R9, -R8 -C (0) -R11-C (NR9) R9, -R8-C (0) -Rn-C (0) OR9, -R8-C (0) -Rn-C (S) OR9, -R8-C (0) -R11-C (NR9) OR9, -R8-C (0) -RX1-C (O) N (R9) 2l -R8-C (0) -Ru-C (S) N (R9) 2, -R8-C (0) -Ru-C (NR9) N (R9) 2, -R8-C (0) -R1X-C (0) SR9, -R8-C (0) -Ru-C (S) SR9 and -R8-C (0) -Rn-C (NR9) SR9; R6 is hydrogen; R7 is aryl or heteroaryl, wherein each is optionally substituted with one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (O) OR14, -R13-C (S) OR14, -R13-C (NR1) OR14, -R13-C (O) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR1 ) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) tOR14 (where t is 1 or 2) , -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R1) 2 (where t is 1 or 2), -R13- S (0) tN (R1) N = C (R1) 2, -R13-S (O) tN (R14) C (O) R15 (where t is 1 or 2), -R13-S (O) tN ( R14) C (O) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R1) C (NR14) N (R14) 2 (where t is 1 or 2) and -R13-N (R14) S (O) tR15 (where t is 1 or 2); wherein each R8 and R13 are independently a straight bond or an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted or optionally substituted heteroaralkyl; or wherein two R9, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or wherein two R, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; Wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally heteroaryl substituted or optionally substituted heteroaralkyl; Y Wherein each R 11 is independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; As a single isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. Another embodiment are compounds of the formulas (I) - (IV) wherein R4 is where: n is from 0 to 4; each R 18 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, cycloalkenyl optionally. substituted, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8- SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9 , -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9 ) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8-S (0) tN ( R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), ~ R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, ~ R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8-0C (NR9) R10, -R8-0C (S) R10, · ~ R8-0C (0) 0R10, '-R8-OC (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9, -R8-OC (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-0C (S) N (R9) 2, -R8-C (0) -RX1-C (0) R9, -R8-C (0) -Rn-C (S) R9, -R8-C (O) -R11-C (NR9) R9, -R8 -C (0) -R1X-C (0) OR9, -R8-C (0) -R11-C (S) OR9, -R8-C (0) -R1X-C (NR9) OR9, -R8-C (0) -R -C (0) N (R9) 2, -R8-C (0) -R1X-C (S) N (R9) 2, -R8-C (0) -R ^ -C (NR9) N (R9) 2r ~ 8-C (0) -R11-C (0) SR9, -R8-C (0) -RX1-C (S) SR9 and -R8-C (0) -R -C (NR9) SR9; R19 is halo, optionally substituted alkyl, optionally substituted alkenyl, haloalkoxy, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-C (0) R9, -R8-C (0) OR9 or -R8-C (0) N (R9) 2; Where each R8 is independently a direct bond, an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain; Where each R9 is independently selected from the group consisting of hydrogen, alkyl optionally substituted alkyl, alkenyl optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl optionally substituted heterocyclyl optionally substituted heterocyclylalkyl optionally substituted heteroaryl, optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; Wherein each R is independently selected from the group consisting of alkyl optionally substituted alkyl, alkenyl optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted, cicloalauilalquilo optionally substituted aryl, optionally substituted, aralkyl optionally substituted heterocyclyl optionally substituted heterocyclylalkyl optionally substituted, heteroaryl optionally substituted and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain.

Another embodiment are compounds of the formulas (I) - (IV) wherein R7 is where m is from 0 to 4; and R25 and R26 are each independently selected from the group consisting of halo, nitro, optionally substituted alkyl, alkenyl optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted, cycloalkenyl optionally substituted, cycloalkenyl optionally substituted, aryl optionally substituted, aralkyl optionally substituted aralkenyl optionally substituted heterocyclyl optionally substituted heterocyclylalkyl optionally substituted heterocyclyl optionally substituted heteroaryl, optionally substituted heteroaralkyl optionally, substituted heteroaralkyl optionally substituted, -R13-OR14, -R13-SR14, -R13-S (0) TR15 ( where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R1, - R 13 -C (0) OR 14, R 13 -C (S) OR 14, -R -C (NR) OR, -R -C (O) N (R) 2, -R 13 -C (S) N (R 14) 2, ~ R13-C (NR14) N (R14) 2, ~ R13 ~ C (0) SR14, -R13-C (S) SR14, -R13-C (NR1) SR14, -R13-S (0) t0R14 (where t is 1 or 2), -R13-S (0) tN (R1) 2 (where t is 1 or 2), - R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R1) 2, -R13 ~ S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13 -S (0) tN (R14) C (NR14) N (R1) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) C (0 ) OR15, -R13-N (R14) C (0) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R13- N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-0C (0) R15, -R13-OC (NR14 ) R15, -R13-0C (S) R15, -R13-0C (O) OR15, -R13-OC (NR1) OR15, -R13-OC (S) OR15, -R13-0C (0) SR14, -R13 -0C (0) N (R14) 2 / -R13-OC (NR1) N (R1) 2, -R13-OC (S) N (R1) 2, -R13-C (0) -R16-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R15-C (0) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (0) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; Where each R13 is independently a direct bond, an optionally substituted straight or branched alkylen chain or optionally straight or branched alkenylene chain substituted; Where each R14 is independently selected from the group consisting of hydrogen ,. optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or wherein two R14, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl; Where each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaralkyl heteroaryl optionally substituted; and wherein each R16 is independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain.

In another embodiment, the compounds for use in the compositions and methods provided are given in Table I.

C. EVALUATION OF THE ACTIVITY OF THE COMPOUNDS There are standard physiological, pharmacological and biochemical procedures to test the compounds to identify those that possess biological activities that selectively modulate the activity of spheroidal nuclear receptors. Such assays include, for example, biochemical assays such as binding assays, fluorescence polarization assays, coactivator recruitment assays based on fluorescence resonance energy transfer (FRET) (see generally Glickman et al., J. Biomolecular Screening, 1_ (1): 3-10 (2002)), as well as cell-based assays that include the co-transfection assay, the use of LBD-Gal 4 chimeras, and protein-protein interaction assays (see Lehmann, et al., J. Biol Chem., 272 (6): 3137-3140 (1997).

Commercially available high performance detection systems (see, for example, Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments Inc., Fullerton, CA; Precision Systems, Inc., Natick, MA) they allow these tests to be carried out in a high performance mode. These systems generally automate complete procedures, including pipetting the entire sample and reagent, liquid distribution, timed incubations, and final readings of the microplate in a detector (s) appropriate for the assay. These configurable systems provide high performance and fast startup as well as a high level of flexibility and customization. The manufacturers of these systems provide detailed protocols for different high performance systems. Thus, for example, Zymark Corp. provides technical bulletins describing detection systems for detecting the modulation of gene transcription, ligand binding and the like.

Assays that do not require washing or liquid separation steps are preferred for those high performance detection systems and include biochemical assays such as fluorescence polarization assays (see for example, Owicki, J., Biomol Screen 2000 Oct; (5): 297) scintillation proximity assays (SPA) (see for example, Carpenter et al., Methods Mol Biol 2002; 190: 31-49) and FRET-based or FRET-based coactivation recruitment assays solved at (Mukherjee et al., J Steroid Biochem Mol Biol 2002 Jul; 81 (3): 217-25; (Zhou et al., Mol Endocrinol, 1998 Oct; 12 (10): 1594-604). Assays may be performed using the full-length receptor or a fragment including the isolated LED.In the case of the mineralocorticoid receptor, a useful fragment comprises amino acids 671-984 of the full-length sequence.

If there is a ligand labeled in fluorescent form, the fluorescence polarization assays provide a way to detect the binding of the compounds to the nuclear receptor of interest by measuring changes in fluorescence polarization that occur as a result of the displacement of a trace amount of the ligand labeled, by the compound. In addition, the approach can also be used to monitor the ligand-dependent association of a coactivator peptide labeled fluorescently to the nuclear receptor of interest to detect binding of the ligand to the nuclear receptor of interest.

The ability of a compound to bind to a receptor, a heterodimeric carrier with RXR, can also be measured in a homogeneous assay format by determining the level at which the compound can compete with a radiolabelled ligand with a known affinity to the receptor using an assay proximity of scintillation (SPA). In this approach, the radioactivity emitted by the radio-labeled compound generates an optical signal when approached to a scintillator such as an account containing Ysi-copper, to which the nuclear receptor is attached. If the radiorotulated compound is displaced from the nuclear receptor the amount of light emitted from the nuclear receptor bound to the scintillator decreases, and this can be easily detected using standard microplate liquid scintillation plate readers such as, for example, a Wallac MicroBeta reader. .

The ability of a compound to effect an interaction dependent on the ligand of a coactivator peptide with a nuclear receptor can also be determined by fluorescence resonance energy transfer (FRET), or FRET resolved in , to characterize the activity of the agonist or antagonist of the compounds disclosed herein Both approaches depend on the fact that the transfer of energy from a donor molecule to an acceptor molecule occurs only when the donor and the acceptor are closely adjacent. this case consists of using a ligand binding domain fusion protein (LBD) of recombinant Guatatase-S-transferase (GST) nuclear receptor and synthetic biotinylated peptide in sequence derived from the domain that interacts with the receptor of a coactivator peptide such as the spheroid 1 receptor coactivator (SRC-1). Generally, the GST-LBD is labeled with a europium urate (donor) through an anti-GST antibody labeled with europium, and the coactivator peptide is labeled with allophycocyanin via a streptavidin-biotin ligation. . »In the presence of an agonist for the nuclear receptor, the peptide is recruited to the GST-LBD approaching europium and allophicocyanin very close to allow the transfer of energy from the europium chelate to the allophycocyanin. By exciting the complex with light at 340 nm the energy of the. Excitation absorbed by the europium chelate is transmitted to the allophicocyanin group which results in the emission at 665 nm. If the europium chelate does not approach the allophycocyanin group there is little or no energy transfer and the excitation of the europium chelate results in emission at 615 nm. Therefore, the intensity of the light emitted at 665 gives an indication of the resistance of the protein-protein interaction. The activity of a nuclear receptor antagonist can be measured by determining the ability of a compound to competitively inhibit (ie, IC5o) the activity of an agonist for the nuclear receptor.

In addition, a variety of cell-based assay methodologies can be successfully used in screening assays to identify and profile the specificity of the compounds of the present invention. These approaches include transfection assays, translocation assays, complementation assays and the use of genetic activation technologies to overexpress endogenous nuclear receptors.

The basic co-transfection assay is based on the co-transfection into the cell of an expression plasmid to produce the nuclear receptor of interest in the cell with a reporter plasmid comprising a reporter gene whose expression is under the control of an element of hormone response that is capable of interacting with the nuclear receptor. (See, for example, U.S. Patent Nos. 5,071,773, 5,298,429, 6,416,957, WO 00/76523). The treatment of cells transfected with an agonist for the nuclear receptor increases the transcriptional activity of that receptor which is reflected by an increase in the expression of the reporter gene, which can be measured by a variety of standard procedures.

In one embodiment of this method, the host cell endogenously expresses the nuclear receptor and appropriate co-factors or heterodimeric partners. Generally, that situation can occur with a primary cell or cell lines derived directly from a primary cell type, used to characterize compounds of the present invention. Accordingly, the creation of the assay system requires only transfection into the cell of a reporter gene (s) described herein.

A cell line that endogenously expresses MR includes, for example, the mouse collecting duct cell line described in Am. J. Physiol. Endocrinol Metab. 279 E386-E394 (2000). Alternatively, the expression of endogenous genes (detected through RT-PCR) can be used to monitor the transcription activity of MR in response to the addition of a test compound.

In another aspect, the host cell may not have sufficient endogenous expression of a suitable nuclear receptor, in which case one may be introduced by transfecting the cell line with an expression plasmid, as described below. Generally, the expression plasmid comprises: (1) a promoter, such as an SV40 early region promoter, the HSV tk promoter or the phosphoglycerate kinase (pgk) promoter, CMV promoter, Sra promoter, or other elements of suitable controls known in the art, (2) a cloned polynucleotide sequence, such as a cDNA encoding a receptor, co-factor, or a fragment thereof, linked to the promoter in the sense orientation so that transcription from the promoter produces an RNA that encodes a functional protein, and (3) a polyadenylation sequence. As an example that should not be interpreted as restrictive, an expression cassette of the invention may comprise the cDNA expression cloning vectors, or other known preferred expression vectors and which exist commercially from vectors such as an invitrogen, (CA ), Stratagene, (CA) or Clontech, (CA). Alternatively, expression vectors developed by academic groups such as the pCMX vectors originally developed in the Evans laboratory may also be used (Illey et al., Genes. &Development (1995) 9: 1033-1045). The transcriptional regulatory sequences in an expression cassette are selected by the practitioner based on the desired application, depending on the specific use, the transcription regulation may employ a type of promoter or "control sequence inducible, repressible, constitutive, specific to the type of cell, specific to the stage of development, specific to sex or other desired type.

Alternatively, the expression plasmid may comprise an activation sequence to activate or increase the expression of an endogenous chromosomal sequence. These activation sequences include for example, a synthetic zinc indicator motif (e.g., see U.S. Patent Nos. 6,534,261 and 6,503,7171) or a resistant promoter or enhancer sequence together with a targeting sequence to allow recombination homologous or non-homologous of the activating sequence above the gene of interest.

In one aspect of these methods, chimeras are used in place of the full-length nuclear receptor. These chimeras generally comprise the ligand-binding domain and the hinge region of the nuclear receptor bound to the heterologous DNA binding domain (DBD).

Generally for those chimeric constructs, heterologous DNA binding domains of distinguishable well-defined nuclear receptors are used, or alternatively the DNA binding domains of yeast transcriptional regulators or obtained bacterially such as members of the GAL 4 and superfamilies can be used. Lex A (access number of GenBan ILEC) / ümud.

GAL4 (GenBank Accession Number P04386) is a positive regulator for the expression of genes induced by galactose (see for example, Keegan et al, Science 231: 699-704 (1986)). Preferably, the first 96 amino acids of the Gal4 protein are used, more preferably the first 147 amino acid residues of the yeast Gal4 protein. For those receptors that can function as heterodimers with RXR, the method generally includes the use of expression plasmids for both the nuclear receptor of interest and for RXR. These sequences include, but are not limited to, the following members of the RXR gene family, including RXRoc (GenBank Access No. NM_002957), RXR (GenBank Access No. XM_042579) and RXRy (GenBank Access No. XM_053680). .

To identify compounds that act to modulate the cofactor, or heterodimerization of the nuclear receptor, a two-hybrid mammalian assay can be used (see for example U.S. Patent Nos. 5,667,973, 5,283,173 and 5,468,614). This approach identifies protein-protein interactions in vivo through the reconstitution of a resistant transcriptional activator when the interaction of two proteins, one "bait" and "prey" (Fields S and Song O (1989) Nature 340: 245; Willey et al., (1995) Gene &Development 9 1033-1045). The system depends on the functional dimeric interactions between the two fusion proteins, one that transports the fusion of the GAL4 DNA binding domain with the ability to bind to the reporter gene containing GAL4UAS- The other translates the fusion of the transactivation domain of VP16. When expressed together, DNA binding and transcriptional activation is reconstituted into a single complex. The functional interaction, for example between a GAL-SRC-1 fusion protein and the VP16-VDR fusion protein, must result in the constitutive activation of a suitable reporter plasmid, that luciferase reporter construct comprising GAL4 above the Activating Sequences (UAS).

These reporter plasmids can be constructed using standard molecular biological techniques by placing cDNA encoding the reporter gene under a suitable minimum promoter. For example, luciferase reporter plasmids can be constructed by placing the cDNA encoding luciferase (generally with the small intron of SV40 and poly-A tail (de Wet et al., (1987) Mol. Cell. Biol. -735) under the herpes virus thymidine kinase promoter (located at nucleotide residues -105 to +511 of the thymidine kinase nucleotide sequence, pBLCAT2 (Lucko &Schutz (1987) Nucí. Acid. Res.l_5 5490-5494)) that in turn binds to the appropriate response elements.

The transactivation domains are known in the art and can be easily identified by the expert. Examples include the activation domain of GAL4, TAT, VP16 and analogs thereof.

The response elements (RE) are known and have been fully described in the art. These response elements may include direct repeat structures or inverted repeat structures based on defined hexrad media sites, which are described in more detail below. Examples of hormone response elements are composed of at least one direct repeat of two or more half sites, separated by a spacer having in the range of 0 to 6 nucleotides. The spacer nucleotides can be selected randomly from any one of A, C, G or T. Each half site of response elements contemplated for use in the practice of the invention comprises the sequence: -RGBNNM-, wherein R is select from A or G; B is selected from G, C or T; each N is independently selected from A, T, C, or G; and M is selected from A or C; with the proviso that at least 4 nucleotides of said sequence -RGBNNM- are identical to the nucleotides in the corresponding positions of the sequence -AGGTCA-. The response elements used to profile the compounds of the present invention may optionally be preceded by N, wherein x is in the range of 0 to 5. Preferred response elements useful in the methods of the present invention include response elements of hormones such as the Glucocorticoid response element (GRE), for example the one found in the MMTV LTR.

The choice of the hormone response element depends on the type of assay used. In the case where a cell line that endogenously expresses a steroid receptor is used, a known steroid RE is generally used. In the case of a fusion of ~ MR-LED-Gal4, a GAL4 UAS will be used. Generally the GAL4 UAS would comprise the sequence 5 'CGGRNNRCYNYNCNCCG-3', where Y = C or T, R = A or G, and N = A, C, T or G, and would be present as a tandem repeat of 4 copies.

Numerous reporter gene systems are known in the art and include, for example, alkaline phosphatase (see, Berger, J., et al., Gene (1988), Vol. 66, pp. 1-10; and ain, SR, Methods, Mol. Biol. (1997), Vol. 63, pp. 49-60), β-galactosidase (see U.S. Patent No. 5,070,012, issued Dec. 3, 1991, by Nolan et al., And Bronstein , I., et al., J. Chemilum, Biolum. (1989), Vol.4, pp. 99-111), chloramphenicol acetyltransferase (see Gorman et al., Mol Cell Biol. (1982), Vol. 2 , pp. 1044-51), ß-glucuronidase, peroxidase, ß-lactamase (U.S. Patent Nos. 5,741,657 and 5,955,604), catalytic antibodies, luciferases (U.S. Patents 5,221,623; 5,683,888; 5,674,713; 5,650,289 and 5,843,746) and natural fluorescent proteins (Tsien, RY, Annu, Rev. Biochem. (1998), Vol. 67, pp. 509-44).

Numerous methods of co-transfection of expression plasmids and reporters are known to those skilled in the art and can be used for the co-transfection assay to introduce the plasmids into a suitable cell type.

Any compound that is a candidate for the modulation of the activity of a nuclear steroid receptor can be tested by these methods. Generally, the compounds are tested at various different concentrations to optimize the chances that the modulation of receptor activity will be detected and recognized if present. Generally the tests are performed in triplicate or quadruplicate and vary within the experimental error by less than 15%. Each experiment is usually repeated three or more times with similar results.

The activity of the reporter gene can be conveniently normalized to the internal control and the data is plotted as the activation in relation to the untreated cells. A positive control compound (agonist) can be included together with DMSO as high and low controls for the normalization of the test data. Similarly, the activity of the antagonist can be measured by determining the ability of a compound to competitively inhibit the activity of an agonist.

In addition, the compounds and compositions can be evaluated for their ability to increase or decrease the expression of genes known to be modulated by a nuclear steroid receptor and other nuclear receptors in vivo, using Northern blot analysis, RT PCR or oligonucleotide microgroups to analyze RNA levels. Western blot analysis can be used to measure the expression of proteins encoded by mineralocorticoid receptor target genes. Genes that are known or suspected to be regulated by the mineralocorticoid receptor, for example, include: sgk (serum-regulated kinase and glucocorticoid (NM_005627)), Na / K ATPase, a?,?,? Subunits, ENaCalpha (channel of epithelial Na (NM_001038)), GILZ (glucocorticoid-induced leucine zipper (BC 061979)), and NDRG2, (gene regulated below N-myc 2 (NM_016250)).

There are established animal models and they can be used to further profile and characterize the claimed compounds. These model systems for MR include the agawa bioassay of urinary electrolytes (Bhargava et al., Endocrinology 142 (4): 1587-94, (2001)), the Goldblatt model (Nicoletti et al., Hypertension 26 (1) : 101-11, (1995)), the model of cardiac fibrosis described in Ramires et al., (J. Mol. Cell, Cardiol.Mar; 30 (3): 475-83, (1998)), the vascular lesion. renal disease in hypertensive rats prone to the attack drinking SHRSP saline solution described in Rocha et al., (Hypertension 33 (1 Pt 2): 232-7, (1999)), and the rodent model of myocardial necrosis and renal arteriopathy described in Rocha et al., (Endocrinology Oct; 141 (10): 3871-8 (2000)).

D. METHODS OF USE OF COMPOUNDS AND COMPOSITIONS Also provided herein are methods of using the disclosed compounds and compositions for local or systemic treatment or prophylaxis of human and veterinary diseases, disorders and conditions mediated by or otherwise affected by one or more spheroidal nuclear receptors, or in which is involved in the activity of the spheroidal nuclear receptor, including but not limited to: (a) Diseases or disorders associated with an excess or a lack of spheroid receptor ligands, or spheroid receptor activity, including, for example, Alzheimer's disease, Cushing's syndrome, Crohn's syndrome, Turner syndrome, hormone replacement therapies, menopause, hypogonadism, somatopause, andropause, and viropause; (b) Diseases or disorders related to cancer, including cancers that depend on hormones such as breast cancer (US Patent No. 6,306,832), prostate cancer (US Patent No. 5,656,651), benign prostatic hyperplasia (U.S. Patent No. 5,656,651), ovarian cancer, endometrial cancer (U.S. Patent No. 6,593,322), leukemia (U.S. Patent No. 6,696,459), and lymphoma (U.S. Patent No. 6,667,299); '(c) Diseases or disorders related to infertility including endometriosis, control of menstruation, dysfunctional uterine bleeding, dysmenorrhea, endometriosis, meningiomas, leiomiornas (uterine fibroids), induction of labor (US Patent No. 6,358. 947, U.S. Patent No. 5,943,933) and as modulators of male and female fertility (e.g., as contraceptives or antigestational agents); (d) Diseases or disorders related to metabolic syndromes including Syndrome X, hyperglycemia, insulin insensitivity, diabetes, obesity, storage or distribution of fat, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, dyslipidemia, hyperinsulinemia, atherosclerosis and hyperuricemia (patent U.S. Patent No. 6,699,893, U.S. Patent No. 6,680,310, U.S. Patent No. 6,593,480, U.S. Patent Application No. 2003/0028910); (e) Diseases or disorders related to bone or cartilage dysfunction, including osteoporosis, weakness, decreased bone density and hypercalcemia (U.S. Patent No. 6,686,351, U.S. Patent No. 6,660,468, U.S. Patent Application No. 2002/0187953); (f) Inflammatory diseases or disorders related to immune dysfunction, including: immunodeficiency, immunomodulation, autoimmune diseases, tissue rejection, wound healing, allergies, inflammatory bowel disease, Lupus Erythematosis, arthritis, osteoarthritis, rheumatoid arthritis, asthma and rhinitis (U.S. Patent No. 6,699,893, U.S. Patent No. 6,380,223, U.S. Patent No. 6,716,829); (g) Disease or disorders related to cognitive dysfunction, including psychosis, cognitive disorder, mood disorder, anxiety disorder, personality disorder and Parkinson's disease and Alzheimer's disease (U.S. Patent 6,620,802, U.S. Patent No. 6,734) .211); (h) Diseases or disorders related to high blood pressure, including fluid retention, edema, cardiovascular disease and hypertension (U.S. Patent No. 6,608,047); (i) Diseases or disorders related to cardiac disease, including, for example, ischemic heart disease, heart failure, systolic deterioration, diastolic deterioration, myocardial necrosis, pulmonary venous congestion, atrial fibrillation, myocardial infarction, myocardial fibrosis- and chronic heart failure (U.S. Patent No. 6,716,829, U.S. Patent No. 6,391,867); (j) Diseases or disorders related to kidney disease, including diabetic nephropathy, chronic glomerulonephritis, polycystic kidney disease, non-diabetic nephropathy, and chronic kidney disease (U.S. Patent No. 6,716,829, U.S. Patent No. 6,391,867); (k) Diseases or disorders related to fibrosis (U.S. Patent No. 6,716,829, U.S. Patent No. 6,391,867); (1) Diseases or disorders releacted with epidermal dysfunction including, for example, acne, hirsutism, alopecia and skin atrophy; (m) diseases or disorders related to muscle wasting including, for example, low muscle mass, muscle weakness, poor ratio of muscle mass to fat.

Also provided are methods of using the compounds and compositions disclosed for contraception, methods of regulating hair growth, methods of regulating muscle mass, methods of inducing weight loss, methods of regulating deposition or distribution, methods of stimulation of metabolic rate, methods of altering the relationship of muscle mass to fat, methods of regulating the development and growth of epidermal tissue, methods of regulating cognitive function, methods of regulating electrolyte balance, methods of regulating blood pressure and methods of regulating immune function.

In one embodiment, those compounds or compositions exhibit selective agonist activity for at least one nuclear steroid receptor, in one of the in vitro assays described herein. In one embodiment the nuclear steroid receptor is MR. In another embodiment the nuclear steroid receptor is AR. In another embodiment the nuclear steroid receptor is PR. In another embodiment the nuclear steroid receptor is GR. In another embodiment the nuclear steroid receptor is ER. In another embodiment the nuclear steroid receptor is an ERR.

In another embodiment, those compounds or compositions exhibit selective partial agonist activity for at least one nuclear steroid receptor, in one of the in vitro assays described herein. In one embodiment the nuclear steroid receptor is MR. In another embodiment the nuclear steroid receptor is AR. In another embodiment the nuclear steroid receptor is PR. In another embodiment the nuclear steroid receptor is GR. In another embodiment the nuclear steroid receptor is PR. In another embodiment the nuclear steroid receptor is GR. In another embodiment the nuclear steroid receptor is ER. In another embodiment the nuclear steroid receptor is an ERR.

In another embodiment, those compounds or compositions exhibit selective partial antagonistic activity for at least one nuclear steroid receptor, in one of the in vitro assays described herein. In one embodiment the nuclear steroid receptor is MR. In another embodiment the nuclear steroid receptor is AR. In another embodiment the nuclear steroid receptor is PR. In another embodiment the nuclear steroid receptor is GR. In another embodiment the nuclear steroid receptor is ER. In another embodiment the nuclear steroid receptor is an ERR.

In another embodiment, those compounds or compositions exhibit selective antagonistic activity for at least one nuclear steroid receptor, in one of the in vitro assays described herein. In one embodiment the nuclear steroid receptor is MR. In another embodiment the nuclear steroid receptor is AR. In another embodiment the nuclear steroid receptor is GR. In another embodiment the nuclear steroid receptor is PR. In another embodiment the nuclear steroid receptor is ER. In another embodiment the nuclear steroid receptor is an ERR.

Those skilled in the art will understand that while the compounds, isomers, prodrugs and pharmaceutically acceptable derivatives thereof of the present invention are generally employed as agonists, partial agonists, partial antagonists or selective antagonists, there may be instances in which a compound with a profile of a mixed steroid nuclear receptor. In another embodiment, those compounds or compositions modulate at least two spheroidal nuclear receptors, in one of the in vitro assays described herein. In one aspect, the two steroid receptors are MR and at least one other nuclear receptor is selected from the group consisting of AR, PR, GR, ER and ERR. In another aspect those compounds or compositions modulate any combination of the two nuclear receptors selected from AR, PR, GR, ER and ERR.

Also provided herein are methods of using the disclosed compositions and compositions, or pharmaceutically acceptable derivatives thereof., for the local or systemic treatment or the prophylaxis of diseases, disorders or human and veterinary conditions modulated or otherwise affected by MR, or in which MR activity is involved. In one embodiment, those disorders and conditions include, for example, diseases associated with an excess or a lack of MR or mineralocorticoid activity in the body, heart disease, fibrosis, metabolic syndromes, cognitive dysfunction, kidney disease and elevated blood pressure.

Also provided herein are methods of using the disclosed compounds or compositions for the local or systemic treatment or prophylaxis of human or veterinary diseases, disorders or conditions modulated or otherwise affected by the PR, or in which the activity is involved. of the PR. In one embodiment, those disorders and conditions include, for example, diseases associated with an excess or a lack of activity of the PR or progestins in the body, infertility, cognitive dysfunction and cancers.

Also provided herein are methods of using the disclosed compounds or compositions for local or systemic treatment or prophylaxis of human or veterinary diseases, disorders or conditions modulated or otherwise affected by the RA, or in which the activity is involved. of the AR. In one embodiment those disorders and conditions include, for example, diseases associated with an · excess or a lack of activity of the AR or androgens in the body, heart disease, cognitive dysfunction, kidney disease, cancers, anemia, epidermal dysfunction, constipation, eyes dry, periodontal disease, immune dysfunction, bone or cartilage dysfunction, low muscle mass and metabolic syndromes.

Also provided herein are methods of using the disclosed copounds or compositions for local or systemic treatment or prophylaxis of human or veterinary diseases, disorders or conditions modulated or otherwise affected by the ER, or in which the activity is involved. of the ER. In one embodiment those disorders and conditions include, for example, diseases associated with an excess or a lack of activity of the ER or estrogens in the body, bone or cartilage dysfunction, infertility, epidermal dysfunction, metabolic syndromes, cancers, heart disease and cognitive dysfunction.

Also provided herein are methods of using the disclosed copounds or compositions for local or systemic treatment or prophylaxis of human or veterinary diseases, disorders or conditions modulated or otherwise affected by the GR, or in which the activity is involved. of the GR. In one embodiment those disorders and conditions include, for example, diseases associated with an excess or a lack of activity of the GR or glucocorticoids in the body, metabolic syndromes, hypertension, cognitive dysfunction, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency (AIDS), bone or cartilage dysfunction, immune dysfunction, postsurgical bone fracture, low muscle mass and prevention of muscle weakness.

Also provided herein are methods of using the disclosed copounds or compositions for local or systemic treatment or prophylaxis of human or veterinary diseases, disorders or conditions modulated or otherwise affected by the ERR, or in which the ERR activity. In one embodiment those disorders and conditions include, for example, diseases associated with an excess or a lack of ERR activity in the body, bone and cartilage dysfunction, metabolic syndromes, cancers, infertility, cognitive dysfunction, and epidermal dysfunction.

E. COMBINATION THERAPY Further, those skilled in the art will understand that the compounds, isomers, prodrugs and pharmaceutically acceptable derivatives thereof of the present invention, including pharmaceutical compositions and formulations containing these compounds, can be used in a wide variety of combination therapies to treat the conditions and diseases described herein. Therefore, the use of compounds, isomers, prodrugs and pharmaceutically acceptable derivatives of the present invention in combination with other active pharmaceutical agents for the treatment of the diseases / conditions described herein is also contemplated herein.

Also contemplated herein are combination therapies using one or more compounds or compositions provided herein., or pharmaceutically acceptable derivatives thereof, combined with one or more of the following: ACE inhibitors, angiotensin II blockers, anticoagulants, anticancer agents, antiarrhythmics, anti-inflammatory agents, beta-blockers, calcium channel blockers, lipid modulating agents , cytokine antagonists, digital medicines, diuretics, endothelin blockers, vasodilators, immunosuppressants and glucose-lowering agents.

The compound or composition provided herein or a pharmaceutically acceptable derivative thereof, may be administered simultaneously, before or after the administration of one or more of the preceding agents.

Also provided are pharmaceutical compositions containing a compound provided herein or a pharmaceutically acceptable derivative thereof and one or more of the preceding agents.

A combination therapy is also provided that addresses the undesirable side effects of spheroid treatment. These side effects include, but are not limited to, metabolic effects, weight gain, muscle wasting, disqualification of the skeleton, osteoporosis, thinning of the skin and thinning of the skeleton. However, according to the present invention, the compounds or compositions disclosed herein, or pharmaceutically acceptable derivatives thereof can be used in combination with spheroid receptor agonists to block some of these side effects, without inhibiting the efficacy of the treatment. .

Also provided is a combination therapy that treats or prevents the onset of symptoms, or associated complications of cancer and related diseases and disorders comprising administration to a subject in need thereof, of one or more compounds or compositions disclosed herein, or pharmaceutically acceptable derivatives thereof, with one or more anticancer agents.

A combination therapy is also provided that treats or prevents the onset of symptoms, or associated complications of infertility, and related diseases and disorders, comprising administration to a subject in need thereof, of one or more compounds or compositions disclosed in present, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents, estrogen antagonists, and progesterone agonists.

A combination therapy is also provided that treats or prevents the onset of symptoms, or associated complications of metabolic syndromes and related diseases and disorders, comprising administration to a subject in need thereof, of one of the compounds or compositions disclosed in the present, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents, which are selected from the group formed phenylpropanolamine, phentermine, diethylpropion, mazindol, fenfluramine, dexfenfluramine, fentiramine, ß3 adrenoceptor agonist agents; sibutramine, gastrointestinal lipase inhibitors (such as orlistat), leptin, a glucose-lowering agent and lipid-modulating agent.

A combination therapy is also provided that treats or prevents the onset of symptoms, or associated complications of bone or cartilage dysfunction, and related diseases and disorders, comprising administration to a subject in need thereof, of one of the compounds or compositions disclosed herein, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents selected from the group consisting of immunosuppressants and anti-inflammatory agents.

Also provided is a combination therapy that treats or prevents the onset of symptoms, or associated complications of immune dysfunction, and related diseases and disorders, comprising administration to a subject in need thereof, of one of the disclosed compounds or compositions. herein, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents selected from the group consisting of anti-inflammatory, immunosuppressive and cytokine antagonists.

Also provided is a combination therapy that treats or prevents the onset of symptoms, or associated complications of cognitive dysfunction, and related diseases and disorders, comprising administration to a subject in need thereof, of one of the disclosed compounds or compositions. in the present, or pharmaceutically acceptable derivatives thereof, with an antidepressant.

A combination therapy is also provided that treats or prevents the onset of symptoms, or associated complications of elevated blood pressure, and related diseases and disorders, comprising administration to a subject in need thereof, of one of the compounds or compositions disclosed herein, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents selected from the group consisting of ACE inhibitors, angiotensin II blockers, anticoagulants, antiarrhythmics, beta-blockers, calcium channel blockers, agents modulators of lipids, antagonists. of cytokine, digital medicines, diuretics, endothelin blockers and vasodilators.

· A combination therapy is also provided that treats or prevents the onset of symptoms, or associated complications of heart disease and related diseases and disorders, comprising administration to a subject in need thereof, of one of the disclosed compounds or compositions. herein, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents' selected from the group consisting of AGE inhibitors, angiotensin II blockers, anticoagulants, antiarrhythmics, beta blockers, calcium channel blockers, modulating agents of lipids, cytokine antagonists, digital medicines, diuretics, endothelin blockers and vasodilators.

A combination therapy is also provided that treats or prevents the onset of symptoms, or associated complications of kidney disease, and related diseases and disorders, comprising administration to a subject in need of one of the compounds or compositions. disclosed herein, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents selected from the group consisting of AGE inhibitors, angiotensin II blockers, beta blockers, cytokine antagonists, glucose reducing agents, and erythropoietin .

Also provided is a combination therapy that treats or prevents the onset of symptoms, or associated complications of fibrosis, and related diseases and disorders, comprising administration to a subject in need thereof, of one of the disclosed compounds or compositions. herein, or pharmaceutically acceptable derivatives thereof, with one or more of the following active agents selected from the group consisting of ACE inhibitors, cytokine antagonists, xnmunosuppressants and anti-inflammatory agents.

Also provided is a combination therapy that treats or prevents the onset of symptoms, or associated complications of epidermal dysfunction, and related diseases and disorders, comprising administration to a subject in need thereof, of one of the disclosed compounds or compositions. in the present, or pharmaceutically acceptable derivatives thereof, with one or more of the following a lipid modulating agent, an antibiotic or an anti-inflammatory agent.

F. PREPARATION OF THE COMPOUNDS OF THE INVENTION The starting materials in the synthesis examples provided herein are available from commercial sources or through literature procedures (eg, March Advanced Organic Chemistry: Reactions, Mechanisms and Structure , (1992) 4th Ed.; Wíley Interscience, New York) All commercially available compounds were used without further purification unless otherwise indicated.In all the indicated experiments CDCI3 (99.8% D, Cambridge Isotope Laboratories) Nuclear magnetic resonance (NR) spectra of Protons (½) were recorded on a Bruker Avance 400 MHz NMR spectrometer Significant peaks were tabulated and generally include: number of protons and multiplicity (s, singlet, d, doublet, t, triplet, m, multiplet, br s, wide singlet.) Chemical shifts are reported as parts per million (5) relative to tetramethylsilane Low-resolution mass spectra (MS) were obtained as electrospray ionisation mass spectra (ESI), which are recorded on Perkin-Elmer SCIEX HPLC / MS instrument using inverted phase conditions (acetonitrile / water, 0.05% trifluoroacetic acid). Rapid chromatography was performed using Merck Silica Gel 60 (230-400 mesh) following the standard protocol (Still et al (1978) J. Org. Chem. 43: 2923). It is understood that in the following description, combinations of substituents and / or variables of the formulas shown are permissible only if those combinations derive into stable compounds under standard conditions.

Those skilled in the art will also appreciate that in the process described below the functional groups of intermediates may need to be protected by suitable protecting groups. Those functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkysilyl (for example, t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C (0) -R (where R is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like. Suitable protecting groups for the carboxylic acid include alkyl, aryl or aralkyl esters; The protecting groups can be added or removed according to standard techniques, which are known to those skilled in the art and which are described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1991), 2nd Ed., Iley-Interscience. An expert in the art can easily determine which options for each substituent are possible for the reaction conditions of each Scheme. Moreover, the substituents are selected from components indicated in the specification to this point, and can be attached to the starting materials, intermediates, and / or final products according to the schemes known to those skilled in the art.

It will also be apparent that many of the products may exist as one or more isomers, ie E / Z isomers, enantiomers and / or diastereomers. The compounds of the formula (I) can be prepared as depicted in Scheme 1. In general acylation of a primary or secondary amine, R6R7NH, with a pyrrole-3-carbohydric acid chloride under basic conditions and with heating can give a pyrrole amide of the formula (I). For example, a primary heteroaryl amine can be acylated with this acid chloride to give the corresponding amide (I), wherein R6 is hydrogen and R7 is heteroaryl.

Scheme 1. General synthesis of the compounds of the formula (I) Moreover, a substituted aniline, such as [(R26) (R25) raPhN (R6) H], can react with a pyrrole-3-carboxylic acid chloride in a manner described above to give the corresponding pyrrole product of the formula ( Ib), equivalent to formula (I) wherein R7 is a substituted phenyl.

The compounds of the formula (Ib) and the analogous compounds of the formula (I) wherein R7 is a substituted aryl or heteroaryl can also be synthesized under other conditions shown in Scheme 2.

Scheme 2. Preparation of compounds of the formula (Ib) of pyrrole-3-carboxylic acid under basic conditions to give the corresponding carboxamide. This intermediate amide can then be reacted with an aryl bromide (or heteroaryl) (chloride, bromide, triflate or tosylate) such as, for example, substituted bromobenzene under conditions mediated by copper or palladium to give the corresponding product of the formula (Ib) , equivalent to formula (I) wherein R7 is substituted phenyl. The synthetic methodology can be adapted from one of the general and highly robust conditions for the amidations catalyzed by a transition metal that have been reported in Buchwald (J. Am. Chem. Soc. 2002, 124, 7421-7428; Org. Lett., 2000, 2, 1101-1104).

In general, a chloride of pyrrole-3-carboxylic acid can be prepared as depicted in Scheme 3.

Scheme 3. General synthesis of a pyrrole-3-carboxylic acid chloride A haloketone (X = halo) can react with a β-ketoester under basic conditions such as, for example, sodium hydride in THF, to give the corresponding 1,4-diketone. This intermediate diketone can be condensed with a primary amine (R4NH2) such as, for example, where R 4 is aryl or heteroaryl, under acidic conditions and with heating to give the respective pyrrole-3-carboxylic acid ester. This intermediate ester can then be converted to its corresponding acid chloride under typical conditions such as, for example, first by hydrolysis with 2N NaOH in methanol and then by treatment with oxalyl chloride in DCM. Similarly, other types of primary amines such as, for example, benzyl amines (aralkyl) can be used in the sequence of the reaction to provide the corresponding pyrrole intermediates wherein R4 is benzyl.Other pyrrole-3-carboxylic acid chlorides, such as those wherein R1 = R2 and R3 = H, can be synthesized as shown in Scheme 4.

Scheme 4. Preparation of other chlorides of pyrrole-3-carboxylic acid e.g. where R = R2 Therefore, a primary amine (R4NH2) and a symmetric 1,4-diketone can be condensed under the conditions of Paal-Knorr to give the corresponding 5, 5-disubstituted pyrrole, which can be converted to its pyrrole-3-carboxaldehyde in typical conditions such as, for example, the Vilsmeier-Haack formulation. This intermediate aldehyde can then be oxidized to the corresponding carboxylic acid under conditions such as, for example, aqueous KMn0, in acetone. Then, the intermediate acid can be converted to its corresponding acid chloride under typical conditions.

The products of the formula (I) wherein R1 is N¾, equivalent to 2-aminopyrroles (Ic), can be prepared as depicted in Scheme 5. This reaction sequence has been described in the prior literature (WO 03/027069 ). First, the alkylation of a cyanoacetamide such as, for example, wherein R7 is substituted phenyl, with a bromoketone in the presence of a base, for example NaOMe in methanol, can give the corresponding intermediate diketone. A mixture of the diketone and a primary amine, R 4 NH 2, can be heated under acidic conditions to give the 2-aminopyrrole product of the formula (Ic).

Scheme 5. Preparation of compounds of the formula (Ic) (Ic) 2-amynopyrrole (Ic) can subsequently be converted into other products, some of whose sample reactions are represented in Scheme 6.

Scheme 6. Representative compounds derived from 2-aminopyrroles (Ic) For example, treatment with an electrophile such as an acid chloride or isocyanate under basic conditions can give the corresponding amide or urea, respectively. Alternatively, diazotization of 2-aminopyrrole can provide the diazonium salt, which can be converted to its 2-halopyrrole or 2-cyanopyrrole under Sandmeyer conditions. Subsequently, the 2-halopyrrole can pass through other reactions catalyzed by transition metals such as aryl-aminations, aryl-amidations, ether synthesis of üllman and cross-linking reactions (for example, Heck, Negishi, Suzuki and Sonogashira). For example, treatment with amines or alcohols under suitable conditions promoted by a palladium catalyst can give aryl amines (Y = NR) or ethers (Y = 0). Also 2-halopyrrole can pass through carbonylation reactions to provide the corresponding pyrrole-2-carboxylic acid esters. These transformations represent a sampling of the numerous reactions that can be conceived for these 2-aminopyrroles.

The pyrrole compounds of the formula (II) can also be prepared as depicted in Scheme 7. First, an appropriate ketone can be alkylated with a halo-ketoester at basic conditions to give the corresponding 2, 5-diketoester. This diketo ester intermediate can react with an amine (R5N¾) under the conditions of Paal-Knorr to give the corresponding pyrrole-2-carboxylic ester. Then this intermediate ester can subsequently be converted to the corresponding amide of the formula (II) under the conditions described above.

Scheme 7. Preparation of compounds of the formula (II) Thus, for example, a ketone wherein R 4 is substituted phenyl can be alkylated with ethyl 3-bromo-2-ketopyruvate (R 3 = H) to give the corresponding 2, 5-diketoester. an amine such as an alkyl amine to provide the corresponding pyrrole-2-earboxylate ester, wherein R5 is alkyl This intermediate ester can be converted to its acid chloride and then condensed with an amine, such as heteroaryl amine, to give the product of the formula (Ilb), equivalent to the formula (II) wherein R 4 is substituted phenyl and R 7 is heteroaryl.

The compounds of the formula (III) can be prepared as depicted in Scheme 8. Here, a haloketone can react with a β-ketoester under basic conditions to give a 1,4-diketone. The intermediate diketone can be condensed as, previously described with an amine, R5NH2, to provide the ester of the corresponding pyrrole-3-carboxylic acid. Then this ester intermediate can be converted to its acid chloride and then condensed with an amine, R6 (R7) NH, to give the product of the formula (III).

Scheme 8. General preparation of compounds of the formula (III) Thus, for example, ethyl acetoacetate can be alkylated with a haloketone such as one where R 4 is substituted phenyl to give the corresponding diketone. Under the conditions of Paal Knorr this diketone can be condensed with an alkyl amine for give the appropriate pyrrole-3-carboxylic acid ester, which can to be converted to its acid chloride and then condensed with an amine, such as heteroaryl amine, to give the product of the formula (Illb), equivalent to the formula (III) wherein R 4 is substituted phenyl and R 7 is heteroaryl.

Other compounds of the formula (III), such as those wherein R = H, can be prepared as depicted in the Scheme 9. Here a haloketone can react with a cyanoacetate ester under basic conditions to give the corresponding α-ketoester. The intermediate ketoester can then be cyclized in a reductive manner under conditions such as with Raney Ni and formic acid to provide the corresponding pyrrole-3-carboxylic acid ester. This intermediate ester can be oxidized under conditions such as through transfer hydrogenation with 10% Pd / C to give the corresponding pyrrole, which can be alkylated with a suitable electrophile, R5X. The resulting pyrrole-3-carboxylic acid ester can be converted to an amide of the formula (lile) as previously described. For example, methyl cyanoacetate can be alkylated with a haloketone, for example, R 4 is substituted heteroaryl, to give the corresponding 2-cyano-4-ketoester. This intermediate ester can be converted to its methyl ester of pyrrole-3-carboxylic acid as previously described and then alkylated by sequential treatment with a base, for example, sodium hydride, and then a suitable electrophile, for example, bromide I rent. The resulting ester can be converted to its acid chloride and then treated with an amine, such as a substituted aniline, to give the corresponding product of the formula (lile), equivalent to the formula (III), wherein R 4 is substituted heteroaryl and R7 is substituted phenyl.

Scheme 9. Synthesis of other pyrrole compounds of the formula (IIIc).

Alternatively these analogs (IIIc) can be prepared as depicted in Scheme 10. Here, an ester of pyrrole-3-carboxylic acid can be brominated under typical conditions, such as with NBS, to give the corresponding 5-bromopyrrole intermediate. Subsequent treatment with a base followed by a suitable electrophile (R5X) can then give the intermediate N-substituted pyrrole. Then, a cross-linking reaction of a boronic acid and its intermediate in the Suzuki conditions can provide the corresponding intermediate pyrrole, analogous to that shown in Scheme 9. Similarly, the resulting pyrrole-3-carboxylic acid ester can become amides of the formula (lile) as previously described. In addition, the list of suitable boronic acids is quite extensive and may include examples, where R 4 may be alkyl, alkenyl, aryl, heteroaryl and several others.

Scheme 10. Alternative preparation of pyrrole (lile) compounds. The compounds of the formula (III) wherein R3 is OR9, equivalent to 2-alkoxypyrols (Illd) can be prepared as depicted in Scheme 11. Here, a malonate ester can be alkylated with a suitable bromoketone under basic conditions, Example NaH in THF, to give a ketoester, which can be condensed with an amine (R5N¾) under typical conditions, to give the corresponding pyrrolinone-3-carboxylic acid ester. . This pyrrolinone can be alkylated with a suitable electrophile under basic conditions and the resulting ester can be converted to its amide of the formula (Illd) under conditions previously described.

Scheme 11. Synthesis of pyrrole compounds of the formula (Illd) In addition, the compounds of the formula (III) in which R3 is YR9 can be prepared as depicted in Scheme 12. Here, the pyrrolinone-3-carboxylic acid ester, previously described in Scheme 11, can be converted to a sulfonate activated as by sequential treatment with a suitable base, for example NaH in THF, and then trifluoromethanesulfonic anhydride. This intermediate pyrrole can then pass through reactions catalyzed by transition metal such as bonds with amines or thiols under the appropriate conditions to give the respective aryl amines and sulfides. In a similar manner, these intermediates can be converted to amides of the formula (lile), equivalent to the formula (III) wherein R3 is an amine (Y = NR9) or a sulfide (Y = S).

Scheme 12. Synthesis of pyrrole compounds of the formula (lile) The compounds of the formula (III) can also be prepared as depicted in Scheme 13. Thus, for example, the triflate prepared in Scheme 12 can pass through the Suzuki reactions such as with B-alkyl-9-? ?? to give the corresponding pyrrole, wherein R3 is alkyl. And other reactions catalyzed by transition metals for this substrate can be envisaged.

Scheme 13. Synthesis of pyrrole compounds of the formula Similarly, the compounds of the formula (IV) can be prepared as depicted in Scheme 14. Here, a ketone can be alkylated with a halo-ketoester, for example, bromopyruvate (R1 = H), under basic conditions to give the Corresponding 2,5-diketoester. This intermediate di-ester ester can be condensed as previously described with an amine, R 32 NH 2, to provide the corresponding pyrrole-2-carboxylic ester. Then, this intermediate ester can be converted to its acid chloride and then condensed with an amine to give the product of the formula (IV).

Scheme 14. Preparation of pyrrole compounds of the formula (IV) Also compounds of formula (IV) can be prepared as depicted in Scheme 15. Here, an ester of pyrrole-2-carboxylic acid can be brominated under typical conditions such as bromine in carbon tetrachloride to give the bromopyrrole ester correspondent. Then, this intermediate can pass through the cross-linking reactions of Suzuki with boronic acids to provide the corresponding products esters, which can be converted into the final product amides as previously described. And other reactions catalyzed by transition metals can be foreseen for this substrate, such as Heck, Stille, aril amination and amidation.

Scheme 16. Preparation of pyrrole compounds of the formula (IV) Schemes 1-15 depict the preparation of different isomers of pyrrole amide (I-IV), many of which can be generated from commercially available amines, R6R7NH. In addition, an expert in the art of chemical synthesis must be familiar with numerous procedures reported for preparing amines from the literature. The following schemes concentrate on various reactions used for the synthesis of aryl and heteroaryl amines. In particular, the reaction schemes exemplify the preparation of amines carrying the following functional groups: ketone, sulfone, sulfonamide and ether. Various other modifications and syntheses can be envisaged for substituted aryl or heteroaryl amines. In general, aliphatic amines are readily available from commercial sources. Also the preparation of aliphatic amines has been thoroughly documented in the literature and therefore, will not be elaborated here.

As shown in Scheme 16, the aminoaryl ketones (V) can be prepared from acetanilides under the Friedel-Crafts conditions [see J. Med. Chem. 1983, 26, 96-100]. Thus, the acetanilides can be acylated, for example, with aryl chlorides to acetamido-benzophenones wherein R14 is substituted phenyl. Deprotection of the acetamides under typical conditions can provide the corresponding amino-benzophenones (V), which can be incorporated into amides of the formulas (I-IV).

Scheme 16. Preparation of aminoaryl ketones (V) (V) The aminoaryl ketones (V) can also be prepared through organometallic intermediates as depicted in Scheme 17. Thus, for example, an aryl-lithium species can be generated from a bromo-acetanilide and then added to an acid chloride to give the corresponding ketone. Subsequent deprotection under typical conditions can then provide the desired aminoaryl ketone (V). Alternatively, a suitable Weinreb amide can be treated with a Grignard reagent to give the corresponding ketone, which can be deprotected in a similar manner. These reaction sequences can also be applied to suitable starting materials for the preparation of ortho and meta-isomers.

Scheme 17. Alternative synthesis of aminoaryl ketones (V) (V) The aminoaryl sulfones can be prepared from fluoro-nitrobenzenes and sulfinic acid metal salts as depicted in Scheme 18. Thus, the fluoro-nitrobenzene species can react, for example, with sodium methanesulfonate to give the 4-methanesulfonyl- corresponding nitrobenzene. The reduction of the intermediate nitro under typical conditions such as in tin chloride then provides the desired 4-methanesulfonyl-aniline (VI), which can be incorporated into the amides of the formulas (I-IV). Similar chemical compositions are pursued for isomeric species as well as for heteroaryl analogues such as that represented by the pyridine species (VII).

Scheme 18. Preparation of aminoaril sulfones (VI) and pyridine analogs (VII) Similarly, the aminoaryl sulfones (VI) can be prepared as depicted in Scheme 19. Here, the thiols or thiolates can be reacted with aryl halides or activated heteroaryl halides to give the corresponding sulfides, which can be oxidized under the conditions of the bibliographies such as with mCPBA to give intermediate sulfones. The subsequent reduction of the nitro group under typical conditions, for example tin chloride, can provide the respective intermediate aryl or heteroaryl amine, which can be incorporated into the amides of the formulas (I-IV). Therefore, the alkyl or aryl thiolates can pass through the reaction sequence with appropriate substituted fluoro-nitrobenzenes as described to give the corresponding sulfones (VI), where R 15 is alkyl or aryl, respectively. Similar chemical compositions can be pursued for other aryl or heteroaryl isomers, such as those derived from the ortho-fluoro species.

Scheme 19. Alternative synthesis of aminoaril sulfones (VI) Also, the aryl and heteroaryl troles can be substituted, for example, alkylated with an alkyl bromide, and then converted to the corresponding sulfones (VI and VII) as shown in Scheme 20.

Scheme 20. Alternative synthesis of aminoaril sulfones (VI) The sulfonamides (VIII) can be prepared as depicted in Scheme 21. Here, different nitroanilines can be diazotized under typical conditions and then converted directly to the corresponding sulfonyl chloride, for example, with sulfur dioxide and cuprous chloride under acidic conditions. [U.S. Patent 4,456,469; British Patent Application GB 2,246,352 A; J. Med. Chem. 2003, 46, 1811-1823]. Subsequent treatment of the isolated -sulfonyl chloride with an amine, (R14) 2NH, followed by reduction under typical conditions, can give the corresponding aminoaryl sulfonamide (VIII), which can be incorporated into amides of the formulas (I-IV). Similar chemical compositions for heteroaryl analogues can be pursued starting with the appropriate nitro-heteroarylamines.

Scheme 21. Preparation of aminoaryl sulfonamides (VIII) Alternatively, the aminoaryl sulfonamides (VIII) can be synthesized as depicted in Scheme 22. Here, nitroarylsulfonyl chlorides can be prepared from nitroaryl sulphides by reaction with a chlorinating agent., for example, chlorine, in a suitable solvent such as chloroform in the presence of water [British Patent Application GB 2,246,352 A]. The sulfonyl chloride can then be converted to its aminoaryl sulfonamide as previously described. Thus, for example, a nitroaryl halide can react with sodium benzylthiolate to give the corresponding sulfide wherein R15 is benzyl. Then, this sulfide can be converted to its sulfonyl chloride, condensed with an amine and then reduced to give the corresponding sulfonamide (VIII), which can be incorporated into the amides of the formulas (I-IV).

Scheme 22. Alternative synthesis of aminoaril 'sulfonamides (VIII) In addition, the acetanilides can pass through chlorosulfonation under typical conditions, such as with chlorosulfonic acid [see, for example, J. Med. Chem. 2003, 46, 2187-2196], to give the chlorosulfonyl acetanilides as shown in Scheme 23. Subsequently, the intermediate can be converted directly into the corresponding sulfonamides by treating it with an amine, HN (R14) 2- The aminoaryl sulfonamide product (VIII) can then be obtained by deprotecting acetamide under typical conditions.

Scheme 23. Alternative synthesis of aminoaryl sulfonamides (VIII) The aminoaryl ethers (IX) can be prepared by any of the methods depicted in Scheme 24. First, for example, an alkoxide can react with an activated nitroaryl species such as 4-fluoro-nitrobenzene to give the alkyl nitrophenyl ester correspondent. The intermediate ether can then be reduced, such as by hydrogenation, to give an amino aryl ether product (IX). Similar chemical compositions can be provided wherein the alkoxide is replaced by a phenoxide or heterocyclic analogue. Also, the nitroaryl species can be replaced by a halo-nitroheteroaromatic analogue. In the second sequence, for example, a nitro-phenol species can be substituted, for example, by alkylating with an alkyl bromide, and then reducing as previously described to give the corresponding aminoaryl ethers (IX). In addition, the nitro-phenol species can undergo a substitution under Mitsunobu conditions with alcohols to give similar alkyl nitrophenyl ethers, which can undergo the reduction to give the corresponding ethers (IX). All of these aminoaryl ethers can subsequently be incorporated into the amides of the formulas (I-IV).

Scheme 24. Preparation of aminoaryl ethers Alternatively, the aminoaryl ethers (IX) wherein R is aryl or heteroaryl can be prepared as depicted in Scheme 25. An acetamido-phenol can undergo reactions mediated by copper with aryl or heteroaryl boronic acids to give the corresponding aryl ethers. These intermediate ethers can then be deprotected under typical conditions to provide the desired diaryl ethers of the formula (IX) wherein R15 is aryl or heteroaryl. Therefore, for example, the reaction with a substituted phenyl boronic acid can give the corresponding diphenyl ether, which can be deprotected and then incorporated into the amides of the formulas (I-IV).

Scheme 25. Alternative synthesis of amino-aryl ethers (IX) The compounds of the formula (I) wherein R 4 is acyl or sulfonyl can be prepared as depicted in Scheme 26. Here, the amides of the formula (I) wherein R 4 is benzyl can be converted to the amides (I) wherein R4 is hydrogen under typical conditions such as through palladium catalyzed hydrogenation. The resulting pyrroles can then undergo reactions with suitable electrophiles such as, for example, acid chlorides to give the corresponding amides (Id), equivalent to formula (I) wherein R 4 is acyl. Similarly, the intermediate pyrrole can react with sulfonyl chlorides to give different amides, ie equivalent to the formula (I) wherein R4 is sulfonyl.

Scheme 26. Synthesis of compounds of the formulas (Id) e (le) G. EXAMPLES The preceding examples are provided only to illustrate the present invention and are in no way intended to limit the scope thereof. The skilled artisan will understand that considerable variations in the practice of this invention are possible within the spirit and scope that is claimed below.

EXAMPLE 1 PREPARATION OF 1- (4-FLUORO-2-TRIFLUOROMETHYL-PHENYL) -2,5-DIMETHYL-1H-PIRROL-3-CARBALDEHYDE A. A mixture of 4-fluoro-2- (trifluoromethyl) aniline (4.4 g, 24.6 mmol), 2,5-hexanedione (2.8 g, 24.5 mmol) and acetic acid (0.28). mL) was heated to 100 ° C. After 3 hours, the reaction mixture was cooled and partitioned between EtOAc and water. The organic layer was separated, dried (MgSO4) and concentrated in vacuo. The residue was purified by flash chromatography (Si02) eluting with EtOAc / Hex (0: 100 to 10:90) to give 1- [4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-1H-pyrrole as a yellow oil (3.19 g, 50%); ½ NMR (CDC13): d 7.52 (dd, J = 8, 3 Hz, 1H), 7.35 (dt, J = 3.8 Hz, 1H), 7.25 (dd, J = 5, 8 Hz, 1H), 5.90 (s, 2H), 1.91 (s, 6H); MS (ESI) m / z 258 [M + H] +.

To anhydrous DMF (10 mL) cooled under nitrogen at 0 ° C was added phosphorus oxychloride (1.2 mL, 13.1 mmol). The resulting mixture was stirred at 0 ° C for 30 minutes and then a portion of 1- [4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-1H-pyrrole was added portion by portion (3.19 g, 12.4 mmol) in anhydrous DF (15 mL). The reaction mixture was kept at 0 ° C-3 ° C for 10 minutes and then the reaction flask was heated on an oil bath at 95 ° C-100 ° C. After heating for 1.5 h, the reaction mixture was cooled and poured into 200 mL of ice cold 1M NaOH. The resulting suspension was extracted twice with DCM. The combined extracts were dried (Na 2 SO 3) and concentrated in vacuo. The residue was purified by flash chromatography (Si02) eluting with EtOAc / Hex (10:90 to 30:70) to give the title compound as a light yellow solid (1.3 g, 37%); 1 H-NMR (CDC13):? 9.90 (s, 1H), 7.58 (dd, J = 8, 3 Hz, 1H), 7.43 (m, 1H), 7.29 (dd, J = 5, 8 Hz, 1H), 6.39 (s, 1H), 2.20 (s, 3H), 1.91 (s, 3H); MS (ESI) 'm / z 286 | [M + H] +.

PREPARATION OF CHLORIDE 1- [4-FLUORO-2- (RIFLUOROMETHYL) PHENYL] -2,5-DIMETHYL-1H-PIRROL-3-CARBONYL B. To a solution of 1- [4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carbaldehyde (1.5 g, 5.3 mmol) in acetone (150 mL ) a 0.3 solution of KMn04 (150 mL) was added. The reaction mixture was stirred for 3 hours at room temperature and then charged with 10% H202 (5 mL). After 15 minutes the reaction mixture was filtered and the filtrate was concentrated in vacuo to remove the acetone. The remaining aqueous suspension was acidified with acetic acid. The precipitates were recovered by filtration and dried under high vacuum to give 1- (4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (0.99 g, 62%) as a weakly yellow powder; ¾ NMR (CDC13): d 7.56 (dd, J = 8, 3 Hz, 1H), 7.41 (m, 1H), 7.27 (dd, J = 5 , 8 Hz, 1H), 6.42 (s, 1H), 2.21 (s, 3H), 1.90 (s, 3H), MS (ESI) m / z 302 [M + H] +. ? a suspension of 1- (4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (0.65 g, 2.16 mmol) in anhydrous toluene (5.0 mL) cooled to 0 ° C-3 ° C thionyl chloride (0.25 mL) and DMF (20 μL) were added The reaction mixture was allowed to warm to room temperature where it remained for 3 hours and then concentrated in The residue was evaporated twice with 5 mL of toluene to remove thionyl chloride and then triturated in 3 mL of hexanes The solids were removed by filtration and the filtrate was concentrated under reduced pressure and dried under high vacuum to give the title compound (0.44 g, 64%) as a pale brown solid, 1 H NMR (CDC13): 57.59 (dd, J = 8, 3 Hz, 1H), 7.44 (m, 1H), 7.27 (dd, J = 5, 8 Hz, 1H), 6.51 (s, 1H), 2.17 (s, 3H), 1.89 (s, 3H), MS (ESI) m / z 320 [M + H] +.

PREPARATION OF [4- (SULFAMOIL) PHENYL] -AMIDE OF ACID l- [4-FLUORO-2- (TRIFLUOROMETHYL) PHENYL] -2,5-DIMETHYL-1H-PIRROL-3-CARBOXYLIC C. In a 1 dram flask dried in the oven was added 2,5-dimethyl-l- [4-fluoro-2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid chloride (106 g, 332 mmol). , sulfanilamide (62.0 mg, 360 μta), anhydrous THF (2.0 mL) and diisopropylethylamine (50 μL). The bottle was sealed and heated at 80 ° C overnight. The residue was purified by flash chromatography (SIO2), eluting with EtOAc / Hexanes (30:70 to 60:40) to give the title compound as an off white solid (99 mg, 66%); ½ NMR (CDCI3): 58, 85 (s, 1H), 7.88 (d, J = 7 Hz, 2H), 7.84 (d, J = 7 Hz, 2H), 7.58 (dd, J = 8, 3 Hz, 1H), 7.46 (m, 1H), 7.31 (dd, J = 5, 8 Hz, 1H), 6.46 (s, 1H), 6.19 (s, 2H) ), 2.25 (s, 3H), 1.94 (s, 3H); MS (ESI) m / z 456 [M + H] +.

D. In a manner similar to that described in Examples 1A-1C, but replacing 4-fluoro-2- (trifluoromethyl) aniline with 2- (trifluoromethyl) aniline, the following compound was prepared: (4-sulfamoyl-phenyl) -2,5-Dimethyl-l-f2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid amide; ½ NMR (DMSO-d ^): 9.5 (s, 1H), 7.77 (d, J = 1 Hz, 1H), 7.68 (m, 3H), 7.57 (t, J = 7 Hz, 1H), 7.51 (d, J = 1 Hz, 2H), 7.26 (d, J = 7 Hz, 1H), 6.98 (s, 2H), 6.42 (s, 1H), 3.08 (s, 3H) ), 1.90 (s, 3H); MS (ESI) m / z 438 [M + H] +.

E. In a manner similar to that described in Example 1C but replacing the sulfanilamide with the appropriate amine, the following compounds were prepared: 1- [4-fluoro-2- (trifluoromethyl) 4- (Benzoyl) phenyl] -amide phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid; "" "H NMR (CDC13): d 7.84 (d, J = 8 Hz, 2H), 7, 75-7, 80 (m, 3H), 7.74 (d, J = 8 Hz, 2H) , 7.55-7.6 (m, 2H), 7.48 (t, J = 1 Hz, 2H), 7.43 (dt, J = 3.8 Hz, 1H), 7.28 (dd, J = 5, 8 Hz, 1H), 6.25 (s, 1H), 2.26 (s', 3H), 1.94 (s, 3H), MS (ESI) m / z 481 [M + H ]. [1- (4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid [1/2] NMR (CDCl3): d 7.90 (d, J = 7 Hz, 2H), 7.83 (d, J = 7 Hz, 2H), 7.72 (s, 1H), 7.58 (dd, J = 8, 3 Hz , 1H), 7.44 (dt, J = 8, 3 Hz, 1H), 7.29 (dd, J = 5, 8 Hz, 1H), 6.23 (s, 1H), 3.06 (s) , 3H), 2.26 (s, 3H), 1.95 (s, 3H), MS (ESI) m / z 455 [M + H] +.

F. In a manner similar to that described in Example ID but replacing the sulfanilamide with the appropriate amines, the following compounds were prepared: Ethyl ester of 1- [4- (. {2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carbonyl} -amino) -phenyl] -3- methyl-lH-pyrazole-4-carboxylic acid; XH NMR (CDC13): 5 8, 04 (s, 1H), 7.87 (d, J = 8 Hz, 1H), 7, 72-7, 77 (m, 3H), 7, 64-7, 68 (m, 2H), 7.38 (d, J = 7 Hz, 2H), -7.28 (d, J = -8 Hz, 1H), 6.23 (s, 1H), 4.33 (q , J = 6 Hz, 2H), 2.56 (s, 3H), 2.27 (s, 3H), 1.95 (s, 3H), 1.38 (t, J = 6 Hz); MS (ESI) m / z 511 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid [4-benzenesulfonyl) phenyl] -amide; ?? NMR (CDCl 3): d 7, 89-7, 95 (m, 4H), 7.87 (d, J = 8 Hz, 1H), 7, 71-7, 76 (m, 3H), 7.66 ( t, J = 7 Hz, 2H), 7, 47-7, 57 (m, 3H), 7.26 (d, J = 8 Hz, 1H), 6.19 (s, 1H), 2.23 ( s, 3H), I, 93 (s, 3H); MS (ESI) m / z 499 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (9-oxo-9H-fluoren-3-yl) -amide; NMR (CDCl 3): d 8.13 (s, 1H), 7.81 (d, J = 7 Hz, 1H), 7.55-7.68 (m, 5H), 7.49 (d, J = 7 Hz, 1H), 7.40 (t, J = 7 Hz, 1H), 7.19-7.24 (m, 2H), 7.14 (d, J = 8 Hz, 1H), 6, 16 (s, 1H), 2.21 (s, 3H), 1.88 (s, 3H); MS (ESI) m / z 461 [M + H] +. [5- (sulfamoyl) phenyl] -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; XH NMR (CD3OD): d 8.21 (s, 1H), 7.85 (d, J = 8 Hz, 1H), 7.73 (m, 2H), 7.66 (t, J = 8 Hz, 1H), 7.51 (d, J = 8 Hz, 1H), 7.39 (t, J = 8 Hz, 1H), 7.29 (d, J = 8 Hz, 1H), 6.43 (s) , 1H), 2.10 (s, 3H), 1.84 (s, 3H); MS (ESI) m / z 438 [M + H] +. Ethyl 3- (. {2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carbonyl} -amino) -benzoic acid ester; 1H NMR (CDC13): d 8, 04-8, 08 (m, 2H), 7.87 (d, J = 8 Hz, 1H), 7.76 (d, J. = 8"Hz, 1H), 7.72 (t, J = 8 Hz, 1H), 7.65 (t, J = 8 Hz, 1H), 7.60 (s, 1H), 7.42 (t, J = 8 Hz, 1H) , 7.27 (d, J = 8 Hz, 1H), 6.22 (s, 1H), 4.38 (q, J = 7 Hz, 2H), 2.26 (s, 3H), l, 94 (s, 3H), l, 40 (t, J = 7 Hz, 3H); MS (ESI) m / z 431 [M + H] +. (l-oxo-indan-5-yl) -amide of the acid 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; H NMR (CDCl 3): d 8.12 (s, 1H), 7.88 (d, J = 8 Hz, 1H), 7, 64-7.76 (m, 4H), 7.26-7.31 (m, 2H), 6.22 (s, 1H), 3.13 (m, 2H), 2 69 (m, 2H), 2.27 (s, 3H), 1.95 (s, 3H), MS (ESI) m / z 413 [M + H] + ethyl ester · acid 1- [ 4- ( { 2, 5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carbonyl} - amino) -phenyl] -3,5-dimethyl-lH-pyrazole- 4-carboxylic acid XH NMR (CDC13): d 7.87 (d, J = 8 Hz, 1H), 7.71-7.75 (m, 3H), 7.64-7.68 (m, 2H) , 7.36 (d, J = 8 Hz, 2H), 7.28 (d-, J = 8 Hz, 1H), 6.23 (s, 1H), 4.33 (q, J = 7 Hz, 2H), 2.51 (s, 6H), 2.27 (s, 3H), I, 94 (s, 3H), l, 38 (t, J = 1 Hz, 1H); MS (ESI) m / z.525 [M + H] +. [4- (Benzoyl) phenyl] -amide of 1- [4-fluoro-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid; 1 H NMR (CDCl 3): d 7.71-7, 88 (m, 9H), 7.65 (t, J = 8 Hz, 1H), 7.58 (t, J = 7 Hz, 1H), 7, 82 (t, J = 7 Hz, 2H), 7.27 (d, J = 7 Hz, 1H), 6.25 (s, 1H), 2.27 (s, 3H), 1.93 (s, 3H); MS (ESI) m / z 463 [M + H] +. [4- (Methanesulfonyl) phenyl] -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; - "? NMR (CDCI3): d 7.90 (t, J = 9 Hz, 2H), 7.88 (d, J = 8 Hz, 1H), 7.82 (d, J = 9 Hz, 2H) , 7.74 (t, J = 8 Hz, 1H), 7.72 (s, 1H), 7.67 (t, J = 8 Hz, 1H), 7.27 (d, J = 8 Hz, 1H ), 6.23 (s, 1H), 3.05 (s, 3H), 2.26 (s, 3H), 1.94 (s, 3H), MS (ESI) m / z 437 [M + H ] +. [2,5-Dimethyl-l-, [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid [4- (trifluoromethanesulfonyl) phenyl] -amide: XH NMR (CDC13): d 7, 98 (d, J = 9 Hz, 2H), 7.93 (d, J = 9 Hz, 2H), 7.88 (d, J = 8 Hz, 1H), 7.83 { S, 1H) , 7.75 (t, J = 8 Hz, 1H), 7.68 (t, J = 8 Hz, 1H), 7.28 (d, J = 8 Hz, 1H), 6.23 (s, 1H) ), 2, 26 (s, 3H), 1, 94 (s, 3H); MS (ESI) m / z 491 [M + H] +. [4- (Butyryl) phenyl] -amide of acid 2, 5 -dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; ½ NMR (CDCl 3): d 8.06 (d, J = 7 Hz, 2H), 7.96 (d, J = 8 Hz, 1H), 7.75-7, 85 (m, 4H), 7.36 (d, J = 1H), 6.31 (s, 1H), 3.01 (t, J = 7 Hz , 2H), 2.36 (s, 3H), 2, 03 (s, 3H), l, 86 (sextet, J = 7 Hz, 2H), l, 10 (t, J = 3 H); MS ( ESI) m / z 429 [M + H] +. (S-ox 2,5-dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid o-5, 6, 7, 8-tetrahydro-naphthalen-2-yl) -amide; "" "HNR (CDCI3): d 7.95 (d, J = 8 Hz, 1H), 7, 78-7, 82 (m, 2H), 7.67 (t, J = 8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.53 (s, 1H), 7.29 (s, 1H), 7.20 (d, J = 8 Hz, 1H), 6.13 ( 3, 1H), 2.90 (m, 2H), 2.56 (111, 2H), 2.19 (3, 3H), 2.06 (m, 2H), 1.87 (s, 3H); MS (ESI) m / z 427 [M + H] + Methyl ester of 4- (. {2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carbonyl .}. -mino) -2-methoxy-benzoic; xu NMR (CDC13): d 7, 74-7, 81 (m, '3H), 7.66 (t, J = 8 Hz, 1H), 7, 59 (t, J = 8 Hz, 1H), 7.55 (s, 1H), 7.20 (d, J = 8 Hz, 1H), 6.80 (d, J = 9 Hz, 1H), 6 , 14 (s, 1H), 3.89 (s, 3H), 3.80 (s, 3H), 2.20 (s, 3H), l, 87 (s, 3H); MS (ESI) m / z 447 [M + H] + (2-methyl-4-oxo-4H-chromen-7-yl) -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole -3-carboxylic acid, 1H NMR (CDC13): d 8.20 (s, 1H), 8.04 (d, J = 9 Hz, 1H), 7.81 (d, J = 8 Hz, 1H), 7 , 76 (s, 1H), 7.67 (t, J = 8 Hz, 1H), 7.59 (t, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, .1H) , 7.16 (d, J. = 9 Hz, 1H), 6.18 (s, 1H), 6, ll (s, H ), 2.31 (s, 3H), 2.20 (s, 3H), 1.87 (s, 3H); MS (ESI) m / z 441 [M + H] +. [2,5-Dimethyl-1- (2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid [(4-phenylsulfanyl) phenyl] -amide; 1H NMR (OMSO-dg): d 9.6 (s, 1H), 8.01 (d, J = 7 Hz, 1H), 7.92 (t, J = 8 Hz, 1H), 7.80- 7.85 (m, 3H), 7.50 (d, J = 8 Hz, 1H), 7.40 (d, J = 7 Hz, 2H), 7.33 (t, J = 7 Hz, 2H) , 7, 19-7, 24"(m, 3H), 6.63 (s, 1H), 2.14 (s, 3H), 1.89 (s, 3H), MS (ESI) m / z 467 [M + H] +. [2,5-Dimethyl-1- (2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid [(4-dimethylsulfamoyl) phenyl] -amide; 1H NR (CDCl 3): d 7.87 (d, J = 8 Hz, 1H), 7.80 (01, J = 1 Hz, 2H), 7.7-7.8 (m, 4H), 7, 66 (t, J = 8 Hz, 1H), 7.27 (d, J = 8 Hz, 1H), 6.24 (s, 1H), 2, 70 (s, 6H), 2.26 (s, 3H), I, 94 (s, 3H); MS (ESI) / z 466 [+ H] +. [4- (Pyridine-4-carbonyl) phenyl] -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; ½ NMR (CDCl 3): d 8.75 (d, J = 6 Hz, 2H), 7.81 (d, J = 8 Hz, 1H), 7.78 (d, J = 9 Hz, 2H), 7 , 71 (d, J = 9 Hz, 2H), 7, 61-7, 68 (m, 4H), 7, 57-, .60 (m, 3H), 7.21 (d, J = 8 Hz, 1H), 6.16 (s, 1H), 2.21 (s, 3H), 1.88 (s, 3H); MS (ESI) m / z 464 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-guanidinosulfonyl-phenyl) -amide; 1H NMR (salt in TFA-DMS0-de): d 9.8 (s, 1H), 8.12 (d, J = 7 Hz, 1H), 8.03 (t, J = 8 Hz, 1H), 7.98 (d, J = 7 Hz, 2H), 7.92 (t, J = 8 Hz, 1H), 7.79 (d, J = 1 Hz, 2H), 6.8 (br s, 4H ), 6.76 (s, 1H), 2.25 (s, 3H), 2.00 (s, 3H); MS (ESI) m / z 480 [M + H] +. [4- (Cyano-phenyl-methyl) -phenyl] -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; 1 H NMR (CDCl 3): d 7, 88 (d, J = 8 Hz, 1 H), 7, 74-7.76 (m, 2 H), 7.67 (t, J = 8 Hz, 1 H), 7, 61 (d, J = 1 Hz, 2H), 7.26-7.40 (m, 8H), 6.24 (s, 1H), 5.15 (s, 1H), 2.24 (s, 3H) ), 1.94 (s, 3H); MS (ESI) m / z 474 [M + H] +. [4- (piperidine-l-sulfonyl) -phenyl] -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; ¾ NMR (CDC13): d 7.89 (d, J = 8 Hz, 1H), 7, 66-7, 82 (m, 7H), 7.29 (d, J = 8 Hz, 1H), 6, 26 (s, 1H), 3.00 (m, 4H), 2.26 (s, 3H), 1.97 (s, 3H), 1.66 (m, 4H), 1.44 (m, 2H) ); MS (ESI) m / z 506 [M + H] +. [(4-Methylsulfanyl) phenyl] -amide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; XH NMR (CDC13): d 7.86 (d, J = 8 Hz, 1H); 7r72 (t, J = 8 Hz, 1H), 7.62 (t, J = 8 Hz, 1H), 7.51 (d, J = 9 Hz, 2H), 7.2-7.3 (m, 4H), 6.20 (s, 1H), 2.47 (s, 3H), 2.22 (s, 3H), 1.92 (s, 3H); MS (ESI) m / z 405 [M + H] +. 2,5-Dimethyl-1- (2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (5-methyl-thiazol-2-yl) -amide; 1 H NMR (CDCl 3): d '7.87 (d, J = 8 Hz, 1H), 7.74 (t, J = 8 Hz, 1H), 7.66 (t, J = 8 Hz, 1H), 7.25-7.28 (m, 2H), 7.09 (s, 1H), 6.75 (s, 1H), 2.42 (s, 3H), 2.29 (s, 3H), l, 94 (s, 3H); MS (ESI) m / z 380 [M + H] +. 5- Acid ethyl ester. { [2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carbonyl] -amino} - [1, 3, 4] thiadiazole-2-carboxylic acid; ½ NMR (CDCI3): d 7.85 (d, J = 8 Hz, 1H), 7.71 (t, J = 8 Hz, 1H), 7.63 (t, J = 8 Hz, 1H), 7 , 23-7.27 (m, 2H), 6.38 (s, 1H), 4.28 (q, J = 7 Hz, 2H); 2.19 (s, 3H), 1.89 (s, 3H), 1.35 (t, J = 7 Hz, 3H) / MS (ESI) m / z 439 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-benzoyl-phenyl) -amide; ½ NMR (CDC13): d 7, 71-7, 88 (m, 9H), 7.65 (t, J = 8 Hz, 1H), 7.58 (t, J = 8 Hz, 1H), 7, 48 (t, J = 7 Hz, 2H), 7.27 (d, < J = 1H), 6.25 (s, 1H), 2.27 (s, 3H), l, 93 (s, 3H); MS (ESI) m / z 463 [M + H] +. 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid indan-5-ylamide; 1 H NMR (CDCl 3): d 7.86 (d, J = 8 Hz, 1H), 7.72 (t, J = 8 Hz, 1H), 7.64 (t, J = 8 Hz, 1H), 7 , 57 (s, 1H), 7.49 (br s, 1H), 7.27 (d, J = 8 Hz, 1H), 7.15-7.23 (m, 2H), 6.19 (s) , 1H), 2, 89 (quintet, J = 8 Hz, 4H), 2.24 (s, 3H), 2, 09 (quintet, J = 8 Hz, 2H), l, 93 (s, 3H); MS (ESI) m / z 399 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (3-benzoyl-phenyl) -amide; 1 H NMR (CDCl 3): d 8, 11 (d, J = 8 Hz, 1H), 7.81-7.89 (m, 4H), 7.74 (t, J = 8 Hz, 1H), 7, 66 (t, J = 8 Hz, 1H), 7.60 (t, J = 7 Hz, 2H), 7.45-7.52 (m, 4H), 7.27 (d, J = 8 Hz, 1H), 6.27 (s, 1H), 2.26 (s, 3H), 1.94 (s, 3H); MS (ESI) m / z 463 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (3-methylsulfanyl-phenyl) -amide; ¾ NMR (CDCl 3): d 7.88 (d, J = 8 Hz, 1H), 7.75 (t, J = 8 Hz, 1H), 7.66 (t, J = 8 Hz, 1H), 7 , 63 (s, 1H), 7.59 (s, 1H), 7.23-7.33 (m, 3H), 7.01 (d, J = 8 Hz, 1H), 6.22 (s, 1H), 2.52 (s, 3H), 2.26 (s, 3H), 1.95 (s, 3H); MS (ESI) m / z 405 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-benzyloxy-phenyl) -amide; 1H NMR (CDC13): d 7.84 (d, J = 8 Hz, 1H), 7.70 (t, J = 8 Hz, 1H), 7.62 (t, J = 8 Hz, 1H), 7 , 54 (s, 1H), 7, 40-7, 48 (m, 4H), 7.37 (t, J = 1 Hz, 2H), 7.31 (t, J = 7 Hz, 1H), 7 , 24 (d, J = 8 Hz, 1H), 6.96 (d, J = 7 Hz, 2H), 6.19 (s, 1H), 5.04 (3, 2H), 2.23 (s) , 3H), I, 91 (s, 3H); MS (ESI) 2, 5-dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-phenoxy-phenyl) -amide; XH NMR (CDCl 3): d 7.86 (d, J = 8 Hz, 1H), 7.72 (t, J = 8 Hz, 1H), 7.64 (t, J = 8 Hz, 1H), 7 , 57 (br s, 1H), 7.56 (d, J = 7 Hz, 2H), 7.32 (t, J = 7 Hz, 2H), 7.26 (d, J = 8H, 1H) , 7.07 (t, J-1 H), 6, 97-7, 02 (m, 4H), 6.21 (s, 1H), 2.25 (s, 3H), 1.93 (s, 3H); MS (ESI) m / z 451 [M + H] +. 2,3-benzyl [l, 3] dioxol-5-ylamide of 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; "" "H NMR (CDCl 3): d 7.86 (d, J = 8 Hz, 1H), 7.72 (t, J = 8 Hz, 1H), 7.64 (t, J = 3H), 7 , 39 (s, 1H), 7.35 (s, 1H), 7.26 (d, J = 8 Hz, 1H), 6.85 (d, J = 8 Hz, 1H), 6.76 (d , J = 8 Hz,), 6.17 (s, 1H), 5.95 (s, 2H), 2.25 (s, 3H), 1.93 (s, 1H), MS (ESI) m / z 403 [M + H] + .2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (3-acetyl-phenyl) -amide; H NMR (CDCl 3): d 8.14 (s, 1H), 7.96 (d, J = 8 Hz, 1H), 7.88 (t, J = 8 Hz, 1H), 7.86 (s, 1H), 7.65-7.74 (m, 4H), 7.44 (t, J = 8 Hz, 1H), 7.27 (d, J = 8 Hz, 1H), 6.26 (s, 1H), 2.62 (s, 3H), 2.25 (s, 3H), 1.93 (s, 3H), MS (ESI) m / z 401 [M + H] +. 2, 5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-acetyl-phenyl) -amide; XH NMR (CDC13): d 7.96 (d, J = 9 Hz, 2H), 7f87 (d, J = 8 Hz, 1H), 7.83 (s, 1H), 7.71-7.55 ( m, 3H), 7.66 (t, J = 8 Hz, 1H), 7.27 (d, J = 8 Hz, 1H), 6.25 (s, 1H), 2.58 (s, 3H) , 2.26 (s, 3H), 1.93 (s, 1H); MS (ESI) m / z 401 [M + H] +. 2,5-Dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (5-methylsulfanyl- [1, 3, 4] thiadiazol-2-yl) -amide; "" "H NMR (CDC13): d 7.88 (d, J = 8 Hz, 1H), 7.74 (t, J = 8 Hz, 1H), 7.67 (t, J = 8 Hz, 1H ), 7.27 (d, J = 8 Hz, 1H), 6.58 (s, 1H), 2.75 (s, 3H), 2.29 (s, 3H), 1.92 (s, 3H) ); MS (ESI) m / z 413 [M + H] +. (2,5-Dimethyl-1- [2- (2-ethylsulfanyl- [1, 3, 4] thiadiazol-2-yl) -amide] (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid; E NMR (CDCl 3): d 7.88 (d, J = 8 Hz, 1H), 7.74 (t, J = 8 Hz, 1H), 7 , 67 (t, J = 8 Hz, 1H), 7.28 (d, J = 8 Hz, 1H), 6.55 (s, 1H), 3.26 (q, J = 7 Hz, 2H), 2.29 (s, 3H), l, 94 (s, 3H), 1.45 (t, J = 7 Hz, 3H); MS (ESI) ?? /? 427 [M + H] +. (Pyridine 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-prrol-3-carboxylic acid-2-ylmethyl) -amide: 374 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid trifluoromethyl-benzylamide; MS (ES): 441 (MH +); 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-prrl-3-carboxylic acid 3-methyl-benzylamide; MS (ES): 387 (MH +); [2- (2, 4-dichloro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 4,55 (MH +) / | 2-ethoxy-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 417 (MH +); 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid methyl-phenethyl-amide; MS (ES): 401 (MH +); (1,3-Dihydro-isoindol-2-yl) - [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-yl] -methanone; MS (ES): 385 (MH +); (3,4-Dihydro-lH-isoquinolin-2-yl) - [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-yl] -methanone; MS (ES): 399 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-methyl-benzylamide; MS (ES): 387 (MH +); 3-Chloro-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 407 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-p-tolyl-ethyl) -amide; MS (ES): 401 (MH +); 2-5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3-methoxy-benzylamide; MS (ES): 403 (MH +); [2- (4-Fluoro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 405 (MH +); [2- (2-methoxy-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 417 (MH +); [2- (3-chloro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 421 (MH +); [2- (3-Fluoro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 405 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1-phenyl-propyl) -amide; MS (ES): 401 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (l-methyl-3-phenyl-propyl) -amide; MS (S): 415 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid trifluoromethyl-benzylamide; MS (ES): 441 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (thiophene-2-ylmethyl) -amide: MS (ES): 379 (H +); 4-Fluoro-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 391 (MH +); (2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (furan-2-ylmethyl) -amide; MS (ES): 363 (MH +); [2- (3, 4-dimethoxy-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 447 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-fluoro-benzylamide; MS (ES): 391 (MH +); Indan-l-ilamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 399 (MH +); [2- (2-Fluoro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 405 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lfi-pyrrole-3-carboxylic acid 2-trifluoromethyl-benzylamide MS (ES): 441 (MH +); Ethyl ester of 3- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -furan-2-ylmethyl-amino} -propionic; MS (ES): 463 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-thiophen-2-yl-ethyl) -amide; MS (ES): 393 (H +); 2, 4-difluoro-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 409 (MH +); 4-chloro-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 407 (MH +); [2- (4-chloro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 421 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-phenyl-propyl) -amide; MS (ES): 401 (MH +); 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2,4-dimethyl-benzylamide; MS (ES): 401 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2 ~ (3-methoxy-phenyl) -ethyl] -amide; MS (ES): 417 (MH +); 2, 5-difluoro-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 409 (MH +); [2- (4-bromo-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 465 (MH +); [2- (2-Chloro-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 421 (MH +); 3-Fluoro-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 391 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid phenetyl-amide; MS (ES): 387 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-furan-2-ylmethyl) -amide; MS (ES): 377 (MH +); 2-Bromo-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 451 (MH +); 4-phenoxy-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 465 (MH +) / 2, 5-dimethyl-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 401 (MH +); 3, 4-dimethyl-benzylamide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 401 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzylsulfanyl-ethyl) -amide; MS (ES): 433 (MH +); 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid benzyl-ethyl-amide (ES): 401 (MH +); (2-phenyl-propyl) -amide "of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 401 (MH +); [2- (1H-indol-3-yl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES); 426 (MH +); 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, 3-dihydro-benzo [1,4] dioxin-6-ylmethyl) -amide; MS(ES): 431 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-fluoro-4H-benzo [1,3] dioxin-8-ylmethyl) -amide; MS (ES): 449 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-fluoro-2-trifluoromethyl-benzylamide; MS (ES): 459 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-chloro-6-phenoxy-benzylamide; MS (ES): 499 (MH +); [(S) -1,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [(S) -1- (4-bromo-phenyl) -ethyl] -amide; MS (ES): 465 (MH +); (2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ((R) -1-naphthalene-2-yl-ethyl) -amide; MS (ES): 437 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [bis- (4-methoxy-phenyl) -methyl] -amide; S (ES): 509 (MH +); [(R) -1- (3-methoxy-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 417 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-methylsulfanyl-benzylamide; MS (ES): 419 (H +); 2-5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid-4-methanesulfonyl-benzylamide; MS (ES): 451 (H +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [1- (2-chloro-phenyl) -ethyl] -amide; MS (ES): 421 (MH +); 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-p-tolyloxy-benzylamide; MS (S): 479 (H +); Tere-butyl ester of (S) -2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -3- (4-hydroxy-phenyl) -propionic; MS (ES): 503 (MH +); 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, 2-diphenyl-propyl) -amide; MS (ES): 477 (MH +) / [2- (3-ethoxy-4-methoxy-phenyl) -ethyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole -3-carboxylic; MS (ES): 461 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4 '-fluoro-biphenyl-2-ylmethyl) -amide; MS (ES): 467 (MH +); G. In a manner similar to that described in Examples 17A-1C, but replacing 4-fluoro-2- (trifluoromethyl) aniline with the appropriate amine and replacing the sulfonylamide with 4- (methanesulfonyl) aniline, the following compounds were prepared: 1- [2,3-Dichloro-phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 437 [M + H] +. 1- (2-Bromophenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 447, 449 each [M + H] +. (1- (2-isopropyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 411 [M + H] +. (1- (2-tert-Butyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 425 [M + H] +. 2, 5-Dimethyl-1-naphthalene-1-yl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 419 [M + H] +. (1- (2-tert-Butyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 425 [M + H] +.

EXAMPLE 2 PREPARATION OF PHENYLAMIDE OF 2, 5-DIMETHYL-L- [2- (TRIFLONOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXYLIC ACID AND VARIATIONS A. A solution of 0.125 M material of l- [2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid chloride was prepared in THF. The anilines and heterocyclic amines were individually weighed and dissolved at 0.125 M using the Tecan Genesis processing station and a 1.0M solution of diisopropylethylamine in THF. Tecan was used to disperse 200 μL of 0.125 M 1- [2- (trifluoromethyl) phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid chloride to each reaction vessel and then used to distribute 200 μL of solutions of amine material to the individual reaction vessels. The reaction vessels were sealed and allowed to react at room temperature with stirring for 18 hours. The seal was removed from the reaction vessels and THF (0.80 mL) was added. The THF was removed by filtration and the reaction vessels were washed with 2 x 500 μ? of THF. The sample solutions were dried in vacuum.

B. The samples were dissolved in 500 μ? > of DMSO and 500 μL of methanol. The purity was determined by LC-MS using a combination of V254, UV220 and ELSD detection [purity = = (UV254 + UV220 / 2)]. The HPLC conditions were: C18 column of 4.6 mm x 50 rom, 10% -90% acetonitrile gradient for 5 minutes (the mobile phases were ¾0 with 0.05% TFA and acetonitrile with 0.035% TFA), a flow rate of 3.5 ml / minute. Samples with less dele 80% purity were purified using a mass-directed LC-MS purification. The purified samples were concentrated in vacuo, dissolved in DMSO and reformatted in 96-well microfilter plates. The samples were tested for purity using LC-MS and the amount was estimated by correlating the ELSD response to an ELSD response curve at the standard concentration. The samples were then concentrated to dry and dissolved in DMSO at a final concentration of 10 μ? based on the quantification of ELSD.

C. The following compounds were prepared in a manner similar to that described in Examples 2A-2B using the following appropriate amines: 12,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-6-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid benzothiazol-2-ylamide; MS (ESI) m / z 416 [M + H] +; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dichloro-phenyl) -amide; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methylsulfanyl-phenyl) -amide; MS (ESI) m / z 405 [M + H] +; (2,4-dichloro-phenyl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 427 [M + H] +; 5,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl- [1, 3, 4] thiadiazol-2-yl) -amide; MS (ESI) m / z 381 [M + H] +; (5, 6, 7, 8-tetrahydro-naphthalen-1-yl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 413 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4-fluoro-phenyl) -amide; MS (ESI) m / z 411 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-fluoro-phenyl) -amide | MS (ESI) m / z 411 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-4-methyl-phenyl) -amide; MS (ESI) m / z 391 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methoxy-2-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-methyl-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; (3,5-difluoro-phenyl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 395 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methylsulfanyl-phenyl) -amide; MS (ESI) m / z 405 [M + H] +; (2,5,6-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-diethyl-phenyl) -amide; MS (ESI) m / z 415 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-propyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] + (4-fluoro-2-methyl-phenyl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-amide -carboxylic; MS (ESI) m / z 391 [M + H] +; (2, 3-difluoro-phenyl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 395 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dimethoxy-phenyl) -amide; MS (ESI) m / z 419 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-bromo-4-fluoro-phenyl) -amide; MS (ESI) m / z 455 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-5-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-difluoromethoxy-phenyl) -amide; MS (ESI) m / z 425 [M + H] +; (2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, β-diisopropyl-phenyl) -amide; MS (ESI) m / z 443 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-ethyl-6-methyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-ethoxy-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-bromo-phenyl) -amide; MS (ESI) m / z 437 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-2-methyl-phenyl) -amide; MS (ESI) m / z 391 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrolo-3-carboxylic acid (2-fluoro-5-methyl-phenyl) -amide; MS (ESI) m / z 391 [M + H] +; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid indan-5-ylamide; MS (ESI) m / z 399 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-ethyl-phenyl) -amide; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dimethyl-phenyl) -amide; MS (ESI) m / z 387 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-difluoro-phenyl) -amide; MS (ESI) m / z 395 [M + H] +; (3-ethyl-phenyl) -amide 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-2-methyl-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ethyl-phenyl) -amide; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-bromo-4-methyl-phenyl) -amide; MS (ESI) m / z 451 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-bromo-2-methyl-phenyl) -amide; MS (ESI) m / z 451 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,6-trimethyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-naphthalene-1-yl) -amide; MS (ESI) m / z 443 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzoyl-phenyl) -amide; MS (ESI) m / z 463 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzyloxy-phenyl) -amide; MS (ESI) m / z 465 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dichloro-3-methyl-phenyl) -amide; MS (ESI) m / z 441 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-3-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 461 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-benzoyl-phenyl) -amide; MS (ESI) m / z 463 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (9H-fluoren-2-yl) -amide; MS (ESI) m / z 447 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-pyridin-3-yl) -amide; MS (ESI) m / z 394 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dichloro-phenyl) -amide; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-phenoxy-phenyl) -amide; MS (ESI) m / z 451 [M + Hj +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-3-methyl-phenyl) -amide; MS (ESI) m / z 451 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-pyridin-2-yl) -amide; MS (ESI) m / z 374 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-4-methoxy-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-sec-butyl-phenyl) -amide; MS (ESI) m / z 415 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-5-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,,. Β-trichloro-phenyl) -amide; MS (ESI) m / z 461 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-phenyl) -amide; MS (ESI) m / z 393 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-difluoro-phenyl) -amide; MS (ESI) m / z 395 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-prrl-3-carboxylic acid (4-bromo-2-fluoro-phenyl) -amide; MS (ESJ) m / z 455 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-methyl-phenyl) -amide; MS (ESI) · m / z 407 [M + H] +; (2, 4, ß-trifluoro-phenyl) -amide of 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 413 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-isopropyl-6-methyl-phenyl) -amide; MS (ESI) m / z 415 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-dichloro-phenyl) -amide; MS (ESI) m / z 427 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-thiazol-2-yl) -amide; MS (ESI) m / z 380 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-bromo-phenyl) -amide; MS (ESI) m / z 437 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methyl-pyridin-2-yl) -amide; MS (ESI) m / z 374 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-methoxy-5-methyl-phenyl) -amide; MS (ESI) m / z 437 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, -difluoro-phenyl) -amide; MS (ESI) m / z 395 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,5-trichloro-phenyl) -amide; MS (ESI) m / z 461 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzoyl-phenyl) -amide; MS (ESI) m / z 463 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-difluoromethoxy-phenyl) -amide; MS (ESI) m / z 425 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-methyl-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methylsulfanyl-phenyl) -amide; MS (ESI) m / z 405 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-isopropyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-3-nitro-phenyl) -amide; MS (ESI) m / z 438 [M + H] +; 3-Chloro-2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 437 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-nitro-phenyl) -amide; MS (ESI) m / z 404 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-benzyloxy-phenyl) -amide; MS (ESI) m / z 465 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl- [1, 3, 4] thiadiazol-2-yl) -amide; MS (ESI) m / z 423 [M + H] +; Acid 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 403 [M + H] +; Methyl ester of acid 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 417 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-cyclohexyl-phenyl) -amide; MS (ESI) m / z 441 [M + H] +; (2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (lH-indazol-5-yl) -amide; MS (ESI) m / z 399 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-biphenyl-4-yl) -amide; MS (ESI) m / z 465 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid naphthalene-2-ylamide; MS (ESI) m / z 409 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-ethoxy-phenyl) -amide; MS (ESI) / z 403 [M + H] +; methyl ester of 4- acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 417 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-phenyl) -amide.; MS (ESI) m / z 377 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-phenyl) -amide; MS (ESI) m / z 377 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-phenoxy-phenyl) -amide; MS (ESI) m / z 451 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid biphenyl-2-ylamide; MS (ESI) / z 435 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-hydroxy-naphthalene-1-yl) -amide; MS (ESI) m / z 425 [M + H] + (2,3-dihydro-benzo [1,4] dioxin-6-yl) -amide of 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3 -amide. -carboxylic; MS (ESI) m / z 417 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinoline-6-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid isoquinolin-5-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-isopropoxy-phenyl) -amide; MS (ESI) m / z 417 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3-chloro-2- (2-hydroxy-ethyl) -phenyl] -amide; MS (ESI) m / z 437 [M + H] +; (4- {[2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -phenyl) -acetic acid ethyl ester; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxymethyl-2-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-diethoxy-4-morpholin-4-yl-phenyl) -amide; MS (ESI) m / z 532 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methyl-3-nitro-phenyl) -amide; S (ESI) m / z 418 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-hydroxymethyl-2-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-5-nitro-phenyl) -amide; MS (ESI) m / z 418 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxy-phenyl) -amide; MS (ESI) m / z 375 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (acetyl-methyl-amino) -phenyl] -amide; MS (ESI) m / z 430 [M + H] +; 2- Isopropyl ester. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-lH-indol-5-yl) -amide; MS (ESI) m / z 412 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-hydroxymethyl-4-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 3,5-Dichloro-4-ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 499 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, 5-dichloro-4-pyrr-1-yl-phenyl) -amide; MS (ESI) m / z 492 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-isopropoxy-phenyl) -amide; MS (ESI) m / z 417 [M + H] +; Phenyl ester of 2- acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 479 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-fluoro-phenyl) -amide; MS (ESI) m / z 411 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-bromo-5-nitro-phenyl) -amide; MS (ESI) m / z 482 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxy-2-methyl-phenyl) -amide; MS (ESI) m / z 389 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-5-nitro-phenyl) -amide; MS (ESI) m / z 434 [M + H] +; [2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-yl] - (2-methyl-3,4-dihydro-2H-quinolin-1-yl) -methanone; MS (ESI) m / z 413 [M + H] +; Ethyl 5- (4- {[2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -phenyl} -2-methyl acid ester -furan-3-carboxyl; MS (ESI) m / z 511 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-fluoro-phenyl) -amide; MS (ESI) m / z 411 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2, 4-dimethoxy-phenyl) -amide; MS (ESI) m / z 453 [M + H] +; [2- (5-Methyl-thieno [2r 3-d] irimidin-4-ylsulfanyl) -phenyl] -amide of 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3 -amide. carboxylic; MS (ESI) m / z 539 [M + H] +; [[2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lfi-pyrrole-3-carbonyl] - (4-trifluoromethoxy-phenyl) -amino] -acetic acid ethyl ester; MS (ESI) m / z 529 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-trifluoromethoxy-phenyl) -amide; MS (ESI) m / z 477 [M + H] +; (3-Bromo-4-trifluoromethoxy-phenyl) -amide 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 521 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-tert-butylcarbamoyl-phenyl) -amide; MS (ESI) m / z 458 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-benzothiazol-6-yl) -amide; MS (ESI) m / z 430 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-2-fluoro-phenyl) -amide; MS (ESI) m / z 411 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4,6-dimethoxy-phenyl) -amide; MS (ESI) m / z 453 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,, 5-trimethyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-3-methoxy-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-methyl-benzoyl) -phenyl] -amide; MS (ESI) 'm / z [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzoyl-5-methyl-phenyl) -amide; MS (ESI) m / z 477 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2, 2, 2-trifluoro-ethoxy) -5-trifluoromethyl-phenyl] -amide; MS (ESI) m / z 525 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-piperidin-1-yl-5-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 510 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzoyl-4-chloro-phenyl) -amide; MS (ESI) m / z 497 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-chloro-benzoyl) -phenyl] -amide; MS (ESI) m / z 497 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-cyclohexyl-2-methoxy-phenyl) -amide; MS (ESI) m / z 471 [M + H] +; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2-methoxy-phenoxy) -5-trifluoromethyl-phenyl] -amide; MS (ESI) m / z 549 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-methoxy-phenoxy) -5-trifluoromethyl-phenyl] -amide; MS (ESI) m / z 549 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2, 6-dimethyl-phenyl) -amide; MS (ESI) m / z 421 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4,6-dimethyl-phenyl) -amide; S (ESI) m / z 421 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl-2-methoxy-phenyl) -amide; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methoxy-biphenyl-3-yl) -amide; MS (ESI) m / z 465 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-pyrrol-1-phenyl) -amide; MS (ESI) m / z 424 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-5-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 457 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methoxy-2-methyl-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sec-butyl-phenyl) -amide; MS (ESI) m / z 415 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-2,6-diethyl-phenyl) -amide; MS (ESI) m / z 449 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-phenyl) -amide; MS (ESI) m / z 393 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, 3, 4-trifluoro-phenyl) -amide; MS (ESI) m / z 413 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-isopropyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-tert-butyl-phenyl) -amide.; MS (ESI) m / z 415 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-propyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; Acid 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -4-methyl-benzoic; MS (ESI) m / z 417 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinoline-5-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-hydroxy-3-methyl-phenyl) -amide; MS (ESI) m / z 389 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-2-ethyl-phenyl) -amide; MS (ESI) m / z 465 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (8-hydroxy-quinolin-5-yl) -amide; MS (ESI) m / z 426 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sulfamoyl-phenyl) -amide; MS (ESI) m / z 438 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-imidazol-1-yl-phenyl) -amide; MS (ESI) m / z 425 [M + H] +; Acid 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -nicotinic; MS (ESI) m / z 404 [M + H] +; . { 4- [2- (2-chloro-phenylcarbamoyl) -acetyl] -phenyl} -2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid amide; MS (ESI) m / z 554 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-methyl-2-oxo-imidazolidin-1-yl) -phenyl] -amide; MS (ESI) m / z 457 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (pyrimidin-2-ylsulfamoyl) -phenyl] -amide; MS (ESI) m / z 516 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (3, 5-dimethyl-pyrazol-l-yl) -phenyl] -amide; MS (ESI) m / z 453 [M + H] +; 5-Chloro-4- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carbonyl] -amiho} -2-methoxy-benzoic; MS (ESI) m / z 467 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- ((E) -2-pyridin-2-yl-vinyl) -phenyl] -amide; MS (ESI) m / z 462 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (thiazol-2-ylsulfamoyl) -phenyl] -amide; MS (ESI) m / z 521 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (morpholin-4-sulfonyl) -phenyl] -amide; MS (ESI) m / z 508 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ethoxy-phenyl) -amide; MS (ESI) m / z 403 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-phenyl) -amide m / z 389 [M + H] +; (4,5-Trifluoromethoxy-phenyl) -amide of 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 443 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, -dimethyl-phenyl) -amide; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-methyl-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-phenyl) -amide; MS (ESI) m / z 377 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methoxy-phenyl) -amide; MS (ESI) m / z 389 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-dimethyl-phenyl) -amide; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 461 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid isoxazol-3-ylamide; MS (ESI) m / z 350 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-methyl-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; (4-bromo-phenyl) -amide. 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 437 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-phenoxy-phenyl) -amide; MS (ESI) m / z 451 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-fluoro-phenyl) -amide; MS (ESI) m / z 411 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, 3, 5, 6-tetrafluoro-phenyl) -amide; MS (ESI) m / z 431 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-dimethyl-phenyl) -amide.; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-methoxy-phenyl) -amide; MS (ESI) m / z 423 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-methox-phenyl) -amide; MS (ESI) m / z 423 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methoxy-phenyl) -amide; MS (ESI) m / z 389 [M + H] +; 3,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4,5-trimethoxy-phenyl) -amide; MS (ESI) m / z 449 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-methoxy-phenyl) -amide; MS (ESI) m / z 423 [M + H] +; (3,5-dichloro-phenyl) -amide of 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-pyridin-2-yl) -amide; MS (ESI) m / z 394 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid benzo [1,3] dioxol-5-ylamide; MS (ESI) m / z 403 [M + H] +; 2- ethyl ester. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 431 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinoline-8-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dimethyl-phenyl) -amide; MS (ESI) m / z 387 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH "-pyrrole-3-carboxylic acid (3,4-dimethoxy-phenyl) -amide, m / z 419 [M + H] ] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-2-methyl-phenyl) -amide; S (ESI) m / z 451 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid naphthalene-l-amide; MS (ESI) m / z 409 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-dimethoxy-phenyl) -amide; MS (ESI) m / z 419 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-2-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 445 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-isoxazol-3-yl) -amide; MS (ESI) m / z 364 [M + H] +; Acid 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-prrol-3-carbonyl] -amino} -3-methyl-benzoic; MS (ESI) m / z 417 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (lH-indol-5-yl) -amide; MS (ESI) m / z 398 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-3-nitro-phenyl) -amide; MS (ESI) m / z 422 [M + H] +; Pentyl ester of 4-acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 473 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,5-trifluoro-phenyl) -amide; MS (ESI) m / z 413 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (bromo-2-chloro-phenyl) -amide; MS (ESI) m / z 471 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-acetyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-acetyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; Acid 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -5-methyl-benzoic; MS (ESI) m / z 417 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methyl-benzothiazol-2-yl) -amide; MS (ESI) m / z 430 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-hydroxy-5-isopropyl-2-methyl-phenyl) -amide; MS (ESI) m / z 431 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-acetyl-phenyl) -amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-nitro-phenyl) -amide; MS (ESI) m / z 404 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-trifluoromethoxy-phenyl) -amide; MS (ESI) m / z 443 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-dimethyl-phenyl) -amide; MS (ESI) m / .z 387 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methylsulphane- [l, 3,] thiadiazol-2-yl) -amide; MS (ESI) m / z 413 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methyl-isothiazol-5-yl) -amide; MS (ESI) m / z 380 [M + H] +; 2,5-Dimethyl-l- '(2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-acetyl-benzo [1,3] dioxol-5-yl) -amide; MS (ESI) m / z 445 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid thiazole-2-ylamide; MS (ESI) m / z 366 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid pyridin-4-ylamide; MS (ESI) m / z 360 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-benzothiazol-2-yl) -amide; MS (ESI) m / z 450 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-dichloro-phenyl) -amide; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methyl-thiazol-2-yl) -amide; MS (ESI) m / z 380 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-ethylsulphane- [1, 3, 4] thiadiazol-2-yl) -amide; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-benzothiazol-5-yl) -amide; MS (ESI) m / z 430 [M + HJ +; [1, 3, 4] thiadiazol-2-ylamide of 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI) m / z 367 [M + H] +; 5- ethyl ester. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} - [1, 3, 4] thiadiazole-2-carboxylic acid; MS (ESI) m / z 439 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (l-methyl-lH-benzoimidazol-2-yl) -amide; MS (ESI) m / z 413 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-benzoylamino-2-methoxy-5-methyl-phenyl) -amide; MS (ESI) m / z 522 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl-isoxazol-3-yl) -amide; MS (ESI) m / z 406 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinolin-2-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid isoquinolin-3-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-acetyl-5-phenyl-thiophen-3-yl) -amide; MS (ESI) m / z 483 [M + H] +; methyl ester of acid 3-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -5- (4-fluoro-phenyl) -thiophene-2-carboxylic acid; MS (ESI) m / z 517 [M + H] +; Ethyl (2- {[2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -thiazol-4-yl) -acetic acid ethyl ester; MS (ESI) m / z 452 [M + H] +; Acid ester of 2- acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -4, 5, 6, 7-tetrahydro-benzo [b] thiophene-3-carboxylic acid; MS (ESI) m / z 491 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-oxo-4-trifluoromethyl-2H-chromen-7-yl) -amide; MS (ESI) m / z 495 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-hydroxy-phenyl) -amide; MS (ESI) m / z 409 [M + H] +; 2, 5-Dimethyl-1- (2-.trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-hydroxy-phenyl) -amide; MS (ESI) m / z 409 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid methylphenyl-amide; MS (ESI) m / z 373 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid biphenyl-4-ylamide; MS (ESI) m / z 435 [M + H] +; (2,3-Dihydro-indol-1-yl) - [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-yl] -methanone; MS (ESI) m / z 385 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4-dimethoxy-phenyl) -amide; MS (ESI) m / z 419 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl- (2-trifluoromethoxy-phenyl) -amide; MS (ESI) m / z 471 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-carbamoyl-phenyl) -amide; MS (ESI) m / z 402 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-cyanomethyl-phenyl) -amide; MS (ESI) m / z 398 [M + H] +; Methyl ester of 5-Bromo-2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 495 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl-m-tolyl-amide; MS (ESI) m / z 401 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-cyano-phenyl) -amide; MS (ESI) m / z 384 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-sulfamoyl-phenyl) -amide; MS (ESI) m / z 438 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-cyano-phenyl) -amide; MS (ESI) m / z 384 [M + H] +; (3, 4-Dihydro-2H-quinolin-1-yl) - [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-yl] -methanone; MS (ESI) m / z 399 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid o-tolylamide; MS (ESI) m / z 373 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 427 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid propyl-m-tolyl-amide; MS (ESI) m / z 415 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl- (5-hydroxy-2-methyl-phenyl) -amide; MS (ESI) m / z 417 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid acetyl- (3-ethylamino-4-methyl-phenyl) -amide; MS (ESI) m / z 458 [M + H] +; (5-Bromo-2, 3-dihydro-indol-1-yl) - [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-yl] -methanone; MS (ESI) m / z 463 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl-o-tolyl-amide; MS (ESI) m / z 401 [M + H] +; 4-ethyl ester. { Butyl- [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -benzoic; MS (ESI) m / z 487 [M + H] 4; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-pyridin-4-yl) -amide; MS (ESI) m / z 394 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid pyrimidin-4-ylamide; MS (ESI) m / z 361 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-dimethyl-isoxazol-5-yl) -amide; MS (ESI) m / z 378 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dimethyl-2H-pyrazol-3-yl) -amide; MS (ESI) m / z 377 [M + H] +; methyl ester of 3- acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -thiophen-2-carboxylic acid; MS (ESI) m / z 423 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methyl-isoxazol-5-yl) -amide; MS (ESI) m / z 3.64 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-cyano-phenyl) -amide; MS (ESI) m / z 418 [M + H] +; (2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (lH-indazol-6-yl) -amide; MS (ESI) m / z 399 [M + H] +; 2- (5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-carbazol-9-yl-phenyl) -amide, m / z 524 [M] + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-acetylsulfamoyl-phenyl) -amide; MS (ESI) m / z 480 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ureidosulfonyl-phenyl) -amide; MS (ESI) m / z 481 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-phenyl-thiazol-2-yl) -amide; MS (ESI) m / z 442 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-carbamoyl-phenyl) -amide; MS (ESI) m / z 402 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-mercapto-benzothiazol-6-yl) -amide; MS (ESI) m / z 448 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-3-fluoro-phenyl) -amide; MS (ESI) m / z 455 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-pyridin-3-yl) -amide; MS (ESI) m / z 390 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-ethyl-pyridin-2-yl) -amide; MS (ESI) m / z 388 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (l-bromo-isoquinolin-3-yl) -amide; MS (ESI) m / z 488 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-cyano-5-methyl-phenyl) -amide; MS (ESI) m / z 398 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-trifluoromethyl-pyridin-3-yl) -amide; MS (ESI) m / z 428 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4'-fluoro-biphenyl-3-yl) -amide amide; MS (ESI) m / z 453 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3 '-fluoro-biphenyl-4-yl) -amide; MS (ESI) m / z 453 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-fluoro-phenyl) -thiazol-2-yl] -amide; MS (ESI) m / z 460 [M + H] +; (1,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1,3-dihydro-isobenzofuran-5-yl) -amide; MS (ESI) m / z 401 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [5- (4-fluoro-phenyl) -2H-pyrazol-3-yl] -amide; MS (ESI) m / z 443 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzyl-phenyl) -amide; MS (ESI) m / z 449 [M + H] +; Acid ethyl ester 2-. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -5-methyl-4-phenyl-thiophene-3-carboxylic acid; MS (ESI) m / z 527 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (9-ethyl-9H-carbazol-3-yl) -amide; MS (ESI) m / z 476 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methyl-5-phenyl-2H-pyrazol-3-yl) -amide; MS (ESI) m / z 439 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1-methyl-lH- [1,2,4] triazol-3-yl) -amide; MS (ESI) m / z 364 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-chloro-phenoxy) -phenyl] -amide; MS (ESI) m / z 485 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-5-methyl-isoxazol-3-yl) -amide; MS (ESI) m / z 442 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [6- (4-tert-butyl-phenoxy) -pyridin-3-yl] -amide; MS (ESI) m / z 508 [M + H] +; methyl ester of 3- acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -5-phenyl-thiophene-2-carboxylic acid; MS (ESI) m / z 499 [M + H] +; Acid ester of 2- acid. { [2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amino} -4-furan-2-yl-thiophene-3-carboxylic acid; MS (ESI) m / z 503 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-butyl-2-methyl-phenyl) -amide; MS (ESI) m / z 429 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-3-methyl-phenyl) -amide; MS (ESI) m / z 407 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-3-chloro-phenyl) -amide; MS | (ESI) m / z 471 [M + H] +; 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-1H-pyrazol-3-yl) -amide; MS (ESI) m / z 363 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methoxy-benzothiazol-2-yl) -amide; MS (ESI) m / z 446 [M + H] +; 2, 5-Dimethyl-1- (2-, trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-chloro-pyridin-3-yl) -amide; MS (ESI) m / z 394 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinoline-3-ylamide; MS (ESI) m / z 410 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4,6-dimethyl-pyridin-2-yl) -amide; MS (ESI) m / z 388 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-ethoxy-benzothiazol-2-yl) -amide; MS (ESI) m / z 460 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methoxy-pyridin-3-yl) -amide; MS (ESI) m / z 390 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-trifluoromethoxy-phenyl) -amide; MS (ESI) -m / z 443 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-4-nitro-phenyl) -amide; MS (ESI) m / z 434 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-hydroxy-5-nitro-phenyl) -amide; MS (ESI) m / z 420 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl-2-hydroxy-phenyl) -amide; MS (ESI) m / z 431 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-mercapto-phenyl) -amide; MS (ESI) m / z 391 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-nitro-phenylsulphane) -phenyl] -amide; MS (ESI) m / z 512 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-nitro-3-trifluoromethyl-phenyl) -amide; MS (ESI) m / z 472 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl) -amide; MS (ESI) m / z 439 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1,3,5,5-trimethyl-1H-pyrazol-4-yl) -amide; MS (ESI) m / z 391 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-pyrazol-l-yl-phenyl) -amide; MS (ESI) m / z 425 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-dicyano-phenyl) -amide; MS (ESI) m / z 409 [M + H] +; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methoxy-2-methyl-4-nitro-phenyl) -amide; MS (ESI) m / z 448 [M + H] +; and [2-methoxy-5- (1-methyl-1-phenyl-ethyl) -phenyl] -amide of 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid MS (ESI) m / z 507 [M + H] +.

EXAMPLE 3 PREPARATION OF [4- (4-FLUOROBENZOYL) -PHENYL] -2-DIMETHYL-1- (2-TRIFLOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC ACID A. A solution of tin chloride dihydrate (II) (1.05 g, 4.7 mmol) in concentrated hydrochloric acid (4.2 mL) was added to 4-fluoro-4'-nitrobenzophenone (0.37 g, 1.5 mmol) in a mixture of DME (4 mL) and EtOH (5 mL) at a rate such that the internal temperature remained below 35 ° C. After 5 hours the reaction mixture was cooled by adding ice water (40 mL). The mixture was diluted with DCM (25 mL), made basic (pH = 11) by adding 10% NaOH and then extracted with DCM (2x25 mL). The combined extracts were washed with water and saline, dried (anhydrous Na 2 SO 4) and concentrated under reduced pressure. The crude material was subjected to chromatography (silica, EtOAc / Hexanes, 0: 100 to 40:60) to give 4'-amino-4-fluorobenzophenone (0.27 g, 83%) as a white solid. 1H-NMR (DMSO-d6) d 7.68 (2H, dd, J = 5.6, 8.8), 7.51 (2H, d, J = 8.8), 7.32 (2H, app t, J = 8.8), 6.61 (2H, d, J = 8.8), 6.18 (2H, br s) '. A solution of tin chloride dihydrate (II) (1.05 g, 4.7 mmol) in concentrated hydrochloric acid (4.2 mL) was added to 4-fluoro-4'-nitrobenzophenone (0.37 g, 1, 5 mmol) in a mixture of DME (4 The title compound was prepared from 4'-amino-4-fluorobenzophenone in a manner similar to that described in Example ID.1H-NMR (DMSO-d6) 5 9, 82 ( 1H, s), 8.01 (1H, d, J = 7.8), 7.97 (2H, d, J = 8.8), 7.92 (1H, app t, J = 7.6) , 7.78-7.84 (3H, m), 7.74 (2H, d, J = 8.8), 7.51 (1H, d, J = 7.6), 7.39 (2H, app t, J = 8.8), 6.68 (1H, s), 2.15 (3H, s), 1.89 (3H, s); S (ESI): 481 (MH +).

B. In a manner similar to that described for Example 3A, the following compounds were prepared from the appropriate benzophenones: 2,5-dimethyl-1- (2- (3-fluorobenzoyl) -phenyl] -amide of the acid -trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI): 481 (MH +); [2- (2-Fluorobenzoyl) -phenyl] -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI): 481 (MH +).

EXAMPLE 4 PREPARATION OF (4-ETHYLTH-PHENYL) -AMIDE OF 2, 5-DIMETHYL-L- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC ACID A. To a solution of NaOH (0.13 g, 3.2 mmol) in EtOH (10 mL) was added 4-nitrothiophenol (0.50 g, 3.2 mmol) and iodoethane (0.26 mL, 3, 2 mmol). After stirring for 2 hours the reaction mixture was added to water (30 mL) and extracted with Et0 (3 x 25 mL). The combined extracts were washed with said NH 4 Cl (3 x 25 mL) and saline, dried (MgSO) and concentrated under reduced pressure. The crude material was subjected to chromatography (silica, EtOAc / Hexanes 0: 100. 30:70) to give l-ethylthio-4-nitrobenzene (0.35 g, 59%) as a yellow crystalline solid. ½-NMR (CDC13) d 8.13 (2H, d, J = 8.8), 7.32 (2H, d, J = 8.8), 3.06 (2H, q, J = 7.3) ), 1.41 (3H, t, J = 7.3).

The title compound was prepared from 1-ethylthio-4-nitrobenzene in a similar manner to that described in Example 3A. MS (ESI): 419 (MH +).

PREPARATION OF (4-ETANOSULFO IL-FENIL) -AMIDE OF THE ACID 2,5-DIMETHYL-1- (2-TRIFLUOROMETIL-FENIL) -1H-PIRROL-3-CARBOXÍLICO B. To a solution of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ethylthio-phenyl) -amide (0.13 g, "0.30 mmol) in DCM (3 mL) was added 3-chloroperoxybenzoic acid (77%, 0.17 g, 0.75 mmol). After stirring for 1.5 h the reaction mixture was diluted with DCM (50 mL), washed with saturated NaHCO3 (2 x 20 mL) and saline (20 mL), then dried (Na2SC > anhydrous) and concentrated under reduced pressure. The crude material was purified by inverted phase chromatography (C18 column) eluting with 0.05% TFA in MeCN / H20. (30:70 to 90:10) to give the title compound (30 mg) as a white solid. 1 H-NMR (DMSO-d 6) d 9.87 (1H, s), 7, 99-8, 06 (3H, m), 7.92 (1H, app t, J = 7, 6), 7, 77 -7, 85 (3H, m), 7.51 (1H, d, J = 7.6), 6.67 (1H, s), 3.24 (2H, q, J = 7.3), 2 14 (3H, s), 1.89 (3H, s), 1.10 (3H, t, J = 7.3); MS (ESI): 451 (MH +).

C. In a manner similar to that described for Examples 4A-B, the following compound was prepared by replacing iodoethane with 2-bromopropane. 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (propane-2-sulfonyl) -phenyl] -amide. 1 H-NMR (DMSO-de) d 9.88 (1H, s), 8.04 (2H, d, J = 8.8), 8.01 (1H, d, J = 7.8), 7, 92 (1H, app t, J = 7.8), 7.83 (1H, app t, J = 7.8), 7.77 (2H, d, J = 8.8), 6, ßß (1H, s), 3.34 (H, sept, J = 6.8), 2.14 (3H, s), 1.89 (3H, s), 1.16 (6H, d, J = 6.8); MS (ESI): 465 (MH +).

EXAMPLE 5 PREPARATION OF (4-METHANOSULPHONYL-3-TRIFLUOROMETHYL-PHENYL) -AMIDE OF 2, 5-DIMETHYL-L- (2-TRIFLOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC A. A mixture of 2-fluoro-5-nitro-benzotrifluoride (0.50 g, 2.4 mmol) and sodium methanesulfonate (0.25 g, 2.4 mmol) in anhydrous DMF (1.0 mL) was added. heated at 120 ° C with stirring. After 18 hours the reaction mixture was cooled, concentrated and chromatographed (silica, EtOAc / Hexanes, 0: 100 to 40:60) to give 2-methanesulfonyl-5-nitro-benzotrifluoride (0.41 g , 64%) as a white solid. "" "H-NMR (CDC13) 6 8, 76 (1H, d, J = 2.0), 8.62 (1H, dd, J = 2.0, 8.8), 8.57 (1H, d, J = 8.8), 3.26 (3H, s) The title compound was prepared from 2-methanesulfonyl-5-nitro-benzotrifluoride in a manner similar to that described in Example 3A.XH-NMR (DMSO ^ -de) d 10.14 (1H, s), 8.50 (1H, d, J = 2.0), 8.35 (1H, dd, J = 2.0, 8.6), 8, 16 (1H, d, J = 8.8), 8.02 (1H, d, J = 7.8), 7.92 (1H, app t, J = 7.8), 7.82 (1H, app t, J = 7.8), 7.52 (1H, d, J = 7.8), 6.69 (1H, s), 3.26 (3H, s), 2.15 (3H, s ), 1.89 (3H, s); MS (ESI): 505 (MH +).

B. In a manner similar to that described for Example 5A, the following compound was prepared by replacing 2-fluoro-5-nitrobenzotrifluoride with 3-chloro-4-fluoro-nitrobenzene: (3-chloro-4-methanesulfonyl-phenyl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid: 1H-NMR (CD2C12). d 8.12 (1H, d, J = 2.3), 8.03 (1H, d, J = 8.6), 7.89 (1H, d, J = 7.8), 7.77 ( 1H, ap t), 7.73 (1H, s), 7.69 (1H, app t), 7.57 (1H, dd, J = 2.3, 8.6), 7.30 (1H, d, J = 7.8), 6.24 (1H, s), 3.22 (3H, s), 2.23 (3H, s), 1.94 (3H, s); MS (ESI): 471 (MH +).

C. In a manner similar to that described for Example 5 ?, the following compound was prepared by replacing 2-fluoro-5-nitro-benzotrifluoride with 2-chloro-5-nitropyridine: (6-methanesulfonyl-pyridin-3-yl) -2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -amide. -lH-pyrrole-3-carboxylic acid: 1H-NMR (DMSO-d6) d 10.08 (1, s), 9.09 (1H, d, J = 2.3), 8.51 (1H, dd, J = 2.3, 8.6), 8.02 (2H, d, J = 8.6), 7.93 (1H, app t), 7.82 (1H, app t), 7.52 ( 1H, d, J = 7.6), 6.68 (1H, s), 3.24 (3H, s), 2.15 (3H, s), 1.90 (3H, s); S (ESI): 438 (MH +).

D. In a manner similar to that described for Example 1C, the following compounds were prepared from the appropriate amines generated for Examples 5B-C. (1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (3-chloro-4-methanesulfonyl-phenyl) -amide: 1H-NMR (CD2C12) d 8.12 (1H, d, J = 2.0), 8.03 (1H, d, J = 8.6), 7.73 (1H, s), 7.60 (1H, dd, J = 2.8, 8.6), 7.57 (1H, dd, J = 2.0, 8.6), 7.47 (1H, m), 7.32 (1H, dd, J = 5.0, 8 , 6), 6.24 (1H, s), 3.22 (3H, s), 2.24 (3H, s), 1.94 (3H, s); MS (ESI): 489 (MH +). 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (6-methanesulfonyl-pyridin-3-yl) -amide (DMSO-d6) ) d 10.08 (1, s), 9.08 (1H, d, J = 2.3), 8.51 (1H, dd, J = 2.3, 8.6), 8.02 (1H , d, J = 8.6), 7.97 (1H, dd, J = 2.8, 8.8), 7.81 (1H, m), 7.62 (1H, dd, J = 5, 1, 8.8), 6.68 (1H, s), 3.24 (3H, s), 2.16 (3H, s), 1.90 (3H, s); S (ESI): 456 (MH +).

E. In a manner similar to that described for Example 1, the following compound was prepared from 2-chloro-4-methanesulfonyl-aniline. In a manner similar to that described for Example ID, the following compound was prepared from 2-chloro-4-methanesulfonyl-aniline: 2,5-dimethyl-l- (2-chloro-4-methanesulfonyl-phenyl) -amide of 2,5-dimethyl-l- ( 2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ES): 471 (MH +); EXAMPLE 6 PREPARATION OF (3-MET0XI-4-SULFAM0IL-PHENYL) - DIMETHYL ACID-1- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC A. To a concentrated solution of ammonium hydroxide (28%, 2.5 mL, 20 minol) was added 2-methoxy-4-nitrobenzenesulfonyl chloride (0.25 g, 1.0 mmol) carefully. After stirring 24 hours the reaction mixture was added to said NH 4 Cl (50 mL) and extracted with DCM (2 x 50 mL). The combined extracts were washed with saline, dried (anhydrous Na 2 SO 4) and concentrated under reduced pressure. The crude residue was subjected to chromatography (silica, MeOH / DCM, 0.100 to 10:90) to give 2-methoxy-4-nitrobenzenesulfonamide (0.16 g, 68%) as a pale brown solid. 1 H-NMR (DMS0-d 6) d 7.99 (1H, d), 7, 90-7, 95 (2H, m), 7.47 (2H, br s), 4.04 (3H, s).

The title compound was prepared from 2-methoxy-4-nitrobenzenesulfone in a similar manner to that described for Example 3A. 1H-NMR (DMSO-d6) d 9.69 (1H, s), 8.01 (1H, d, J = 8.1), 7.92 (1H, app t, J = 7.6), 7 , 81 (1H, app t, J = '7.6), 7.74 (1H, d, J = 1.8), 7.63 (1H, d,' J = 8.6), 7.50 (1H, d, J = 7.6), 7.47 (1H, dd, J = 1.8, 8.6), 6.93 (2H, s), 6.66 (1H, s), 3 , 88 (3H, s), 2.14 (3H, s), 1.89 (3H, s); MS (ESI): 468 (MH +).

B. In a manner similar to that described for Example 6A, the following compound was prepared by replacing the ammonium hydroxide with dimethylamine. 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-methoxy-phenyl) -amide. 1 H-NMR (DMSO-de) d 9.76 (??, 's), 8.01 (1H, d, J = 7.8), 7.92 (1H, app t, J = 7.8) , 7.81 (1H, app t, J = 7.8), 7.78 (1H, d, J = 1.8), 7.64 (1H, d, J = 8.6), 7.48 -7.54 (2H, m), 6.65 (1H, s), 3.86 (3H, s), 2.70 (6H, s), 2.14 (3H, s), 1.89 ( 3H, s); MS (ESI): 496 (MH +).

C. In a manner similar to that described for Example 1C, the following compound was prepared from the amine generated for the Example 6A: 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (3-methoxy-4-sulfamoyl-phenyl) -amide: 1H-NMR (DMSO -d6) d 9.69 (1H, s), 7.96 (1H, dd, J = 3.0, 8.8), 7.80 (1H, ddd, 'J = 3.0, 8.3 , 8.3), 7.74 (1H, d, J = 2.0), 7.63 (1H, d, J = 8.6), 7.61 (1H, dd, J = 5.0, 8.6), 7.47 (??, 'dd, J = 2.0, 8.6), 6.93 (2H, s), 6.66 (1H, s), 3.88 (3H, s), 2.15 (3H, s), 1.89 (3H, s) / MS (ESI): 486 (MH +).

EXAMPLE 7 PREPARATION OF (3-CHLORO-4-SULFAMOIL-PHENYL) -AMIDE OF THE ACID 2,5-DIMETHYL-1- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC A. To a solution of 2-chloro-4-nitroaniline (2.10 g, 12.1 mmol) in TFA (40 mL) was added concentrated HC1 (4 mL). The reaction mixture was cooled to 0 ° C and then charged with a solution of sodium nitrite (1.06 g, 15.4 mmol) in 3 mL of water over a period of 20 minutes while maintaining an internal temperature of 0 ° C. After a further 20 minutes the reaction mixture was poured into a solution of CuCl (80 mg), CuCl 2 (0.826 g, 6.2 mmol) sulfurous acid (40 mL) in acetic acid (40 mL) cooled to 0 ° C. . After the initial effervescence ceased, the reaction mixture was allowed to stir at room temperature. After 30 minutes the reaction mixture was diluted with water (200 mL) and extracted with hexanes (2 x 100 mL). The combined extracts were concentrated under reduced pressure to give the crude sulfonyl chloride (1.8 g) as an amber oil. This intermediate product was dissolved in acetone (25 mL) and treated with concentrated ammonium hydroxide (5 mL). After 1 hour the reaction mixture was diluted with ammonium chloride (25 mL) and water (100 mL), then extracted with DCM (2 x 75 mL). The combined extracts were washed with saline, dried (Na 2 SO 4), concentrated under reduced pressure and subjected to chromatography (silica, EtOAc / hexanes, 0: 100 to 50:50) to give 2-chloro-4-nitro Benzenesulfonamide (1.1 g, 38%) as a pale yellow solid. ^ - MR (SOD-d6) d 8.44 (1H, d, J = 2.3), 8.35 (1H, dd, J = 2.3, 8.6), 8.22 (1H, d, J = 8.6), 7.99 (2H, s). The title compound was prepared from 2-chloro-4-nitro-benzenesulfonamide in a manner similar to that described for Example 3A. 1 H-NMR (DMSO-de) d 9.86 (1H, s), 8.13 (1H, d, J = 1.8), 8.01 (1H, d, J = 7.6), 7, 87-7.95 (2H, m), 7.78-7.86 (2H, m), 7.51 (1H, d, J = 7.6), 7.47 (2H, s), 6, 66 (1H, s), 2.14 (3H, s), 1.88 (3H, s); MS (ESI): 472 (MH +).

B. In a manner similar to that described in Example 7A, the following compound was prepared by replacing 2-chloro-4-nitroaniline with 4-nitro-2-trifluoromethyl-amine: (4-sulfamoyl-3-trifluoromethyl-phenyl) -amide of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid. 1H-NMR (DMSO-d6) d 10.01 (1H, s), 8.40 (1H, d, J = 2.0), 8.24 (1H, dd, J = 2.0, 8.8 ), 8.09 (1H, d, J = 8.8), 8.02 (1H, d, J = 7.8), 7.92 (1H, app t), 7.82 (1H, app t ), 7.56 (2H, s), 7.52 11H, s), 6.68 (1H, s), 2.15 (3H, s), 1.89 (3H, s); MS (ESI): 506 (MH +).

C. In a manner similar to that described in Example 1C, the following octets were prepared from the appropriate anilines generated in Examples 7A-B: 1- (4- (4- chloro-4-sulfamoyl-phenyl) -amide) fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid; |'-fi-NMR (DMS0-d6) d 9.86 (1H, s), 8.13 (1H, d, J = 1.8), 7.96 (1H, dd, J = 2.8, 8.8), 7.90 (1H, d, J = 8.8), 7.84 (1H, dd, J = 1.8, 8.8), 7, 77-7, 82 (1H, m ), 7.61 (1H, dd, J = 5.1, 8.8), 7.47 (2H, s), 6.65 (1H, s), 2.15 (3H, s), 1, 89 (3H, s); MS (ESI): 490 (MH +). L- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-sulfamoyl-3-trifluoromethyl-phenyl) -amide (DMSO-d6) ) 5 10.02 (1H, s), 8.39 (1H, d, J = 2.0), 8.24 (1H, dd, J = 2.0, 8.8), 8.09 (1H , d, J = 8.8), 7.96 (1H, dd, J = 2.8, 8.8), 7.80 (1H, ddd, J = 2.8, 8.3, 8.3 ), 7.62 (1H, dd, J = 5.1, 8, 6), 7.56 (2H, s), 6.68 (1H, s), 2.16 (3H, s), 1, 90 (3H, s); MS (ESI): 524 (MH +).

D. In a manner similar to that described for Example 1C, the following compound was prepared from 2,5-dimethyl-l-naphthalen-1-yl-1H-pyrrole-3-carboxylic acid chloride (used in Example 1G) and 4-amino-2-chloro-benzenesulfonamide (see Example 7A): 2,5-Dimethyl-1-naphthalene-1-yl-1H-pyrrole- (3-chloro-4-sulfamoyl-phenyl) -amide. 3-carboxylic; MS (ESI): 454 (MH +).

EXAMPLE 8 PREPARATION OF ACID 4- ( { 2, 5-DIMETHYL-L- [2- (TRIFLUOROMETHYL) PHENYL] 1H-PIRR0L-3-CARB0NIL.} -AMINO) -BENZOIC In a manner similar to that described in Example 1F ethyl ester of 4- (. {2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -IH-pyrrole-3-carbonyl} -amino ) -benzoic acid was prepared from ethyl 4-aminobenzoate, MS (ESI) m / z 431 [M + H] +.

A mixture of 4- (. {2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carbonyl} -amino) -benzoic acid ethyl ester (0.46 g) g, 1.1 mmol), lithium hydroxide monohydrate (0.15 g, 3.5 mmol, 3.3 equivalents), 2 mL of water, 2 mL of THF, and 3 mL of MeOH was stirred for 17 hours and then it was concentrated under reduced pressure. The resulting suspension was treated with 200 L of. TFA and washed in a separatory funnel with DCM and water. The water was separated and extracted with DCM. The combined extracts were dried (aaSCa) and concentrated in vacuo. The crude acid was purified by inverted phase HPLC to give the title compound (65 mg, 15%) as a colorless solid. 1H NR (DMSO-d6): 512.7-12.8 (br s, 1H), 9.84 (s, 1H), 8.12 (d, J = 8 Hz, 1H), 8.03 (t , J = 8 Hz, 1H), 8.00 (s, 4H), 7.93 (t, J = 8 Hz, 1H), 7.61 (d, J = 2H), 6.77 (s, 1H) ), 2.26 (s, 3H), 2.00 (s, 3H); MS (ESI) m / z 403 [M + H] +.

EXAMPLE 9 PREPARATION OF [4- (METANOSULPHINIL) PHENYL] -AMIDE OF THE ACID l- (2-BROMOFE IL) -2,5-DIMETHYL-1H-PIRROL-3-CARBOXYLIC In a manner similar to that described in Examples 1A-1C, but replacing 4-fluoro-2- (trifluoromethyl) aniline with 2-bromoaniline and replacing sulfanilamide with 4-methylthioaniline, the following compound was prepared: (4-methylthio) 1- (2-Bromo-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid phenyl) -amide; ½ NMR (CDC13): d 7.68 (d, J = 8 Hz, 1H), 7.47 (d, J = 9 Hz, 2H), 7.40 (t, J = 8 Hz, 1H), 7 , 30 (t, J = 8 Hz, 1H), 7.19-7.23 (m, 3H), 6.12 (s, 1H), 2.43 (s, 3H), 2.24 (s, 3H), I, 90 (s, 3H); MS (ESI) m / z 415 and 417, both [M + H] +.

A suspension of (4-methylthio-phenyl) -amide of the acid.1- (2-bromo-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (2.4 g, 5.8 mol) in MeOH (5 mL) was prepared and then cooled to -10 ° C. To this suspension was added an Oxona solution (3, 92 g, 6.4 mmol) in water (10 mL) dropwise for 15 minutes. Then a solution of said sodium sulfite (40 mL) was added and the reaction mixture was washed in a separatory funnel with DCM (200 mL). The aqueous phase was separated and extracted with DCM. The combined extracts were dried (anhydrous a2SO) and concentrated in vacuo to give the title compound (2.5 g, 100%). ½ NMR (CDC13): d 9, 5 (s, 1H), 7.75 (d, J = 9 Hz, 2H), 7.69 (d, J = 8 Hz, 1H), 7.37-7, 43 (m, 3H), 7.26-7, 32 (m, 2H), 6.44 (s, 1H), 2.50 (s, 3H), l, 96 (s, 3H), l, 70 (s, 3H); MS (ESI) m / z 431 and 433, both [M + H] +.

EXAMPLE 10 PREPARATION OF (4-ETILSULFAMOIL-PHENYL) -2-DIMETHYL-1- [2- (TRIFLUOROMETHYLENE) PHENYL] -1H-PIRROL-3-CARBOXYLIC AND (4-DIETILSÜLFAMOIL-PHENYL) -AMIDE OF THE ACID ACID 2, 5-DI ETHYL- [2- (TRIFLUOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXYLIC To a suspension of 2,5-dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-sulfamoyl-phenyl) -amide (83 mg, 0.19 mmol) and 2C03 (34 mg) in anhydrous DMF (0.5 mL) was added ethyl iodide (15 μL, 0.19 mmol). After 19 hours, additional ethyl iodide (10 μL) was added. After 23 hours the reaction mixture was concentrated to dryness in vacuo. The residue was purified by reverse phase HPLC to give 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-ethylsulfamoyl-phenyl) -amide (17 mg, 19%) as a colorless powder; ½ NMR (D SO-cfc): d 9.7 (s, 1H), 7.90 (d, J = 8 Hz, 1H), 7.85 (d, J = 8 Hz, 2H), 7.81 (t, J = 8 Hz, 1H), 7.70 (t, J = 8 Hz, 1H), 7.60 (d, J = 8 Hz, 2H), 7.39 (d, J = 8 Hz, 1H), 7.28 (d, J-8 Hz, 1H), 6.54 (s, 1H), 2.66 (quintet, J = 7 Hz, 2H), 2.03 (s, 3H), l , 77 (s, 3H), 0.86 (t, J = 1 Hz, 3H); MS (ESI) m / z 466 [M + H] +. Also recovered from the reaction was dimethyl-1- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-diethylsulfamoyl-phenyl) -amide (12 mg, 13%) as a colorless solid; 1 H NMR (DMSO-d 6): d 9.9 (s, 1H), 8.11 (d, J = 8 Hz, 1H), 8.08 (d, J = 7 Hz, 2H), 8.04 ( t, J = 8 Hz, 1H), 7.92 (t, J = 8 Hz, 1H), 7.82 (d, J = 7 Hz, 2H), 7.60 (d, J = 8 Hz, 1H ), 6.77 (s, 1H), 3.25 (q, J = 7 Hz, 4H), 2.24 (s, 3H), l, 99 (s, 3H), l, 45 (t, J = 7 Hz, .6H); MS (ESI) ra 494 [M + H] + EXAMPLE 11 PREPARATION OF (4-METHANOSHLPHONYL-PHENYL) -AMID OF THE ACID 2,5-DIMETHYL-1- [4- ((E) -STIRIL) -2- (TRIFLONOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXYLIC L- [Bromo-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid [4- (methanesulfonyl) phenyl] -amide was prepared as described in Example 1G. A material solution was prepared 0.25M in DMF. A solution of trans-p-styreneboronic acid material was prepared 0.25 M in DMF, a solution of sodium carbonate material was prepared 1.0 M in water, and a solution of dihydrogen di-cycloobis material ( di-tert-butylphosphino- ??) dipaladate (2-) (P0Pd2) was prepared 0.025M in DMF. In a 1 dram reaction bottle were placed 100 of bromide material, 600 μl / of boronic acid material, and 150 μ? of PDPd2 material solutions. The solution was heated to 60 ° C-70 ° C and 150 μl > of solution of sodium carbonate material. After heating for 16 hours with stirring, the reaction flask was cooled and the seal was removed. Additional aliquots of the solutions of boronic acid (300 μ ??) and POPd2 (150 μ ?.) were added to the bottle, which was sealed and heated for 1 hour. The reaction mixture was cooled, filtered to remove solids, and. He concentrated in vacuum. The residue was purified by inverted phase HPLC to give the product as an off-white solid, yield: 22 mg (54%); ¾ NMR (CDC13.:5 7, 96 (s, 1H), 7.90 (d, J = 8 Hz, 2H), 7.8-7.85 (m, 3H), 7.76 (s, 1H ), 7.57 (d, J = 7 Hz, 2H), 7.42 (t, J = 8 Hz, 2H), 7.35 (m, 1H), 7.25 (d, J = 8 Hz, 1H), 7.19 (s, 1H), 6.25 (s, 1H), 3.06 (s, 3H), 2.28 (s, 3H), 1.97 (s, 3H), MS ( ESI) m / z 539 [M + H] +.

B. In a manner similar to that described for Example HA, the following compound was prepared by replacing the trans-β-styrenoboronic acid with the appropriate boronic acid: 1- (4'-Carbamoyl) (4-methanesulfonyl-phenyl) -amide. -3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid; 1 H NMR (DMSO-d 6): d 9.89 (s, 1 H), 8.26 (d, J = 9 Hz, 2 H), 8.12 (3, 1 H), 8.05 (d, J = 8 Hz, 4H), 7.7 (d, J = 9 Hz, 2H), 7.86 (d, - J = 9 Hz, 2H), 7.63 (d, J = 8 Hz, 1H), 7, 49 (s, 1H), 6.71 (s, 1H), 3.18 (s, 3H), 2.21 (s, 3H), 1.95 (s, 3H); MS (ESI) m / z 556 [M + H] +. 1- (4 '-Dimethylcarbamoyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1H NMR (DMS0-d6): d 9.89 (s, 1H), 8.24 (d, J = 8 Hz, 2H), 8.04 (d, 2H), 7.95 (d, J = 8 Hz, 4H), 7.86 (d, J = 9 Hz, 2H), 7, 62 (d, J = 8 Hz, 1H), 7.58 (d, J = 9 Hz, 2H), 6.70 (s, 1H), 3.18 (s, 3H), 3.02 (3, 3H), 2.97 (s, 3H), 2.20 (s, 3H), 1.95 (s, 3H); MS (ESI) m / z 584 [M + H] +. 1- [4- (1H-Indol-5-yl) -2-trifluoromethyl-phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1 H NMR (DMSO-d 6): d 11.49 (s, 1 H), 10.07 (s, 1 H), 8.38 (d, J = 7 Hz 2 H), 8.24 (d, J = 9 Hz, 3 H ), 8.06 (d, J = 9 Hz, 2H), 7.75 (m, 3H), 7.64 (m, 1H), 6.89 (s, 1H), 6.75 (m, 1H) ), 3.38 (s, 3H), 2.42 (s, 3H), 2.16 (s, 3H); MS (ESI) m / z 552 [M + H] +.

PREPARATION OF (-METANOSULFONIL-PHENYL) -AMIDE OF THE ACID l- (3-TRIFLÓOROMETIL-BIFENIL-4-IL) -2, 5-DIMETHYL-1H-PIRROL-3-CARBOXÍLICO AND VARIATIONS C. A solution of 0.25M material of 1- [4-bromo-2- (trifluoromethyl) phenyl] -2,5-dimethyl-1H-pyrrole-3 [4- (methanesulfonyl) phenyl] -amide was prepared. -carboxylic (Example 1G) in anhydrous DMF. The boronic acids (or boronate esters) were weighed individually and dissolved in DMF to give solutions of 0.25M material using a Tecan Genesis station. Material solutions of 1.0M Na2CO3 (aqueous) and 0.025M dihydrogen di-chlorobis (di-tert-butylphosphino-??) dipaladate (2-) (POPd2) in anhydrous DMF were also prepared. The Tecan was used to distribute 200 L of boronic acids, 100 μL of bromide, and 50 μL of solutions of POPd2 material in individual reaction flasks. The group of flasks was heated to 60-7 ° C and then each flask was treated with 50 μL of 1 M Na2C03. The bottles were sealed and shaken at 60 ° C-70 ° C. After heating overnight, the seal was removed from the flasks and another 100 μL of each boronic acid and 50 μL of POPd2 material solutions were distributed in respective flasks. After heating for 1 hour more, the samples were cooled, filtered and concentrated in vacuo. A solution of 0.25 M material of [4- (methanesulfonyl) phenyl] -amide of 1- [4-bromo-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3- was prepared. carboxylic acid (Example 1G) in anhydrous DMF.

D. Samples from the literature were processed as described in Example 2C. The following compounds were prepared in the manner described above in Examples 11A and C using the appropriate boronic acids. 1- (3'-Hydroxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 529 [M + H] +. 1- (4'-Butyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 569 [M + H] +. 1- (4'-Ethyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 541 [M + H] +. 1- (2 ', 61 -Difluoro-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) / z 549 [M + H] +. 1- (2'-Methoxy-5'-methyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide (ESI) ) m / z 557 [M + H] +. (1- (2'-Ethoxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide MS (ESI) m / z 557 [M + H] +. 1- (4'-Acetylamino-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide MS (ESI) m / z 570 [M + H] +. (1- (2'-Isopropyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide MS (ESI) m / z 555 [M + H] +. 1- (3'-amino-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide (ESI) m / z 528 [M + H] +. 1- (4-Benzo [b] thiophen-2-yl-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 569 [M + H] +. 4 '- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -3 * -trifluoromethyl-biphenyl-3-carboxylic acid; MS (ESI) m / z 557 [M + H] +. (1- (2'-Fluoro-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide MS (ESI) m / z 531 [M + H] +. 1- (3 '-Fluoro-4'-methoxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 561 [M + H] +. 1- (2'-Fluoro-6'-methoxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 561 [M + H] +. 1- [4- (5-Cyano-thiophen-2-yl) -2-trifluoromethyl-phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide.; MS (ESI) m / z 544 [M + H] +. 2, 5-Dimethyl-1- (4 '-methylcarbamoyl-3-trifluoromethyl-biphenyl-4-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 570 [M + H] +. 1- (3 ', 4'-Dimethyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 541 [M + H] +. 2, 5-Dimethyl-1- (4-naphthalen-2-yl-2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 563 [M + H] +. 1- (4'-Hydroxymethyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 543 [M + H] +. (1-4- (2, 3-Dihydro-benzofuran-5-yl) -2-trifluoromethyl-phenyl] -2,5-dimethyl-lH-pyrrole-3-methanesulfonyl-phenyl) -amide. carboxylic; MS (ESI) m / z 555 [M + H] +. 2, 5-Dimethyl-1- (4-quinolin-8-yl-2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 564 [M + H] +. 2, 5-Dimethyl-l- [4- (1-methyl-lH-indol-5-yl) -2-trifluoromethyl-phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide.; MS (ESI) m / z 566 [M + H] +. 1- (4'-Methoxy-2'-methyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI) m / z 557 [M + H] +.

EXAMPLE 12 PREPARATION OF 2, 5-DIMETHYL-L- (2-TRIFLU0R0METIL-PHENYL) -1H-PIRR0L-3-CARBOXAMIDE A. To concentrated ammonium hydroxide (28%, 9.8 mL, 70 mmol) at 0 ° C was added a solution of 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole chloride. -3-carbonyl (2.1 g, 7.0 mmol) in THF (10 mL). After 10 minutes the reaction mixture was removed from the ice bath and allowed to stir at room temperature. After 1 hour the mixture was added to said NH4C1 (30 mL) and extracted with DCM (3 x 30 mL). The combined extracts were washed with water (2 x 50 mL) and saline (50 mL), dried (anhydrous Na 2 SO 4) and concentrated under reduced pressure to give the title compound (1.9 g, 96%) as a pale brown solid, which was used without purification in the next step. XH-NMR (DMS0-d6) d 7.98 (1H, d, J = 7.8), 7.88 (1H, app t, J = 7.8), 7.78 (1H, app t, J = 7.8), 7.44 (1H, d, J = 7.8), 7.17 (1H, br s), 6.66 (1H, br s), 6.35 (1H, s), 2.07 (3H, s), 1.81 (3H, s).

PREPARATION OF 4-BROMO-2, N, -TRIMETHYL-BENCENOSULFONAMIDE B. To a mixture of 40% dimethylamine (aqueous, 2.5 mL, 20 mmol) in THF (2.5 mL) was added 4-bromo-2-methylbenzenesulfonyl chloride (0.27 g, 1.0 mmol). ) with agitation. After 5 hours the reaction mixture was partitioned between DCM (50 mL) and water (50 mL), washed with water (2 x 50 mL) and saline (50 mL), dried (anhydrous Na 2 SO 4) and concentrated under reduced pressure to provide the title compound (0.28 g, quantitative) as a colorless liquid, which was used without purification in the next step. 1H-NMR (CDC13) d 7.74 (1H, d, J = 8.3), 7.49 (1H, d, J = 1.8), 7.46 (1H, dd, J = 1.8 , 8.3), 2.80 (6H, s), 2.60 (3H, s); Rf = 0.38 (silica, 1: 4 EtOAc / Hex). To a mixture of 40% dimethylamine (aqueous, 2.5 mL, 20 mmol) in THF (2.5 mL) was added 4-bromo-2-methylbenzenesulfonyl chloride (0.27 g, 1.0 mmol) with stirring . After 5 hours PREPARATION OF (4-DI ETILSULFAMOIL-3-ETHYL-PHENYL) -AMIDE OF 2, 5-DIMETHYL-L- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC ACID C. A jar sprayed with oven-dried argon was charged with 4-bromo-2, N, N-trimethyl-benzenesulfomamide (70 mg, 0.25 mmol), 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) ) -lH-pyrrole-3-carboxamide (85 mg, 0.30 mmol), anhydrous K2C03 (69 mg, 0.50 mmol) and copper iodide (I) (10 mg, 0.05 mmol) and then sprayed briefly with argon. To the flask under argon was added anhydrous toluene (0.5 mL) and?,? '-dimethyl-ethylenediamine (11 μL, 0.10 mmol), then capped and heated to 120 ° C. After 24 hours the reaction mixture was cooled, diluted with EtOAc, filtered through Celite and concentrated under reduced pressure. The crude material was chromatographed (silica, EtOAc / Hexanes, 0: 100 to 50:50) to give the title compound (95 g, 79%) as a white solid. 1 H-NMR (DMSO-d 6) d 9.74 (1H, s), 8.01 (1H, d, J = 7.8), 7.92 (1H, app t, J = 7.8), 7 , 78-7.86 (3H, m), 7.71 (1H, d, J = 8.3), 7.51 (1H, d, J = 7.8), 6.65 (1H, s) , 2.69 (6H, s), 2.53 (3H, s), 2.14 (3H, s), 1.88 (3H, s); MS (ESI): 480 (MH +); A jar sprayed with oven-dried argon was charged with 4-bromo-2, N, N-trimethyl-benzenesulfonamide (70 mg, 0.25 mmol), 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) - lH-pyrrole-3-carAn D. In a manner similar to that described for Examples 12B-C, the following compounds were prepared from the appropriate aryl bromides: 2,5-dimethyl-4-dimethylsulfamoyl-3-ethyl-phenyl) -amide. (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; MS (ESI): 494 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-trifluoromethyl-phenyl) -amide; MS (ESI): 534 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-acetylamino-phenyl) -amide; MS (ESI): 416 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methanesulfonylamino-phenyl) -amide; MS (ESI): 452 (MH +). 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-dimethylsulfamoyl-phenyl) -amide; MS (ESI): 500 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-dimethylamino-4-dimethylsulfamoyl-phenyl) -amide; MS (ESI): 509 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-3-trifluoromethoxy-phenyl) -amide; MS (ESI): 521 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-dimethylsulfamoyl-thiophen-2-yl) -amide; MS (ESI): 472 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-acetylamino-phenyl) -amide; MS (ESI): 416 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methanesulfonylamino-phenyl) -amide; MS (ESI): 452 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonylamino-phenyl) -amide; MS (ESI): 452 (MH +); 1- (2,3-dichloro-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-phenyl) -amide; MS (ESI): 466 (MH +).

PREPARATION OF (4-METANOSULFONYLMETHYL-PHENYL) -AMIDE OF ACID 2, DIMETHYL-1- [2- (TRIFLUOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXYLIC E. Sodium thiomethoxide (1.0 g, 14.3 mmol) and 4-bromobenzyl bromide (2.65 g, 10.6 mmol) were combined with anhydrous THF (50 mL) and the reaction mixture was stirred at 60 ° C. After 3 hours the reaction mixture was concentrated in vacuo and the residue was washed in a separatory funnel with EtOAc and water. The organic layer was separated, dried (anhydrous MgSO 4) and concentrated in vacuo to give l-bromo-4-methylthiomethyl-benzene. To a solution of this crude thioether in DCM (100 mL) was added 3-chloroperoxybenzoic acid (77%, 4.0 g) in portions. After stirring overnight the reaction mixture was poured into a separatory funnel, washed with 1N NaOH, dried (Na2SO4) and concentrated in vacuo. The residue was crystallized from EtOAc-hexanes to give l-bromo-4-methanesulfonylmethyl-benzene (2.02 g, 76%) as light tan needles. 1H-NMR (CDC13) d 7.56 (2H, d, J = 8 Hz), 7.29 (2H, d, J = 8 Hz), 4.20 (2H, s), 2.78 (3H, s); MS (ESI) m / z 249 and 251, both [M + H] + The title compound was prepared from l-bromo-4-methanesulfonylmethyl-benzene in a manner similar to that described for Example 12C: (DMSO-d6) d 9.52 (1H, s), 8.01 (1H, d, J = 8.1), 7.91 (1H, app t, J = 8.1), 7.81 (1H, app t, J = 8.1), 7.77 (2H, d, J = 8.6), 7.49 (1H, d, J = 8.1), 7.33 (2H, d, J = 8.6 ), 6.63 (lH, 's), 4.41 (2H, s), 2.88 (3H, s), 2.13 (3H, s), 1.88 (3H, s); MS (ESI) m / z 451 [M + HJ +.

EXAMPLE 13 PREPARATION OF (4-METHANOSULFONYL-PHENYL) -AMIDE OF THE ACID l- (3'-CHLORO-BIFENIL-2-IL) -2,5-DIMETHYL-1H-PIRROL-3-CARBOXYLIC ' A. To a solution of 1- (2-bromophenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide (100 mg, 0.23 mmol) and 3-methanesulfonyl-phenyl-amide. Chlorophenylboronic acid (0.95 g, 0.57 mmol) in DME / EtOH (2: 1, 5 mL), 1 M Na 2 CO 3 (0.80 mL) and Pd (dppf) 2 C 12 (36 mg, 0.046 mmol) were added. ). The reaction mixture was degassed and heated at 80 ° C under Argon for 1 hour and monitored by. LC-MS. The mixture was diluted with DCM (20 'mL) and washed with 15 mL of saline. The aqueous phase was extracted with DCM (20 mL) twice. The combined extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel, eluting with EtOAc-Hexanes (0-50%) to give the title compound (53 mg, 48%) as a pale yellow solid.

^ -NMR (CDC13): d 7.89 (2H, d), 7.80 (2H, d), 7.65 (1H, s), 7.57 (3H, m), 7.26 (3H, m), 7.04 (1H, t), 6.87 (1H, m), 6.13 (1H, s), 3, 03 (3H, s), 2.23 (3H, s), 1, 89 (3H, s). MS (ESI): 479 (MH +).

B. In a manner similar to that described for Example 13A, the following compounds were prepared from the appropriate boronic acids. 1- (2'-Chloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI): 479 (MH +); 1- (4'-Chloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI): 479 (MH +); 1- (2 ', 3'-Dichloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI): 513 (MH +); 1- (2 ', 5'-Dichloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ESI): 513 (MH +); 1- (3'-Hydroxymethyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 475 (MH +); [1- (2- (3,4-Dihydro-2H-benzo [b] [1,4] dioxepin-7-yl) -phenyl] -2,5-dimethyl- (4-methanesulfonyl-phenyl) -amide. lH-pyrrole-3-carboxylic acid; MS (ES): 517 (MH +); [1- (2- ((E) -3, 3-Dimethyl-but-l-enyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide.; MS (ES): 451 (MH +); (1- (3'-Diethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; S (ES): 544 (MH +); 1- [2- (5-Formyl-thiophen-2-yl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 479 (MH +); 1- (4'-Methoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (methanesulfonyl-phenyl) -amide; MS (ES): 475 (MH +); 1- (4'-Ethanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 537 (MH +) / 1- (3'-Acetylamino-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenli) -amide; MS (ES): 502 (MH +) / 1- (3'-tert-Butyl-5'-methylsulfanyl-biphenyl-2-yl) -2,5-dimethol-1H (4-methanesulfonyl-phenyl) -amide -pyrrole-3-carboxylic; MS (ES): 547 (MH +); 1- (4 '-Metanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 523 (MH +); 1- (4'-Acetylamino-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 502 (MH +); 1- (4'-Cyano-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 470 (MH +); 2 '- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -biphenyl-4-carboxylic acid methyl ester; MS (ES): 1- (3'-Ethanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (MH +) / (4-methanesulfonyl-phenyl) -amide; MS (S): 537 (MH +); 2, 5-Dimethyl-1- [3 '- (pyrrolidin-1-carbonyl) -biphenyl-2-yl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 542 (MH +); 1- (51-Ethyl-3 '-methylsulfanyl-biphenyl-2-yl) -2,5-dimethyl-lH-prrl-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 519 (MH +) (4-methanesulfonyl-phenyl) -amide of 1- (4'-Ethoxy-3'-trifluoromethyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole- 3-carboxylic; MS (ES): 557 (MH +); 1- (31-Methoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 475 (MH +); 2, 5-Dimethyl-1- (2-thiophen-3-yl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 451 (MH +); 1- (4'-Fluoro-2'-hydroxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 479 (MH +); 2, 5-Dimethyl-1- (5'-propylsulfanyl-3'-trifluoromethyl-biphenyl-2-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 587 (MH +); 2, 5-Dimethyl-l- [31-trifluoromethyl-5 '- (2-trimethylsilanyl-ethylsulfanyl) -biphenyl-2-yl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide.; MS (ES): 645 (MH +); 1- (3'-Chloro-41-methyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 493 (MH +); (1- (51-Isopropylsulfanyl-31-trifluoromethyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 587 (MH +); (1- (3'-Ethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 516 (MH +); 1- (3'-Carbamoyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 488 (MH +); 1- [2- (5-Cyano-6-ethoxy-pyridin-3-yl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 515 (MH +); 1- (4'-Hydroxymethyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 475 (MH +); 1- (4'-Ethoxy-3'-methanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 567 (MH +); 2, 5-Dimethyl-1- (2-pyrimidin-5-yl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 447 (MH +); 2 '- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -biphenyl-3-carboxylic acid methyl ester; MS (ES): 503 (MH +); (1- (3'-Hydroxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 461 (MH +); 1- (5'-Fluoro-2'-methoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 493 (MH +); 1- (31-Ethoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 489 (MH +); (1- (2'-Fluoro-51-methoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 493 (MH +); 2, 5-Dimethyl-l- [4 '- (morpholin-4-carbonyl) -biphenyl-2-yl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 558 (MH +); 1- (4'-Ethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 516 (MH +); (1- (2'-Acetyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 487 (MH +); L- (4'-Methanesulfonylamino-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 538 (MH +); 2, 5-Dimethyl-1- [4 '- (piperidin-1-carbonyl) -biphenyl-2-yl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 556 (MH +); 1- (4'-Dimethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 516 (MH +); 1- (3'-Acetyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS. (ES): 487 (MH +); 2, 5-Dimethyl-1- [2- (5-methyl-furan-2-yl) -phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 449 (MH +); 2 '- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -biphenyl-4-carboxylic acid ethyl ester; MS (ES): 517 (MH +); 1- (3 ', 4'-Dimethoxy-biphenyl-2-yl) -2,5-dinaethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 505 (MH +); 1- [2- (2,3-Dihydro-benzofuran-5-yl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 487 (MH +); (1- (2'-Acetylamino-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 502 (MH +); 2, 5-Dimethyl-1- (31-methylsulfanyl-biphenyl-2-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 491 (MH +).

EXAMPLE 14 PREPARATION OF [4- (METANOSULPHONYL) PHENYL] -METIL-AMIDE OF 2, 5-DIMETHYL-L- [2- (TRIFLUOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXYLIC To a solution of 4-methylsulfonyl-aniline (0.20 g, 1.2 mmol) in anhydrous THF (2.0 mL) was added 1.43 M butyllithium in hexanes (0.82 mL, 1.2 mmol). The resulting suspension was sonic to create a fine suspension and then iodomethane (80 μL, 1.29 mmol, 1.1 equivalent) was added. The suspension was sonicated for 0.5 hour and then washed in a separatory funnel with EtOAc and water. The organic layer was separated, dried (anhydrous MgSO 4) and concentrated in vacuo to give a 4: 1 mixture of (4-methylsulfonyl-phenyl) -methyl-amine and (4-methylsulfonyl-phenyl) -dimethyl-amine as a solid toasted (180 mg). The crude mixture was used directly in the next step without purification. The title compound was prepared from the crude sample of (4-methylsulfonyl-phenyl) -methyl-amine in a manner similar to that described in Example ID; ½ NMR (CDCl 3): d 7, 77 (d, J = 9 Hz, 2H), 7, 72 (d, J = 8 Hz, 1H), 7, 61 (t, J = 8 Hz, 1H), 7 , 52 (t, J = 8 Hz, 1H), 7.24 (d, J = 9 Hz, 2H), 7.12 (d, J = 8 Hz, 1H), 5.49 (s, 1H), 3.44 (s, 3H), 2.97 (s, 3H), 1.82 (s, 3H), 1.66 (s, 3H); MS (ESI) m / z 451 [M + H] +.

EXAMPLE 15 PREPARATION OF (5-SULFAMOIL- [1,3,4] TIADIAZOL-2-IL) -AMIDE OF 2, 5-DIMETHYL-l- [2- (TRIFLUOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXYLIC ACID A. Acetazolamide (2.03 g, 9.13 mmol) was combined with 1N HC1 (20 mL) and then heated to 100 ° C. The initial suspension became a clear solution within 3 hours. After cooling to 0 ° C the reaction mixture was carefully neutralized by adding solid KOH. With the rest, precipitates were formed that were collected by filtration. The solids were dried under high vacuum to give 5-amino- [1, 3, 4] thiadiazole-2-sulfonic acid amide (1.2 g, 70%) as a colorless solid. 1 H NMR (DMSO-d 5): d 8, 06 (s, 2 H), 7, 82 (s, 2 H). Acetazolamide (2.03 g, 9.13 mmol) was combined with 1N HC1 (20 mL) and then heated to 100 ° C. The initial suspension became a clear solution within 3 hours. After cooling to 0 ° C A.

The title compound was prepared from 5-amino- [1, 3, 4] thiadiazole-2-sulfonic acid amide in a similar manner to that described in Example ID. ¾ NMR (DMSO-cfe): d 8.09 (s, 2H), 7.82 (d, J = 8 Hz, 1H), 7.73 (t, J = 8 Hz, 1H), 7.63 ( t, J = 8 Hz, 1H), 7.32 (d, J = 8 Hz, 1H), 6.74 (s, 1H), l, 98 (s, 3H), l, 67 (s, 3H); MS (ESI) m / z 446 [M + H] +.

PREPARATION OF (5-DIMETILSULFAMOIL-4-METHYL-TIAZOL-2-IL) -AMIDE OF 2, 5-DIMETHYL-L- [2- (RIFLUOROME IL) FENIL] -1H-PIRROL-3-CARBOXYLIC ACID B. A 2.0 M solution (10 mL) of dimethylamine in THF, diisopropylamine (1.0 mL) and 2-acetamido-4-methyl-5-thiazolesulfonyl chloride (0.97 g, 3.8 mmol) were added. They combined. After stirring for 3 hours, the reaction mixture was concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic layer was separated, dried (MgSO4) and concentrated in vacuo to give the intermediate N- (5-dimethyl-sulfamoyl-4-methyl-thiazol-2-yl) -acetamide as a tan semisolid. The intermediate was treated with IN HCl (10 mL) and then heated at 95 ° C-100 ° C. After 2 hours additional IN HCl was added and heating was continued for another • 2 hours. The aqueous solution was cooled and transferred to a separatory funnel, where it was washed with DCM. The aqueous phase was made basic by adding IN NaOH (30 mL) and then extracted with DCM. The combined extracts were dried (Na2SO) and concentrated in vacuo to give 2-amino-4-methyl-thiazole-5-sulfonic acid dimethylamide (0.48 g, 57%) as a light tan solid semi-crystalline solid. 1ti NMR (CDC13): d 9.36 (s, 1H), 7.81 (d, J = 8 Hz, 1H), 7.70 (t, J = 8 Hz, 1H), 7.60 (t, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 1H), 6.12 (s, 1H), 2.76 (s, 6H), 2.51 (s, 3H), 2 , 22 (s, 3H), 1.85 (s, 3H); MS (ESI) m / z 487 [M + H] +.

EXAMPLE 16 PREPARATION OF ACID METHYL ESTER 2-CYAN0-3-METHYL-4-OXO-4- (2-TRIFLOROMETHYL-PHENYL) -BUTYRIC A. To a solution of 2 '-trifluoromethyl-propiophenone (10 g, 48 mmol) in carbon tetrachloride (50 mL) was added a solution of bromine (2.72 mL, 52.8 mmol) in carbon tetrachloride (20 mL). mL) drop by drop. After the aggregate was finished, stirring was continued for another 2 hours. The solution was washed with saturated NaHCO 3 and water, dried (anhydrous Na 2 SO 4) and concentrated under reduced pressure to give 2-bromo-1- (2-trifluoromethyl-phenyl) -propan-1-one as an oil (12.8 g. g, 95%), which was used in the next step without purification. 1 H-NMR (CDC13): d 7.73 (m, 2H), 7.58-7.67 (m, 2H), 4.96 (q, 1H), 1.90 (d, 3H). To a solution of 2'-trifluoromethyl-propiophenone (10 g, 48 mmol) in carbon tetrachloride (50 mL) was added a solution of bromine (2.72 mL, 52.8 mmol) in carbon tetrachloride (20 mL). . To a suspension of NaH (60%, 2.88 g, 72 mmol) in anhydrous THF (200 mL) was added methyl cyanoacetate (4.5 mL, 50 mmol).

After this mixture was stirred for 3 hours at 20 ° C, a solution of 2-bromo-1- (2-trifluoromethyl-phenyl) -propan-1-one (13.5 g, 48 mmol) was added and the The mixture was stirred overnight at 20 ° C. The mixture was cooled with water and the organic layer was separated. The aqueous layer was extracted with EtOAc. The combined extracts were washed with saline, dried (Na2SO4) and concentrated under reduced pressure to give the title compound as an oil (13.3 g, 93%), which was used in the next step without purification. MS (ES): 300 (MH +).

PREPARATION OF METHYL ESTER OF 4-METHYL-5- (2-TRIFLOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC ACID B. To a solution of 2-cyano-3-methyl-4-oxo-4- (2-trifluoromethyl-phenyl) -butyric acid methyl ester (13.27 g, 44.4 mmol) in formic acid (100 mL) was added fresh Raney's nickel [Al-Ni (1: 1), 117 g] and the mixture was heated to reflux with stirring for 2 hours. After cooling, the catalyst was removed by filtration and washed with ethanol. The combined filtrates were concentrated to give an oil, which was redissolved in DCM and filtered to remove residual solids. Evaporation of the solvent gave 4-methyl-5- (2-trifluoromethyl-phenyl) -2,3-dihydro-1H-pyrrole-3-carboxylic acid methyl ester as an oil (10 g, 79%), which was used in the next step without purification. MS (ES): 286 (MH +).

To a solution of 4-methyl-5- (2-trifluoromethyl-phenyl) -2,3-dihydro-lH-pyrrole-3-carboxylic acid methyl ester (10 g, 35 mmol) in toluene was added 10% Pd / C (3.3 g). The resulting suspension was heated to reflux for 3 days. After cooling the solids were removed by filtration. The filtrate was washed with toluene and concentrated under reduced pressure to give an oil, which was purified by column chromatography (silica), eluting with EtOAc-hexane (1: 1) to give the title compound (2.9 g, 29%). MS (ES): 284 (MH +).

PREPARATION OF 1, 4-DIMETHYL-5- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC ACID C. To a solution of 4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid methyl ester (2.9 g, 10.2 mmol) in anhydrous THF (40 mL). Lithium bis (trimethylsilyl) amide (1.0 M solution in THF, 12.3 mL, 12.3 mmol) was added slowly at 20 ° C. After stirring for 0.5 hour, iodomethane (0.96 mL, 15.4 mmol) was added and the mixture was stirred for 3 hours at 20 ° C. After cooling with water, the organic layer was separated and the aqueous layer was extracted with EtOAc. The combined extracts were washed with water, dried (a2SO4-anhydrous) and concentrated under reduced pressure to give methyl ester of 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-methyl ester. carboxylic acid as an oil (2.8 g, 92%), which was used in the next step without purification. MS (ES): 298 (MH +). To a solution of 4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid methyl ester (2.9 g, 10.2 mmol) in anhydrous THF (40 mL) was added lithium bis (trimethylsilyl) amide C.

To a solution of 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid methyl ester (2.5 g, 8.4 mmol) in MeOH (20 mL) was added. added 4N NaOH (10 mL) and the mixture was heated to reflux overnight. Evaporation of the solvent gave a solid, which was redissolved in water. The solution was acidified with formic acid. The resulting solids were collected by filtration, washed with water and then dried under high vacuum to give the title compound as an off-white solid (2.15 g, 90%). MS (ES): 284 (MH +).

PREPARATION OF (4-METHANOSULPHONYL-PHENYL) -AMIDE OF 1,4-DIMETHYL-5- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC ACID D. To a solution of 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (56 mg, 0.20 mmol) in DCM (4 mL) was added oxalyl chloride (22 μ?, 0.25 mmol). After stirring for 30 minutes, the solvent was removed in vacuo to give an oil, which was dissolved in anhydrous THF (4 mL). To this solution were added 4-methanesulfonyl-aniline (68 mg, 0.40 mmol) and DIEA (140 μl., 0.8 mmol) and the mixture was stirred at 60 ° C overnight. After cooling, the solvent was removed in vacuo to give a crude residue, which was purified by column chromatography on silica gel, eluted on EtOAc-hexane, (0: 100 to 25:75) to give the title compound (24 mg, 28%). XH-NMR (CDC13): d 7.89-7.91 (m, 2H), 7.80 (m, 3H), 7, 57-7, 66 (m, 3H), 7.33 (d, 1H ), 7.30 (s, 1H), 3.32 (s, 3H), 3.05 (s, 3H), 2.12 (s, 3H). MS (ES): 437 (H +).

E. In a manner similar to that described for Example 16D, the following compounds were prepared from the appropriate anilines. 1,4-Dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-3-trifluoromethyl-phenyl) -amide; 1 H NMR (CDCl 3): d 8.25 (1H, d), 8.08 (2H, m), 7.83 (lH, d), 7.77 (1H, s), 7.63 (2H, m), 7.33 (2H, m), 3.33 (3H, s), 3.18 (3H, s), 2.10 (3H, s); MS (ES): 505 (MH +); [4 (2-Fluorobenzoyl) -phenyl] -amide of 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid; ½ - ??? (CDCl 3): d 7.81-7.86 (3H, m), 7.72 (2H, m), 7.63 (3H, m), 7.52 (2H, m), 7.33 (1H , d), 7.29 (1H, s), 7.26 (1H, m), 7.16 (1H, m), 3.30 (3H, s), 2.08 (3H, s); MS (ES): 481 (MH +); 1,4-Dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sulfamoyl-phenyl) -amide; 1 H-NMR (DMSO-d 6): d 9.84 (1H, s), 7.88 (3H, m), 7.79 (1H, m), 7.72 (3H, m), 7.67 ( 1H, s), 7.43 (1H, d), 7.21 (2H, s), 3.32 (3H, s), 1.92 (3? 'S). MS (ES): 438 (MH +); 1,4-Dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrroli-3-carboxylic acid (3-chloro-4-sulfoamoyl-phenyl) -amide; ^ MR (CDC13): d 8.04 (1H, d), 7.95 (1H, d), 7.83-7.79 (2H, m), 7.67-7.58 (2H, m) , 7.45-7, 43 (1H, dd), 7.33 (2H, m), 5.19 (2H, s), 3.33 (3H, s), 2.08 (3H, s). MS (ESI): 472 (MH +).

F. In a manner similar to that described for Examples 16A-D, but replacing 2 '- (trifluoromethyl) propiophenone with 4' -fluoro-2 '- (trifluoromethyl) propiophenone, the following compound (4-methanesulfonyl-phenyl) was prepared 5- (4-fluoro-2-trifluoromethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid amide; 1HNMR (CDC13): d 7.90 (2H, m), 7.80 (2H, m), 7.68 (1H, s), 7.53 (1H, dd), 7.29-7.39 ( 3H, m), 3.32 (3H, s), 3.05 (3H, s), 2.08 (3H, s); MS (ES): 455 (MH +).

G. In a manner similar to that described for Example 16F, the following compounds were prepared from the appropriate anilines. - (4-Fluoro-2-trifluoromethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide; 1 H-NMR (CDCl 3): d 8.06 (1H, d), 7.98 (1H, d), 7.70 (1H, s), 7.54 (1H, dd), 7.44 (1H, dd), 7.35 (2H, ni), 7.32 (1H, s), 5.14 (2H, s), 3. 32 (3H, s), 2.08 (3H, s). S (ES): 490 (MH +); 5- (4-Fluoro-2-trifluoromethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (3-trifluoromethyl-4-sulfamoyl-phenyl) -amide; 1 H NMR (CDCl 3): d 8.22 (1H, d), 8.09 (1H, d), 7.98 (1H, dd), 7.73 (1H, s), 7.54 (1H, dd), 7.36 (2H, m), 7.31 (1H, s), 4.98 (2H, s), 3. 33 (3H, s), 2.09 (3H, s). MS (ES): 524 (MH +).

EXAMPLE 17 PREPARATION OF ETHYL 5-BROMO-L, 4-DIMETHYL-1H-PIRROL-3-CARBOXYLATE A. To a solution of ethyl 4-methyl-3-pyrrolcarboxylate (1.57 g, 10 mmol) in anhydrous THF (30 mL) cooled to -78 ° C was added NBS (1.9 g, 10 mmol). After stirring 1 hour at -30 ° C, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography, eluting with EtOAc-Hexanes (0: 100 to 30:70), to ethyl 5-bromo-4-methyl-lH-pyrrole-3-carboxylate (2.0, 86%) as a white solid. 1H-NMR (CDC13): d 8, 54 (1H, brs), 7.38 (1H, d), 4.27 (2H, q), 2.24 (3H, s), 1.33 (3H, t). To a solution of ethyl 5-bromo-4-methyl-lH-pyrrole-3-carboxylate (2.0 g, 8.6 mmol) in anhydrous DMF (30 mL) at 0 ° C was added portion by NaH portion (60 mL). % in mineral oil, 705 mg, 17.6 mmol) under nitrogen. After 1 hour at room temperature, the reaction mixture was charged with iodomethane (1.5 mL, 24 mmol) and then stirred at room temperature overnight. The reaction mixture was cooled by carefully adding water and then extracted with DCM. The combined extracts were washed with water, dried over Na 2 SO 4, concentrated under reduced pressure and purified by column chromatography, eluting with EtOAc-Hexanes (0: 100 to 20:80), to provide the title compound (1, 64 g, 78%) as a white solid. 1H-NMR (CDC13): d 7.33 (1H, s), 4.25 (2H, q), 3.58 (3H, s), 2.24 (3H, s), 1.33 (3H, t).

PREPARATION OF (4-METANOSULFONIL-PHENYL) -MAID OF 1,4-DIMETHYL-5- (4-FLUOROPHENYL) -1H-PIRROL-3-CARBOXYLIC ACID B. A mixture of ethyl 5-bromo-1,4-dimethyl- lH-pyrrole-3-carboxylate (246 mg, 1.0 mmol), 4-fluorophenyl-boronic acid (210 mg, 1.5 mmol), Na2CO3 (320 mg, 3.0 mmol) and Pd (PPh3) 4 ( 116 mg, 0.1 mmol) in DMF / H20 (10: 1, 10 mL) was sprayed with nitrogen for 10 minutes. The reaction flask was sealed and heated to 110 ° C with stirring. After 18 hours, the reaction mixture was diluted with DCM and then filtered. The filtrate was concentrated under reduced pressure and then purified by column chromatography, eluting with EtOAc-Hexanes (0: 100 to 50:50), to give 1,4-dimethyl-5- (4-fluorophenyl) ethyl ester. ) -lH-pyrrole-3-carboxylic acid (252 mg, 96%) as a pale yellow solid. 1 H-NMR (CDCl 3): d 7.30 (1H, s), 7.26-7.20 (2H, m), 7.15-7.10 (2H, m), 4.28 (2H, q ), 3.48 (3H, s), 2.20 (3H, s), 1.36 (3H, t). MS (ESI): 262 (MH +). The title compound was prepared from 1,4-dimethyl-5- (4-fluorophenyl) -lH-pyrrole-3-carboxylic acid methyl ester in a manner similar to that described for Examples 16C-D. 1 H-NMR (DMSO-d 6): d 9.94 (1H, s), 8, 00-7.95 (2H, m), 7, 87-7, 84 (2H, d), 7.69 (1H , s), 7, 43-7, 39 (2H, m), 7, 35-7, 30 (2H, m), 3.52 (3H, s), 3.18 (3H, s), 2, 15 (3H, s); MS (ESI): 387 (MH +).

C. In a manner similar to that described for Example 17B, but replacing 4-fluorophenylboronic acid with 1-naphthaleneboronic acid, the following compound was prepared. 1,4-Dimethyl-5- (naphthalen-1-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; XH-NMR (CDC13): d 7, 97-7, 80 (7H m), 7.59-7.41 (6H, m), 3.35 (3H, s), 3.06 (3H, s) , 2.16 (3H, s) MS (ESI): 419 (MH +).

EXAMPLE 18 A. PREPARATION OF [4- (SULFAMOIL) PHENYL] -AMIDE OF 2-BROMINE 1, 3-DIMETHYL-1H-PIRROL-4-CARBOXYLIC ACID In a 250 mL circular bottom flask, 2.06 g of methyl ester of 2-bromo-1,3-dimethyl-1H-pyrrole-4-carboxylic acid (8.88 mmol), 1.61 g were weighed ( 9.40 mmol) of aminophenyl methyl sulfone, and 20 mL of toluene. To the resulting suspension was added 4.5 mL of 2.0 M trimethylaluminium in toluene. The resulting solution was heated at 100 ° C-105 ° C for 1.5 hour and then the reaction was cooled and washed in a separatory funnel with ethyl acetate and saturated potassium sodium tartrate. The ethyl acetate was separated, washed with saturated sodium and potassium tartrate and saline, then dried (MgSO 4) and concentrated in vacuo. The residue was crystallized from ethanol to give [4- (sulfamoyl) phenyl] -amide of 2-bromo-1,3-dimethyl-lH-pyrrole-4-carboxylic acid as a weakly yellow semicrystalline solid, yield: 2.81 g (85%). 1H NMR (DMSO-d): d 10.06 (s, 1H), 8.04 (d, J = 9 Hz, 2H), 7.94 (d, J = 9 Hz, 2H), 7.88 (s, 1H), 3.72 (s, 3H), 3.26 (s, 3H), 2.28 (s, 3H); MS (ESI) m / z 371 and 373, each [M + H] +.

B. PREPARATION OF (4-METAN0SÜLF0NIL-PHENYL) -AMIDE OF 1,4-DIMETHYL-5- (2-PHENOXY-PHENYL) -1H-PIRR0L-3-CARB0XYLIC ACID Into a 50 mL circular bottom flask were weighed 100 mg of [4- (sulfamoyl) phenyl] -amide of 2-bromo-1,3-dimethyl-lH-pyrrole-4-carboxylic acid (0.27 mmol), 230 mg of (2-phenoxy) phenylboronic acid, potassium hydroxide (30.2 mg, 0.54 mmol) and DAPCy '(J. Org Chem (2004), 69_: 4330-4335) (6.2 mg, 4 Mol% ) and Ethanol / DMF (3 mL, 50:50) was added. The solution was heated to 100 ° C overnight. The reaction was cooled and washed with a separatory funnel with ethyl acetate and water. The ethyl acetate was washed with water and saline, then dried (MgSO / i) and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si02) eluting with 0-80% EtOAc / Hexanes to give the title compound as a white solid (10 mg, 8%). 1 H NMR (DMSO-dff): d 7.88 (d, J = 9 Hz, 2 H), 77, 7 (d, J = 9 Hz, 2 H), 7.60 (s, 1 H), 7.43- 7.37 (m, 1H), 7.32-7.20 (m, 4H), 7.04 (d, J = 9 Hz, 2H), 6.85 (d, J = 8 Hz, 2H), 3, 52 (s, 3H), 3, 04 (s, 3H), 2, 20 (s, 3H); MS (ESI) m / z 461 [M + H] + C. In a manner similar to that described in Example 18B, but replacing (2-phenoxy) phenylboronic acid with the appropriate boronic acid, the following compounds were prepared. 1,4-Dimethyl-5- (4-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenli) -amide; MS (ES): 437 (MH +); 5- (2-Isopropoxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 427 (MH +); 5- (2-Benzyloxy-5-fluoro-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 493 (MH +); 5- (2-Butoxy-5-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 455 (MH +); 5- (3-Benzyloxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 475 (MH +); - (3-Bromo-2-methoxy-5-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 491 (MH +); 5-Benzo [b] thiophen-2-yl-1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 425 (MH +); 5- (3-Bromo-2-butoxy-5-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 533 (MH +); 5- (5-Acetyl-thiophen-2-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 417 (H +); 5- (3-Cyano-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 394 (MH +); 3- [4- (4-Methanesulfonyl-phenylcarbamoyl) -1,3-dimethyl-lH-pyrrol-2-yl] -benzoic acid methyl ester; MS (ES): 427 (MH +); 1,4-Dimethyl-5- (2-methylsulfanyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 415 (MH +); 5- (3,5-Bis-trifluoromethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 505 (MH +); 5- ((E) -3,3-Dimethyl-but-1-enyl) -1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; . MS (ES): 375 (MH +); - (2-Amino-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 384 (H +); 5- (2-Isopropoxy-5-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 441 (MH +); 5-Benzo [1, 3] dioxol-5-yl-1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 413 (MH +); 5- (1H-Indol-5-yl) -1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 408 (MH +); 1,4-Dimethyl-5-naphthalen-1-yl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 419 (MH +); Methyl ester of (E) -3- acid. { 3- [4- (4-methanesulfonyl-phenylcarbamoyl) -1,3-dimethyl-lH-pyrrol-2-yl] -phenyl} -acrylic; MS (ES): 453 (MH +); 5- (2-Butoxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES):. 441 (MH +); 5- (3-Acetyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 411 (MH +); 5-Dibenzofuran-4-yl-1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 459 (MH +); 5- (3-Benylcarbamoyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 502 (MH +); 1,4-Dimethyl-5- (4-methyl-naphthalen-1-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 433 (MH +); - (2-Benzyloxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 475 (MH +); 5- (1-Benzylsulfonyl-lH-indol-3-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 548 (MH +); 5- (3-Carbamoyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide MS (ES): 412 (MH +); 3- [4- (-methanesulfonyl-phenylcarbamoyl) -1,3-dimethyl-lH-pyrrol-2-yl] -phenyl ester of tert-butyl ester of carbonic acid; MS (ES): 485 (MH +); 1,4-Dimethyl-5-pyrimidin-5-yl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 371 (MH +); 5-Acenaften-5-yl-l, 4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 445 (MH +); 1,4-Dimethyl-5- (2,, 5-trimethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 411 (MH +); 1,4'-Dimethyl-5- (1-methyl-1H-indol-5-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 422 (MH +); and 5- (1-Benzyl-lH-pyrazol-4-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 449 (MH +).

EXAMPLE 19 PREPARATION OF ETHYL ESTER OF 3, 5-DIMETHYL-4- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-2-CARBOXYLIC ACID To a solution of ethyl 3, 5-dimethyl-lH-pyrrole-2-carboxylate (3.42 g, 20 mmol) in carbon tetrachloride (40 mL) was added a solution of bromine in carbon tetrachloride (10 mL) drop drop to 20 ° C. After it was finished adding, stirring was continued for 2 hours. The reaction mixture was diluted with DCM, washed with NaHCO3 and water and then dried over a2SO4. Evaporation of the solvent gave ethyl 4-bromo-3,5-dimethyl-1H-pyrrole-2-carboxylate as a solid (4.8 g) which was used in the next step without purification. 1H-NMR (CDC13): d 9.36 (1H, s), 4.30 (2H, q), 2.28 (3H, s), 2.26 (3H, s), 1.36 (3H, t). To a solution of ethyl 4-bromo-3,5-dimethyl-lH-pyrrole-2-carboxylate (2.4 g, 10 mmol) in DMF (25 mL) was added tetrakis (triphenylphosphine) palladium (2.3 g, 1 mmol). After stirring 15 minutes, the reaction mixture was charged with 2- (trifluoromethyl) -benzeneboronic acid (2.4 g, 12.5 mmol) and sodium carbonate (in 5 mL of water). The reaction mixture was heated to reflux overnight with stirring. After cooling, the reaction mixture was diluted with water and extracted with DCM. The combined extracts were washed with water and dried over Na2SO4. Evaporation of the solvent gave a crude material, which was purified by chromatography on a column of silica gel eluting with EtOAc-hexane (1: 1) to give the title compound (1.5 g). MS (ES): 312 (MH +).

PREPARATION OF (-METANOSÜLFONIL-PHENYL) -THE AMID OF 3,5-DIMETHYL-4- (2-TRIFLUOROME IL-FENIL) -1H-PIRROL-2-CARBOXYLIC To a solution of 3,5-dimethyl-4- (2-trifluoromethyl-phenyl) -lH-pyrrole-2-carboxylic acid ethyl ester (0.96 g) in methanol was added 4 N NaOH (6 mL). The reaction mixture was then heated to reflux by stirring overnight. After cooling, the solvent was removed and the crude material was diluted with water. The solids were removed by filtration and washed with water. The aqueous filtrate was acidified with formic acid to precipitate the product. The precipitates were collected by filtration and washed with water, and then dried under high vacuum to give 3,5-dimethyl-4- (2-trifluoromethyl-phenyl) -1H-pyrrole-2-carboxylic acid (0.30. g). MS (ES): 284 (MH +).

In a manner similar to that described in Example 16D, the title compound was prepared from 3,5-dimethyl-4- (2-trifluoromethyl-phenyl) -lH-pyrrole-2-carboxylic acid. 1H-NMR (CDC13): d 9.68 (1H, s), 7.89 (2H, m), 7.79 (3H, m), 7.73 (1H, s), 7.59 (1H, m), 7.50 (1H,), 7.24 (1H, d), 3.05 (3H, s), 3.05 (3H, s), 2.19 (3H, s), 2.06 (3H, s); MS (ES): 437 (MH +) EXAMPLE 20 PREPARATION OF (4-METHANOSULPHONYL PHENYL) -AMIDE OF THE ACID 5- (4-FLUOROPHENYL) -2-METHYL-L- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC A. In a manner similar to that described for Examples 16C-D, the title compound was prepared from ethyl ester of 5- (4-fluorophenyl) -2-methyl-1- (2-trifluoromethylphenyl) -lH-pyrrole- 3-carboxylic acid, which was synthesized from 2-trifluoromethyl-aniline and 2-acetyl-4- (4-fluorophenyl) -4-oxobutyric acid ethyl ester using the procedures described in WO 03/027069. 1H-NMR (CDC13): d 7, 92-7, 84 (5H, m), 7.77-7, 69 (2H, m), 7, 63-7, 60 (1H, m), 7.42. (1H, d), 7.07-7.03 (2H, m), 6.88-6.84 (2H, m), 6.60 (1H, s), 3.05 (3H, s), 2.33 (3H, s). MS (ESI): 517 (MH +). B. In a manner similar to that described for Example 20A but replacing 2-trifluoromethyl-aniline with 4-fluoroaniline, the following compound was prepared: 1,5-bis- (4-fluorophenyl) (4-methanesulfonyl-phenyl) amide ) -2-methyl-lH-pyrrole-3-carboxylic acid; 1HNMR (CDC13): d 7, 93-7, 80 (5H, m), 7.25-7.11 (4H, m), 7.09-7.01 (2H, m), 6, 93-6 , 87 (2H, m), 6.56 (1H, s), 3.04 (3H, s), 2.45 (3H, s). MS (ESI): 467 (MH +).

C. In a manner similar to that described for Example 20A, but replacing 4-methanesulfonyl-aniline with the appropriate amines in the last step, the following compounds were prepared: acid (3-methoxy-4-sulfamoyl-phenyl) -amide 5- (4-fluoro-phenyl) -2-methyl-1- (2-trifluoromethyl-phenyl) -lH-prrol-3-carboxylic acid; MS (ES): 548 (MH +); 5- (4-fluoro-phenyl) -2-methyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid dimethylamide; MS (ES): 391 (MH +).

EXAMPLE 21 PREPARATION OF ACID .2- [3- (4-METHANOSULPHONYL-PHENYLCARBAMOYL) -2,5-DIMETHYL-PIRROL-1-IL] -BENZOIC A. 2- [3- (Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoic acid methyl ester was prepared from methyl anthranilate in a similar manner to that described for Example 1G. 1 H-NMR (DMSO- < ¾): d 9.58 (1H, s), 7.83 (2H, d, J = 8.8), 7.79 (1H, dd J = 7.8.1 , 5), 7.63 (2H, d, J = 7.8), 7.58 (1H, dd, J = 7.8.1.5). 7.48 (1H, td, J = 7.6.1.3), 7.21 (1H, dd, J = 7.8.1.0), 7.15 (lH, s), 6.42. (1H, d, J = 1.0), 3.43 (3H, s), 2.96 (3H, s), 1.94 (3H, s), 1.66 (3H, s); MS (ESI): 427 (MH +).

To a solution of 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoic acid methyl ester (0.7 g, 1.6 mmol) in MeOH / THF (8 mL: 16 mL) was added LiOH (0.275 g, 6.4 mmol). After stirring 14 hour at room temperature, the reaction mixture was concentrated in vacuo. The crude reaction mixture was redissolved in water and washed with EtOAc. The water layer was separated and then acidified with 1N HC1. The resulting suspension was extracted with EtOAc. The combined extracts were dried (Na2SO4) and concentrated in vacuo to provide the title compound (0.67 g, 99%) as a white solid. 1 H-NMR (DMSO-d 6): 5 13.03 (1H, s), 9.81 (1H, s), 8.06 (2H, d, J = 9.1), 8.02 (1H, s). J = 7.8), 7.87 (2H, d, J = 8.6), 7.78 (1H, t, J = 7.3). 7.68 (1H, t, J = 7.8), 7.39 (1H, d, J = 7.6), 6.65 (1H, s), 3.20 (3H, s), 2, 23 (3H, s), 1.92 (3H, s); MS (ESI): 413 (MH +) (4-METHANOSULPHONYL-PHENYL) -AMIDE OF ACID 1- (2-CARBAMOIL-PHENYL) -2,5-DIMETHYL-1H-PIRROL-3-CARBOXYLIC B. In a manner similar to that described for Examples 1B-C, the title compound was prepared from 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoic acid and ammonia. . XH-NMR (DMSO-d6): d 9.82 (1H, s), 8.08 (2H, d, J = 9.1), 7.90 (2H, d, J-9.1), 7 , 67 (4H, m), 7.39 (1H, s). 7.34 (1H, m), 6.63 (1H, s), 3.23 (3H, s), 2.27 (3H, s), 2.00 (3H, s); MS (ESI): 412 (MH +) C. In a manner similar to that described for Example 21B, the following compounds were prepared from the appropriate amines: 1- (2- (4-methanesulfonyl-phenyl) -amide) ((R) -2-Hydroxy-1-methyl-ethylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid; MS (ES): 470 (MH +); [1- (2- (3-Hydroxymethyl-piperidine-l-carbonyl) -phenyl] -2,5-dimethyl-lH-prrl-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; -MS (ES) : 510 (MH +); 1- [2- (4-Acetyl-piperazine-1-carbonyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 523 (MH +); 1- (4-methanesulfonyl-phenyl) -amide. { 2- [(2-Cyano-ethyl) -cyclopropyl-carbamoyl] -phenyl} -2, 5-dimethyl-lH-pyrrole-3-carboxylic acid; MS (ES): 505 (MH +); 1- [2- (3-Ethoxy-phenylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 532 (MH +); 2, 5-Dimethyl-1- [2- (3-nitro-phenylcarbamoyl) -phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 533 (MH +); (4-methanesulfonyl-phenyl) -amide of 1- [2- (lH-Indazol-5-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid; MS (ES): 528 (MH +); 2, 5-Dimethyl-1- [2- (2-methyl-lH-indol-5-ylcarbamoyl) -phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES) 541 (MH +) (4-methanesulfonyl-phenyl) -amide 'of 1- [2- (2-Dimethylamino-1-methyl-ethylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole- 3-carboxylic; MS (ES): 497 (MH +); (4-methanesulfonyl-phenyl) -amide of l- acid. { 2- [4- (2-Hydroxy-ethyl) -piperazine-1-carbonyl] -phenyl} -2, 5-dimethyl-lH-pyrrole-3-carboxylic acid; MS (ES): 525 (MH +); 1- [2- (3-Imidazol-1-yl-propylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 520 (MH +); L- [2 - ((S) -l-Hydroxymethyl-3-methylsulfanyl-propylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 530 (1-4- (1,3-Dihydro-isobenzofuran-5-ylcarbamoyl) -phenyl] -2,5-dimethyl (MH + j ~; 1-4- (1,3-methanesulfonyl-phenyl) -amide). -lH-pyrrole-3-carboxylic acid MS (ES): 530 (MH +); 2,5-Dimethyl-1- (2- (2-methyl-aziridin-1-methanesulfonyl-phenyl) -amide) carbonyl) -phenyl] -lH-pyrrole-3-carboxylic acid; MS (ES): 452 (MH +); 2,4-Dimethyl-1- (2-methanesulfonyl-phenyl) -amide. - (1-methyl-lH-pyrazol-4-yl) -ethylcarbamoyl] -phenyl} - lH-pyrrole-3-carboxylic acid, MS (ES): 520 (MH +); (1- (2- ((IR, 2S) -2- Hydroxy-indan-l-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide.; MS (ES): 544 (H +); [1- (2- (1,1-Dioxo-tetrahydro-l-thiophen-3-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide.; MS (ES): 530 (MH +); 1- [2- (3-Methanesulfonyl-pyrrolidin-1-carbonyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 544 (MH +); 1- [2- (3-Hydroxy-4-methyl-phenylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 518 (MH +); 2, 5-Dimethyl-1- [2- ([1,3,4] thiadiazol-2-ylcarbamoyl) -phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 496 (MH +) / 1- [2- (4,5-Dimethyl-thiazol-2-ylcarbamoyl) -phenyl] -2,5-dimethyl-l (4-methanesulfonyl-phenyl) -amide. -pyrrole-3-carboxylic; MS (ES): 523 (MH +); Methyl esters of (R) -3-Hydroxy-2- acid. { 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamino} -propionic; MS (ES): 514 (MH +); 2, 5-Dimethyl-l- (4-methanesulfonyl-phenyl) -amide. { 2- [Methyl- (4-methyl-thiazol-2-ylmethyl) -carbamoyl] -phenyl} -lH-pyrrole-3-carboxylco; MS (ES): 537 (MH +); 3- ethyl ester. { 2- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamino} -propionic; MS (ES): 512 (MH +); 1- [2- (2-Ethyl-sulfanyl-ethylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 500 (MH +); (1- (2- ((S) -l-Carbamoyl-3-methyl-butylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 525 (MH +); 1- [2- (4-Carbamoyl-phenylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 531 (MH +); 4- acid. { 2 ~ [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamino} -cyclohexanecarboxylic; MS (ES): 538 (MH +); 2, 5-Dimethyl-l- (4-methanesulfonyl-phenyl) -amide. { 2- [(5-methyl-4 H- [1,2,4] triazol-3-ylmethyl) -carbamoyl] -phenyl} -lH-pyrrole-3-carboxylic; MS (ES): 507 (MH +); Methyl ester of l- acid. { 2- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoyl} -piperidine-2-carboxylic acid; MS (ES): 538 (MH +); (4-methanesulfonyl-phenyl) -amide of l- acid. { 2- [2- (1H-Imidazol-4-yl) -ethylcarbamoyl] -phenyl} -2,5-dimethyl-1H-pyrrole-3-carboxylic acid; MS (ES): 506 (MH +); acid { 2- [3- (-Metanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamino} -acetic; MS (ES): 470 (MH +); 2, 5-Dimethyl-1- (2-methylcarbamoyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 426 (MH +); (1- (2-Isopropylcarbamoyl phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; MS (ES): 1- (2-Dimethylcarbamoyl phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4,4-methanesulfonyl-phenyl) -amide (MH +) and (4-methanesulfonyl-phenyl) -amide; MS (ES): 440 (MH +).

EXAMPLE 22 PREPARATION OF 4-METHYL-N- [4- (METILSULFONIL) PHENYL] -l-PHENYL-5- [2 (TRIFLUOROMETHYL) PHENYL] -1H-PIRROL-3-CARBOXAMIDE 22A 22B A bottle with a screw cap was loaded with 22A (4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide) (175 mg, , 41 mmol), bromobenzene (52 μ ??, 0.48 mmol), palladium acetate (31 mg, 0.048 mmol, 11% by mole), 1,1 '-diphenylphosphinoferrocene (DPPF) (32 mg, 0.058 mmol, 14 mol%) and cesium carbonate (200 mg, 0.61 mmol). Anhydrous toluene (20 mL) was added to the bottle and the mixture was purged with 2 for 5 minutes, after which time, the bottle was capped. The reaction mixture is stirred at 105 ° C for 12 hours. The product, 22B, was purified by silica column chromatography (1: 1 EtOAc: Hexanes) in 8% yield.

¾ NMR (CDCI3) d 8.31 (s, 1H), 7.81 (d, 9.0 Hz, 3H), 7.65 (t, 7.8Hz, 1H), 7.56-7, 45 ( m, 9H), 7.36 (s, 1H), 3.03 (m, 3H), 2.28 (s, 3H). LC S: m / z 499 (M + H) +.

EXAMPLE 23 PREPARATION 1- (3-HYDROXYPROPYL) -4-METHYL-N- [4- (METILSULFONIL) FENILJ -5- [2- (RIFLUOROME IL) PHENYL] -1H-PIRROL-3-CARBOXAMIDE a solution of 23A (4-methyl-N- [4- (methylsulfonyl) phenyl] -1-prop-2-en-l-yl-5- [2-trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide) (156 mg, 0.34 mmol) in THF (20 mL) was cooled to 0 ° C, 9-BBN (0.73 mL, 0.5 M solution in THF, 0.36 mmol) was added at 0 ° C. and the reaction mixture was heated to RT. After 12 hours, NaOH (0.4 mL, 1 N solution, 0.4 mmol) and hydrogen peroxide (0.3 mL, 50% by weight of solution) were added to the reaction mixture and the mixture was added to the reaction mixture. stirring at RT for 3 hours, after said time, the mixture was diluted with EtOAc and extracted with water. The product, 23B, was purified with HPLC with NH4Oac as eluent in 35% yield.

½ NMR (DMSO-d6) d 9.92 (s, 1H), 7.96 (d, 9.0 Hz, 2H), 7.90-7.82 (m, 3H), 7.79-7, 76 (m, 2H), 7.72-7, 68 (m, 1H), 7.44 (d, 7.6Hz, 1H), 4.51 (m, 1H), 3.72-3.65 (m, m, 1H), 3.63-3.46 (m, 1H), 3.28 (s, 1H), 3.15 (s, 3H), 1.91 (s, 3H), 1, 73-1 , 65 (m, 3H), LCMS: m / z 481 (M + H) +.

EXAMPLE 24 Following the procedures mentioned above and the present preparations and examples, the compounds of the present invention can be prepared: - (2-Fluoro-phenyl) -4-methyl-l-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR, (400 MHz, CDC13) d 8.50 (d, 1H), 7.91 (d, 2H), 7.80 (d, 2H), 7.23 (s, 1H), 7.58 (m, 1H), 7.45 (s) , 1H), 7.39 (m, 1H), 7.17 (m, 4H), 6.71 (d, 1H), 5.08 (m, 2H), 3.06 (s, 3H), 2 , 25 (s, 3H); MS (El) for C25H22FN3O3S: 464.3 (MH +), - (2-Fluoro-phenyl) -1- (2-hydroxy-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.91 (d, 2 H), 7.81 (d, 2 H), 7.74 (s, 1 H), 7.49 (s, 1 H), 7.44 (m , 1H), 7.28 (m, 2H), 7.20 (m, 1H), 3.93 (t, 2H), 3.72 (m, 2H) 3.06 (s, 3H), 2, 22 (s, 3H), 1.62 (t, 1H); MS (El) for C 21 H 21 F 2 O 4 S: 417.2 (MH +). 1,4-Dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1, l-dioxo-hexahydro-116-thiopyran-4-yl) -amide. 1 H NMR (400 MHz, CDC13) d 7.80 (d, 1 H), 7.61 (m, 2 H), 7.30 (d, 1 H), 7.18 (s, 1 H), 5.67 (d , 1H), 4.28 (m, 1H), 3.28 (s, 3H), 3.13 (m, 4H), 2.42 (m, 2H), 2.20 (m, 2H), 2 , 00 (s, 3H); MS (El) for C19H21F3N2O3S: 415.2 (MH +). - (2,6-Dimethyl-phenyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, CDC13) 68.12 (1H, s) 7.93-7.91 (2H, d), 7.84-7.82 (2H, d), 7.75 (1H, s), 7.46-7.45 (1H, d), 7 , 26-7.22 (1H, t), 7.14-7.15 (1H, d), 3.06 (3H, s), 2.14 (3H, s), 2.09 (6H, s ); MS (El) for C23 H22 2 O 3 S: 383 (MH +). - (2,6-Dimethyl-phenyl) -4-methyl-1- (2-morpholin-4-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) 5 7, 92-7.89 (2H, d), 7.83-7.81 (2H, d), 7.76 (1H, s), 7.48 (1H, s), 7.25-7.23 (1H, d), '7, 15-7, 13 (2H, m), 3.64-3.61 (6H, m), 3.06 (3H, s ), 2, 47-2, 44 (2H, t), 2.29-2.27 (4H, m), 2.09 (3H, s), 2.05 (6H, s); MS (El) for C2-7H33N3O4S: 496 (MH +). 4-Methyl-1- (2-morpholin-4-yl-ethyl) -5- (2-phenoxy-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.90-7.88 (2H, d), 7.79-7.77 (2H, d), 7.63 (1H, -s), 7, 52-7 , 40 (1H, m), 7.38 (1H, s), 7.32-7.22 (4H, m), 7, 06-7, 02 (2H, t), 6, 86-6, 84 (2H, d), 4, 00-3, 85 (2H, m), 3.64-3.62 (4H, m), 3.04 (3H, s), 2.55-2.52 (2H , t), 2.33-2.29 (4H, m), 2.17 (3H, s) MS (El) for C31H33N3O5S: 560 (MH +), 1- (2-Diethylaraine-ethyl) -4-methyl-5- (2-phenoxy-phenyl) -IH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7, 87-7, 84 (2H, d), 7, 80-7.77 (3H, m), 7.40-7.38 (2H, m), 7, 32-7.19 (4H, m), 7.05-7.01 (2H, m), 6.86-6.84 (2H, d), 3.91-3.82 (2H, m), 3.02 (3H, s), 2, 60-2.54 (2H, m), 2.44-2.40 (4H, m), 2.17 (3H, s), 0.90-0, 86 (6H, t); MS (El) for C 31 H 35 N 3 O 4 S: 546 (MH +). 4-ethyl-5- (2-phenoxy-phenyl) -1- (2-piperidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) 57, 88-7, 86 (2H, d), 7.79-7.77 (2H, d), 7.71 (1H, s), 7, 42-7.36 (2H, m), 7.31-7.19 (4H, m), 7.05-7.01 (2H, m), 6, 86-6, 84 (2H, d), 3.93-3 , 86 (2H, m), 3.03 (3H, s), 2, 53-2, 47 (2H, m), 2.27-2.22 (4H, m), 2.17 (3H, s ), 1.54-1.49 (4H, m), 1, 40-1.39 (2H, m); MS (El) for C 32 H 35 N 3 O 4 S: 558 (MH +). 4-Methyl-5- (2-phenoxy-phenyl) -l-pyridin-3-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 8, 45-844 (1H, m), 8.22 (1H, s), 7.91 (1H, s), 7.83-7.81 (2H, d) , 7.75-7.73 (2H, d), 7.38-7.34 (1H, m), 7.30 (1H, s), 7.27-7.23 (3H, m), 7 , 19-7.12 (3H, m), 7.07-7.03 (1H, t), 6, 98-6, 96 (1H, d), 6.81-6.79 (2H, m) , 4.99 (2H, s), 3.00 (3H, s), 2.20 (3H, s); MS (El) for C3iH27 304S: 538 (MH +). 4-Methyl-5- (2-phenoxy-phenyl) -1- (2-pyrrolidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7, 88-7, 86. (2H, d), 7, 79-7.77 (2H, d), 7.70 (1H, s), 7.41-7 , 38 (1H, m), 7.37 (1H, s), 7.31-7.19 (4H, m), 7, 06-7, 00 (2H, m), 6, 86-6, 84 (2H, d), 3, 97-3, 90 (2H, m), 3.03 (3?, • s), 2, 68-2, 62 (2H, m), 2, 42-2.36 (4H, m), 2.17 (3H, s), 1.74-1, 72 (4H, m); MS (El) for C 31 H 33 N 3 O 4 S: 544 (MH +). 1- (3-Dimethylamine-propyl) -4-methyl-5- (2-phenoxy-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1H NMR (400 MHz, CDC13) 57, 89-7, 87 (2H, d), 7.81-7.78 (2H, d), 7, 77 (1H, s), 7.41-7.36 (1H, m), 7.34 (1H, s), 7.30-7.19 (4H, m), 7.06-7.01 (2H, m), 6, 87-6, 85 (2H , d), 3, 96-3, 80 (2H, m), 3.03 (3H, s), 2.18-2.13 (11H, m), 1.77-1, 73 (2H, t ); MS (El) for C3oH33 304S: 532 (MH +). 1- (2-Hydroxy-ethyl) -4-methyl-5- (2-phenoxy-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 9.00 (1H, s), 7.92-7.90 (2H, d), 7.85-7, 83 (2H, d), 7.56 (1H, s), 7.39-7.18 (5H, m), 7, 06-7, 04 (1H, t), 6, 99-6, 96 (1H, d), 6, 87-6, 85 ( 2H, d), 4.01-3.88 (2H, m), 3.86-3.83 (1H, t), 3, 78-3, 64 (2H, m), 3.04 (3H, s), 2.19 (3H, s); MS (El) for C27H26N205S: 491 (MH +). - (2,6-Dimethyl-phenyl) -1- (2-hydroxy-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 791-7, 89 (2H, d), 7.83-7.81 (2H, d), 7.77 (1H, s), 7.51 (1H, s) , 7.25-7.23 (1H, m), 7.15-7.13 (2H, m) 3, 69-3, 66 (4H, m), 3.06 (3H, s), 2, 09 (3H, s), 2.04 (6H, s); MS (El) for C 23 H 26 2 O 4 S: 425 (MH-). - (2,6-Dimethyl-phenyl) -4-methyl-1-pyridin-3-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 8.48 (1H, m), 8.10-8.07 (2H, d), 7.87-7, 85 (2H, d), 7.83-7, 81 (2H, d), 7.52 (1H, s), 7.25-721 (2H, m), 7.18-7.10 (1H, m), 7.10-7.08 (2H, d), 4.68 (2H, s), 3.05 (3H, s), 2.08 (3H, s), 1.84 (6H, s); MS (El) for C27H27N303S: 474 (MH +). - (2,6-Dimethyl-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.91-7.88 (2H, d), 7.87 (1H, s), 7.85-7.82 (2H, d), 7.48 (1H, s), 7.26-7.22 (1H, m), 7.14-7.12 (2H, d), 3, 67-3, 64 (2H, t), 3.05 (3H, s) , 2, 62-2, 58 (2H, t), 2.40-2.37 (4H, m), 2.08 (3H, s), 2.04 (6H, s), 1.74-1 , 71 (4H, m); MS (El) for C27H33N303S: 480 (MH +). - (2,6-Dimethyl-phenyl) -4-methyl-1- (2-piperidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7, 90-7, 88 (2H, d), 7.87 (1H, s), 7.85-7.82 (2H, d), 7.50 (1H, s), 7.26-7.22 (1H, m), 7.14-7.12 (2H, d), 3.65-3.61 (2H, t), 3.05 (3H, s) , 2.45-2.41 (2H, t), 2.25 (4H, m), 2.08 (3H, s), 2.03 (6H, s), 1.52-1.48 (4H , m), 1.39-1.38 (2H, m); MS (El) for C28H35 3O3S: 494 (MH +). - (2,6-Dimethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.92-7.90 (2H, d), 7.83-7.81 (2H, d), 7.69 (1H, s), 7.36 (1H, s), 7.27-7.23 (1H, m), 7.15-7.13 (2H, d), 3.29 (3H, s), 3.06 (3H, s), 2.10 (3H, s), 2.02 (6H, s); MS (El) for C 22 H 24 N 2 O 3 S: 397 (MH +). - (2, β-Dimethyl-phenyl) -4-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1H NMR (400 Hz, CDC13) d 8.52-8.50 (1H, d), 7.92 (1H, s), 7.90-7.7.8 (2H, d), 7.84- 7.81 (2H, d), 7.56-7, 52 (2H, m), 7.25-7.21 (1H, t), 7.19-7.16 (1H, m), 7, 09-7, 07 (2H, m), 6, 66-6, 64 (1H, d), 4.79 (2H, s), 3.05 (3H, s), 2.09 (3H, s) 1.87 (6H, s); MS (El) for C27H27N3O3S: 474 (MH +). - (4-Benzyloxy-2-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7, 92-7, 89 (2H, d), 7, 83-7, 80 (2H, d), 7.69 (1H, s), 7.48-7, 36 (5H, m), 7.31 (1H, s), 7.10-7.07 (1H, d), 6.96 (1H, s), 6.90-6.87 (1H, m) , 5.10 (2H, s), 3.35 (3H, s), 3.06 (3H, s), 2.15 (3H, s), 2.07 (3H, s); MS (El) for C ^ Has ^ C ^ S: 489 (MH +). - (4-Hydroxy-2-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.91-7.89 (2H, d), 7, 82-7, 80 (2H, d), 7, 68 (1H, s), 7.30 (1H, s), 7, 04-7, 02 (1H, d), 6.80 (1H, s), 6, 75-6, 72 (1H, m), 3.64 (3H, s), 3.05 (3H, s), 2.14 (3H, s), 2.04 (3H, s); MS (El) for C 21 H 22 N 2 O S: 399 (MH +). 1- [3- (4-Fluoro-phenoxy) -2- (R) -hydroxy-propyl] -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.91-7.88 (2H, d), 7, 83-7, 82 (1H, d), 7, 80-7, 77 (2H, d), 7, 71 (1H, s), 7, 62-7, 57 (2H, m), 7.51-7.48 (1H, d), 7.31-7.29 (1H, m), 6, 98- 6, 94 (2H, t), 6.75-6, 68 (2H, m), 4.13-4.01 (1H, m), 3, 93-3, 67 (4H, m), 3, 05 (3H, s), 2.08 (3H, s); MS (El) for C 29 H 26 F 4 2 O 5 S: 591 (MH +). 1,4-Dimethyl-5- [2-methyl-4- (3-morpholinyl-propoxy) -phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.90-7.88 (2H, d), 7.83-7.80 (2H, d), 7.74 (1H, s), 7.31 (1H, s), 7.26 (1H, s), 7.07-7, 05 (1H, d), 6.86 (1H, s), 6.81-6.78 (1H, m), 4.08 -4.05 (2H, t), 3.76-3.73 (4H, m), 3.34 (3H, s), 3.05 (3H, s), 2.59-2.55 (2H , t), 2.51 (4H, m), 2.13 (3H, s), 2.06 (3H, s), 2, 03-2, 00 (2H, t); MS (El) for C28H35 305S: 526 (MH +), l-Cyclopropylmethyl-4-methyl-5- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 1 H NMR (400 MHz, CDC13) d 7.92-7.90 (2H, d), 7.83-7.81 (3H, m), 7.73 (1H, s), 7.67-7, 58 (2H, m), 7.54 (1H, s), 7.37-7.35 (1H, d), 3.37-3.35 (2H, d), 3.05 (3H, s) , 2.09 (3H, s), 1.04 (1H, m), 0.61-0.59 (2H, m), 0.25-0.14 (2H, m); S (E) for C 24 H 23 F 3 2 O 3 S: 477 (MH +). 4-Methyl-l-prop-2-ynyl-5- (2-trifluoromethyl-phenyl) -IH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NR (400 MHz, CDC13) d 9 , 11 (1H, s), 7, 97-7, 94 (2H, d), 7.88-7.86 (2H, d), 7, 82-7, 80 (1H, d), 7.65 -7.61 (2H, m), 7.60 (1H, s), 7.39-7.37 (1H, d), 6, 39-6.36 (1H, t), 5.41-5 , 39 (2H, d), '3.05 (3H, s), 2.09 (3H, s), MS (El) for C23H19F3N2O3S: 461 (MH +), - (2-Chloro-phenyl) -1- [3- (4-fluoro-phenoxy) -2- (S) -hydroxy-propyl] -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide, 1 H NMR (400 MHz, CDC13) d 8, 02-7.99 (1H, d), 7.84-7.81 (2H, d), 7, 78-7, 75 (2H , m), 7.58 ^ 7.52 (1H, d), 7.51-7.47 (1H, m), 7.40-7.24 (3H, m), 6, 94-6, 90 '(2H, m), 6, 68-6, 65 (2H, m), 4.07-3.78 (3H, m), 3.74-3, 64 (2H, m), 3.03 ( 3H, s), 2.14 (3H, s); MS (EI) for C28H26CIF 2O5S: 557 (MH +), - (2-Chloro-phenyl) -1- [3- (4-fluoro-phenoxy) -2- (R) -hydroxy-propyl] -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide, 1 H NMR (400 MHz, CDC13) 57, 90-7, 86 (2H, d), 7.79-7.71 (3H, m), 7.53-7, 46 (2H, m), 7.41-7.27 (3H, m), 6.97-6, 93 (2H, t), 6.72-6.68 (2H, m), 4, 08-3, 82 ( 3H, m), 3.78-3.73 (1H, m), 3.69-3.64 (1H, m), 3.05 (3H, s), 2.16 (3H, s); MS (El) for C28H26CIFN2O5S: 557 (H +), - (2-Chloro-phenyl) -l-cyclopropylmethyl-4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, CDC13) d 7.90-7 , 81 (2H, d), 7.85-7.81 (3H, m), 7.53-7.51 (2H, m), 7, 42-7.34 (2H, m), 7.32 -7.28 (1H, m), 3.57-3.43 (2H, m), 3.05 (3H, s), 2.17 (3H, s), 1, 02-0.98 (1H , m), 0, 58-0, 52 (2H, m), 0.18-0.09 (2H, m); MS (El) for C23H23CIN2O3S: 443 (MH +), - (2-Methoxy-phenyl) -4-methyl-1- (2-piperidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMSO) d 9.91 (s, 1 H), 7.97 (d, 2 H), 7.84 (d, 2 H), 7.70 (s, 1 H), 7.45 (t, 1 H), 7.19 (m, 2 H), 7.06 (t, 1 H), 3.75 (s, 3 H), 3.73 (m, 2 H), 3.17 (s, 3 H), 2.38 (t, 2 H), 2.16 (m, 4 H), 2.01 (s, 3 H), 1.37 (m, 6 H); MS (El) for C27H33 304S: 496 (MH +), 5- (2-Methoxy-phenyl) -1, -dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -methyl-amide, 1H NMR (4? 0 MHz, CDC13) d 7.86 (d, 2 H), 7.39 (d, 2 H), 7.37 (m, 1 H), 7.06 (m, 1 H), 6 , 96 (m, 2 H), 6.39 (s, 1 H), 3.74 (s, 3 H), 3.51 (s, 3 H), 3.23 (s, 3 H), 3 , 06 (s, 3 H), 1.89 (s, 3 H); MS (El) for C22H24N2O4S: 413 (MH +), - (2-Methoxy-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 Hz, d6-DMSO) d 9.91 (s, 1 H), 7.97 (d, 2 ti), 7.85 (d, 2 H), 7.71 (s, 1 H), 7.44 (m, 1 H), 7.16 (m, 2 H), 7.06 (m, 1 H), 3.75 (s, 3 H), 3.77 (m, 2 H), 3.17 (s, 3 H), 2.51 (m, 2 H), 2.24 (m, 4 H), 2.01 (s, 3 H), 1.57 (m, 4 H); MS (El) for C 26 H 31 3 O 4 S: 482 (MH +), 1,4-Dimethyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, d6-DMS0) d 9.94 (s, 1 H) , 7.98 (d, 2 H), 7.85 (d, 2 H), 7.69 (s, 1 H), 7.37 (m, 2 H), 7.29 (m, 1 H) , 7.18 (d, 1 H), 3.17 (s, 3 H), 2.07 (s, 3 H), 1.99 (s, 3 H); MS (El) for C21H22 203S: 383 (MH +), 1- (2-Diethylamine-ethyl) -4-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) - amide, 1 H NMR (400 MHz, d 6 -DMSO) d 9.92 (s, 1 H), 7.99 (d, 2 H), 7.85 (d, 2 H), 7.77 (s, 1 H), 7.36 (m, 2 H), 7.30 (m, 1 H), 7.20 (m, 1 H), 3.75 (m, 2 H), 3.58 (m, 2 H), 2.43 (m, 2 H), 2.28 (q, 4 H), 2.09 (s, 3 H), 1.98 (s, 3 H), 0.75 (t, 6) H); MS (El) for C 26 H 33 N 3 O 3 S: 468 (MH +), 4-Methyl-1- (2-pyrrolidin-1-yl-ethyl) -5-o-tolyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6) -DMS0) d 9.92 (s, 1 H), 7.99 (d, 2 H), 7.86 (d, 2 H), 7.76 (s, 1 H), 7.37 (m, 2 H), 7.30 (m, 1 H), 7.18 (m, 1 H), 3.80 (m, 1 H), 3.65 (m, 1 H), 3.18 (s, 3 H), 2.48 (m, 2 H), 2.21 (m, 4 H), 2.07 (s, 3 H), 1.97 (s, 3?), 1.58 (m, 4 H); MS (El) for C 26 H 31 N 3 O 3 S: 466 (MH +), 4-Methyl-l-pyridin-2-yl-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMSO ) d 9.99 (s, 1 H), 8.44 (m, 1 H), 7.99 '(d, 2 H), 7.85 (m, 3 H), 7.68 (m, 1) H), 7.27 (m, 4 H), 7.06 (m, 1 H), 6.71 (m, 1 H), 3.17 (s, 3 H), 1.99 (s, 3 H), 1.92 (s, 3 H); MS (El) for C 26 H 25 N 3 O 3 S: 460 (MH +), 1- (3-Dimethylamine-propyl) -4-methyl-5-o-tolyl-1 H -pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) - amide, 1 H NMR (400 MHz, d 6 -DMSO) 6 9.91 (s, 1 H), 7.99 (d, 2 H), 7.85 (d, 2 H), 7.75 (s, 1 H), 7.36 (m, 2 H), 7.29 (m, 1 H), 7.20 (m, 1 H), 3.73 (m, 1 H), 3.60 (m, 1 H), 3.17 (s, 3 H), 2.06 (s, 3 H), 2.04 (m, 2 H), 1.97 (s, 3 H), 1.95 (s, 3 H), 1.57 (m, 2 H); MS (El) for C25H31N303S: 454 (MH +), 4-Methyl-1- (2-piperidin-1-yl-ethyl) -5-o-tolyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6) -DMSO) 59.91 (s, 1 H), 7.99 (d, 2 H), 7.85 (d, 2 H), 7.75 (s, 1 H), 7.36 (m, 2 H), 7.27 (m, 1 H), 7.20 (m, 1 H), 3.80 (m, 1 H), 3.62 (m, 1 H), 3.17 (s, 3 H), 2.35 (m, 2 H), 2.12 (m, 4 H), 2.07 (s, 3 H), 1.97 (s, 3 H), 1.35 (m, 6) H); MS (El) for C27H33N3-O3S: 480 (MH +), 4-Methyl-l- (2-morpholin-4-yl-ethyl) -5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, d6) -DMSO) d 9.92 (s, 1 H), 7.99 (d, 2 H), 7.86 (d, 2 H), 7.77 (s, 1 H), 7.36 (m, 2 H), 7.32 (d, 1 H), 7.20 (m, 1 H), 3.82 (m, 1 H), 3.65 (m, 1 H), 3.46 (m, 4 H), 3.17 (s, 3 H), 2.40 (m, 2 H), 2.16 (m, 4 H), 2.08 (s, 3 H), 1.98 (s, 3 H); MS (El) for C 26 H 31 N 3 O S ': 482 (MH +), 1- (2-Hydroxy-3-phenoxy-propyl) -4-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methane) sulfonyl-phenyl) -amide, 1 H NMR (400 MHz, d 6 -DMSO) d 9.95 (s, 1 H), 8.00 (d, 2 H), 7.85 (m, 3 H), 7, 24 (m, 6 H), 6.91"(m, 1 H), 6.73 (m, 2 H), 5.45 (m, 1 H), 3.70 (m, 5 H), 3 , 17 (s, 3 H), 2.03 (s, 3 H), 1.98 (s, 3 H); MS (El) for C29H30N2O5S: 519 (MH +), 1- (2-Diethylamine-ethyl) -5- (2, β-difluoro-phenyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMS0) 5 9, 98 (s, 1 H), 7.99 (d, 2 H), 7.86 (m, 3 H), 7.61 (m, 1 H), 7.29 (m , 2 H), 3.76 (m, 2 H), 3.17 (s, 3 H), 2.46 (m, 2 H), 2.29 (q, 4 H), 2.04 (s) , 3 H), 0.76 (t, 6 H); MS (El) for C25H29F2 3O3S: 490 (MH +), 1- (2-Hydroxy-ethyl) -4-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMS0) d 9 , 94 (s, 1 H), 7.99 (d, 2 H), 7.85 (d, 2 H), 7.79 (s, l H), 7.36 (m, 2 H), 7 , 29 (m, 1 H), 7.18 (m, 1 H), 3.74 (m, 1 H), 3.58 (m, 1 H), 3.42 (m, 2 H), 3 , 17 (s, 3 H), 2.06 (s, 3 H), 1.97 (sr 3 H); MS (El) for C22H24F2 2O4S: 413 (MH +), 5- (2,6-Difluoro-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-acid. carboxylic (-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, d 6 -DMSO) 5 10.06 (s, 1 H), 7.99 (d, 2 H), 7.87 (m, 3 H) , 7.62 (m, 1 H), 7.30 (m, 2 H), 3.88 (m, 2 H), 3.17 (s, 3 H), 2.64 (m, 2 H) , 2.33 (m, 2 H), 2.04 (s, 3 H), 1.62 (m, 4 H); MS (El) for C25H27F2N303S: 488 (MH +), - (2,6-Difluoro-phenyl) -4-methyl-1- (2-piperidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMSO) d 10.00 (s, 1 H), 7.97 (d, 2 H), 7.87 (m, 3 H), 7.63 (m, 1 H), 7 , 29 (m, 2 H), 3.81 (m, 2 H), 3.17 (s, 3 H), 2.39 (m, 2 H), 2.14 (m, 4 H), 2 , 04 (s, 3 H), 1.30 (m, 6 H); MS (El) for C 26 H 29 2 N 3 O 3 S: 502 (MH +), - (2,6-Difluoro-phenyl) -4-methyl-l-pyridin-2-ylmethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6- DMS0) d 10.09 (s, 1 H), 8.39 (m, 1 H), 7.99 (m, 3 H), 7.86 (d, 2 H), 7.67 (m, 1 H), 7.51 (m, 1 H), 7.17 (m, 3 H), 6.75 (m, 1 H), 5.09 (s, 2 H), 3.17 (s, 3 H), 2.05 (s, 3 H); MS (El) for C25H21F2 3O3S: 482 (H +), - (2,6-Dimethoxy-phenyl) -1, -dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMSO) d 9.89 (s, 1 H), 7.97 (m, 2 H), 7.84 (m, 2 H), 7.62 (m, 1 H), 7.40 (m, 1 H), 6.76 (m, 2 H), 3.71 (s, 6 H), 3.30 (s, 3 H), 3.17 (s, 3 H), 1.92 (s, 3 H); MS (El) for C 22 H 24 F 2 N 2 O 5 S: 429 (MH +), 1,4-Dimethyl-5- (2-trifluoromethoxy-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, d6-DMSO) d 10.00 ( s, 1 H), 7.98 (d, 2 H), 7.85 (d, 2 H), 7.74 (s, 1 H), 7.62 (m, 1 H), 7.50 ( m, 3 H), 3.42 (s, 3 H), 3.17 (s, 3 H), 2.04 (s, 3 H); MS (El) for CziH ^ FsNzC S: 453 (MH +), 1- (2-Hydroxy-3-phenyl-propyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMSO) d 10.00 (s, 1 H), 8.00 (m, 2 H), 7.80 (m, 6 H), 7.40 (m, 1 H), 7.15 (m, 4 H), 6.90 (m, 1 H), 3.72 (m, 1 H), 3.62 (m, 1 H), 3.54 (m, 1 H), 3.38 (m, 1 H), 3.17 (s, 3 H), 2.55 (m, 2 H), 1.191 (, 3 H); MS (El) for C29H27F3 2O4S: 557 (MH +), ' - (2-Chloro-phenyl) -1- (2-hydroxy-2-phenyl-ethyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMSO) d 10.00 (s, 1 H), 8.01 (d, 2 H), 7.85 (m, 3 H), 7.64 (m, 1 H), 7.52 (m, 2 H), 7.24 (m, 4 H), 6.96 (m, 2 H), 5.75 (m, 1 H), 4.50 (m, 1 H), 3.90 (m, 1 H), 3.66 (m, 1 H), 3.17 (s, 3 H), 2.02 (s, 3 H); MS (El) for C27H25C1N204S: 509 (MH +), - (2-Chloro-phenyl) -1- (2-hydroxy-3-methoxy-propyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, d6-DMS0) d 9.99 (s, 1 H), 7.99 (d, 2 H), 7.84 (m, 3 H), 7.62 (m, 1 H), 7.45 (m, 3 H), 5.17 (br s, 1 H), 3.75 (m, 2 H), 3.54 (m, 1 H), 3.17 (s, 3 H), 2, 01 (s, 3 H); MS (EI) for C23H25C1N205S: 477 (MH +), - (2-Chloro-phenyl) -4-methyl-1- (3,3,3-trifluoro-2-hydroxy-propyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H N R (400 MHz, d 6 -DMSO) d 10.02 (s, 1 H), 8.01 (d, 2 H), 7.88 (m, 3 H), 7.65 (m, 1 H), 7.50 (m, 3 H), 6.81 (m, 1 H), 3.90 (m, 3 H), 3.18 (s, 3 H), 2.03 (s, 3 H); MS (El) for C22H20CIF3 2O4S: 501 (MH +), | 1- (3-tert-Butoxy-2-hydroxy-propyl) -5- (2-chloro-phenyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, CDCl3) d 7.84 (m, 5 H), 7.51 (m, 2 H), 7.39 (m, 2 H), 7.30 (m, 1 H), 3, 78 (m, 3 H), 3.18 (m, 1 H), 3.07 (m, 1 H), 3.05 (s, 3 H), 2.58 (m, 1 H), 2, 16 (s, 3 H), 1.11 (s, 9 H); MS (El) for C 26 H 31 Cl 2 O 5 S: 519 (MH +), - (2-Chloro-phenyl) -1- (2-hydroxy-3-isopropoxy-propyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, CDCl3) d 7.84 (m, 5 H), 7.51 (m, 2 H), 7.38 (m, 2 H), 7.29 (m, 1 H), 3.79 ( m, 3 H), 3.50 (m, 1 H), 3.26 (m, 1 H), 3.10 (m, 1 H), 3.05 (s, 3 H), 2.16 ( s, 3 H), 1.09 (d, 6 H); MS (El) for C25H29C1N205S: 505 (MH +), 1- (2-Hydroxy-ethyl) -5- (4-methoxy-2-trifluoromethyl-phenyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, CDCl3) d 8.02 (br s, 1 H), 7.84 (m, 4 H), 7.50 (m, 2 H), 7.27 (m, 2 H), 7.11 (m, 1 H), 3.91 (s, 3 H), 3.67 (m, 4 H), 3.04 (s, 3 H), 2.06 (s, 3 H); MS (El) for C23H23 F3 2O5S: 497 (MH +),. 1,4-Dimethyl-5- [4- (3-morpholin-4-yl-propoxy) -2-trifluoromethyl-phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H NMR (400 MHz, CDCl3) d 7.90 (d, 2 H), 7.80 (d, 2 H), 7.68 (m, 1 H), 7.25 (m, 3 H), 7, 14 (m, 1 H), 4.13 (m, 2 H), 3.76 (m, 5 H), 3.31 (s, 3 H), 3.05 (s, 3 H), 2, 55 (m, 6 H), 2.09 (s, 3 H), 2.05 (m, 2 H); MS (El) for C28H32F3 305S: 580 (MH +), - (2-Benzyloxy-4-fluoro-phenyl) -1- (2-dimethylamine-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ½ NMR (400 MHz, CDCl 3): d 9.07 (s, 1?), 8.11 (d, 2H), 7.88 (d, 2H) 7.68 (m, lH), '7.35 (m, 2?), 7.18 (m, 1?), 6.93 (m, 1?), 6.84 (m, 1?), 5.04 (s, 2?), 4.35 (m, 1?), 4.21 (m, 2?), 3.46 (m, 2?), 3.33 (m, 2?), 3.05 (s, 3?), 2.96 (p? 2?), 2.35 (m, 1?), 2.22 (s, 2?) 1.64 (s, 6?); MS (El) for C 31 H 34 FN 3 O 4 S: 564 (MH +), - (2-Benzyloxy-4-fluoro-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ½ NMR (400 MHz, CDCl 3): d 8.78 (s, 1H), 8.00 (m, 2H), 7.89 (m, 2H) 7.60 (s, lH), 7.33 (m , 2H), 7.22 (m, 2H), 7 ', 16 (m, 1H), 6.84 (m, 1H), 5.02 (s, 2H), 3.80 (m, 2H), 3.05 (s, 3H), 2.59 (s, 2H), 2.42 (s, 2H), 2.20 (s, 2H), 2.96 (m, 2H), 2.35 (m , 1H), 2.22 (s, 2H) 1.64 (s, 6H); MS (El) for C32H34 FN3O4 S: 576 (MH +), - (2-Benzyloxy-4-fluoro-phenyl) -4-methyl-1- (2-piperidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1 H NMR (400 MHz, CDC13) -: 87.91 (m, 2 H), 7.84 (m, 2 H), 7.46 (m, 1 H) 7.60 (s, 1 H), 7.31 (m , 2H), 7.23 (m, 2H), 7.16 (m, 2H), 6.78 (m, 2H), 5.05 (s, 2H), 3.83 (m, 2H), 3 , 45 (m, 1H), 3.05 (s, 3H), 2.24 (m, 2H), 2.18 (s, 3H), 2.07 (s, 1H), 1.80 (m, 5H), 1.50 (m, 2H) 1.37 (m, 2H); MS (El) for C33H36F 3O4S: 590 (MH +), - (2-Chloro-phenyl) -1- (2-methoxy-ethyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, xu NMR (400 MHz, CDC13) : 57.91 (m, 2H), 7.82 (m, 2H), 7.70 (s, 1H) 7.52 (m, 1H), 7.44 (m, 1H), 7.39 (m , 2H), 7.29 (m, 1H), 3.85 (m, 2H), 3.45 (m, 2H), 3.28 (s, 3H) 3.06 (s, 3H), 2, 16 (s, 3H); MS (El) for C22H23CIN2O4S: 447 (MH +), l-Allyl-5- (2-chloro-phenyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, XH NMR (400 MHz, CDC13): 67, 92 (m , 2H), 7.82 (m, 2H), 7.70 (s, 1H), 7.52 (m, 1H), 7.40 (m, 1H), 7.35 (m, 1H), 7, 29 (m, 1H), 5.81 (m, 1H), 5.17 (m, 1H), 5.00 (m, 1H), 4.33 (m, 1H), 4.23 (m, 1H) ) 3.05 (s, 3H), 2.18 (s, 3H); MS (El) for C22H21CIN2O3S: 429 (MH +), -Biphenyl-2-yl-1- (2-diethylamine-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ½ NMR (400 MHz, CDC13): 67 , 92-7, 04 (m, 14H), 3.42 (m, 2H), 3.26 (m, 2H), 3.05 (s, 3H), 2.29 (m, 4H), 2, 21 (m, 3H), 0.82 (m, 6H); MS (El) for C31H35N3O3S: 530 (MH +), -Biphenyl-2-yl-4-methyl-1- (2-morpholin-4-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, XH NMR (400 MHz, CDCl 3): 57, 94-7, 08 (m, 14H), 3.79 (m, 4H), 3.39 (m, 2H), 3.26 (m, 2H), 3.03 (s, 3H ), 2.29 (m, 4H), 2.19 (m, 3H); MS (El) for C31H33N3O4S: 544 (MH +), -Biphenyl-2-yl-4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ¾ NMR (400 MHz, CDCl 3): 67, 94-7, 08 (m, 14H), 3.48 (m, 2H), 3.02 (s, 3H), 2, 78-2.30 (m, 4H), 2.24 (m, 3H) 1.87 (m, 4H); MS (EI) for C 31 H 33 N 3 O 4 S: 528 (MH +), - (2-Chloro-phenyl) -4-methyl-1-pyrazin-2-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ¾ NMR (400 MHz, CDCl 3) : 68, 62 (m, 2H), 7.99 (m, 2H), 7.91-7.79 (m, 4H) 7.52 (m, 2H), 7.43 (m, 1H), 7 , 39 (m, 1H), 7.27 (m, 2H), 7.18 (m, 1H), 5.05 (m, 2H), 3.06 (s, 3H), 2.16 (s, 3H); MS (EI) for C24H21CIN.4O3S: 481 (MH +), 5- (2-Chloro-phenyl) -4-methyl-l-pyrimidin-4-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) ) -amide, ½ NMR (400 MHz, CDC13): 59.07 (s, 1H), 8.61 (m, 1H), 8.02 (s, 1H), 7, 87-7, 79 (m, 4H) 7.52 (m, 2H), 7.43 (m, 1H), 7.39 (m, 1H), 7.27 (m, 1H), 7.18 (m, 2H), 6.69 (m, 1H), 5.07 (m, 2H), 3.07 (s, 3H), 2.16 (s, 3H); MS (El) for C24H21CIN4O3S: 481 (MH +), 1- (1-Hydroxy-2-methoxy-ethyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1H 'MR ( 400 MHz, CDC13): 57, 82-7, 68 (m, 5H), 7, 76-7, 63 (m, 2H) 7.52 (m, 1H), 7.38 (m, 1H), 3 , 92 (m, 1H), 3, 87-3, 63 (m, 2H), 3.59-3.51 (m, 1H), 3.37-3.13 (m, 5H), 3.06 (s, 3H), 2.16 (s, 3H); MS (El) for C 24 H 25 F 3 N 2 O 5 S: 511 (MH +), 4-Methyl-1- (tetrahydro-furan-2-ylmethyl) -5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, XH NMR (400 MHz, CDCI3): 57, 94-7.29 (m, 9H), 4, 07-3, 43 (m, 5H), 3.06 (s, 3H), 2.16 (s, 3H), 1.78 (m, 4H); MS (El) for C25H25F3N2O4S: 507 (MH +), 1- (3, 3-Dimethyl-2-oxo-butyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ½ NMR (400 MHz, CDC13): d7, .91 (m, 2H), 7.82 (m, 3H), 7.59 (m, 2H), 7.22 (m, 3H), 4.59 (m, 2H), 3.03 (s, 3H), 2.09 (s, 3H), (0.97 (s, 9H); MS (El) for C26H27 3 2O4 S: 521 (MH +), l-Furan-2-ylmethyl-4-methyl-5- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide,? NMR (400 MHz, CDC13): 57, 95-7, 62 (m, 6H), 7.29 (m, 2H), 7.59 (m, 2H), 7.22 (m, 2H), 6, 30 (m, 1H), 6.05 (m, 1H), 4.65 (m, 2H), 3.05 (s, 3H), 2.09 (s, 3H); MS (El) for C26H21 F3 2O4S: 503 (MH ÷), 1- (3-Fluoro-pyridin-2-ylmethyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, ½ NMR (400 MHz, CDC13): 67, 95-7.43 (m, 8H), 7.29 (m, 2H), 7.18 (m, 1H), 6.82 (m, 1H), 6.65 (m , 1H), 4.82 (m, 2H), 3.05 (s, 3H), 2, 09 (s, 3H); MS (El) for C 26 H 21 F 4 3 O 3 S: 532 (MH +), - (2-Chloro-phenyl) -1- (2-hydroxy-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide, XH NMR (400 MHz, DMSO-d6): 510.01 (s, 1H), 8.17 (s, 1H), 7.95-7.39 (m, 8H), '3, 81-3, 39 (m, 6H ), 2.05 (s, 3H); MS (El) for C20H19Cl2N3O4S: 468 (MH +), 5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (pyridin-2-ylmethyl) ) -lH-pyrrole-3-carboxamide, ½ NMR (400MHz, d6-DMSO): 10.6 (s, 1H), 8.48 (dd, 1H), 8.02 (d, 2H), 7.88 (m, 3H), 7, 82-7, 72 (m, 2H), 7.5 (t, 1H), 7.3 (m, 1H), 7.2 (m, 1H), 6.94 ( d, 1H), 5.15 (d, 1H), 4.75 (d, 1H), 3.2 (s, 3H), 1.95 (s, 3H); MS (El) for C26H21F N3O3S: 532 (MH +), N ~ [4- (aminesulfonyl) -3-chlorophenyl] -5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-1- (pyridin-3-ylmethyl) -lH-pyrrole-3-carboxamide , ½ NMR (400MHz, d6-DMSO): 10.3 (s, 1H), 8.48 (dd, 1H), 8.2 (s, 1H), 8.08 (s, 1H), 7.91 (d, 1H), 7.83-7.76 (m, 3H), 7.56 (t, 1H), 7.5 (s, 2H), 7, 42-7, 32 (m, 2H), 7.28 (m, 1H), 5.05 (d, 1H), 4.75 (d, 1H), 1.94 (s, 3H); MS (El) for C25H19CI F4N4O3S: 567 (MH +), - [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -1H pyrrole-3-carboxamide, ½ NMR (400MHz, d6-DMSO): 9.98 (s, 1H), 8.0 (d, 2H), 7.86 (d, 2H), 7.83 (dd, 1H), 7.8 (s) , 1H), 7.7 (t, 1H), 7.55 (m, 1H), 3.76 (m, 1H), 3.52 (m, 1H), 3.18 (s, 3H), 2 , 62 (m, 2H), 2.3 (m, 4H), 1.94 (s, 3H), 1.62 (t, 4H); S (H) for C 26 H 27 F 4 N 303 S: 538 (MH +), 1- [3- (dimethylamine) propyl] -5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide, ½ NR (400MHz, d6-DMSO): 9.96 (s, 1H), 8.0 (d, 2H), 7.86 (d, 2H), 7.83 (dd, 1H), 7.8 (s) , 1H), 7.7 (dt, 1H), 7.57 (m, 1H), 3.66 (m, 1H), 3.48 (m, 1H), 3.18 (s, 3H), 2 , 1 (m, 2H), 2.05 (s, 6H), 1.94 (s, 3H); MS (El) for C25H27F4N303S: 526 (MH +), - [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidin-1-ylethyl) -lH-pyrrole-3-carboxamide ¾ NMR (400MHz, d6-DMSO): 9.97 (s, 1H), 7, .98 (d, 2H), 7.8 (d, 2H), 7.84 (dd, 1H), 7.78 ( s, 1H), 7.7 (dt, 1H), 7.56 (m, 1H), 3.75 (m, 1H), 3.5 (m, 1H), 3.18 (s, 3H), 2.46 (m, 2H), 2.2 (b, 4H), 1.93 (s, 3H), 1.45-1.3 (m, 6H); MS (El) for C27H29F4N303S: 552 (MH +), - [4-Fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-morpholin-4-ylethyl) -lH-pyrrole-3-carboxamide? ? NMR (400MHz, d6-DMSO): 9.97 (s, 1H), 7.98 (d, 2H), 7.86 (d, 2H), 7.83 (dd, 1H), 7.6 (dt) , 1H), 7.56 (m, 1H), 3.78 (m, 1H), 3, 56-3, 48 (m, 5H), 3.18 (s, 3H), 2.5 (m, · 2?), 2.24 (b, 4H), 1.92 (s, 3H) / MS (El) for C26H27F4N3O4 S: 554 (MH +), 4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl] -1- (pyridin-3-ylmethyl) -lH-pyrrole-3-carboxamide ¾ NMR (400MHz, d6- DMSO): 9.98 (s, 1H), 8.4 (t, 1H), 8.12 (s, 1H) r 7.97 (d, 2H), 7.84 (d, 2H), 7.77 (s, 1H), 7.4 (dt, 1H), 7.27 (m, 2H), 7.12-6.96 (m, 3H), 5.03 (d, 1H) 4.9 (d, 1H), 3.68 (s, 3H), 3.18 (s, 3H), 2.03 (s, 3H); MS (El) for C 26 H 25 3 O 4 S: 476 (MH +), 4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl] -1- (2-morpholin-4-ylethyl) -lH-pyrrole-3-carboxamide aH NMR (400MHz, d6-DMSO): 9.91 (s, 1H), 7.98 (d, 2H), 7.84 (d, 2H), 7.72 (s, 1H), 7.44 (dt, 1H), 7.2-7.04 (m, 3H), 3.86-3.66 (m, 2H), 3.76 (s, 3H), 3.46 (t, 4H), 3.16 (s, 3H), 2.42 (t, 2H), 2.18 (b, 4H), 2.0 (s, 3H); MS (El) for C 26 H 31 N 3 O 5 S: 498 (MH +), 1- [2- (diethylamine) ethyl] -4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400MHz d6- DMSO): 9.91 (s, 1H), 7.98 (d, 2H), 7.84 (d, 2H), 7.71 (s, 1H), 7.44 (dt, 1H), 7.2-7.03 (m, 3H), 3.8-3.6 (m, 2H), 3.75 (s, 3H), 3.17 (s, 1H), 2.42 (t, 2H), 2.3 (q, 4H), 2.02 (s, 3?), 0.75 (t, 4) ?); MS (El) for C26H33 3O4S: 484 (MH +), 4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl] -1- (pyridin-2-ylmethyl) -lH-pyrrole-3-carboxamide XH NMR (400MHz, d6- DMSO): 9.98 (s, 1H), 8.42 (d, 1H), 8.0 (d, 2H), 7.84 (d, 2H), 7.82 (s, 1H), 7.68 (t, 1H), 7.37 (t, 1H), 7.22 (m, 1H) , 7.04 (m, 1H), 6.92 (t, 1H), 6.7 (d, 1H), 5.08 (d, 1H), 4.92 (d, 1H), 3.66 ( s, 3H), 3.17 (s, 3H), 2.05 (s, 3H); MS (The) for. C26H25 3O4S: 476 (MH +), - (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1H-pyrrole-3-carboxamide XH NMR (400MHz, d6-DMSO): 11.6 (s, 1H) , 10.0 (s, 1H), 8.1 (d, 2H), 7.84 (d, 2H), 7.8 (s, 1H), 7.47 (m, 1H), 7.4 ( t, 1H), 7.2 (t, 1H), 3.18 (s, 3H), 2.2 (s, 3H); MS (El) for C19H16F2 2O3S: 391 (MH +), - (2,4-difluorophenyl) -1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -1H-pyrrole-3-carboxamide ½ NMR (400MHz, d6-DMSO): 10.1 (s, IR), 8.05 (d, 2H), 7.88 (s, 1H), 7.8 (d, 2H), 7.48 (m, 2H), 7.2 (t, 1H), 3.48 (s, 3H), 3.18 (s, 3? ), 2.05 (s, 3?); MS (El) for C20H18F2N2O3S: 405 (MH +), 1- [(6-chloropyridin-2-yl) methyl] -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR ( 400MHz, d6-DMSO): 10.2 (s, 1H), 8.0 (d, 2H), 7.9 (s, 1H), 7.86 (d, 2H), 7.77 (t, 1H), 7.4-7.28 (m, 3H), 7.12 (t, 1H), 6.7 ( d, 1H), 5.2 (d, 1H), 5.05 (d, 1H), 3.18 (s, 3H), 2.05 (s, 3H); MS (El) for C25H2oClF2 303S: 516 (MH +), 1- [2- (diethylamine) ethyl] -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide ½ NMR (400MHz, d6- DMSO):, 9.98 (s, 1H), 8.0 (d, 2H), 7.9-7.8 (m, 3H), 7.45 (m, 2H), 7.23 (t, 1H), 3.85 (d, 1H), 3.75 (d, 1H), 3.18 (s, 3H), 2.45 (s, 2H), 2.3 (m, 4H), 2 / 05 (s, 3H), 0.8 (t, 6H); MS (El) for C25H29F2 3O3S: .490 (MH +), - (2, -difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -lH-pyrrole-3-carboxamide ¾ NMR (400MHz, d6- DMSO): 9.98 (s, 1H), 8.0 (d, 2H), 7.85 (d, 2H), 7.82 (s, 1H), 7.45 (m, 2H), 7.23 (t, 1H), 3.9 (m, 1H), 3.78 (m, 1H) , 3.18 (s, 3H), 2.54 (m, 2H), 2.25 (t, 4H), 2.05 (s, 3H), 1.58 (t, 4H); MS (El) for C25H27 F2 303S: 488 (MH +), 1- [(6-aminapyridin-2-yl) methyl] -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl ) phenyl] -lH-pyrrole-3-carboxamide ¾ NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 8.0 (d, 2H), 7.84 (m, 3H), 7, 4 (m, 2H), 7.25 (t, 1H), 7.15 (t, 1H), 6.28 (d, 1H), 6.0 (s, 2H), 5.84 (d, 1H) ), 4.9 (d, 1H), 4.72 (d, 1H), 3.18 (s, 3H), 2.05 (s, 3H); MS (El) for C25H22F2N4O3S: 497 (MH +), 1- [(6-aminapyridin-2-yl) methyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ½ NMR (400MHz, d6-DMSO): 10.2 (s, 1H), 8.05 (d, 2H), 7.97 (s, 1H), 7.9-7.8 (m, 3H), 7.77-7, 65 (m, 3H), 7.27 (d, 2H), 6.84 (d, 1H), 6.12 (d, 1H), 5.2 (d, 1H), 4.78 (d, 1H), 3.18 (s, 3H), 1.98 (s, 3H); MS (El) for C26H23F3N403S: 529 (MH +), - (2, -difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- [(6-pyrrolidin-l-ylpyridin-2-yl) methyl] -lH-pyrrole-3-carboxamide aH NMR (400MHz, d6-DMSO): 10.0 (s, 1H), 8.0 (d, 2H), 7.85 (m, 3H), 7.5-7.35 (m, 3H), 7.2 (t, 1H), 6.25 (d, 1H), 6.0 (d, 1H), 4.95 (d, 1H), 4.78 (d, 1H), 3.3 (t , 4H), 3.18 (s, 3H), 2.08 (s, 3H), 1.9 (t, 4H); MS (El) for C29H28 2N4O3S: 551 (MH +), 5- (2,4-difluorophenyl) -4-methyl-l- [(6-methylpyridin-2-yl) methyl] -N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3- XH NMR carboxamide (400MHz, d6-DMSO): 10.1 (s, 1H), 8.0 (d, 2H), 7.93 (s, 1H), 7.84 (d, 2H), 7.6 (t, 1H), 7.4-7.3 (m, 2H), 7.1 (m, 2H), 6 , 6 (d, 1H), 5.15 (d, 1H), 4.95 (d, 1H), 3.18 (s, 3H), 2.38 (s, 3H), 2.05 (s, 3H) MS (El) for C26H23F2N3O3S: 496 (MH +), methyl (6- { [2- (2, -difluorophenyl) -3-methyl-4- ( { [4- (methylsulfonyl) phenyl] amine} carbonyl) -IH-pyrrole-l- il] methyl.}. pyridin-2-yl) 2HNMR (400MHz, d6-DMSO): 10.12 (s, 2H), 8.02 (d, 2H), 7.94 (s, 1H), 7.85 (d, 2H), 7.68 (d, 2H), 7.4 (q, 1H), 7.35 (t, 1H), 7.13 (t , 1H), 6.41 (t, 1H), 5.1 (d, 1H), 4.9 (d, 1H), 3.64 (s, 3H), 3.18 (s, 3H), 2 , 08 (s, 3H); MS (EI) for C27H24F2 405S: 555 (MH +), l-. { [6- (acetylamine) pyridin-2-yl] methyl} -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400MHz, d6-DMSO): 10.38 (s, 1H ), 10.08 (s, 1H), 8.0 (d, 2H), 7, 95-7, 83 (m, 4H), 7.68 (t, 1H), 7.4-7.3 (m, 2H), 7.12 (t, 1H), 6.44 (d, 1H), '5.12 (d, 1H), 4.95 (d, 1H), 3.18 (s, 3H), 2.04 (s, 3H), 2 03 (s, 3H); MS (El) for C27H2 F2 4O4S: 539 (MH +), 1- (. {6- [bis (methylsulfonyl) amine] pyridin-2-yl] methyl) -5- (2,4-difluorophenyl) -4-methyl-N - [4- (Methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400MHz, d6-DMSO): 10.07 (s, 1H), 8.0 d, 2H), 7.95 (s, 1H), 7.92 (t, 1H), 7.84 (d, 2H), 7.58 (d, 1H), 7.3 (t, 1H), 7.2 (q, 1H) , 7.06 (d, 1H), 7.0 (t, 1H), 5.33 (d, 1H), 5.08 (d, 1H), 3.55 (s, 6H), 3.18 ( s, 3H), 2.05 (s, 3H); MS (El) for C27H26F2 407S3: 653 (MH +), - (2-chlorophenyl) -1- [2-hydroxy-3- (4-methylpiperazin-1-yl) propyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3- carboxamide ¾ NMR (400MHz, d6-DMSO): 10.0 (d, 1H), 8.0 (d, 2H), 7.85 (d, 2H), 7.8 (s, 1H), 7.6 (m, 1H),. 7.5-7.38 (m, 3H), 5.0 (s, 1H), 4.0 (m, 1H), 3.6-3.4 (m, 2H), 3.18 (s, 3H), -2.3-2.0 (m, 14H), 1.8-1.7 (m, 2H); MS (El) for C27H33CIN4O4S: 545 (MH +), - (2-chlorophenyl) -1-. { 2-hydroxy-3- [(2-methylpropyl) amine] propyl} -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide ½NMR (400MHz, d6-DMSO): 9.98 (s, 1H), 8.0 (d, 2H), 7.86 (d, 2H), 7.8 (d, 1H), 7.62 (d, 1H), 7.52-7, 42 (m, 2H), 7.4 (m, 1H), '5.0 (s, 1H), 3.9-3.73 (m, 1H) ,. 3.7-3.4 (m, 2H), 3.18 (s, 3H), 2.3 (t, 2H), 2.2-2.0 (m, 2H), 2.02 (s, 3H), 1.5 (m, 1H), 0.75 (t, 6H); MS (El) for C26H32CIN3O4S: 518 (MH +), - (2-chlorophenyl) -1-. { 2-hydroxy-3- [(phenylmethyl) amine] propyl} -4- Methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide ^ NMR (400MHz, d6-DMSO): 10.0 (s, 1H), 8.0 (d, 2H) , 7.86 • (d, 2H), 7.82 (d, 1H), 7.6 (d, 1H), 7.5-7.37 (m, 3H), 7.3-7.15 (m, 5H) , 3, 92-3, 74 (m, 1H), 3.7-3.5 (m, 2H), 3.56-3.48 (m, 2H), 3.18 (s, 3H), 2 , 32-2.26 (m, 2H), 2.02 (d, 3H); MS (El) for C29H30CIN3O4S: 552 (MH +), 6: 1- (3-amine-2-hydroxypropyl) -5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400MHz, d6 -DMSO): 10.0 (s, 1H), 8.0 (d, 2H), 7.87 (d, 2H), 7.83 (d, 1H), 7.62 (d, 1H), 7 , 52-7.38 (m, 3H), 4.95 (s, 1H), 3.84-3.6 (m, 1H), 3.54-3.3 (m, 2H), 3.18 (s, 3H), 2.4-2.23 (m, 2H), 2.02 (s, 3H); MS (El) for C22H24CIN3O4S: 462 (MH +), 4-methyl-l-. { 2- [(2-Methypropyl) amine] -2-oxoethyl} -N- [4- (Methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400MHz, CDCl 3): 7.92 (d, 2H), 7.87 -7.8 (m, 4H), 7.63 (t, 2H), 7.38 (s, 1H), 7.3 (m, 1H), 5.42 (t, 1H), 4.35 ( d, 1H), 4.16 (d, ÍH), 3.12-2.98 (m, 2?), 3.07 (s, 3?), 2.1 (s, 3?), 1, 7 (m, 1?), 0.86 (d, 6H); MS (El) for C26H28F3 3O4S: 536 (MH +), N- [4- (aminesulfonyl) -3-chlorophenyl] -1,4-dimethyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide aH NMR (CDCl3), d 808 (d, 2.2 Hz, 1H), 7.99 (d, 8.6 Hz, 1H), 7.83 (d, 7.2 Hz, 1H), -7.71 (s, 1H), 7.68-7.61 (m, 2H), 7.45 (dd, 8.8 Hz, 2.1 Hz, 1H), 7.35-7.26 (m, 2H), 5.13 (s) , 2H), 3.32 (s, 3H), 2.09 (s, 3H), LCMS: m / z 472 (M + H) +, N-. { 4- [(acetylamine) sulfonyl] -3-chlorophenyl} -1,4-dimethyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ½ NMR (DMSO-d6), d 12.3 (s, 1H), 10.03 (s, 1H ), 8.10 (s, 1H), 7.96 (m, 1H), 7.86 (m, 1H), 7.71 (m, 4H), 7.41 (m, 1H), 3.29 (s, 3H), 1.92 (s, 3H), 1.88 (s, 3H), LCMS: m / z 514 (M + H) +, (N- { 4- [(acetylamine-kappan ) sulfonyl] -3-chlorophenyl.} - l, 4-dimethyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamidate) sodium ½ NMR (DMSO-d6), d 9.71 ( s, 1H), 7.87 (d, 1H), 7.82 (d, 2.0 Hz, 1H), 7.78-7, 68 (m, 3H), 7.63 (s, 1H), 7.54 (dd, 8.9 Hz, 2.0 Hz, 4H), 7.42 (d, 7.0 Hz, 1H), 3.24 (s, 3H), 1.88 (s, 3H) , 1.61 (s, 3H), LCMS: m / z 514 (M + H) +, 1- (2-hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2 - (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide 1H NMR (DMSO-d6), d 9.97 (s, 1H), '7.97 (d, 9.0 Hz, 2H), 7.95 -7.89 (m, 1H), 7, 87-7, 84 (m, 2H), 7.82-7, 76 (m, 2H), '7, 72-7, 68 (m, 1H), 7.49-7.45 (m, 1H), 4.93 (t, 4.9Hz, 1H), 3, 69-3, 65 (m, 1H), 3.55-3.44 (m, 3H) ), 3.16 (s, 3H), 1, 91 (s, 3H), LCMS: m / z 467 (M + H) +, 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -5- [ 2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ½ NMR (DMSO-d6), d 9.96 (s, 1H), 7.98 (d, 8.8 Hz, 2H), 7.92 (d, 7.6 Hz, 1H), 7.87-7.85 (m, 2H), 7.83-7.78 (m, 2H), 7.75-7.72 (m, 1H), 7.49-7.47 (m, 1H), 3.75 (m, 1H), 3.52 (m, 1H), 3.18 (s, 3H), 2.27 (m, 4H), 1 , 93 (s, 3H), 1.61 (br s, 4H), 1.23 (br s, 2H), LCMS: m / z 520 (M + H) +, 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-morpholin-4-ylethyl) -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ¾ NMR (DMSO-d6), d 10.09 (s) , 1H), 7, 97-7, 92 (m, 3H), 7.86-7.81 (m, 3H), 7, 80-7, 32 (m, 2H), 7.53 (d, 7 , 0Hz, 1H), 4.05-3.21 (m, 12H), 3.16 (s, 3H), 1.90 (s, 3H), LCMS: m / z 536 (M + H) +, 4-Methyl-N- [4- (methylsulfonyl) phenyl] -1- (pyridin-2-ylmethyl) -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide 1H NMR (DMSO-d5) , d 10.04 (s, 1H), 8.46 '(d, 6.6 Hz, 1H), 7.99 (d, 7.0 Hz, 2H), 7.88-7.84 (m, 4H), 7.73 (td) , 7.4Hz, 1.6Hz, 1H), 7.66 (t, 1H), 7.60 (t, 7.4Hz, 1H), 7.28 (dd, 7.0Hz, 4.3Hz, 1H) , 7.14 (d, 7.2 Hz, 1H), 6.87 (d, 8.0Hz, 1H), 5.12 (d, 16Hz, 1H), 4.70 (d, 16Hz, 1H), 3 , 18 (s, 3H), 1.95 (s, 3H), LCMS: m / z 514 (M + H) +, 1- [2- (diethylamine) ethyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ¾ NMR (DMSO-d6), d 9.95"(s, 1H), 7.99 (d, 8 , 8 Hz, 2H), 7.92 (d, 7.4 Hz, 1H), 7, 87-7, 78 (m, 4H), 7.74 (t, 7.8Hz, 1H), 7.50 (d, 7.4Hz, 1H), 3.74-3, 67 (m, 1H), 3.47-3, 40 (m, 1H), 3.18 (s, 3H), 2.53 (t , 7.8Hz, 2H), 2.32 (q, 7.2Hz, 4H), 1.94 (s, 3H), 0.78 (t, 7.0Hz, 6H), LC S: m / z 522 (M + H) +, 5- ethyl carboxylate, l-dimethyl-4- (phenylmethyl) -1, 2, 3, 6-tetrahydroazepino [4, 5-b] ½ NMR (DMSO-d6), d 10 , 00 (s, 1H), 8.45 (dd, 4.7 Hz, 2.9Hz, 1H), 8.13 (d, 1.6 Hz, 1H), 7.95 (d, 9.0Hz, 2H), 7, 88-7, 80 (m, 4H), 7, 68-7, 63 (m, 2H), 7.37-7.30 (m, 2H), 7.18 (d, 6, 8Hz, 1H), 5.03 (d, 16Hz, 1H) 4.69 (d, 16Hz, 1H), 3, 16 (s, 3H), 1.92 (s, 3H), LCMS: m / z 514 (M + H) +, 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidine -l-ylethyl) -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (DMSO-d6), d 9.94 (s, 1H), 7.96 (d, 8, 8 Hz, 2H), 7.89 (d, 7.2 Hz, 1H), 7.83 (d, 9.0Hz, 1H), 7.81-7.69 (m, 4H), 7.46 ( d, 7.2 Hz, 1H), 3.74-3, 69 (m, 1H), 3.50-3.44 (m, 1H), 3.16 (s, 3H), 2, 45-2, 40 (m, 2H), 2.16 (br s, 4H), 1.91 (s, 3H), 1.37 (m, 4H), 1.29 (m, 2H), LCMS: m / z 534 (M + H) +, 5- (2-chlorophenyl) -1- [2-hydroxy-3- (phenyloxy) rovyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3 -carboxamide ½ NMR (DMSO-de), 69, 90 (s, 1H), 7.99 (d, 8.6 Hz, 2H), 7.88-7.84 (m, 3H), 7.61-7, 58 (m, 1H), 7.51-7.38 (m, 3H), 7.26-7.22 (m, 2H), 6.91 (t, 7.4Hz, 1H), 6.73 ( dd, 12Hz, 7.8Hz, 2H), 5.46 (d, 5.3Hz, 1H), 4.01-3.82 (m, 2H), 3.78-3, 65 (m, 3H), 3.18 (s, 3H), 2.02 (s, 3H) LCMS: m / z 539 (M + H) +, - (2-chlorophenyl) -1- (2,3-dihydroxypropyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (DMSO-d6), d 9 , 90 (s, 1H), 8.00 (d, 9.0 Hz, 2H), 7.86-7.80 (m, 3H), 7.61 (d, 7.4Hz, 1H), 7, 51-7.38 (m, 3H), 4.98 (m, 1H), 4.63 (m, 1H), 3.89-3.73 (m, 1H), 3.64-3.44 (m. m, 2H), 3.17 (s, 3H), 3.11 (m, 2H), 2.01 (s, 3H), LC S: m / z 463 (M + H) +, 4-methyl- N- [4- (Methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ½ NMR (DMSO-d6), d 11.40 (s, 1H), , 94 (s, 1H), 7.99 (d, 9.0 Hz, 2H), 7, 88-7, 84 (m, 3H), 7.76 (t, .7.2Hz / 1H), 7 , 69-7, 65 (m, 2H), 7.46 (d, 7, 4Hz, 1H), 3.18 (m, 3H), 2.03 (s, 3H), LCMS: m / z 423 ( M + H) +, 4-methyl-N- [4- (methylsulfonyl) phenyl] -l-prop-2-en-l-yl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3- carboxamide XH NMR (DMSO-d6), d 10.00 (s, 1H), 7.99 (d, 9.0 Hz, 2H), 7.91-7.84 (m, 3H), 7.80- 7.70 (m, 3H), 7.42 (d, 7.4Hz, 1H), 5.87-7.79 (m, 1H), 5.15 (dd, 10Hz, 1.4Hz, 1H), 4.97 (dd, 17Hz, 1.4Hz, 1H), 4.31 (dd, 16Hz, 5.7Hz, 1H), 4.07 (dd, 16Hz, 5.5Hz, 1H), 3.18 (m, 3H), 1.95 (s, 3H), LCMS: m / z 463 (M + H) +, l-. { (2S) -3- [(4-fluorophenyl) oxy] -2-hydroxypropyl} -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (CDC13), 57.90 (d, 8.8 Hz , 2H), 7, 84-7.77 (m, 3H), 7.67-7.57 (m, 3H), 7.49 (d, 12Hz, 1H), 7.36-7.27 (m , 1H), 6.97 (t, 8.2Hz, 2H), 6.76-6, 69 (m, 2H), 4.12-3.92 (m, 1H), 3, 90-3, 67 (m, 4H), 3.05 (s, 3H), 2.38 (dd, 12Hz, 5.5Hz, 1H), 2.09 (s, 3H), LCMS: m / z 591 (M + H) +, 1- (4-idroxybutyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide a? NMR (DMSO-d6), d 7.96 (d, 9.0 Hz, 2H), 7.89 (d, 8.2Hz, 1H), 7, 85-7, 77 (m, 5H), 7, 71 (t, 7.6Hz, 1H), 7.43 (d, 7.2Hz, 1H), 4.39 (m, 1H), 3.62 (p, 7.4Hz, 1H), 3.41 (p. p, 7.2 Hz, 1H), 3.32-3.25 (m, 2H), 3.16 (s, 3H), 1.91 (s, 3H), 1.58 (p, 7.0Hz, 2H), 1.27 (p, 6.4Hz, 2H), LCMS: m / z 495 (M + H) +, 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- [2- ( tetrahydro-2 H -pyran-2-yloxy) ethyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ¾ NMR (DMSO-de), d 9.97 (d, 3,1Hz, 1H), 7.96 (d, 8.8z, 2H), 7.90-7.76 (m, 5H), 7.71 (t, 8.0Hz, 1H), 7.44 (dd, 11Hz, 7.6Hz, 1H), 4.45 (d, 29Hz, 1H), 3, 88-3, 43 (m, 6H), 3, 15 (s, 3H), 1.91 (s, 3H), 1 , 64 (m, 1H), 1.55 (m, 1H), 1.41 (m, 4H), LCMS: m / z 551 (M + H) +, 1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ¾ NMR (CDC13), d 7.91 (d, 8.8Hz, 2H), 7, 84-7, 80 (m, 3H), 7.66-7.61 (m, 3H), 7.35 (d, 6.6Hz, 1H), 7.27 (s, 1H), 3.32 (s, 3H) , 3.06 (s, 3H), 2.10 (s, 3H), LCMS: m / z 435 (M + H) +, N- [4- (aminesulfonyl) -3-chlorophenyl] -1- (2-hydroxyethyl) -4-methyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (DMSO-de), d 9.99 (s, 1H), 8.10 (d, 2.0Hz, 1H), 7.92-7.90 (m, 2H), 7, 82-7.78 ( m, 3H), 7.72 (t, 7.6Hz, 1H), 7, 48-7, 47 (m, 3H), 4.96 (t, 5,1Hz, 1H), 3, 70-3, 67 (m, 1H), 3.54 (irt, 3H), 1.92 (s, 3H), LCMS: m / z 502 (M + H) +, 4-methyl-l- [2- (4-methylpiperazin-1-yl) -2-oxoethyl] -N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrol- 3-carboxamide 1HNMR (400MHz, d6-DMSO): 10.6 (s, 1H), 8.0 (d, 2H), 7.88 (t, 1H), 7.85 (d, 2H), 7.8-7.68 (m, 2H), 7.63 (s, 1H), 7.32 (d, 1H), 4.9 ( d, 1H), 4.3 (d, 1H), 3.18 (s, 3H), 1.92 (s, 3H); MS (El) for C27H29F3N404S: 563 (MH +), 1- (2-amine-2-oxoethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400MHz, d6-DMSO): 10, 3 (s, 1H), 8.01 (d, 2H), 7.9 (t, 1H), 7.85 (d, 2H), 7.8-7.69 (m, 3H), 7.36 (d, 2H), 7.27 (s, 1H), 7.1 (s, 1H), 4.5 (d, 1H), 3.98 (d, 1H), .3.18 (s, 3H), 1.93 (s, 3H); MS (El) for C22H20F3N3O4 S: 480 (MH +), 1- [2- (Butylamine) -2-oxoethyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR ( 400MHz, d6-DMSO): 10.5 (s, 1H), 8.01 (d, 2H), 7.9-7.83 (m, 3H), 7.78 (t, 1H), 7.74-7.7 (M, 3H), 7.32 (m, 1H), 4.5 (d, 1H), 4.02 (d, 1H), 3.18 (s, 3H), 3.0 (m, 2H), 1.93 (s, 3H), 1.26 (t, 2H), 1, 2 (t, 2H), 0.84 (t, 3H); MS (El) for C 26 H 28 3 3 O 4 S: 536 (MH +), 5- (2-chlorophenyl) -1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -1 H -pyrrole-3-carboxamide ½ NMR (400 MHz, 'd-CDCl 3) 7, 94-7, 88 (m, 2H), 7, 84-7.78 (m, 2H), 7.68 (bs, 1H), 7.56-7.51 ( m, 1H), 7, 44-7, 34 (m, 2H), 7.33-7.28 (m, 2H), 3.42 (s, 3H), 3.03 (s, 3H), 2 18 (s, 3H) 5- (2-fluorophenyl) -1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -1H-pyrrole-3-carboxamide ½ NMR (400 MHz, d-CDCl 3) , 94-7, 88 (m, 2H), 7, 84-7, 78 (m, 2H), 7.68 (bs, 1H), 7.41-7.48 (m, 1H), 7.33 (s, 1H), 7.29-7.17 (m, 3H), 3.46 (s, 3H), 3.07 (s, 1H), 2.23 (s, 3H) 5- (2- chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidin-1-ylethyl) -lH-pyrrole-3-carboxamide XH NMR (400 Hz, d-CDCl 3) 7, 94 -7, 88 (m, 2H), 7, 84-7, 79 (m, 2H), 7.72 (bs, 1H), 7.51-7.54 (m, 1H), 7, 46-7 , 28 (m, 4H), 3.03 (s, 3H), '2.46 (t, 2H), 2.23-2.20 (m, 4H), 2.16 (s, 3H), 2 , 1 (s, 2H), 1.61-1.35 (m, 6H) 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-morpholine) n-4-ylethyl) -lH-pyrrole-3-carboxamide XH NMR (400 MHz, d-CDCl3) "7, 95-7, 99 (m, 2H), 7.84-7.79 (m, 2H) , 7, 68 (bs, 1H), 7.55-7.52 (m, 2H), 7.45-7.34 (m, 3H), '7.29-7.33 (m, 1H), _ 3, 90-3, 71 (m, 2H), 3.59-3, 62 (t, 4H), 3.06 (s, 3H), 2, 55-2, 46 (t, 2H), 2 , 32-2.23 (m, 4H), 2.08 (s, 3H) 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (pyridine-2- ilmethyl) -lH-pyrrole-3-carboxamide a? NMR (400 MHz, d-CDCl 3) 8.51-8.44 (m, 1H), 7.94-7.88 (m, 2H), 7.83-7.78 (m, 2H), 7, 72 (bs, 1H), 7, 59-7.53 (m, 1H), 7.49-7.44 (m, 2H), 7.38-7.32 (m, 1H), 7.19- 7.13 (m, 2H), 6.73-6, 68 (m, 1H), 5.12-4.95 (m, 2H), 3.05 (s, 3H), 2.22 (s, 3H) 5- (2-chlorophenyl) -1- (2-hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400 MHz, d-CDCl 3) 7, 92-7, 88 (m, -2H), 7.84-7.78 (m, 2H), 7.71 (bs, 1H), 7.52-7.55 (m, 1H), 7 , 46 (s, 1H), 7, 44-7.35 (m, 2H), 7/33-7, 30 (m, 1H), 3.95-3.81 (m, 2H), 3.78 -3.61 (m, 2H), 3.21 (s, 3H), 2.16 (s, 3H) N- [4- (aminesulfonyl) -3-chlorophenyl] -1,4-dimethyl-5- [ 2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ½ NMR (400 MHz, d-CDCl 3) 8.10-8.07 (m, 1H), 8, 02-7, 98 (m, 1H) , 7, 85-7, 81 (m, 1H), 7.70-7.58 (m, 3H) 7, 47-7, 42 (m, 1H), 7.36-7.31 (m, 2H ), 5.13 (s, 2H), 3.33 (s, 3H), 2.08 (2, 3H), 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl ] -1- (2-pyrrolidin-1-ylethyl) -lH-pyrrole-3-carboxamide ½ NMR (400 MHz, d-CDCl 3) 7, 94-7, 89 (m, 2H), 7, 86-7, 82 (m, 2H), 7.53-7.51 (m, 1H), 7, 43 (bs, 1H), 7.42-7.32 (m, 2H), 7.31-7.26 (m, 2H), 3.95-3.82 (m, 2H), 3.05 ( s, 3H), 2.65 (t, 2H), 2.49-2.38 (m, 2H), 2.18 (s, 3H), 1.82-1.52 (m, 6H) 5- (2-chlorophenyl) -1- [3- (dimethylamine) propyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide a H NMR (400 MHz, d-CDCl 3) , 94-7, 88 (m, 2H), 7, 84-7, 78 (m, 2H), 7.69 (bs, 1H), 7.55-7.51 (m, 1H), 7, 43 -7.33 (m, 3H), 7.33-7.26 (m, 1H), 3.86-3.68 (m, 2H), 3.06 (s, 3H), 2.18 (s) , 3H), 2.14-2.06 (m, 8H), 1.76 (t, 2H) 5- (2-chlorophenyl) -1- [2- (diethylamine) ethyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide XH NMR (400 MHz, d-CDCl 3) 7, 94-7, 89 (m, 2H), 7, 84-7, 80 (m, 2H ), 7.67 (bs, 1H), 7, 54-7, 52 (m, 1H), 7, 44-7, 34 (m, 3H), 7.34-7.30 (m, 1H), 3.82-3.64 (m, 2H), 3.07 (s, 3H), 2.53 (t, 2H), 2.42-2.34 (m, 4H), 2.18 (s, 3H), 0; 88 (t, 6H) 1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide ¾ NMR (400 Hz, d-CDCl3) 7, 93-7, 89 (m, 2H), 7.86-7.78 (m, 3H), 7.69-7, 58 (m, 3H), 7.37-7.33 (m, 1H), 7.30 (s, 1H), 3.33 (s, 3H), 3.06 (s, 3H), 2.10 (s, 3H) 1- [(6-chloropyridin-2-yl) methyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5-phenyl-lH-pyrrole-3-carboxamide XH NR (400 MHz, DMSO) 10.05 (s, 1H), 8, 05-7, 98 (m, 2H), 7.88-7.74 (m, 4H), 7.45-7.41 (m, 4H) , 7.32-7.23 (m, 2H), 6.76-6.71 (m, 1H), 5.18 (s, 2H), 3.19 (s, 3H), 2.16 (s) , 3H) 5- (2-chlorophenyl) -4-ethyl-l-methyl-N- [4- (methylsulfonyl) phenyl] -1H-pyrrole-3-carboxamide ?? NMR (400 MHz, d-CDCl3) 7, 92-7, 89. (m, _2H), 7, 82-7, 78 '(m, 2H), 7.68 (s, 1H), 7.55- 7.53 (ra, 1H), 7, 45-7.30 (ra, 3H), 7.27 (s, 1H), 3.41 (s, 3H), 3.03 (s, 3H), 2 , 61-2.52 (ra, 2H), 1.12 (t, 3H) EXAMPLE 25 ACID 2, 5-DIMETHYL-L- (2-TRIFLUOROMETHYL-PHENYL) -1H-PIRROL-3-CARBOXYLIC [3- (-FLUORO-BENZYLOXY) -PHENYL] -AMIDE A. 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxy-phenyl) -amide, previously described in Example 2C, was prepared as a white solid ( 0.92 g, 80%), 1 H-NMR (DMSO-d &): d 9.15 (1H, s), 9.13 (1H, s), 7.86 (1H, d, J = 7, 8), 7.77 (1H, t, J = 7.3), 7.66 (1H, t, J = 7, 8), ~ 7, 35 (1H, d, J = 7.8), 7 , 20 (1H, t, J = 2.0), 6.98 (1H, d, J = 8.3), 6.91 (1H, t, J = 7.8), 6.47 (1H, s), 6.29 (1H, d, J = 7.8), 1.98 (3H, s), 1.73 (3H, s); MS (ESI): 375 (MH +). In an oven-dried bottle 1, 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxy-phenyl) -amide (50 mg, 133 Dmol) was added. 2CO3 (22 mg, 160 Oriol), 1-bromomethyl-4-fluoro-benzene (28 mg, 146 Dmol) and 0.5 inL DMF. The bottle was sealed and stirred at room temperature. The crude material was purified with reverse phase chromatography (C18 column), eluting with 0.05% TFA in MeCN / H20 (30:70 to 90:10) to provide the title compound (19 mg, 30%) as a solid color bone. 1H-NR (DMSO-de): d 9.43 (1H, s), 8.00 (1H, d, J = 7.8), 7.90 (1H, t, J = 7.8), 7 , 80 (1H, t, J = 7.3), 7.58 (1H, m), 7.50 (3H, m), 7.35 (1H, d, J = 8.6), 7.22 (3H, m), 6.69 (1H, d, J = 8.3), 6.63 (1H, s), 5.07 (2H, s), 2.14 (3H, s), 1, 88 (3H, s); MS (ESI): 483 (MH +), B. The following compounds were prepared in a manner similar to that described in 25A using alkyl suitable bromides: 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4 -acetylamine-benzyloxy) -phenyl] -amide; MS (ES): 522 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-bromo-benzyloxy) -phenyl] -amide; MS (ES): 543 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid. [3- (naphthalen-2-ylmethoxy) -phenyl] -amide; MS (ES): 515 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (benzo [1,2,5] oxadiazol-5-ylmethoxy) -phenyl] -amide; MS '(ES): 507 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-methoxy-5-nitro-benzyloxy) -phenyl] -amide; MS (ES): 540 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-fluoro-2-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4,5-dimethoxy-2-nitro-benzyloxy) -phenyl] -amide; MS (ES): 570 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (bromo-2-fluoro-benzyloxy) -phenyl] -amide; MS (ES): 561 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,6-dichloro-benzyloxy) -phenyl] -amide; MS (ES): 533 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-methanesulfonyl-benzyloxy) -phenyl] -amide; MS (ES): 543 (MH +); 2, 5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (6-chloro-benzo [1, 2, 5] thiadiazol-5-ylmethoxy) -phenyl] - amide; MS (ES): 557 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-nitro-benzyloxy) -phenyl] -amide; MS (ES): 510 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (benzo [1,2, 5] thiadiazol-4-ylmethoxy) -phenyl] -amide; MS (ES): 523 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-methyl-5-phenyl-isoxazol-4-ylmethoxy) -phenyl] -amide; MS (ES): 546 (MH +); 3- (3. {[2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenoxymethyl) -benzoic acid methyl ester; MS (ES): 523 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-methyl-benzyloxy) -phenyl] -amide; MS (ES): 479 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-bromo-benzyloxy) -phenyl] -amide; MS (ES): 543 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3, 5-dimethyl-benzyloxy) -phenyl] -amide; MS (ES): 493 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,6-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 501 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-chloro-benzyloxy) -phenyl] -amide; MS (ES): 499 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-4-fluoro-benzyloxy) -phenyl] -amide; MS (ES): 517 (H +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3,5-dimethoxy-benzyloxy) -phenyl] -amide; MS (ES): 525 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-chloro-2-fluoro-benzyloxy) -phenyl] -amide; MS (ES): 517 (.MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-6-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-bromo-benzyloxy) -phenyl] -amide; MS (ES): 543 (MH +.); '2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,3,5,6-tetrafluoro-4-methyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-bromo-5-methoxy-benzyloxy) -phenyl] -amide; MS (ES): 573 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3,5-di-tert-butyl-benzyloxy) -phenyl] -amide; MS (ES): 577 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (benzothiazol-2-ylmethoxy) -phenyl] -amide; MS (ES): 522 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (5-methyl-2-phenyl-2H- [1,2,3] triazol-4-ylmethoxy] ) -phenyl] -amide; MS (ES): 546 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (5-trifluoromethyl-furan-2-ylmethoxy) -phenyl] -amide; MS (ES): 523 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-fluoro-5-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-3,6-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 535 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,3-, 4-trifluoro-benzyloxy) -phenyl] -amide; MS (ES): 519 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-fluoro-3-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,4,5-trifluoro-benzyloxy) -phenyl] -amide; MS (ES): 519 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-6-fluoro-benzyl-phenyl) -phenyl] -amide; MS (ES): 517 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-fluoro-2-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-tert-butyl-benzyloxy) -phenyl] -amide; MS (ES): 521 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-isopropyl-benzyloxy) -phenyl] -amide; MS (ES): 507 (MH +); 2, 5-Dimethyl-β- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-difluoromethoxy-benzyloxy) -phenyl] -amide; MS (ES): 531 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-methyl-benzyloxy) -phenyl] -amide; MS (ES): 479 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3, 5-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 501 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-methyl-benzyloxy) -phenyl] -amide; MS (ES): 479 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-benzyloxy) -phenyl] -amide; MS (ES): 483 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2, 3-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 501 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,4-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 501 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 533 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-difluoromethoxy-benzyloxy) -phenyl] -amide; MS (ES): 531 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-4-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-3-methyl-benzyloxy) -phenyl] -amide; MS (ES): 497 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-chloro-2,6-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 535 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2, 5-difluoro-benzyloxy) -phenyl] -amide; MS (ES): 501 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-trifluoromethoxy-benzyloxy) -phenyl] -amide; MS (ES): 549 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (biphenyl-2-ylmethoxy) -phenyl] -amide; MS (ES): 541 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (5-chloro-benzo [b] thiophen-3-ylmethoxy) -phenyl] -amide; MS (ES): 555 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,3,6-trifluoro-benzyloxy) -phenyl] -amide; MS (ES): 519 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 533 (MH +); 4- (3. {[[2,5-Dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenoxymethyl) -benzoic acid methyl ester; MS (ES): 523 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-fluoro-4-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3'-carboxylic acid [3- (3-trifluoromethoxy-benzyloxy) -phenyl] -amide; MS (ES): 549 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-5-fluoro-benzyloxy) -phenyl] -amide; MS (ES): 517 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-5-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-3-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 551 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-5-trifluoromethyl-benzyloxy) -phenyl] -amide; MS (ES): 567 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-benzyloxy) -phenyl] -amide; MS (ES): 499 (MH +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3-. { 2,5-dichloro-benzyloxy) -phenyl] -amide; MS (ES): 533 (MH +); 4- (3. {[2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenoxymethyl) -benzoic acid ethyl ester; MS (ES): 537 (MH +); 2,5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4- [1, 2,] triazol-1-yl-benzyloxy) -phenyl] -amide; MS (ES): 532 (H +); 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-pyrrol-1-yl-benzyloxy) -phenyl] -amide; MS (ES): 530 (MH +).

EXAMPLE 26 ACID 1- [4- (2, 4-BIS-TRIFLUOROMETHYL-BENZOYLAMINE) TRIFLUOROMETHYL-PHENYL] -2,5-DIMETHYL-1H-PIRROL-3-CARBOXYLIC METHANOSULPHONYL-PHENYL) -AMIDE A. 1- [4-Bromo-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid [4- (methanesulfonyl) phenyl] -amide was prepared as described in Example 1G . In a furnace-dried flask 1, 1- [4-Bromo-2- (trifluoromethyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid [4- (methanesulfonyl) phenyl] -amide was added. mg, 50 Dmol), 2,4-Bis (Trifluoromethyl) benzamide (13mg, Dmol) Copper (I) iodide (50mg, 260 Dmol), 2C03 (50mg, 360 Dmol),?,? '- Dimethylenediamine (9 mg , lOOQmol), and 0.4 mL of Toluene. The flask was sealed and stirred for 18 h at 110 ° C. The reaction was worked up by adding 1: 1 solution of 2.0 M NaOH: 0.5 M EDTA (Iml) and ethyl acetate (lml). The ethyl acetate was extracted and dried in vacuo. The crude material was purified with reverse phase chromatography (C18 column), eluting with 0.05% TFA in MeCN / H20 (30:70 to 90:10) to provide the title compound (6.9 mg, 10%) as a white solid, XH-NMR (DMS0-d5): d 11.24 (1H, s), 9.78 (1H, s), 8.28 (1H, d, J = 2 Hz), 8.22 (1H, d, J = 8 Hz), 8.19 (1H, s), 8.02 (4H, m), 7.76 (2H, d, J = 9 Hz), 7.44 (2H, d) , J = 9 Hz), 6.59 (1H, s), 3.09 (3H, s), 2.10 (3H, s), 1.84 (3H, s); MS (ESI): 692 (MH +).

EXAMPLE 27 GAL4-MR CELL-BASED ASSAY The activity of the compound was determined in a cell-based assay using GAL4-MR chimera to idfy compounds with the ability to modulate MR activity.

The expression pCMX-GAL4-MR was constructed by cloning nucleotides encoding amino acids 671 to 984 of human MR (see GenBank sequence? 59571) into the pCMX-GAL4 vector (Perlmann et al., 1993, Genes &Developm7: 1411 -1422) comprising nucleotides encoding amino acids 1-147 of GAL4 DNA.

TK-MH100x4-Luc (GAL4uAs-TK-Luciferase) was constructed by inserting four copies of Gal4 ÜAS (Kang et al, 1993, J, Biol, Chem, 268: 9629-9635) into the Hind III site of TK-Luc . The TK-Luc parl plasmid was prepared by inserting the Herpe simple virus thymidine kinase gene promoter (-105 to +51) obtained from the pBLCAT2 plasmid by digestion with HindIII and Xhol (described in Luckow et al., 1987, Nuc Acid). , Res, 15: 5490) in the MMTV-LUC plasmid described by Hollenberg and Evans, 1988, Cell 55: 899-906) after extracting MMTV-LTR from MMTV-LUC by digestion with HindIII and Xhol. The correct cloning was confirmed by restriction digestion and sequence.

The assays were performed using (African Mono Kidney Cells) (ATCC) cells grown in T175 flasks at a density of 3xl06 cells / flask in DMEM with 5% FBS. Cells were transfected one day after color 70-80 percin confluence with a mixture of DNA containing (per vial T175J 9 Dg pCMX-GAL4-MR, 9 Dg TK-MH100x4-Luc, and 2 Dg pCMX O-Gal using the FuGENE6 transfection reag(Roche Molecular Biochemicals, Indianapolis, IN) following recommended protocols and instructions provided by the manufacturer and incubated with transfection reag for 5 hours at 37 ° C.

For the antagonist format, the compounds were diluted in medium containing aldosterone (30 nM) and dispensed in assay dishes using Multimek (Beckman, FulleTAon, CA). Approximately 5 ID of the medium containing the compound and aldosterone were dispensed into each well of the 384 well plate to achieve a final concation of approximately 10 DM for compounds and 3 nM for aldosterone. The transfected cells were trypsinized, resuspended in the medium, and 45 LD was added to the assay dish at a density of approximately 5,000 cells / well using a MultiDrop dispenser (MTX Lab Systems, Inc., VA). The test dishes containing both compounds and the cells were incubated for approximately 20 hours at 37 ° C and 5% CO2 in a tissue culture incubator.

After incubation of the transfected cells, Lysis buffer (1% Triton X-100, 10% Glycerol, 5 mM DTT, 1 mM EGTA, 25 mM Tricin, pH 7.8) and Luciferin assay buffer (0.73) was prepared. mM ATP, 22.3 mM Tricin, 0.11 mM EDTA, 33.3 mM DTT, 0.2 M MgSO4, 11 mM Luciferin, 6.1 mM Coenzyme A, 0.01 mM HEPES, pH 7.8). The medium was extracted from the dishes with lysis buffer and luciferin assay in a 1: 1 ratio and then 30 μ? of the mixture to each well using a Multidrop dispenser. The dishes were read at Northstar (Applied Biosistems, Foster Citi, CA) and the information was analyzed using ActivitiBase (ID Business Solutions, Ltd,, Guildford, Surrei, UK). If required, luciferase values can be normalized for transfection efficiency by measuring β-galactosidase activity based on the expression of the expression plasmid pCMX-Gal as described above (Illi et al,, 1995, Gene & Developm, 9: 1033-1045).

In certain cases, the compounds were also evaluated for activity in selectivity assays with other spheroid hormone receptor members, including AR, ER, GR and PR, as well as GAL4 alone. The receptors, spheroids used for the selectivity assays were generated essally as described above for pC X-GAL4-MR and compromise LBD and a portion of the hinge region of the nuclear receptor of interest cloned under the pCMX-GAL4 vector (Perlmann et al, 1993, Genes &Developm7: 1411-1422) as described above.

The tests are performed in antagonist mode as follows: AR; 25 nM dihydrotestosterone (DHT), ER; 4.5 nM estradibl, GR; 20 nM dexamethasone, and PR; 2 nM medroxyprogesterone (MPA), respectively. The tests performed in an agonist manner did not contain complementary compounds.

EXAMPLE 28 PROXIMITY TEST FOR ESCINTALATION: The activity of the compound was also characterized by the use of proximity test by scribing (SPA Test). The assay measures the ability of the compound to displace 3H-aldosterone by binding to the human MR ligand binding domain.

Materials Needed: [3H] -Aldosterone (Perkin-Elmer, Cat # NET419, lmCi / ml, 2, 56TBq / mmol, 70, OCi / mmol) MR-LBD lysate SPA drops: Isi copper His-tag (DM 2-5) ) SPA drops (Amersham, Cat # RPNQ0096) Dishes: 96-well plate Non-binding surface (Corning, Cat # 3604) MR lysate buffer: (20 mM Tris-HCl pH 7.3, 1 mM EDTA, 10% Glycerol , 20 mM Sodium Tungstate). SPA Buffer with EDTA: (10 mM K2HPO4 / KH2PO4, pH7.3, 50 mM NaCl, 0.025% Tween 20, 10% Glycerol, 2 mM EDTA) SPA Buffer without EDTA: (10 mM K2HPO4 / KH2PO4, pH7.3, 50mM NaCl, 0.025% Tween 20, 10% Glycerol) Standard Solutions: 0.5 M K2HPO4 / H2PO4 pH 7.3 0.5 M EDTA pH 8.0 5 M NaCl 10% Tween-20 Glycerol Buffer 2X SPA (with EDTA) Buffer 2X SPA (without EDTA) Preparation of protein lysates: A bacolovirus expression plasmid for human MR LBD was made by cloning DNA fragment encoding human amino acids 671-984 of human MR in pBlueBacHis2, the baculovirus transfer vector (Invitrogen, CA) following standard procedures. The insertion of DNAs into the vector pBlueBacHis2 created in a framework fusion for the DNA for an N-terminal poly-His tag present in pBlueBacHis2 to provide the vector pBlueBacHis2-MR-LBD. Viral plaques were formed by co-transformation of pBlueBacHis2-MR-LBD with Bac-N-Blue (Invitrogen, CA) into sf9 insect cells following the instructions provided with the reagents. Recombination between the two vectors will result in the creation of baculovirus R-LBD plate and a titre of 109 pfu / ml was used. Expression was confirmed by SDS-PAGE analysis after purification using Ni-NTA Resin (Qiagen) and "wetern blotting" using anti-his antibody (Invitrogen, CA) using standard procedures. The correct cloning was confirmed by PCR and sequence using specific primers.

The cell lysates were prepared by infecting healthy Sf9 cells at a density of approximately 1.8 × 0.06 / ml at 27 ° C, in a total volume of 500 mL per centrifugal flask. Sf9 cells were infected using viruses in .O.I. of about 5 and they were covered for 48 hours at 27 ° C constantly stirring before harvesting.

After incubation, the cells were harvested by centrifugation and in the form of a pellet. The cell pellets were resuspended in ice prepared with extraction buffer at 1/50 original culture volumes (20 mM Tris-HCl pH 7.3, 1 mM EDTA, 10% Glycerol, 20 mM sodium tungstate, containing free inhibitor tablet of EDTA protease (Roche Catalog No: 1836170) for 10 ml of MR lysate buffer).

Cells were used on ice using Branson Sonifier 450 set at a constant 1.5, 80% production for five sets of 15 drops to achieve 80-90% cell lysis. The homogeneous was set in a pre-cooled rotor (SW55 or SW28, or equivalent) at 40,000 rpm for 20 minutes at 4 ° C. Aliquots of supernatant were frozen and stored frozen at -80 ° C until quantification and quality control. The aliquots of the lysates were tested in the SPA test to ensure total consistency and adjusted for protein concentration and expression level before use in the control assays.

Preparation of control reagents: Solution [3H] -aldosterone ([3H] -Aldo): For each 96 well plate (or 100 wells), 4.5 μL of [3H] -Aldo (70Ci / mmol, lirtCi / mL) was added to 3, 6 mL of SPA buffer with EDTA to provide a final concentration of 14.7 nM. The solution ([3H] -Aldo for each additional 96-well dish was prepared in the same manner immediately before use.The final concentration of [3H] -Aldo in the well was 4.4 nM.

Lisato MR-LBD (prepared as above) was diluted with Lisato buffer MR 1.5 mL of diluted MR-LBD lysate was prepared for each 96-well plate (or 100 wells). The MR lysate solution for each additional 96 well plate was prepared identically immediately before use. SPA solution: for a 96 well (or 100 well) 600] plate of Isi His-tag SPA and 5.6 mL SPA without EDTA were mixed together. The SPA solution for each additional 96 well plate was prepared identically immediately before use.

Process : Suitable dilutions of each compound were prepared and 10 and L were placed in the form of droplets in the appropriate well of a plate of many non-union surface wells. \ íL of [3H] -Aldo was added to each well of a plate of many wells. 10 μ? of diluted MR-LBD lysate was added to each well of the well plate. 50 pL of SPA solution was added to each well the dish, many wells.

Plates were covered with clear sealer and placed in allac Microbeta at room temperature for 30 minutes to one hour. After incubation the dishes were analyzed using a scintillation dish reader (Wallac icrobeta) using the Robin96well3H program. The configurations for Robin96well3H were: Counting form: DP / Sample type: SPA / ParaLux mode: low background / Counting time: 2 minutes. ??? determined represents the average of at least two independent dose response experiments.The binding affinity for each compound can be determined by non-linear regression analysis using the site competition formula to determine the IC5o where: Y = background + (upper part - background (l + 10x_logIC5 °) Ki is then calculated using the Cheng and Prusoff equation where: Ki = IC5o / (1 + [ligand concentration] / Kd of Ligand) For this assay, the concentration of ligand = 4,4 nM and Kd of Aldo for the receptor is commonly 5nM as determined by saturation binding. The compounds of the invention demonstrated the binding capacity to hMR-LBD when controlled in the present assay.

EXAMPLE 29 JOINT TEST OF THE HYDROXYLAPATITE RECEIVER The binding of the compound to AR by measuring the replacement of tritiated R1881 (a selective AR ligand) using a hydroxylapatite binding assay (HAP) to separate unid and free ligand using partially purified AR obtained from a cellular lysate. Partially purified AR was obtained from the MDA-kb2 cell line (ATCC) that endogenously expresses the full length of AR. DA-kb2 cells were grown in DMEM with 5% FBS in T175 bottles. When the cells reached approximately 80% confluence, they were harvested and centrifuged at 1000 rpm for 5 minutes. The cell drop was resuspended in an AR buffer (10 m TRIS, -10% glycerol, 1.5 mM EDTA, 1.0 mM sodium molybdate, 1 mM PMSF, 1.0 mM dithiothreotol, pH 7.4 at 4 ° C) and sonicated using a sonic probe (Sonifier 450, Branson) in a configuration of 1.5, (80% constant) for five configurations of 15 drops to achieve 80-90% cell lysis. After sonication, the cells were incubated on ice for 10 minutes and then centrifuged in a pre-cooled rotor (SW55 or SW28, or equivalent) at 40,000 rpm for 20 minutes at 4 ° C. The supernatant was collected and placed on ice.

For the binding assay, the MDA cell lysate (prepared as above) was diluted 1: 2 in AR buffer and 300 μ? They were pipetted into a 1.2 ml microcentrifuge tube. 50μ1 of triamcinolone (-an selective GR antagonist) (Sigma, St, Louis, MO) was included in all the test tubes in a final concentration of 60 μ ?. The compounds to be tested were prepared in DMSO at an initial concentration of 945 μ? and ?? μ? they were added to the lisato preparation. [3H] R1881 (NEN, Boston, MA) and was first diluted in an AR buffer to create a standard concentration of 94.5 nM. 5 μ? of [3H] R1881 was then added to the lysate mixture to initiate the binding. The non-specific binding was determined using R1881 cold to a 100-fold molar excess over the concentration of [H] R1881 labeled. The tubes were incubated overnight at 4 ° C.

After incubation overnight (18 hours), the lysates were washed to remove the unbound ligand. This was achieved by adding 100 μ? of the lysate at 500μl of a precipitate of 50% hydroxylapatite in a polypropylene tube of 12x75 mm. The tubes were then mixed three times for 20 seconds, allowing the tubes to incubate for five minutes between the mixtures. After the final mixture, the tubes were centrifuged at 1780 rpm at 4 ° C for 5 minutes. The supernatant was decanted and the precipitate was resuspended in an AR buffer. This washing step was repeated four times. Following the final step of washing with buffer AR, the droplet was resuspended in 1.5 ml of ethanol. The tubes were mixed for 20 seconds every 5 minutes at room temperature. This was repeated four times.

After the final mixture, the tubes were centrifuged at 1780 rpm at 4 ° C for 20 minutes. The supernatant was decanted into a 20 ml glass scintillation vial and 15 ml of Ecolume scintillation fluid was added. The samples were counted in a Beckman LS3801 scintillation counter (FulleTAon, CA), EXAMPLE 30 EXPERIMENTAL AND FORMULATION DESIGN A. SOLUTION FORMULATION The test article was administered intravenously at 3 mg / kg formulated in a carrier vehicle of suitable dose for IV administration of the Test Article. The doses of oral solution (or suspension) of 3, 10, 30, 100, 300 and 1000 mg / kg were administered using a. dose carrier vehicle. The compound was also administered at 10 mg / kg as a solid in gelatin capsules. The experimental groups consisted of five animals for each dose group. Blood was collected (100 L) in heparinized tubes via a jugular catheter at 0.02, 0.08, 0.25, 0.5, 1 ,. 2, 4, 6, 8, 10, 12, 24, 32, 48 and 72 hours after the dose for groups IV. Samples were collected similarly to 0.08, 0.25, 0.5.1, 2, 4, 6, 8, 10, 12, 24, 32, 48 and .72 after the dose for PO groups . The obtained plasma was stored at -80 ° C and a volume of 50 L was used for analysis.

B. SOLID DOSE The mini size 9 swine gelatin capsules were used to orally test a dose in solid form at 3 or 10 mg / kg. The capsules were filled with a powder compound based on body weight. The capsules were administered directly into the stomach of the rat with the use of a stainless steel dose device similar to an oral priming needle. Pilot studies with empty capsules revealed that the capsules dissolve in less than 7 minutes in the stomach.

BIOANALITICAL ANALYSIS The concentration of the test article in the plasma and tissue samples was determined by HPLC / MS / MS analysis using sample preparation and analytical conditions suitable for quantification of the test article by this method. A non-compartmental model was applied to calculate pharmacokinetic parameters (PK) for all administration routes using WinNonlin 3.1 software (Farsight Co,, Mountain View, CA).

The compounds of the present invention showed widely increased and improved pharmacokinetic properties.

EXAMPLE 31 KINETIC SOLUBILITY ASSAY The kinetic solubility of. Test compounds in the buffer were evaluated using a 96-well filtration dish. A test solution of 500 μ? in PBS, pH7.4 (or other assay buffer, as necessary) was generated from a standard DMSO solution (up to 10 mM). The samples were transferred to a 96 Millipore MultiScreen HTS 96-well Filtere dish (Cat # MSSLBPC10) mixed by shaking for 1.5 hours and processed by filtration before quantification by HPLC-UV. Amiodarone and testosterone were used as reference controls. The internal historical data show that the solubility of amiodarone · is between 3-5 μ? and testosterone is approximately 330 μ ?. For the separation of analytes in an average mobile phase flow of 2.2 mL / min, Water 4 -x 23mm column YMC / AQ S-5 120AC18 was used. The mobile phase was 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B). The column was maintained at 37 ° C and analyte detection was achieved by quantification of ÜV signal at 220 nm and 254 nm following an injection volume of 10] iL.

The compounds demonstrated kinetic solubility at approximately 500 μ? or less, 400 μ? or less, 300 μ? or less, 200 μ? or less, 100 μ? or less. In an advantageous embodiment, the kinetic solubility is about 50 μ or less, 20 μ? or less, 10 μ? or less, 5 μ? or less, 2, 5μ? or less, or? μ? or less .

EXAMPLE 32 The following table provides in vitro MR activity data MR of representative compounds described in the Examples. The average IC50 values for antagonist activity in the GAL4-MR assay are given as follows: V: less than 0.5 DM; W: 0.5 DM-1 DM; X: 1 DM to 5 DM. Average percentage inhibition with respect to MR activity in relation to the maximum effective concentration of Spironolactone (as determined in a dose response curve in the presence of 3 nM aldosterone), is given as follows: A: 100- 120% control and B: 80-100% control.

Table II EXAMPLE MR IC50% C01ltlOl 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid X B [2- (3-chloro-phenyl) -ethyl] -amide 2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid X B 4-phenoxy-benzilarnide 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid X B (2-Fluoro-5-trifluoromethyl-phenyl) -amide l- [4- (2,4-bis-1-trifluoromethyl-benzoylamine) -2-trifluoromethyl-phenyl] -XB 2,5-dimethyl-lH-pin l- 3-carboxylic (4-methanesulfonyl-phenyl) -amide 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxylic acid X B (4-ethylsulfamoyl-phen) -amide 2,5-dimethyl-l- [2- (trifluoromethyl) phenyl] -lH-pin l-3-carboxylic acid X B (4-guanidinosulfonyl-phenyl) -amide 2, 5-dimethyl-1- (2-thiifluoromethyl-phenyl) -lH-piiTol-3-carboxylic acid WB (2-thiophen-2-yl-ethyl) -amide 2,5-dimethyl-l- (2- ü'ifluoromethyl-phenyl) -lH-piiTol-3-carboxylic WB [2- (2-chloro-phenyl) -ethyl] -amide 2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid W B (3-Fluoro-4-methyl-fem) -amide 2,5-dimethyl-1 - [2- (3-nitro-phenylcarbamoyl) -phenyl] -1H-pyrrole-3-WB carboxylic acid (4-methanesulfonyl- phenyl) -amide 2,5-dimethyl-1- (2-1-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid W B [4- (propane-2-sulfonyl) -phenyl] -amide 235-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-piiTol-3-carboxylic acid W B (4-methanesulfonylamine-phenyl) -amide 2,5-dimethyl-l- (2-trinuoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid V A "phenethyl-amide 2,5-Diinethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid V A (3-chloro-4-methyl-phenyl) -amide 2,5-diinethyl-l- (2-trifluoiOmethyl-phenyl) -lH-pyrrole-3-carboxylic acid V B (5-methyl-thiazol-2-yl) -amide 2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-piiTol-3-carboxylic acid VA nañalen-2-ylamide 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole -3-carboxylic acid VB (4-sulfamoyl-phenyl) -amide 2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid V A (3-methoxy-4-sulfamoyl-phenyl) -amide - (4-fluorophenyl) -2-methyl-1- (2-trifluoromethylphenyl) -lH-pyrrole-3-V carboxylic acid (4-methanesulfonyl-phenyl) amide 2,5-dimethyl-l-naphthalen-l-yl-lH-pyrrole-3-carboxylic acid V A (4-methanesulfonyl-phenyl) -amide l, 4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid V "A (4-sulfamoyl-phenyl) -amide 3,5-dimethyl-4- (2-thyl-iflioromethyl-phenyl) -lH-pyrrole-2-carboxylic acid V A (4-methanesulfoyl-phenyl) -amide 1 - [2 - ((E) -3,3-dimethyl-but-1-enyl) -phenyl] -2,5-dimethyl-lH-pyrroU V A 3 -carboxylic acid 4-methanesulfonyl-phenyl) -amide Table 1

Claims (2)

1. CLAIMS 1. a compound of Formula (I); characterized because: R1 and R2 are each independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, heterocycle optionally substituted, optionally substituted heterocycloalkyl, -0R9, -SR9, -N (R) 2, -C (0) OR9o -C (0) N (R9) 2; R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally-substituted alkynyl; R 4 is hydrogen, -C (0) R 9 or -S (0) 2 R 9; or R4 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkyl, nitro, -OR9, -SR9, -S (O) tR10 (where t is 1 or 2 ), -N (R9) 2, -CN, -C (O) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C ( NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (O) SR9, -C (S) SR9 , -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9 ) N (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (O) R10 (where t is 1 or 2), -S (O) tN (R9) C (O) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) ) 2 (where t is 1 or 2), -N (R9) C (0) R10, ~ N (R9) C (0) OR10, -N (R9) C (O) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (O) SR9, -OC (0) N (R9) 2, '-OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -CÍOJ-R ^ -CÍOJR9, -C (0) -R11-C (S) R9, -C (O) -R1X-C (NR9) R9, -C (O) -Ru-C (O) OR 9, -C (O) -Ru-C (S) OR 9, -C (O) -Rlx-C (NR 9) OR 9, -C (O) -RX1-C (O) N (R9) 2, -C (O) -R12-C (S) N (R9) 2, -C (O) -Ria-C (NR9) N ( R9) 2r -C (O) -R1: LC (O) SR9, -C (O) -R- (S) SR9 and -C (O) -X1-C (NR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, "optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or "2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C ( NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8- S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8 ~ N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) ) C (O) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (O) tR10 (where t is 1 or 2), -R8-OC (O) R10, -R8- OC (NR9) R10, -R8-OC (S) R10, -R8-OC (O) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (O) N (R9) 2, -R8-OC (NR9) N (R9) ) -R8-OC (S) N (R9) 2, -R8-C (O) -R1: LC (O) R9, -R8-C (0) -R -C (S) R9, -R8-C (0) -R -C (NR9) R9, -R8-C (0) -Ru-C (0) 0R9, -R8-C (0) -R1: LC (S) OR9, -R8-C (O ) -R1; LC (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2, -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (0) -Ru C (NR9) N (R9) 2, -R8-C (O) -Ru-C (O) SR9, -R8-C (0) -Ru-C (S) SR9 and -R8-C (0) - R11-C (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of nitro, halo, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (0) R14, -C (S) R14, -C (NR14) R14, -C (0) 0R14, -C (S) 0R14, -C (NR14) OR 14, -C (0) N (R 14) 2, -C (S) N (R 1) 2, -C (NR 14) N (R 1) 2, -C (0) SR 14, -C (S) SR 14, - C (NR14) SR14, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R1) N (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N = C (R14) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R8-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R8-S (0) tN (R14) C (NR14) N (R14) ) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R14) C (0) OR15, -N (R1) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15, -N (R14) C (0) N (R14) 2, -N (R14) C (NR1) N (R14) 2, -N (R14) C (S) N (R14) 2, -N (R14) S (0) tR15 (where t is 1 or 2), - 0C (0) R15, -0C (NR14) R15, -0C (S) R15, -0C (0) 0R15, -OC (NR14) OR15, '-0C (S) 0R15, -0C (0) SR14, - 0C (0) N (R14) 2f -OC (NR14) N (R14) 2, -OCCS) N (R1) 2, -C (0) -R15-C (0) R14, -C (0) -R16-C (S) R14, -C (0) -R16-C (NR14) R14, -C (0) -R16-C (0) OR14, -C (0) -R16-C (S) OR14, -C (0) -R16-C (NR14) OR14, -C (0) -R15-C (0) N (R14) 2, -C (0) -R16-C (S) N (R14) 2, -C (0) -R16C (NR1) N (R1) 2, -C (0) -R16 ~ C (0) SR14, -C (0) -R16-C (S) SR14 and -C (0) ~ R16-C (NR1) SR14; or R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, dioxo, optionally substituted alkyl, optionally substituted alkenyl, alkynyl optionally substituted, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl , optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) ) R14, -R13-C (NR1) R14, -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (O) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR1) N (R14) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (O) tOR14 (where t is 1 or 2), -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R1) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R13-S (0 ) .tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) C (0) OR15, -R13-N (R14) C (0) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (O) N (R14) 2, -R13- (R14) C (NR14) N (R14) 2, -R13-N (R14) C (S) N (R14) 2, -R13-N (R14) S (O) tR15 (where t is 1 or 2), -R13- OC (O) R15, -R13-OC (NR14) R15, -R13-OC (S) R15, -R13-OC (0) OR15, '-R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-OC (O) SR14, -R13-OC (0) N (R14) 2, -R13-OC (NR14) N (R14) 2, -R13-OC (S) N (R14) 2, -R13-C (O) -R16-C (O) R14, -R13-C (O) -R16-C (S) R14, -R13-C (O) -R16-C (NR14) R14, -R13C (O) -R16-C (O) OR14, -R13-C (O) -R16-C (S) OR14, -R13-C (0) -R16-C (NR1) OR14, -R13-C (O ) -R16-C (O) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 21 -R13-C (O) -R16-C (O) SR14, -R13-C (O) -R16-C (S) SR14 and -R13-C (O) -R16-C (NR14) SR14; wherein each R8 and R13 are independently a direct bond, an optionally substituted branched or simple albuilena chain, or an optionally substituted branched or simple alkenylene chain; where each R9 is independently selected from the group consisting of hydrogenoptionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or where two R9s, together with the hydrogen atom to which they are attached, form an optionally substituted heterocycle; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form an optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; wherein each R11 and R16 are independently an optionally substituted branched or simple alkylene chain or an optionally substituted straight or branched alkenylene chain; as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof.
2. 2. The compound of Claim 1 characterized in that: R1 and R2 are each independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, -OR9, -SR9, -N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R3 is independently hydrogen or halo; R 4 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally-substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9 , -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (O) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, '-R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8- N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8-OC (NR9 ) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-0C (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9, -R8-0C (0) 'N (R9) 2, -R8-0C (NR9) N ( R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R -C (0) R9, -R8-C (0) -Rxl-C (S) R9, -R8-C (O) -R ^ - (NR9) R9, -R8-C (0) -R1: LC (0) OR9, -R8 -C (0) -Ru-C (S) OR 9, -R 8 -C (O) -R 11 -C (NR 9) OR 9, -R8-C (0) -Rxl-C (0) N (R9) 2, -R8-C (0) -R -C (S) N (R9) 2, -R8-C (O) -Ria-C (NR9) N (R9) 2, -R8-C (0) -R ^ -C (0) SR9, -R8-C (0) -RX1-C (S) ) SR9 and -R8-C (0) -RX1-C (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; R7 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, "optionally substituted heteroaralkenyl, -R13-OR14, -R13 ~ SR14 , -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, - R13-C (S ) N (R14) 2, -R13-C (NR1) N (R1) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13- S (0) t0R14 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -Rx-S (0) tN (R1) N = C (Ri4) 2, -R -S (0) tN (R) C (0) R (where t is 1 or 2), -R13-S (0) tN (R14 ) C (NR14) N (R1) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R1) C (0) OR15, -R13-N ( R14) C (0) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R1) 2, -R13-N (R14) C (NR1) N (R1) 2, -R13-N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13 -0C (0) R15, -R13-0C (NR14) R15, -R13-0C (S) R15, -R13-0C (0) OR15, -R13-0C (NR14) OR15, -R13-0C (S) OR15, -R13-0C (0) SR14, -R1 -OC (0) N (R14) 2, -R13-0C (NR14) N (R1) 2f -R13-0C (S) N (R14) 2 / -R13-C (0) -R16-C (0) R14, -R13-C (O) -R16-C (S) R14, -R13-C (O) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (O) -R16-C (NR14) OR14, -R13-C (O) -R16-C (O) N (R14) 2, -R13-C (O) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (O) -R16-C (O) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14. wherein each R8 and R13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, heterocycloalkyl. optionally substituted, optionally substituted heteroaryl and optionally substituted heteroaralkyl; two R9s, together with the nitrogen to which they are attached, form optionally substituted heterocycle; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or two R1s, together with the nitrogen to which they are attached, form optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted straight or branched alkenylene chain; and as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. , 3. The compound of any of Claims 1-2 characterized in that: R1 and R2 are each alkyl optionally substituted; or one of R1 and R2 is optionally substituted alkyl and the other R1 and R2 is optionally substituted aryl or optionally substituted heteroaryl; and R3 is hydrogen or halo, composed of Claim 3 characterized in that R is: where: n is 0 to 4; each R18 is selected from. group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8- S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C ( S) N (R9) 2, ~ R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8 -S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N (R9) ) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N = C (R9) 2, -R8-S (O) tN (R9) C (O) R10 (where t is 1 or '2), -R8-S (O) tN (R9) C (O) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8 -N (R9) C (0) OR10, -R8-N (R9) C (O) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (O) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (O) tR10 (where t is 1 or 2), -R8-OC (O) R10, -R8-OC (NR9) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (0) N (R9) 2, '-R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (O) -Ru-C (O) R9, -R8-C (O) -R- (S) R9, -R8-C (O) -R- (NR9) R9, -R8 -C (0) -R11-C (0) OR9, -R8-C (0) -R11-C (S) OR9, -R8-C (O) -R- (NR9) OR9, -R8-C (O) -R1X-C (O) N (R9) 2, -R8-C (O) -R21-C (S) N (R9) z, -R8-C (0) -R11-C (NR9) N (R9) 2,. -R8-C (O) -R -C (O) SR9, -R8-C (O) -Ru-C (S) SR9y -R8-C (O) -R1X-C (NR9) SR9; R19 is halo, optionally substituted alkyl, optionally substituted alkenyl, haloalkoxy, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-C (O) R9, -R8-C (0) OR9 or -R8-C (0) N (R9) 2; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; where each R9 is independently. selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted or branched alkylene chain or an optionally substituted single or branched alkenylene chain. 5. The compound of Claim 4 characterized in that R18 and R19 are each independently selected from the group consisting of halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted aralkenyl, -R8-OR9 , -R8-SR9, -R8-N (R9) 2, -R8-C (0) R9, -R8-C (0) OR9, -R8-C (0) N (R9) 2 and -R8-N , (R9) C (0) R10; wherein each R8 is independently a direct bond, an optionally substituted branched or simple albuylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl, 6. The compound of Claim 5 characterized in that: n is 0 to 4; each R18 is independently selected from the group consisting of halo, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkenyl and -R8-N (R9) C (O) R10; R19 is selected from the group consisting of halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, -R8-OR9, -R8-C (0) R9, -R8-C (0) OR 9 and -R 8 -C (O) N (R 9) 2 I wherein each R 8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein R10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl 7. The compound of Claim 6 characterized in that: n is 0 or 1 and R19 is in the ortho position and is selected from the halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocycle, optionally substituted phenyl, optionally substituted heteroaryl , -R8-OR9, -R8-C (0) OR9 and -R8-C (0) N (R9) 2; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an alkenylene chain. branched or simple optionally substituted; and wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R9s, together with the atom to which they are attached, form optionally substituted heterocycle, 8. The compound of any of Claims 1-7 characterized in that R7 is: where m is 0 to 4; and R25 and R26 are each independently selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, aralkyl optionally substituted, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (O) tR15 ( where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C (S) R14, -R13-C (NR14) R14, - R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (O) N (R14) 2, -R13-C (S) N (R1) 2, -R13-C (NR14) N (R14) 2, -R13-C (O) SR14, -R13-C ( S) SR14, -R13-C (NR14) SR14, -R13-S (0) tOR14 (where t is 1 or 2), -R13-S (0) tN (R1) 2 (where t is 1 or 2), -R13-S (O) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R14) 2, -R13-S (O) tN (R14) C (O) R15, (where t is 1 or 2), -R13-S (O) tN ( R14) C (O) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), - R13-N (R14) C (O) R15, -R13-N (R14) C (O) OR15, -R13-N (R14) C (O) SR15, -R13-N (R14) C (NR14) SR15 , -R13-N (R14) C (S) SR15, -R13-N (R14) C (O) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R13- N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-OC (0) R15, -R13-OC (NR14 ) R15, -R13-OC (S) R15, -R13-OC (O) OR15, -R13-0C (NR14) OR15, -R13-0C (S) OR15, -R13-OC (O) SR14, -R13 -OC (0.) N (R14) 2r -R13-OC (NR1) N (R14) 2, -R13-OC (S) N (R14) 2, -R13-C (0) -R16-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R15 ÷ -C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (O) -R16-C (0) N (R1) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (O) -R16-C (S) SR14 and -R13-C (O) ~ R16-C (NR14) SR14; "wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain, wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, alkynyl optionally substituted, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl, or where two R1s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 9. The compound of Claim 8 characterized in that R25 and R26 are each independently selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally aralkenyl. substituted, optionally substituted heterocycle, optionally substituted heteroaryl,. -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C ( S) R14, -R13-C (NR14) R14, -R13-C (O) OR14, | -R13-C (O) N (R14) 2, -R13-S (0) tN (R14) 2 ( where t is 1 or 2), -R13-S (O) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, - R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (O) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13 -C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (0) -R16C (NR14) N (R14) 2, -R13-C (O) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; wherein each R13 is independently a direct bond, an optionally substituted branched or simple albuilena chain, or an optionally substituted branched or simple alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkenyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; and wherein R16 is optionally a simple or branched alkylene chain. 10. The compound of Claim 9 characterized in that: R25 and R26 are each independently selected from the group consisting of nitro, halo, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, heteroaryl optionally substituted, -R13-OR14; -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2), -R13-N (R14) 2f -R13-CN, -R13-C (0) R14, -R13-C (0 ) OR14, -R13-C (O) N (R14) 2, -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R1 -S (O) tN (R14) C (O) R15, (where t is 1 or 2), ~ R13- S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R1) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-G (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14 , -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) ) 2, -R13-C (O) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (O) -R16-C (O) SR14, -R13-C (O) -R16-C (S) SR14 and -R13-C (O) -R16-C (NR14) SR14; wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl. optionally substituted and. optionally substituted heteroaralkyl; or wherein two R1s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of alkyl optionally. substituted, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein R16 is an optionally substituted branched or simple alkylene chain. 11. The compound of Claim 10 characterized in that R26 is in the para position and is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, heteroaryl optionally substituted, and -R13-N (R14) 2, -R13-OR14, -R13-SR14, -R13-CN, -R13-C (0) R14, -R13-C (0) N (R1) 2, -R13 ~ C (O) OR14, -R13-N (R14) C (O) R15, -R13-N (R14) S (0) t 15 (where t is 1 or 2), -R13-C (0 ) -R16-C (O) R14, -R13C (0) -R16-C (0) OR14, -R13-C (O) -R16-C (S) OR14y -R13-C (O) -R16-C (O) N (R14) 2r wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R1s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 12. The compound of Claim 11 characterized in that: m is 0 or 1; R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, -R13-N (R14) 2, -R13-OR14, -R13-C (O) R14 and -R13-C (0) OR14; wherein each R 13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; or where two R1s, together with the atom to which they are attached, form optionally substituted heterocycle. 13. The compound of Claim 12 selected from the group consisting of the following: 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methylsulfanyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-propyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-difluoromethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-benzyloxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-cyclohexyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-biphenyl-4-yl) -amide; methyl ester of acid 4-. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3'-carboxylic acid (4-phenoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3'-carboxylic acid (4-isopropoxy-phenyl) -amide; (4- {[2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenyl) -acetic acid ethyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (acetyl-methyl-amine) -phenyl] -amide; 5- (4. {[[2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine] -ethyl ester.} - phenyl) -2-methyl-furan -3-carboxylic; [[2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] - (4-trifluoromethoxy-phenyl) -amine] -acetic acid ethyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-tert-butylcarbamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sec-butyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-isopropyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-tert-butyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-imidazol-1-yl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid. { 4- [2- (2-chloro-phenylcarbamoyl) -acetyl] -phenyl} -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (3,5-dimethyl-pyrazol-1-yl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- ((E) -2-pyridin-2-yl-vinyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (-ethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-trifluoromethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methoxy-phenyl) -amide; pentyl ester of 4- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -aminaj-benzoic acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-nitro-phenyl) -amide; 4- ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 1- (4- {[2, 5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} ethyl ester.) -phenyl) ~ 3-methyl-1H -pyzole-4-carboxylic; 1- (4- {[2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenyl} -3,5-dimethyl ethyl ester -lH-pyrazole-4-carboxylic acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid biphenyl-4-ylamide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-cyanomethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-cyano-phenyl) -amide; 2, 5'-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-carbazol-9-yl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-carbamoyl-phenyl) -amide; acid 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3'-fluoro-biphenyl-4-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-chloro-phenoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-nitro-phenylsulphanyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-pyrazol-1-yl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-phenylsulfanyl-phenyl) -amide; 4- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole 3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (cyano-phenyl-methyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonylmethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonylamine-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4-dichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-4-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methoxy-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-methyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-difluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-2-methyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-bromo-4-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-bromo-4-methyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-3-trifluoromethyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-3-methyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-4-methoxy-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-2-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4-difluoro-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-3-nitro-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-biphenyl-4-yl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methyl-3-nitro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-hydroxymethyl-4-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-bromo-4-trifluoromethoxy-phenyl) -amide; 2, 5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-3-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzoyl-4-chloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-hydroxy-3-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-2-ethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4-dimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-dimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-dichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-dimethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-2-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-3-nitro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-2-chloro-phenyl) -amide; 2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -IH-pyrrole-3-carbonyl] -amine} -5-methyl-benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-hydroxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4-dimethoxy-phenyl) -amide; methyl ester of 5-bromo-2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid acetyl- (3-ethylamine-4-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-cyano-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-3-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-butyl-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-3-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-3-chloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-4-nitro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-nitro-3-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3, -dician-phenyl) -amide; and methyl ester of 4- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -2-methoxy-benzoic, 14. The compound of Claim 11 characterized in that: m is 2 to 3; each R25 is independently selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, -R13-N (R1) 2, -R13-OR14, -R13-C (0) R14 and -R13-C (0) OR14; wherein each R 13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle. 15. The compound of Claim 14 selected from the group consisting of the following: 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,6-trimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dichloro-3-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,6-trichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4-b-trifluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2-methoxy-5-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,5-trichlorophenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-diethoxy-4-morpholin-4-yl-phenyl) -amide; 3, 5-dichloro-4- ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dichloro-4-pyrrol-1-yl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2,4-dimethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4,6-dimethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,5-trimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-2,6-dimethyl-phenyl) -amide; 2, 5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4,6-dimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3,4-trifluoro-phenyl) -amide; 5-chloro-4- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carbonyl] -amine} -2-methoxy-benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4,5-trimethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,4,5-trifluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-hydroxy-5-isopropyl-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (-benzoylamine-2-methoxy-5-methyl-phenyl) -amide; and 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methoxy-2-methyl-4-nitro-phenyl) -amide. 16. The compound of Claim 10 characterized in that R26 is in the para position and is selected from the group consisting of -R13-S (0) tR15 (where t is 1 or 2), -R13-C (O) R14, -R13 -S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S ( 0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (NR14) N (R1) 2 (where t is 1 or 2); wherein each R 13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; and R19 is halo, optionally substituted alkyl, optionally substituted alkenyl, -R8-OR9, -R8-C (0) OR9 or -R8-C (O) N (R9) 2; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; and wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R9s, together with the atom to which they are attached, form optionally substituted heterocycle. 17. The compound of Claim 16 characterized in that: m is 0 or 1; R25 is selected from halo, optionally substituted alkyl, -R13-N (R1) 2 or -R13-OR14; wherein each R 13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle.18. The compound of Claim 17 selected from the group consisting of the following: 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic (-benzoyl-phenyl) -amide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-benzenesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-acetylsulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ureidosulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-trifluoromethanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-sulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2,3-dichloro-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ethanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-guanidinosulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methoxy-4-sulfamoyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-4-methanesulfonyl-phenyl) -amide; 1- (4-Bromo-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (propane-2-sulfonyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -methyl-amide; 1- (3'-Hydroxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Butyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Ethyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2 ', 6' -difluoro-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; [1- (2'-methoxy-5 '-methyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2'-ethoxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Acetylamine-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2'-Isopropyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lB-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-amino-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4-Benzo [b] thiophen-2-yl-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 4 '- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -3' -trifluoromethyl-biphenyl-3-carboxylic acid; 1- (2'-Fluoro-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-Fluoro-4'-methoxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2'-Fluoro-61-methoxy-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- [4- (5-Cyano-thiophen-2-yl) -2-trifluoromethyl-phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 2, 5-dimethyl-1- (4 '-methylcarbamoyl-3-trifluoromethyl-biphenyl-4-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-dimethyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (4-naphthalen-2-yl-2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Hydroxymethyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [4- (2, 3-dihydro-benzofuran-5-yl) -2-trifluoromethyl-phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (4-quinolin-8-yl-2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [4- (l-methyl-lH-indol-5-yl) -2-trifluoromethyl-phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-methoxy-2'-methyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, acid 1 - (2-bromo-phenyl) -2,5-dimethyl / lH-pyrrole-3-carboxylic (4-methanesulfinyl-phenyl) -amide; 1- (2,3-dichloro-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-phenyl) -amide; 1- (2-isopropyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-tert-butyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sulfamoyl-phenyl) -amide; acid 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-sulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (pyrimidin-2-ylsulfamoyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (thiazol-2-ylsulfamoyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (morpholin-4-sulfonyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-guanidinosulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methoxy-4-sulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-ethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-dimethylsulfamoyl-3-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (piperidin-1-sulfonyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-ethylsulfamoyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-diethylsulphamoyl-phenyl) -amide, 2,5-dimethyl-1- [4- ((E) -) acid stiril) -2-trifluoromethyl-phenyl] lH-pyrrole-3-carboxylic (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-acetyl-phenyl) -amide; 1- (2-bromo-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-dimethylsulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-dimethylamine-4-dimethylsulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-3-trifluoromethoxy-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-benzoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-butyryl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-fluoro-benzoyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (pyridine-4-carbonyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (3-fluoro-benzoyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (2-fluoro-benzoyl) -phenyl] -amide; 1- [2- ((E) -3,3-Dimethyl-but-l-enyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-3-trifluoromethyl-phenyl) -amide; 1- [4- (1H-indol-5-yl) -2-trifluoromethyl-phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoic acid; 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoic acid methyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-methanesulfonyl-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (3-chloro-4-methanesulfonyl-phenyl) -amide; 5- (4-Fluoro-phenyl) -2-methyl-1- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (3-methoxy-4-sulfamoyl-phenyl) -amide; 1- [2- ((R) -2-hydroxy-1-methyl-ethylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (3-Hydroxymethyl-pyridine-1-carbonyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (4-acetyl-piperazine-1-carbonyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; l- acid. { 2- [(2-cyano-ethyl) -cyclopropyl-carbamoyl] -phenyl} 2, 5-dimethyl-lH-pyrrole-3-carboxylic (4-methanesulfonyl-phenyl) -amide; 1- [2- (3-Ethoxy-phenylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [2- (3-nitro-phenylcarbamoyl) -phenyl] -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (lH-indazol-5-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH 'pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [2- (2-methyl-lH-indol-5-ylcarbamoyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (2-dimethylamine-1-methyl-ethylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; l- acid. { 2- [4- (2-hydroxy-ethyl) -piperazine-1-carbonyl] -phenyl} 2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- [2- (3-imidazol-1-yl-propylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- ((S) -l-hydroxymethyl-3-methylsulphanyl propylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (1, 3-dihydro-isobenzofuran-5-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 2, 5-dimethyl-1- [2- (2-methyl-aziridin-1-carbonyl) -phenyl] -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- acid. { 2- [1- (1-methyl-1H-pyrazol-4-yl) ethylcarbamoyl] -phenyl} -lH-pyrrole-3-carboxylic (4-methanesulfonyl phenyl) -amide; 1- [2- ((IR, 2S) -2-hydroxy-indan-1-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- [2- (1, l-dioxo-tetrahydro-lA6-thiophen-3-ylcarbamoyl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl phenyl) -amide; 1- [2- (3-methanesulfonyl-pyrrolidine-l-carbonyl) -phenyl] acid] 2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- [2- (3-Hydroxy-4-methyl-phenylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [2- ([1, 3, 4] thiadiazol-2-ylcarbamoyl) phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (4,5-dimethyl-thiazol-2-ylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; methyl ester of (R) -3-hydroxy-2- acid. { 2- [3- (4-Methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamine} -propionic; 2, 5-dimethyl-l- acid. { 2- [Methyl- (4-methyl-thiazol-2-ylmethyl) carbámoyl] -phenyl} -lH-pyrrole-3-carboxylic (4-methanesulfonyl phenyl) -amide; 3- ethyl ester. { 2- [3- (4-methanesulfonylphenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamine} -propionic; 1- [2- (2-ethylsulfanyl-ethylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- ((S) -l-carbamoyl-3-methyl-butylcarbamoyl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- [2- (4-Carbamoyl-phenylcarbamoyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4- acid. { 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoylamine} -cyclohexanecarboxylic; acid-2, 5-dimethyl-l-. { 2- [(5-methyl-4 H- [1,2,] triazol-3-ylmethyl) -carbamoyl] -phenyl} -lH-pyrrole-3-carboxylic (4-methanesulfonyl-phenyl) -amide; methyl ester of acid 1-. { 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -benzoyl} -piperidine-2-carboxylic acid; l- acid. { 2- [2- (lH-imidazol-4-yl) -ethylcarbamoyl] -phenyl} -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; acid { 2- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrol-1-yl] -benzoylamine} -acetic; 1- [4- (2,4-bis-trifluoromethyl-benzoylamine) -2- trifluoromethyl-phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-carbamoyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-methylcarbamoyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-isopropylcarbamoyl-phenyl) -2,5-dimethyl-lH-pyrrole 3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 1- (2-dimethylcarbamoyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH acid , pyrrole-3-carboxylic acid (4-sulfamoyl-3-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sulfamoyl-3-trifluoromethyl-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methanesulfonyl-pyridin-3-yl) -amide; 1- (4-Fluoro-2-trifluoromethyl-phenyl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (6-methanesulfonyl-pyridin-3-yl) -amide; 1, 5-bis- (4-fluoro-phenyl) -2-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; and 5- (4-fluoro-phenyl) -2-methyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methoxy-4-sulfamoyl-phenyl) -amide, 19. The compound of Claim 16 characterized in that: m is 2 or 3; each R25 is halo, optionally substituted alkyl, -R13-N (R14) 2 or -R13-OR14; wherein each R 13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R1s, together with the atom to which they are attached, form optionally substituted heterocycle. 20. The compound of Claim 10 characterized in that R26 is found in the para position and is selected from the group consisting of -R13-S (O) tR15 (where t is 1 or 2), -R13-C (0) R14 and - R13-S (0) tN (R1) 2 (where t is 1 or 2); wherein each R13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two 'R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and and R19 is selected from the group consisting of optionally substituted heterocycle, optionally substituted phenyl and optionally substituted heteroaryl. 21. The compound of Claim 20 selected from the group consisting of: 1- (3'-chloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic (-methanesulfonyl-phenyl) -amide; 1- (2'-chloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; l- (2 ', 3'-Dichloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-chloro-bipheni-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2 ', 5'-Dichloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole 3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Carbamoyl-3-trifluoromethyl-biphenyl-4-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (41-dimethylcarbamoyl-3-trifluoromethyl-biphenyl-4-yl) acid 2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- (3'-Hydroxymethyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (3,4-Dihydro-2H-benzo [b] [1,4] dioxepin-7-yl) phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide; 1- [2- ((E) -3,3-Dimethyl-but-1-enyl) -phenyl] -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 1- (31-Diethylcarbamoyl-biphenyl'-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (5-formyl-thiophen-2-yl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 1- (4'-methoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-ethanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-Acetylamine-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole 3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3 '-tert-butyl-5'-methylsulfanyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-methanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Acetylamine-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole 3-carboxylic (4-methanesulfonyl-phenyl) -amide; 1- (4'-cyano-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2 '- [3- (4-methanesulfonylphenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -biphenyl-4-carboxylic acid methyl ester; 1- (3'-ethanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [3 '- (pyrrolidin-1-carbonyl) -biphenyl-2-yl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (5'-Ethyl-3'-methylsulfanyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-ethoxy-3'-trifluoromethyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-methoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-1- (2-thiophen-3-yl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Fluoro-2'-hydroxy-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2,5-dimethyl-1- (5'-propylsulfanyl-3'-trifluoromethyl biphenyl-2-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 2, 5-dimethyl-l- [3 '-trifluoromethyl-5' - (2-trimethylsilanyl-ethylsulfanyl) -biphenyl-2-yl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-Chloro-4'-methyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (5 '-isopropylsulfanyl-3'-trifluoromethyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) amide; 1- (3'-ethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3 '-carbamoyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (5-Cyano-6-ethoxy-pyridin-3-yl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-Hydroxymethyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-ethoxy-3'-methanesulfonyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2,5-dimethyl-1- (2-pyrimidin-5-yl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2 '- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -biphenyl-3-carboxylic acid methyl ester; 1- (3'-Hydroxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (5'-Fluoro-2'-methoxy-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 1- (3'-ethoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2'-Fluoro-5'-methoxy-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [4 '- (morpholin-4-carbonyl) -biphenyl-2-yl] -pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-ethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2'-Acetyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (41-methanesulfonylamine-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [4 '- (piperidin-1-carbonyl) -biphenyl-2-yl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (4'-dimethylcarbamoyl-biphenyl-2-yl) -2,5-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3'-Acetyl-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2, 5-dimethyl-l- [2- (5-methyl-furan-2-yl) -phenyl] -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 2 '- [3- (4-methanesulfonyl-phenylcarbamoyl) -2,5-dimethyl-pyrrol-1-yl] -biphenyl-4-carboxylic acid ethyl ester; 1- (3 ', 4'-dimethoxy-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [2- (2, 3-Dihydro-benzofuran-5-yl) -phenyl] -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2'-Acetylamine-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; and 2,5-dimethyl-1- (3'-methylsulfanyl-biphenyl-2-yl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 22. The compound of Claim 10 characterized in that R26 and each R25, when present, each occupies a position for. 23. The compound of Claim 22 characterized in that: m is 0 or 1; each R25 is independently selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, -R13-N (R14) 2, -R13-OR14, -R13 ~ SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-CN, -R13-C (0) R14, -R13-C (0) OR14, -R13-C (0) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-N (R1) C (0) R15 and -R13-N (R14) S (0) tR15 (where t is 1 or 2); R26 is independently selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, heteroaralkenyl optionally. substituted, optionally substituted aryl, optionally substituted aralkyl, -R13-N (R14) 2, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-CN, -R13-C (0) R14, -R13-C (0) OR14, -R13-C (0) N (R14) ) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-N (R1) C (0) R15 and -R13-N (R14) S (0) tR15 (where t is 1 or 2); or R26 is -R13-OR14 in the ortho position; wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 24. The compound of Claim 23 selected from the group consisting of the following: ethyl ester of 3- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-6-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methylsulfanyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, β-diethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-difluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dimethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-5-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-diisopropyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-ethyl-6-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-bromo-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-5-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-ethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-difluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-ethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-bromo-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-phenoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-sec-butyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-5-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-difluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-isopropyl-6-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3'-carboxylic acid (3,5-dichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-bromo-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-difluoromethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-6-chloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methylsulfanyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-isopropyl-phenyl) -amide; 3-chloro-2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -1H pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-nitro-phenyl) -amide; 2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole 3-carbonyl] -amine} -benzoic; methyl ester of acid 2-. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-ethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid biphenyl-2-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3-chloro-2- (2-hydroxy-ethyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxymethyl-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-hydroxymethyl-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-5-nitro-phenyl) -amide; 2- isopropyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; Phenyl ester of 2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-bromo-5-nitro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-5-nitro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (5-methyl-thieno [2,3-d] pyrimidin-4-ylsulfanyl) phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-tert-butylcarbamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-2-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-methyl-benzoyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-benzoyl-5-methyl-phenyl) -amide; 2r 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2-. { 2, 2, 2-trifluoro-ethoxy) -5-trifluoromethyl-phenyl] amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-piperidin-1-yl-5-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-chloro-benzoyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-cyclohexyl-2-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2-methoxy-phenoxy) -5-trifluoromethyl-phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (-methoxy-phenoxy) -5-trifluoromethyl-phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl-2-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methoxy-biphenyl-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-pyrrol-1-yl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-5-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methoxy-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-propyl-phenyl) -amide; 2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -IH-pyrrole-3-carbonyl] -amine} -4-methyl-benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-methyl-2-oxo-imidazolidin-1-yl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-fluoro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-dimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-fluoro-3-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-trifluoromethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-5-methoxy-phenyl) -amide; 2- ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dimethyl-phenyl) -amide; 2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole 3-carbonyl] -amine} -3-methyl-benzoic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-acetyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-acetyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-trifluoromethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-dimethyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-dichloro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-chloro-2-hydroxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl- (2-trifluoromethoxy-phenyl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-carbamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl-m-tolyl-amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-sulfamoyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-cyano-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid or tolylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic propyl-m-tolyl-amide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl- (5-hydroxy-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoroinethyl-phenyl) -lH-pyrrole-3-carboxylic acid ethyl-o-tolyl-amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-cyano-5-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4 '-fluoro-biphenyl-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzii-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-hydroxy-5-nitro-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl-2-hydroxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-mercapto-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2-methoxy-5- (1-methyl-1-phenyl-ethyl) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-acetylamine-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methanesulfonylamine-phenyl) -amide, 25. The compound of Claim 22 characterized in that R26 is -OR14 in the meta position characterized in that R14 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl and optionally substituted heteroaralkyl. 26. The compound of Claim 25 selected from the group consisting of: 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-ethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-isopropoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-hydroxy-2-methyl-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-phenoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,5-dimethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-trifluoromethoxy-phenyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzyloxy-phenyl) -amide;. 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-fluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-acetylamine-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-bromo-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (naphthalen-2-ylmethoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (benzo [1,2,5] oxadiazol-5-ylmethoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-methoxy-5-nitro-benzyloxy) -phenyl] -amide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-fluoro-2-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4,5-dimethoxy-2-nitro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-bromo-2-fluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,6-dichloro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-methanesulfonyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (6-chloro-benzo [1, 2, 5] thiadiazol-5-ylmethoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-nitro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (benzo [1,2,5] thiadiazol-4-ylmethoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-methyl-5-phenyl-isoxazol-4-ylmethoxy) -phenyl] -amide; 3- (3. {[[2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenoxymethyl) -benzoic acid methyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-methyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-bromo-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3, 5-dimethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,6-difluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-chloro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-4-fluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3,5-dimethoxy-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-chloro-2-fluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-6-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-bromo-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2, 3, 5, 6, 6-tetrafluoro-4-methyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-bromo-5-methoxy-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3,5-di-tert-butyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (benzothiazol-2-ylmethoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (5-methyl-2-phenyl-2H- [1,2,3] triazol-4-ylmethoxy] phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (5-trifluoromethyl-furan-2-ylmethoxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-fluoro-5-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-3,6-difluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,3,4-trifluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-fluoro-3-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,4,5-trifluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3 .carboxylic acid [3- (2-chloro-6-fluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-fluoro-2-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-tert-butyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-isopropyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4-difluoromethoxy-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-methyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3, 5-difluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-methyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-benzyloxy) -phenyl] -amides- 2,5-dimethyl-1-acid (2) -trifluoromethyl-phenyl) -l'H-pyrrole-3-carboxylic [3- (2,3-difluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2, -difluoro-benzyloxy) -phenyl] -amide; 2, 5-Dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-trifluoromethyl-benzyloxy) -phenyl] -amides- 2,5-dimethyl-1-acid (2) -trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-difluoromethoxy-benzyloxy) -phenyl] -amides- 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-acid carboxylic [3- (2-fluoro-4-trifluoromethyl-benzyloxy) -phenyl] amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-3-methyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-chloro-2,6-difluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2, 5-difluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-trifluoromethoxy-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (biphenyl-2-ylmethoxy) -phenyl] -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (5-chloro-benzo [b] thiophen-3-ylmethoxy) -phenyl] -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2,3, β-trifluoro-benzyloxy) -phenyl] -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-trifluoromethyl-benzyloxy) -phenyl] -amide; 4- (3. {[2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenoxymethyl) -benzoic acid methyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-fluoro-4-trifluoromethyl-benzyloxy) -phenyl] -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-trifluoromethoxy-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-5-fluoro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-5-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-fluoro-3-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-5-trifluoromethyl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2-chloro-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (2, 5-dichloro-benzyloxy) -phenyl] -amide; 4- (3. {[2,5-dimethyl-l- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -phenoxymethyl) -benzoic acid ethyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (4- [1, 2,4] triazol-1-yl-benzyloxy) -phenyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [3- (3-pyrrol-1-yl-benzyloxy) -phenyl] -amide; and 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-benzyloxy-phenyl) -amide. 27. The compound of Claim 22 characterized in that: m is 2 or 3; each R25 and R26 is independently selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted heteroalkenkenyl, optionally substituted aryl, optionally substituted aralkyl, -R13-N (R14) 2, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-CN, -R13-C (0) R14, -R13-C (0) OR14, -R13-C (0) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-N (R1) C (0) R15y -R13 -N (R14) S (0) tR15 (where t is 1 or 2); wherein R13 is a direct bond or an optionally substituted branched or simple alkylene chain; wherein R14 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl .. 28. The compound of Claim 27 selected from the group consisting of the following: 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,6-dichloro-3-methyl-phenyl) ) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-2,6-diethyl-phenyl) -amide; and 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3,5,6-tetrafluoro-phenyl) -amide. 29. The compound of Claim 7 characterized in that: R7 is cycloalkyl, heterocyclyl, heteroaryl, or aryl with the exception of optionally substituted phenyl, wherein each is substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, -R13-OR14, -R13-SR14, '-R13-S (0) tR15 (where t is 1 or 2), -R13 ~ N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (0) OR14, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2) and -R13-S (0) tN (R14) C (NR14) N (R14) 2; wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl. 30. The compound of Claim 29 selected from the group consisting of: 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxyl-benzothiazol-2-ylamide acid; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl- [1,3,4] thiadiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5,6,7,8-tetrahydro-naphthalen-1-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid indan-5-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (9H-fluoren-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-pyridin-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-pyridin-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-thiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methyl-pyridin-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl- [1,3,] thiadiazol-2-yl) -amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (lH-indazol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid naphthalen-2-ylamide; 5-dimethyl-l- 2- (2-, 2-dimethyl-5 l- (2-trifluoromethylphenyl) -lh-pyrrole-3"acid, carboxylic acid (2-hydroxy-naphthalen-l-yl) -amide trifluoromethylphenyl) -lh-pyrrole-3-carboxylic acid quinoline-6-ylamide; 5-dimethyl-l- (2-trifluoromethylphenyl) -lh-pyrrole-3-carboxylic acid isoquinolin-5-ylamide acid 2, 2- 5 -dimethyl-l- (2-trifluoromethylphenyl) -lh-pyrrole-3-carboxylic acid quinolin-5-ylamide; acid 2, 5-dimethyl-l- (2-trifluoromethylphenyl) -lh-pyrrole-3-carboxylic acid (8 -hydroxy-quinolin-5-yl) -amide; 2-, 5-dimethyl-l- (2-trifluoromethylphenyl) -lh-pyrrole-3-carboxylic acid (5-chloro-pyridin-2-yl) -amide; acid 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid benzo [1,3] dioxol-5-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinoline-8-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-isoxazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (lH-indol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methyl-benzothiazol-2-yl) -amide; 5-dimethyl-l- (2-trifluoromethylphenyl) -lh-pyrrole-3 carboxylic acid (5-methylsulfanyl- [1, 3, 4] thiadiazol-2-yl) -amide acid 2; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methyl-isothiazol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-acetyl-benzo [1,3] dioxol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid thiazole-2-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic pyridin-4-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-benzothiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methyl-thiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-ethylsulfañyl- [1,3,4] thiadiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-benzothiazol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [1,3,4] thiadiazol-2-ylamide; ethyl ester of 5- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} - [1, 3,4] thiadiazole-2-carboxylic acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (l-methyl-lH-benzoimidazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinolin-2-yl Glamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid isoquinolin-3-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-acetyl-5-phenyl-thiophen-3-yl) -amide; methyl ester of 3- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -5- (4-fluoro-phenyl) -thiofene-2-carboxylic acid; (2- {[2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrol-3-carbonyl] -amine} -thiazol-4-yl) -acetic acid ethyl ester; 2- ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -4, 5, 6, 7-tetrahydro-benzo [b] thiophene-3-carboxylic acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-chloro-pyridin-4-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic pyrimidin-4-ylamide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3,4-dimethyl-isoxazol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,5-dimethyl-2H-pyrazol-3-yl) -amide; methyl ester of 3- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -thiofene-2-carboxyl; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-methyl-isoxazol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (lH-indazol-6-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-phenyl-thiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-mercapto-benzothiazol-6-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methoxy-pyridin-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-ethyl-pyridin-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1-bromo-isoquinolin-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-trifluoromethyl-pyridin-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (4-fluoro-phenyl) -thiazol-2-yl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1,3-dihydro-isobenzofuran-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [5- (4-fluoro-phenyl) -2H-pyrazol-3-yl] -amide; 2- ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -5-methyl-4-phenyl-thiophene-3-carboxylic acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (9-ethyl-9H-carbazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid. (4-methyl-5-phenyl-2H-pyrazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1-methyl-1 H- [1, 2, 4] triazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-bromo-5-methyl-isoxazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [6- (4-tert-butyl-phenoxy) -pyridin-3-yl] -amide; methyl ester of 3- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -5-phenyl-thiophene-2-carboxylic acid; 2- ethyl ester. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -4-furan-2-yl-thiophene-3-carboxylic acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-1H-pyrazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methoxy-benzothiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-chloro-pyridin-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid quinoline-3-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4,6-dimethyl-pyridin-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-ethoxy-benzothiazol-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-methoxy-pyridin-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-5-phenyl-2H-pyrazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1,3,5-trimethyl-1H-pyrazol-4-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (9-oxo-9H-fluoren-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-oxo-5, 6, 7, 8-tetrahydro-naphthalen-2-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-sulfamoyl- [1, 3, 4] thiadiazol-2-yl) -amide; 4- (1, 1-difluoro-propyl) -1- (2-fluoro-benzyl) -6- [5- (6-methanesulfonyl-5-methyl-pyridin-3-yl) -thiophen-2-yl] - 2-oxo-l, 2-dihydro-pyridine-3-carbonitrile; 5- [1- [1- (2'-chloro-biphenyl-2-yl) -2,5-dimethyl-lH-pyrrol-3-yl] -met- (Z) -ylidn] -2- isopropyl ester methyl-4-oxo-4,5-dihydro-lH-pyrrole-3-carboxylic acid; * 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-dimethylsulfamoyl-4-methyl-thiazol-2-yl) -amide; and 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-dimethylsulfamoyl-thiophen-2-yl) -amide, 2,5-dimethyl-1- (2- trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid indan-1-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-chloro-naphthalen-1-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-dihydro-benzo [1,4] dioxin-6-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-1H-indol-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-benzothiazol-6-yl) -amide; 2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -nicotinic; , - 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid, isoxazol-3-ylamide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid naphthalene-1-ylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (l-oxo-indan-5-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-tert-butyl-isoxazol-3-yl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-oxo-4-trifluoromethyl-2H-chromen-7-yl) -amide; and 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-methyl-4-oxo-4H-chromen-7-yl) -amide. 31. The compound of Claim 7 characterized in that R7 is cycloalkylalkyl, heterocyclylalkyl, aralkyl or heteroaralkyl wherein each is substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C (0) OR14, - R13-S (0) tN (R1) 2 (where 't is 1 or 2), -R13-S (0) tN (R1) N (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (O) R15 (where t is 1 or 2) and -R13-S (0) tN (R14) C (NR14) N (R14) 2; wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl, 32. A compound of claim 31 characterized in that said compound is selected from the group consisting of: 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic (pyridin-2-ylmethyl) -amide acid; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-trifluoromethyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3-methyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2,4-dichloro-phenyl) -ethyl] -amides- 2,5-dimethyl-l acid - (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-ethoxy-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid methyl-phenethyl-amide; 2, 5-dimethyl-1- (2-trifluoromethyl-enyl) -lH-pyrrole-3-carboxylic acid 4-methyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3-chloro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-p-tolyl-ethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3-methoxy-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-fluoro-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2-methoxy-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (3-chloro-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (3-fluoro-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (1-phenyl-propyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (l-methyl-3-phenyl-propyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3-trifluoromethyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (thiophen-2-ylmethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-fluoro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (furan-2-ylmethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (3, -dimethoxy-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-fluoro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2-fluoro-phenyl) -ethyl-amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-trifluoromethyl-benzylamide; [2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -furan-2-ylmethyl-amine ethyl ester} -propionic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-thiophen-2-yl-ethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2,4-difluoro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-chloro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-chloro-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-phenyl-propyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2,4-dimethyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (3-methoxy-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2,5-difluoro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (4-bromo-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (2-chloro-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3-fluoro-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic phenethyl-amide; 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (5-methyl-furan-2-ylmethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-bromo-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-phenoxy-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2,5-dimethyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 3,4-dimethyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid or (2-benzylsulfanyl-ethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid benzyl-ethyl-amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2-phenyl-propyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (1H-indol-3-yl) -ethyl] -amide; [[2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] - (4-trifluoromethoxy-phenyl) -amine] -acetic acid ethyl ester; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2,3-dihydro-benzo [1,4] dioxin-6-ylmethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (6-fluoro-4H-benzo [1,3] dioxin-8-ylmethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-fluoro-2-trifluoromethyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-chloro-6-phenoxy-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [(S) -1- (4-bromo-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid ((R) -1-naphthalen-2-yl-ethyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [bis- (4-methoxy-phenyl) -methyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid. [(R) -1- (3-methoxy-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 2-methylsulfanyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid 4-methanesulfonyl-benzylamide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [1- (2-chloro-phenyl) -ethyl] -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-acid. carboxylic 4-p-tolyloxy-benzylamide; tere butyl ester of (S) -2- acid. { [2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carbonyl] -amine} -3- (4-hydroxy-phenyl) -propionic; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (2, 2-diphenyl-propyl) -amide; 2, 5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [2- (3-ethoxy-4-methoxy-phenyl) -ethyl] -amide; and 2,5-dimethyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4'-fluoro-biphenyl-2-ylmethyl) -amide, 33. The compound of Claim 7 characterized in that R7 is alkyl, alkenyl or alkynyl wherein each is substituted with one or more substituents selected from the group consisting of halo, nitro, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (0) R14, -C (0) OR14, -S (0) tN (R1) 2 (where t is 1 or 2), -S (0) tN (R1) N (R1) 2 (where t is 1 or 2), -S (O) tN (R14) C (O) R15 (where t is 1 or 2) and -S (O) tN (R14) C (NR14) N (R14) 2; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 34. The compound of Claim 33 characterized in that said compound is 5- (4-fluoro-phenyl) -2-methyl-1- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid dimethylamide; 35. The compound of Claim 1 characterized in that R7 is cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each is substituted by R26 and optionally substituted by R25; characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; . -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C ( 0) OR14, -R13-C (0) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or '2), -R13-S (O) tN (R14) C (O) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R1) 2 (where t is 1 or 2), -R13-N (R1) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C ( 0) -R16-C (0) N (R14) 2; R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkylalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl, optionally substituted and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 36. The compound of Claim 35 characterized in that R7 is characterized in that m is 0 to 1; R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkylalkyalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl , optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R "L3-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13- C (0) OR14, -R13-C (0) N (R1) 2, -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) ) C (O) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (O) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-.C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C ( 0) -R16-C (0) N (R14) 2; R26 is selected from the group consisting of ~ R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R1) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally cycloalkylalkyl. substituted, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or where two R14s, together, with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; and wherein, each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 37. The compound of Claim 35 characterized in that R26 is in the para position. 38. The compound of Claim 1 characterized in that R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by substituent R25 and optionally substituted by substituent R26 characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, alkenyl optionally substituted, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -0R14; -SR14, -S (0) tR15 (where t is 1 or 2), ~ N (R14) 2, -CN, -C (0) R14, -C (0) 0R14, -C (0) N (R1 ) 2, -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) C (0) R15, (where t is 1 or 2), -S (0 ) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -S (0) tN (R14) C (NR1) N (R1) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R14) S (0) tR15 (where t is 1 or 2), -C (0) -R16-C (0) R14, -C (0) - R16-C (S) R14 and -C (0) -R16-C (0) N (R14) 2; and R26 is selected from the group consisting of -C (0) R14, -S (0) tR15 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2) and -S (0) tN (R1) C (0) R15 (where t is 1 or 2); wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 39. The compound of Claim 1 characterized in that R7 is cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl, wherein each is substituted by R26 and optionally substituted by R25 characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, alkenyl optionally substituted, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C ( 0) OR14, ~ R13-C (0) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R1) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R1) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C ( 0) -R16-C (0) N (R14) 2; R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralguil; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain.40. The compound of any of Claims 35-39 characterized in that R25 is selected from the group consisting of halo, optionally substituted alkyl, optionally substituted cycloalkyl, -R13-OR14, -R13-SR14 and -R13-N (R14) 2; wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or a. optionally substituted branched or simple alkenylene chain; and wherein each R14 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle. 41. The compound of any of Claims 35-40 characterized in that R1 and R2 are each independently selected from the group consisting of cyano, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 42. The compound of Claim 41 characterized in that R1 and R2 are each independently alkyl or haloalkyl. 43. The compound of Claim 41 characterized in that R1 and R2 are alkyl or phenyl. 44. The compound of any of Claims 41-43 characterized in that R4 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8- C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) ) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tO R9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8 -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, '-R8 -0C (NR9) R10, -R8-0C (S) R10, -R8-0C (O) OR10, -R8-0C (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9 -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R1X-C (0) R9, -R8-C (0) -RX1-C (S) R9, -R8-C (0) -R-C (NR9) R9, -R8-C (0) -RX1-C (0) OR9, -R8 -C (0) -R ^ -C (S) OR9, -R8-C (0) -R1X-C (NR9) OR9, -R8-C (0) -R -C (0) N (R9) 2 , '-R8-C (0) -Rn-C (S) N (R9) 2, -R8-C (0) -R ^ -C (NR9) N (R9) 2, -R8-C (0) -R1X-C (0) SR9, -R8-C (0) -RX1-C (S) ) SR9 and -R8-C (0) -R11-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R10 is independently selected from the group consisting of, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 45. The compound of Claim 44 characterized in that R4 is: characterized in that n is 0 to 1; R18 is selected from the group consisting of halo, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted aralkenyl; and R19 is selected from the group consisting of halo, haloalkyl, alkenyl, heterocycle. optionally substituted, optionally substituted aryl, optionally substituted heteroaryl, -R8-OR9 and -R8-C (O) N (R9) 2; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; and wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R9s, together with the atom to which they are attached, form optionally substituted heterocycle. 46. The compound of Claim 44 characterized in that R 4 is optionally substituted naphthyl. 47. The compound of Claim 46 characterized in that said compound is; 2,5-dimethyl-l-naphthalene-l-yl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, or 2,5-dimethyl-L-naphthalene-l-yl-lH- acid pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide. 48. The compound of any of Claims 41-43 characterized in that R4 is hydrogen, -C (0) R9 or -S (0) 2R9; wherein R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 49. The compound of any of Claims 41-43 characterized in that R4 is alkyl, alkenyl or akinyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9 , -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (0) SR9, -C (S) SR9, -C '(NR9) SR9, -S (0) t OR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (O) tN (R9) M = C (R9) 2 · -S (O) tN (R9) C (O) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S ( O) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R9) C (O) OR10, -N (R9) ) C (O) SR10, -N (R9) C (NR9) SR10,. -N (R9) C (S) SR10, -N (R9) C (O) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (O) tR10 (where t is 1 or 2), - OC (0) R10, -OC (NR9) R10, -OC (S) R10f -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC ( 0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (0) -R1X-C (0) R9, -C (O) - R1X-C (S) R9, -C (O) -R11-C (NR9) R9, -C (O) -R 13 -C (O) OR 9, -C (O) -R 11 -C (S) OR 9, -C (O) -Ru-C (NR 9) OR 9, -C (O) -Ru -C (O) N (R9) 2 -C (0) -Rn-C (S) N (R9) 2, -C (0) -Ru-C (NR9) N (R9) 2, -C (0 ) -R11-C (0) SR9, -C (0) -R -C (S) SR9 and -C (0) -R21-C (NR9) SR9; or R 4 is cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, cycloalkylalkyl optionally substitutedoptionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9 , -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) 0R9, -R8-C (0) N ( R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (O) SR9, -R8-C (S) SR9, -R8-C (NR9 ) SR9, -R8-S (0) t0R9 '(where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0 ) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2. (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8- OC (NR) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8-OC (NR9) OR10, -R8-0C (S) OR10, -R8-OC (O) SR9 , -R8-OC (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R1X- C (0) R9, -R8-C (0) -Rn-C (S) R9, -R8-C (O) -Rn-C (NR9) R9, -R8-C (0) -R1X-C (0) OR9, -R8 -C (0) -Rlx-C (S) OR 9, -R 8 -C (0) -Rn-C (NR 9) OR 9, -R8-C (0) -Rai-C (0) N (R9) 2, -R8-C (0) -Ru-C (S) N (R9) 2, -R8-C (0) -Ru C (NR 9) N (R 9) 2, -R 8 -C (0) -R 11 -C (0) SR 9, -R 8 -C (0) -R -C (S) SR 9 and -R 8 -C (O) - Ru-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 50. The compound of the formula (II); characterized because: R2 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocycle, heterocycloalkyl optionally substituted, -OR9, -SR9, -N (R9) i, -C (0) OR9 or -C (0) N (R9) 2; . R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; R4 is hydrogen; -C (0) R9 or -S (0) 2R9; or R4 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkyl, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2 ), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C ( NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (O) SR9, -C (S) SR9 , -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9 ) N (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (O) tN (R9) C (O) N (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9) C (0) 0R10, -N (R9) C (O) SR10, ~ N (R9) ) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, '-N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, v-OC (0) SR9,. -OC (O) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (0) -RX1-C (0) R9, -C ( 0) -R11-C (S) R9, -C (O) ~ R1X-C (NR9) R9, -C (0) -R1: L-C (0) OR9, -C (0) -R11-C (S) OR9, -C (0) -R1X-C (NR9) OR9, -C (0) -R1X-C (0) N (R9), -C (0) -RX1-C (S) N (R9) 2f -C (O) -R -C (NR9) N (R9) 2, -C (O) -R 11 -C (O) SR 9, -C (0) -R -C (S) SR 9 and -C (O) -R 1: LC (NR 9) SR 9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl , optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8 -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t · is 1 or 2), -R8- N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8 ~ 0C (0) R10, - -R8 -0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-0C (S) N (R9) 2, -R8-C (0) -R -C (0) R9, -R8-C (0) -R ^ -C (S) R9, -R8-C (0) -R1X-C (NR9) R9, -R8-C (O) -Ru-C (0) OR9, - R8-C (0) -R1X-C (S) OR9, -R8-C (0) -R ^ -C (NR9) OR9, -R8-C (0) -R -C (0) N (R9) 2, -R8-C (0) -Ru-C (S) N (R9) 2, -R8-C (0) -R ^ -C (NR9) N (R9) 2, -R8-C (0) -Rn-C (O) SR9, -R8-C (0) -R1: L-C (S) SR9y -R8-C (0) -Rai-C (NR9) SR9; R5 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, -C (0) R9 or -S (0) 2R9; R6 is hydrogen or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, -0R14, -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2r -CN, -C (0) R14, -C (S) R14, -C (NR1) R14, -C (0) OR 14, -C (S) OR 14, -C (NR 14) OR 14, -C (0) N (R 1) 2, -C (S) N (R 14) 2, -C (NR 14) N (R 14) 2, - C (0) SR14, -C (S) SR14, -C (NR14) SR14, -S (0) tOR14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -S (0) tN (R1) N = C (R14) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R8-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -N (R14) ) C (0) R15, -N (R1) C (0) OR15, -N (R1) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15 , -N (R14) C (0) N (R1) 2, -N (R14) C (NR1) N (R14) 2, ~ N (R14) C (S) N (R14) 2, -N (R14) ) S (0) tR15 (where t is 1 or 2), -0C (0) R15, -0C (NR14) R15, -0C ( S) R15, -0C (0) 0R15, "-OC (NR14) OR15, -OC (S) OR15, -0C (0) SR14, -0C (0) N (R1) 2, -OC (NR14) N (R14) 2, -0C (S) N (R14) 2, -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14, -R13 -C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, | -R13-C ( 0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2 , -R13-C (0) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; or R is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, dioxo, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13 -C (0) R14, -R13-C (S) ) R14, -R13-C (NR14) R14, -R13-C (O) OR1, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (O) N (R14) 2, -R13-C (S) N (R14) 2, -R13-C (NR14 ) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR1, -R13-C (NR1) SR1, -R13-S (0) tOR14 (where t is 1 or 2) , -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R1) 2 (where t is 1 or 2), -R13- S (0) tN (R14) N = C (R1) 2, -R13-S (O) tN (R14) C (O) R15, -R13-N (R14) C (O) R15, -R13-N (R14) C (O) OR15, -R13-N (R14) C (O) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (O) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R13- N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-0C (0) R15, -R13-OC (NR1 ) R15, -R13-OC (S) R15, -R13-OC (O) OR15, -R13-OC (NR1) OR15, -R13-OC (S) OR15, -R13-OC (O) SR14, -R13 -0C (0) N (R14) 2, -R13-OC (NR14) N (R1) 2, -R13-OC (S ') N (R14) 2 -R1-C (O) -R16-C (0 ) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, '-R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R1) 2, - R13-C (0) -R16-C (S) N (R14) 2, -R13-C (O) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (O) -R16-C (S) SR14 and -R13-C (O) -R16-C (NR14) SR14; wherein each R 8 and R 13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; or where two R1 s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and wherein each R 1: R 1 and R 16 are independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. 51. The compound of Claim 50 characterized in that: R2 is cyano, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; R3 is hydrogen or halo; R 4 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, . optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, - R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R3-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) t0R9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) 0R10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) RX0, -R8- 0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-0C (NR9) OR10, -R8-OC (S) OR10, -R8-0C (O) SR9, -R8-0C (0) N (R9) 2, -R8-0C (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R11-C (0) R9, -R8-C (0) -R11-C (S) R9, - -R8-C (0) -Rn-C (NR9) R9, -R8-C (0) -R11-C (0) OR9, - R8-C (0) -R1X-C (S) OR9, -R8-C (0) -Ru-C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2 , -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (0) -R11-C (NR9) N (R9) 2, -R8-C (0) -R11-C (0) SR9, -R8-C (0) -R -C (S) SR9 or -R8-C (0) -R11-C (NR9) SR9; R5 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl; R6 is hydrogen; R7 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C (S) R14, -R13-C (NR14) R14 , -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R1) 2, -R13-C (S) N ( R14) 2, -R13-C (NR14) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13- S (O) tOR14 (where t is 1 or 2), -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R1) N = C (R1) 2, -R13-S (O) tN (R14) C (O) R15 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR1) N ( R1) 2 (where t is 1 or 2) and -| R13-N (R14) S (0) tR15 (where t is 1 or 2); where . each R 8 and R 13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or where two R9s, together with the atom al. which are attached, form optionally substituted heterocycle; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. 52. The compound of Claim 50 characterized in that R7 is cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each is substituted by R26 and optionally substituted by R25; characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C ( 0) OR14, -R13-C (0) N (R1) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 ( where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (O) - R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C (0) -R16-C (0) N (R14) z; R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); where each R13 is independently. a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R1s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 53. The compound of any of the Claims characterized in that R7 is: characterized in that: m is 0 to 1; R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally aralkenyl substituted, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C ( 0) OR14, -R13-C (0) N (R1) 2, -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R1) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R1) C (NR14) N (R1) 2 (where t is 1 'or 2), -R13-N (R14) C (O) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (O) -R16-C (O) R14, -R13-C (0) -R16-C (S) R14 and -R13-C (O) -R16-C (O) N (R14) 2; and R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, "optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl, and wherein each R 16 is independently an optionally substituted straight or branched alkylene chain or an optionally substituted straight or branched alkenylene chain. 54. The compound of Claim 53 characterized in that R26 is in the para position. 55. The compound of Claim 50 characterized in that R7 is alkyl, alkenyl or alkynyl, wherein each is substituted by substituent R25 and optionally substituted by substituent R26 characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, alkenyl optionally substituted, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -OR14; -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (O) R14, -C (0) OR14, -C (0) N (R14) ) 2, -S (0) tN (R1) 2 (where t is 1 or 2), -S (O) tN (R14) C (O) R15, (where t is 1 or 2), -S (0 ) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -S (0) tN (R14) C (NR14) N (R1) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R1) S (0) tR15 (where t is 1 or 2), -C (0) -R16-C (0) R14, -C (0) - R16-C (S) R14 and -C (0) -R16-C (0) N (R14) 2; and R26 is selected from the group consisting of -C (0) R14, -S (0) tR15 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2) and -S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R14 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted branched or simple alkenylene chain, 56. The compound of Claim 50 characterized in that R7 is cycloalkylalkyl, heterocyclylalkyl, aralkyl or heteroaralkyl, wherein each is substituted by R26 and optionally substituted by R25 characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, alkenyl optionally substituted, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, ~ R13-C (O) R14, -R13-C ( 0) OR14, -R13-C (0) N (R14) 2, -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (O) R15, (where t is 1 or 2), -R13-S (0) tN (R1) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (O) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C ( 0) -R16-C (0) N (R14) 2; and R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), ~ R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted alkylalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain.57. The compound of any of Claims 51-56 characterized in that R25 is selected from the group consisting of halo, optionally substituted alkyl, optionally substituted cycloalkyl, -R13-0R14, -R13-SR14 and -R13-N (R14) 2; wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted straight or branched alkenylene chain; and wherein each R14 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, alkynyl. optionally substituted, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle. 58. The compound of any of Claims 51-57 characterized in that R2 and R5 are each independently selected from the group consisting of cyano, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 59. The compound of Claim 58 characterized in that R2 and R5 are both alkyl. 60. The compound of Claim 58 characterized in that R2 and R5 are each independently alkyl or phenyl. 61. The compound of any of Claims 58-60 characterized in that R4 is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8- C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (.S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S ') N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8- S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8 ~ S ( 0) tN '(R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8-N (R9) C (0) OR10 , -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N. { R9) S (0) tR10 (where t is 1 or 2), -R8-OC (O) R10, -R8-OC (NR9) R10, -R8-OC (S) R10, -R8-OC (O) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R -C (0) R9, -R8-C (0) -R1X-C (S) R9, -R8-C (0) -R1X-C (NR9) R9, -R8-C (0) -Rn-C (0) 0R9, -R8 -C (0) -R -C (S) OR9, -R8-C (0) -Rn-C (NR9) OR9, -R8-C (0) -Ru-C (0) N (R9) 2, -R8-C (0) -Ru-C (S) N (R9) 2, -R8-C (O) -Ru-C (NR9) N (R9) 2, -R8-C (O) -R- (O) SR9, -R8-C (0) -R12-C (S) SR9 and -R8-C (0) -R11-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkylalkyl optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and heteroaralkyl optionally substituted; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 62. The compound of any of Claims 61 characterized in that R4 is: characterized in that: n is 0 to 4; R18 is halo, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted aralkenyl; R19 is halo, alkyl, haloalkyl, alkenyl, optionally substituted heterocycle, optionally substituted phenyl, optionally substituted heteroaryl, -R8-OR9 or -R8-C (0) N (R9) 2; R8 is a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; and each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R9s, together with the atom to which they are attached, form optionally substituted heterocycle. 63. The compound of any of Claims 61 characterized in that R 4 is optionally substituted naphthyl. 64. The compound of any of Claims 58-60 characterized in that R4 is hydrogen, -C (0) R9o -S (0) 2R9; wherein R9 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl. 65 '. The compound of any of Claims 58-60 characterized in that R4 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9 , -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (O) SR9, -C '(S) SR9, -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (O) tN (R9) C (O) R10 (where t is 1 or 2), -S (0) tN (R) C (0) N (R9) 2 (-where t is 1 or 2), -R8-S ( O) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R9) C (O) OR10, -N (R9) ) C (O) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (O) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (O) tR10 (where t is 1 or 2), - OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (0) -Rai-C (0) R9, -C (0) -R11-C (S) R9, -C (O) -R1X-C (NR9) R9, ~ C (0) -Rn-C (0) OR9, -C (0) -R11-C (S) OR9, -C (0) -Ru-C (NR9) OR9, -C (0) -R11- C (0) N (R9) 2, -C (0) -R11-C (S) N (R9) 2, -C (O) -R11-C (NR9) N (R9) 2, -C (0 ) -R11-C (0) SR9, -C ^ -R ^ -CtSjSR9 and -C (O) -RX1-C (NR9) SR9; or R 4 is cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, cycloalkylalkyl optionally substituted, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9 , -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) 0R9, -R8-C (0) N ( R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2f -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (O) R10, -R8- OC (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) z, -R8-OC (NR9) N (R9) ) 2, -R8-0C (S) N (R9) 2, -R8-C (0) -Rn-C (0) R9, -R8-C (0) -R1: LC (S) R9, -R8-C (0) -R ^ -C (NR9) R9, -R8-C (0) -R ^ -C (0) OR9, -R8-C (0) -R -C (S) OR9, -R8-C (0) -R -C (NR9) OR9, -R8-C (0) -R1X-C (0) N (R9) 2, -R8-C (0) -Ru-C (S) N (R9) 2, -R8-C (0) -Ria-C (NR9) N (R9) 2, ~ R8-C (0) -R -C (0) SR9, -R8-C (0) -R -C (S) SR9 and -R8-C (0) -R11-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 66. The compound of the formula (III); characterized in that: R1 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally heterocycle substituted, optionally substituted heterocycloalkyl -OR9, -SR9, ~ N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R3 is independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R4 is hydrogen; -C (O) R9 or -S (O) 2R9; or R4- is alkyl, alkenyl or alkynyl optionally substituted by one or more substituents selected from the group consisting of halo, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C ( S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (O) SR9 , -C (S) SR9, -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), - S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (O) tN (R9) C ( O) R10 (where t is 1 or 2), -R8-S (O) tN (R9) C (O) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN ( R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R) C (0) OR10, -N (R9) C (0 ) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (O) tR10 (where t is 1 or 2), -OC (0) R10, ~ OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC ( NR9) OR10, -OC (S) OR10, -0C (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -0C (S) N (R9) 2 , -C (0) -R1X-C (0) R97 -C (O) -R11-C (S) R9, -C (0) -R11-C (NR9) R9, -C (0) -Rlx- C (0) OR9, -C (0) -R11-C (S) 0R9, -C (0) -Ru-C (NR9) OR9, -C (0) -R -C (0) N (R9) 2, -C (0) -Rlx-C (S) N (R9) 2, -C (0) -Ru-C (NR9) N (R9) 2, ~ C (0) -Ru-C (0) SR9, -C (0) -Ru-C (S) SR9 and -C (O) -Rn-C (NR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, heteroaralkenyl optionally substituted, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0 ) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -Rs-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8 ~ C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 '(where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, '-R8-N (R9) C (NR9) N (R9) 2, -R8 -N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8-0C ( NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-0C (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2 -R8-C (0) -R11-C (0) R9, -R8-C (0) -R1: LC (S) R9, -R8-C (0) -RX1-C (NR9) R9, -R8-C (0) -R1X-C (0) OR9, -R8 -C (0) -R11-C (S) OR9, -R8-C (0) -R11-C (NR9) OR9, -R8-C (0) -R ^ -C (0) N (R9) 2l -R8-C (0) -R ^ -C (S) N (R9) 2, -R8-C (0) -Rn-C (NR9) N (R9) 2, -R8-C (0) -R1] - ~ C (0) SR9, -R8-C (0) -R1: L-C (S) SR9y -R8-C (0) -R1: L-C (NR9) SR9; R5 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, -C (0) R9 or -S (0) 2R9; R5 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkyl, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (O) SR9, -C (S) SR9, -C (NR9) SR9, -S (O) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN ( R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) C (NR9) N ( R9) 2 (where t is 1 or 2), -N (R9) C (O) R10, -N (R9) C (O) OR10, -N (R9) C (O) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (O) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (O) tR10 (where t is 1 or 2), - OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC (NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (O) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -C (O) -R1X-C (0) R9, -C (O) -R -C (S) R9, -C (O) -R1X-C (NR9) R9, -C (0) -R11-C (0) OR9, -C (O) -R11-C. { S) OR r -C (O) -R -C (NR9) OR9, -C (O) -R ^ -C (O) N (R9) 2, -C (O) -R11-C (S) N (R9) 2, -C (O) -Ru-C (NR9) N (R9) 2, -C (O) -R- (O) SR9, -C (O) -R11-C (S) SR9 and -C (O) -Ru-C (NR9) SR9; R6 is hydrogen, alkyl or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, -OR14, -SR14 , -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (0) R14, -C (S) R14, -C (NR1) R14, -C ( 0) 0R14, -C (S) 0R14, -C (NR14) OR14, -C (0) N (R14) 2, -C (S) N (R14) 2, -C (NR14) N (R14) 2 , -C (0) SR14, -C (S) SR14, -C (NR14) SR14, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N = C (R14) 2, -S (0 ) tN (R14) C (0) R15 (where t is 1 or 2), -S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -N (R14) ) C (0) R15, -N (R1) C (0) OR15, -N (R14) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15 , -N (R14) C (0) N (R14) 2, -N (R1) C (NR1) N (R14) 2, -N (R14) C (S) N (R14) 2, -N (R14) S (0) tR15 (where t is 1 or 2), -0C (0) R15, -0C (NR14) R15, -0C (S) R15, -0C (0) 0R15, -0C ( NR14) OR15, -0C (S) 0R15, -0C (0) SR14, -OC (0) N (R1) 2, -OC (NR14) N (R14) 2, -0C (S) N (R14) 2 , -C (0) -R16-C (0) R14, -C (0) -R16-C (S) R14, -C (0) -R16-C (NR1) R14, C (0) -R16- C (0) OR14, -C (0) -R 16 -C (S) OR 14, -C (0) -R 16 -C (NR 14) OR 14, -C (0) -R 16 -C (0) N (R 14) 2, -C (0 ) -R16-C (S) N (R14) 2, -C (0) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14, -C (0) - R16-C (S) SR14 and -C (0) -R16-C (NR14) SR14; or R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substitutes selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro , dioxo, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl , optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2) -R-13-N (R14) 2, -R13-CN, -R13- C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14 -R13-C (O) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (O) N (R14) 2 -R13-C (S) N (R14) 2, -R13-C ( NR1) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR14 -R13-C (NR14) SR14, -R13-S (O) tOR14 (where t is 1 or 2) , -R13-S (0) tN (R14) (where t is 1 or 2), -R13-S (O) tN (R14) N (R14) 2 (where t is 1 or 2) -R13-S ( O) tN (R14) N = C (R14) 2, -R13-S (O) tN (R14) C (O) R15, -R13-N (R14) C (O) R15 -R13-N (R14) C (O) OR15, -R13-N (R14) C (O) SR15, -R13-N (R14) C (NR14) SR15 -R13-N (R14) C (S) SR15, -R13-N (R1) C (0) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2 -R13-N (R14) C (S) N (R14) 2, -R13-N (R14) S (0) tR15 (where t is 1 or 2) -R13-OC (O) R15, -R13-OC (NR14) R15 , -R13-OC (S) R15, -R13-OC (O) OR15 -R13-OC (NR14) OR15, -R13-OC (S) OR15, -R13-OC (O) SR14, -R13-OC ( O) N (R14) 2 -R13-OC (NR14) N (R14) 2, -R13-OC (S) N (R14) 2 -R13-C (O) -R16-C (O) R14 -R13-C (O) -R16-C (S) R14, -R13-C (O) -R16-C (NR14) R14, -R13C (O) -R16-C (O) OR14-R13-C ( 0) -R16-C (S) OR14, -R13-C (O) -R16-C (NR14) OR14 -R13-C (O) -R16'-C (O) N (R14) 2, -R13-C (O) -R16-C (S) N (R14) 2 -R13-C (O) -R16C ( NR14) N (R14) 2, -R13-C (O) ~ R16-C (O) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; wherein each R8 and R13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R1 s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; and wherein each R 11 and R 16 are independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; 'as a simple isomer, a mixture of isomers, or as a racemic mixture of. isomers; or as a solvate or polymorph; o-as a prodrug; or as a pharmaceutically acceptable salt thereof. , 67. The compound of Claim 66 characterized in that: R5 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C ( 0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8 -C (NR9) OR9, -R8-C (O) N (R9) 2, -R8 ~ C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (O) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8-N (R9) C (O) OR10, -R8-N (R9) C (O) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) ) C (0) N (R9) 2, '-R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (O) tR10 (where t is 1 or 2), -R8-0C (O) R10, -R8- OC (NR9) R10, -R8-0C (S) R10, -R8-0C (0) 0R10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR, -R8-OC (O) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-0C (S) N (R9) 2, -R8-C (0) -R ^ -C (O) R9, -R8-C (0) -R ^ -C (S) R9, -R8-C (O) -Ral-C (NR9) R9, -R8-C (0) -RX1-C (0) OR9, - R8-C (O) -R1X-C (S) OR9, -R8-C (0) -Ru-C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2, -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (O) -Ru C (NR 9) N (R 9) 2, ~ 8-C (O) -Ru-C (O) SR 9, -R 8 -C (0) -R -C (S) SR 9 and -R 8 -C (0) - R11-C (NR9) SR9. 68. The compound of Claim 66 characterized in that: R1 is cyano, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; R3 is hydrogen or halo; R 4 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8 ~ N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, - R8-C (NR9) R9, -R8 ~ C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9 ) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8 ~ S (O) tN ( R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8-N (R9) C (O) ORx0, -R8-N (R9) C (O) SR10, -R8-N (R9) C (NR9) 'SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (O) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- OC (NR9) R10, -R8-OC (S) R10, -R8-OC (O) OR10, ~ R8 ~ OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-0C (O) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2; -R8-C (0) -RU-C (0) R14, -R8-C (0) -R11-C (S) R14, -R8-C (0) -Rn-C (NR14) R14, -R8-C (0) -R1X-C (0) 0R14, -R8 -C (0) -R1: L ~ C (S) OR14, -R8-C (0) -R1X-C (NR14) OR14, -R8-C (0) -Rn-C (0) N (R14) 2 / -R8-C (0) -RU-C (S) N (R14) 2, -R8-C (0) -R11- C (NR14) N (R14) 2,. -R8-C (0) -Rn-C (0) SR14, -R8-C (0) -R11-C (S) SR14 and -R8-C (O) -RX1-C (NR14) SR14; R5 is hydrogen, -C (0) R9 or -S (0) 2R9; R5 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR) R9, -C (0) 0R9, -C (S) 0R9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (0) SR9, -C (S) SR9, - C (NR9) SR9, -S (0) t0R9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -S ( 0) tN (R9) N = C (R9) 2 -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9) C (0) 0R10 , -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, - N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2 / -N (R9) S (0) tR10 (where t is 1 or 2), -0C (0) R10, -0C (NR9) R10, -0C (S) R10, -0C (0) 0R10, -OC (NR9) OR10, -OC (S) OR10, -0C (0) SR9, -OC ( 0) N (R9) 2, -OC (NR9) N (R9) 2, -0C (S) N (R9) 2, -C (0) -Ru-C (0) R9, -C (0) - R11-C (S) R9, -C (0) -R- (NR9) R9, -C (0) -R ^ -C (0) OR9, -C (0) -R1: LC (S) OR9, -C (0) -RX1-C (NR9) OR9, -C (0) -R11-C (0) N (R9) 2, -C (0 ) -Ru-C (S) N (R 9) 2, -C (0) -R -C (NR 9) N (R 9) 2, -C (0) -R -C (0) SR 9, -C (0 ) -R1: LC (S) SR9 and -C (0) -Rn-C (NR9) SR9; or R5 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C ( 0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) ) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S ( 0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) 0R10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, ~ R8 ~ N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- OC (NR9) R10, -Rs-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (O) N (R9) 2, -R8-0C (NR9) N (R9) ) 2, -R8-0C (S) N (R9) 2, -R8-C (O) -Ru-C (O) R9, -R8-C (0) -R -C (S) R9, -R8-C (0) -R11-C (NR9) R9, -R8-C (0) -R -C (O) OR9, -R8 -C (O) -RX1-C (S) OR9, -R8-C (O) -Ru-C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2, -R8-C (O) -R -C (S) N (R9) 2, -R8-C (O) -R1X-C (NR9) N (R9) 2, -R8-C (O) -R ^ -C (O) SR9, -R8-C (O) -Rn-C (S) ) SR9 and -R8-C (O) -RX1-C (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of nitro, halo, -OR14, -SR14, -S (0) tR15 (where t is 1 or 2), - N (R14) 2, -CN, -C (0) R14, -C (S) R14, -C (NR1) R14, -C (0) 0R14, -C (S) 0R14, -C (NR14) OR14 , -C (0) N (R14) 2, -C (S) N (R14) 2, -C (NR1) N (R14) 2, -C (0) SR14, -C (S) SR14, -C (NR1) SR1, -S (0) t0R14 (where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N ( R1) 2 (where t is 1 or 2), -S (O) tN (R14) N = C (R14) 2, -S (0) tN (R14) C (0) R15 (where t is 1 or 2 ), -R8-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R8-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R1) C (0) 0R15, -N (R14) C (0) SR15, ~ N (R14) C ( NR14) SR15, -N (R14) C (S) SR15, -N (R14) C (0) N (R14) 2, -N (R1) C (NR1) N (R14) 2, -N (R14) C (S) N (R1) 2, -N (R14) S (0) tR15 (where t is 1 or 2), - 0C (0) R15, -OC (NR14) R15, -0C (S) R15, -0C (0) 0R15, -0C (NR14) OR15, -0C (S) 0R15, -0C (0) SR14, -0C (0) N (R14) 2, -OC (NR1) N (R14) 2, -OC (S) N (R14) 2, -C (0) -R16-C (0) R14, -C (0) -R16-C (S) R14, -C (0) -R16-C (NR14) R14, -C (0) -R16-C (0) OR14, -C (0) -R16-C (S) OR14 , -C (O) -R15-C (NR14) OR14, -C (0) -R16-C (0) N (R14) 2, -C (O) -R16-C (S) N (R14) 2, -C (0) -R16C (NR1) N (R14) 2, -C (0) -R16-C (0) SR14, -C (0) -R16-C (S) SR14 and -C (0) - R16-C (NR14) SR14; R6 is hydrogen; R7 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0) OR14, -R13-C (S) OR1, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, -R13-C (S) N (R1) ) 2, -R13-C (NR14) N (R14) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) t0R14 (where t is 1 or 2), -R13-S (0) tN (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R1) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) ) 2 (where t is 1 or 2) and -R13-N (R14) S (0) tR15 (where t is 1 or 2); wherein each R8 and R13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; Wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; and as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. 69. The compound of any of Claims 66-68 characterized in that R7 is cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each is substituted by R26 and optionally substituted by 'R25; characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloacylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C ( 0) OR14, -R13-C (0) N (R14) 2, -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C ( 0) -R16-C (0) N (R14) 2; R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 70. The compound of Claim 69 characterized in that R7 is: characterized in that: m is 0 to 1; R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heteroaryl, -R13-OR14; -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2), -R13-N (R1) 2, -R13-CN, -R13-C (O) R14, -R13-C ( O) OR14, -R13-C (O) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (O) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (O) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), and -R13-C (0) -R16-R17; and R26 is selected from the group consisting of -R13-S (0) tR15 (where t is 1 or 2), -R13-C (0) R14 and -R13-S (0) tN (R14) 2 (where t is 1 or 2); wherein each R13 is independently a direct bond or an optionally substituted branched or simple alkylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 71. The compound of Claim 70 characterized in that R26 is in the para position. 72. The compound of any of Claims 66-68 characterized in that R7 is alkyl, alkenyl or alkynyl, wherein each is substituted by R26 and optionally substituted by R25 characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heteroaryl, -OR14; -SR14, -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (0) R14, -C (0) OR14, -C (0) N (R14) ) 2, -S (0) tN (R14) 2 (where t is 1 or 2), -S (O) tN (R1) C (O) R15, (where t is 1 or 2), -S (O ) tN (R14) C (O) N (R14) 2 (where t is 1 or 2), -S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -N (R14) C (0) R15, -N (R1) S (0) tR15 (where t is 1 or 2), and -C (0) -R16-R17; and R26 is selected from the group consisting of -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -C (0) R14 and -S (0) tN (R14) 2 (where t it is 1 or 2); each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl ,. optionally substituted heteroaryl or optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl. 73. The compound of Claim 66 characterized in that R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl except phenyl, aralkyl, heteroaryl or heteroaralkyl, where each is substituted by R26 and optionally substituted by R25 characterized by: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heteroaryl, -R13-OR14; -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R14, -R13-C ( O) OR14, -R13-C (O) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) C (O) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R1) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (O) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), and -R13-C (O) -R16-R17; and R26 is selected from the group consisting of -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -C (0) R14 and -S (O) tN (R14) 2 (where t it is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl. 74. The compound of any of the Claims 67-73 characterized in that R25 is selected from the group consisting of halo, optionally substituted alkyl, optionally substituted cycloalkyl, -R13-OR14, -R13-SR14 and -R13-N (R14) 2; wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle. 75. The compound of any of Claims 67-74 characterized in that R1 and R5 are each independently selected from the group consisting of cyano, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 76. The compound of any of Claims 67-74 characterized in that Rx is hydrogen or optionally substituted alkyl and R5 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl , optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 77. The compound of Claim 76 characterized in that R5 is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R) 2, -R8-CN, -Rs-C (0) R9, -R8-C (S) R9, - R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- 0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-0C (NR9) N (R9) ) 2, -R8-OC (S) N (R) 2, -R8-C (0) -R -C (0) R9, -R8-C (0) -R -C (S) R9, -R8-C (0) -R- (NR9) R9, -R8-C (0) -Rn-C (0) OR9, -R8 -C (0) -R -C (S) OR9, -R8-C (0) -Rn-C (NR9) OR9, -R8-C (0) -R11-C (0) N (R9) 2, -R8-C (0) -R ^ -C (S) N (R9) 2, -R8-C (0) -R- (NR9) N (R9) 2, -R8-C (0) -Rn-C (0) SR9, -R8-C (0) -Rn-C (S) SR9 and -R8-C (0) -R11-C (NR9) SR9; 78. The compound of Claim 75 characterized in that R1 and R5 are each optionally substituted alkyl. 79. The compound of Claim 75 characterized in that R1 and R5 are each independently alkyl or optionally substituted phenyl. 80. The compound of any of Claims 75-79 characterized in that R4 is cycloalkyl, heterocyclyl, aryol or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8- C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) ) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8 ~ C (NR9) SR9, -R8-S (0) t0R9 (where t is .1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8 -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) t "N (R9) N = C (R9) 2, -R8-S (0 ) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) 0R10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2 / -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8- 0C (NR9) R10, -R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -RX1-C (0) R9, -R8-C (0) -R1: LC (S) R9, -R8-C (0) -R1; LC (NR9) R9, -R8-C (0) -R1X-C (0) OR9, -R8 -C (0) -Ria-C (S) OR9, -R8-C (0) -R1: LC (NR9) OR9, -R8-C (0) -Ru-C (0) N (R9) 2, -R8-C (0) -R11-C (S) N (R9) 2, -R8-C (0) -RX1-C (NR9) N (R9) 2, -R8-C (0) -Ru-C (0) SR9, -R8-C (0) -R1X-C (S) SR9 and -R8-C (0) -R11-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 81. The compound of Claim 80 characterized in that said compound is selected from the group consisting of: 5-Benzo [b] thiophen-2-yl-l, 4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (5-Acetyl-thiophen-2-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5-Benzo [1,3] dioxol-5-yl-l, 4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (lH-Indol-5-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5-Dibenzofuran-4-yl-l, 4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (1-Benzenesulfonyl-lH-indol-3-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1,4-Dimethyl-5-pyrimidin-5-yl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5-Acenaften-5-yl-l, 4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1-4-Dimethyl-5- (l-methyl-lH-indol-5-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; and 5- (l-Benzyl-lH-pyrazol-4-yl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5-Biphenyl-2-yl-l- (2-diethylamine-ethyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5-Biphenyl-2-yl-4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5-Biphenyl-2-yl-4-methyl-1- (2-morpholin-4-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Benzyloxy-4-fluoro-phenyl) -4-methyl-l- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide; 5- (2-Benzyloxy-4-fluoro-phenyl) -1- (2-dimethylamine-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Benzyloxy-4-fluoro-phenyl) -4-methyl-1- (2-piperidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-Methyl-1- (2-morpholin-4-yl-ethyl) -5- (2-phenoxy-phenyl) | lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Diethylamine-ethyl) -4-methyl-5- (2-phenoxy-phenyl) -pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-Methyl-5- (2-phenoxy-phenyl) -1- (2-piperidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 4-Methyl-5- (2-phenoxy-phenyl) -1- (2-pyrrolidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3-Dimethylamine-propyl) -4-methyl-5- (2-phenoxy-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Hydroxy-ethyl) -4-methyl-5- (2-phenoxy-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (4-Benzyloxy-2-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 5- (4-Hydroxy-2-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1, 4-Dimethyl-5- [2-methyl-4- (3-morpholin-4-yl-propoxy) phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1,4-Dimethyl-5- [4- (3-morpholin-4-yl-propoxy) -2-trifluoromethyl-phenyl] -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 82. The compound of any of the Claims characterized in that R4 is: characterized in that: n is 0 to 4; R18 is halo, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted aralkenyl; R19 is selected from the group consisting of haloalkyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, -R8-OR9 or -R8-C (O) U (R9) 2; where R8 is a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; and wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; or where two R9s, together with the atom to which they are attached, form optionally substituted heterocycle. 83. The compound of Claim 82 selected from the group consisting of: 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid [4- (2-fluoro-benzoyl) -phenyl] -amide; 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-3-trifluoromethyl-phenyl) -amide; 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-sulfamoyl-phenyl) -amide; 5- (-fluoro-2-trifluoromethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1,4-dimethyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide; 5- (4-fluoro-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (4-fluoro-2-trifluoromethyl-phenyl) -1,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide; 5- (4-fluoro-2-trifluoromethyl-phenyl) -1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-sulfamoyl-3-trifluoromethyl-phenyl) -amide; 1-4-Dimethyl-5- (2-phenoxy-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1-dimethyl-5- (4-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Isopropoxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Benzyloxy-5-fluoro-phenyl) -1,4-dimethyl-lH-pyrrole 3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Butoxy-5-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 5- (3-Benzyloxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (3-Bromo-2-methoxy-5-methyl-phenyl) -1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (3-Bromo-2-butoxy-5-methyl-phenyl) -1, -dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 3- [4- (4-Methanesulfonyl-phenylcarbamoyl) -1,3-dimethyl-lH-pyrrol-2-yl] -benzoic acid methyl ester; 5- (3,5-Bis-trifluoromethyl-phenyl) -1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Isopropoxy-5-methyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Butoxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (3-Benzylcarbamoyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Benzyloxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; and 5- (3-Carbamoyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; N- [4- (aminesulfonyl) -3-chlorophenyl] -5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-1- (pyridin-3-ylmethyl) -lH-pyrrole-3-carboxamide; 5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -1H pyrrole-3-carboxamide; 1- [3- (dimethylamine) ropil] -5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (pyridin-2-ylmethyl) -lH-pyrrole-3-carboxamide; 1- [3- (dimethylamine) propyl] -5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidin-1-ylethyl) -lH-pyrrole-3-carboxamide; 5- [4-fluoro-2- (trifluoromethyl) phenyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-morpholin-4-ylethyl) -lH-pyrrole-3-carboxamide; 4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl] -1 (pyridin-3-ylmethyl) -lH-pyrrole-3-carboxamide; 4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl] -1 (2-morpholin-4-ylethyl) -lH-pyrrole-3-carboxamide; 1- [2- (diethylamine) ethyl] -4-methyl-5- [2- (methyloxy) phenyl] -N- [4 (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -IH-pyrrole-3-carboxamide; 1- [(6-chloropyridin-2-yl) methyl] -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2,4-difluorophenyl) -1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 1- [(6-aminapyridin-2-yl) methyl] -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 1- [2- (diethylamine) ethyl] -5- (2, -difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -lH-pyrrole-3-carboxamide; 1- [(6-aminapyridin-2-yl) methyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- [(6-pyrrolidin-1-ylpyridin-2-yl) methyl] -lH-pyrrole-3- carboxamide; 5- (2,4-difluorophenyl) -4-methyl-l- [(6-methylpyridin-2-yl) methyl] -N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; methyl (6- { [2- (2, 4-difluorophenyl) -3-methyl-4 carbamate ( { [4- (Methylsulfonyl) phenyl] amine.} Carbonyl) -IH-pyrrol-1-yl] methyl} pyridin-2-yl); l-. { [6- (acetylamine) pyridin-2-yl] methyl} -5- (2,4-difluorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole carboxamide; 1- (. {6- [bis (methylsulfonyl) amine] pyridin-2-yl}. Methyl) -5- (2,4-difluorophenyl) -4-methyl- [4- (methylsulfonyl) phenyl] -lH -pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1- [2-hydroxy-3- (4-methylpiperazin-1-yl) propyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3- carboxamide; 5- (2-chlorophenyl) -1-. { 2- idroxy-3- [(2-methylpropyl) amine] propyl} -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1-. { 2-hydroxy-3- [(phenylmethyl) amine] ropil} -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 1- (3-amine-2-hydroxypropyl) -5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-l-. { 2- [(2-methylpropyl) amine] -2-oxoethyl} -N- [4- (Methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-l- [2- (4-methylpiperazin-1-yl) -2-oxoethyl] -N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrol- 3-carboxamide; 1- (2-amine-2-oxoethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 1- [2- (Butylamine) -2-oxoethyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] -1H-pyrrole-3-carboxamide; 5- (2-fluorophenyl) -1,4-dimethyl-N- [4- (methylsulfonyl) phenyl] pyrrole-3-carboxamide; 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-morpholin-4-ylethyl) -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidin-1-ylethyl) -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (pyridin-2-ylmethyl) -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1- (2-hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidin-1-ylethyl) -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1- [3- (dimethylamine) propyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1- [2- (diethylamine) ethyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 1- [(6-chloropyridin-2-yl) methyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] -5-phenyl-lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -4-ethyl-l-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-Fluoro-phenyl) -4-methyl-l-pyridin-2-ylmethyl-lH-pyrrole-3-carboxylic acid (4-methanes-l-phenyl-phenyl) -amide; 5- (2-Fluoro-phenyl) -1- (2-hydroxy-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; N- (1, l-dioxidotetrahydro-2H-thiopyran-4-yl) -1,4-dimethyl-5 [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-Chloro-phenyl) -4-methyl-1-pyrazin-2-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3-Fluoro-pyridin-2-ylmethyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-Methyl-1- (tetrahydro-furan-2-ylmethyl) -5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (1-Hydroxy-2-methoxy-ethyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3, 3-Dimethyl-2-oxo-butyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; l-Furan-2-ylmethyl-4-methyl-5- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Chloro-phenyl) -1- (2-hydroxy-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (3-chloro-4-sulfamoyl-phenyl) -amide; (N- { 4- [(acetylamine-kappaN) sulfonyl] -3-chlorophenyl] -1,4-dimethyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamidate) sodium; 1- (2-hydroxyethyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-pyrrolidin-1-ylethyl) -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) fertile] -1- (2-morpholin-4-ylethyl) - - [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (pyridin-2-ylmethyl) -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 1- [2- (diethylamine) ethyl] -4-methyl-N- [4- (methylsulfonyl) phenyl] - - [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- (2-piperidin-1-ylethyl) - [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1- [2-hydroxy-3- (phenyloxy) propyl] -4-methyl-N [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-chlorophenyl) -1- (2,3-dihydroxypropyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -l-prop-2-en-l-yl-5 - [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -1-phenyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 1- (3-hydroxypropyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 1- . { (2S) -3- [(4-fluorophenyl) oxy] -2-hydroxypropyl} -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 1- (4-hydroxybutyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 4-methyl-N- [4- (methylsulfonyl) phenyl] -1- [2- (tetrahydro-2H-pyran-2-yloxy) ethyl] -5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3 -carboxamide; N- [4- (aminesulfonyl) -3-chlorophenyl] -1- (2-hydroxyethyl) -4-methyl-5- [2- (trifluoromethyl) phenyl] -lH-pyrrole-3-carboxamide; 5- (2-Chloro-phenyl) -1- (2-methoxy-ethyl) -4-methyl-lH-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 5- (2-chlorophenyl) -4-methyl-N- [4- (methylsulfonyl) phenyl] -1-prop-2-en-l-yl-lH-pyrrole-3-carboxamide; 5- (2,6-Dimethyl-phenyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethyl-phenyl) -4-methyl-1- (2-morpholin-4-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethyl-phenyl) -1- (2-hydroxy-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2, β-Dimethyl-phenyl) -4-methyl-1-pyridin-3-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethyl-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethyl-phenyl) -4-methyl-1- (2-piperidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethyl-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethyl-phenyl) -4-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- [3- (4-Fluoro-phenoxy) -2- (R) -hydroxy-propyl] -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) ) -amide; l-Cyclopropylmethyl-4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4- ethyl-l-prop-2-ynyl-5- (2-trifluoromethyl-phenyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Chloro-phenyl) -1- [3- (4-fluoro-phenoxy) -2- (S) -hydroxy-propyl] -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide; 5- (2-Chloro-phenyl) -1- [3- (4-fluoro-phenoxy) -2- (R) -hydroxy-propyl] -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl) phenyl) -amide; 5- (2-Chloro-phenyl) -l-cyclopropylmethyl-4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-methyl-5- [2- (methyloxy) phenyl] -N- [4- (methylsulfonyl) phenyl-1 (2-piperidin-1-ylethyl) -lH-pyrrole-3-carboxamide; 5- (2-Methoxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -methyl-amide; 5- (2-Methoxy-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1,4-Dimethyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Diethylamine-ethyl) -4-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-Methyl-1- (2-pyrrolidin-1-yl-ethyl) -5-o-tolyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-Methyl-l-pyridin-2-yl-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3-Dimethylamine-propyl) -4-methyl-5-o-tolyl-lH-pyrrole 3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 4-Methyl-1- (2-piperidin-1-yl-ethyl) -5-o-tolyl-1H-pyrrole 3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 4-Methyl-l- (2-morpholin-4-yl-ethyl) -5-o-tolyl-lH-pyrrole 3-carboxylic acid (4-methanesulfonyl-phenyl) -amide, 1- (2-Hydroxy-3) acid -phenoxy-propyl) -4-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Diethylamine-ethyl) -5- (2,6-difluoro-phenyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Hydroxy-ethyl) -4-methyl-5-o-tolyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2, β-Difluoro-phenyl) -4-methyl-1- (2-pyrrolidin-1-yl-ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2, β-Difluoro-phenyl) -4-methyl-1- (2-piperidin-1-yl ethyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfoyl-phenyl) -amide; 5- (2,6-Difluoro-phenyl) -4-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2,6-Dimethoxy-phenyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1,4-Dimethyl-5- (2-trifluoromethoxy-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Hydroxy-3-phenyl-propyl) -4-methyl-5- (2-trifluoromethyl-phenyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Chloro-phenyl) -1- (2-hydroxy-2-phenyl-ethyl) -4-methyl-1H-pyrrole-3-carboxylic acid (-methanesulfonyl-phenyl) -amide; 5- (2-Chloro-phenyl) -1- (2-hydroxy-3-methoxy-propyl) -4-methyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 5- (2-Chloro-phenyl) -4-methyl-1- (3,3,3-trifluoro-2-hydroxy-propyl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (3-tert-Butoxy-2-hydroxy-propyl) -5- (2-chloro-phenyl) acid 4-methyl-lH-pyrrole-3-carboxylic (4-methanesulfonyl-phenyl) -amide; 5- (2-Chloro-phenyl) -1- (2-hydroxy-3-isopropoxy-propyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; 1- (2-Hydroxy-ethyl) -5- (4-methoxy-2-trifluoromethyl-phenyl) -4-methyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 84. The compound of any of Claims 80 characterized in that R 4 is optionally substituted naphthyl. 85. The compound of Claim 84 characterized in that said compound is selected from the group consisting of: 1,4-dimethyl-5-naphthalene-1-yl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide; and 1,4-dimethyl-5 ~ (4-methyl-naphthalene- 1-yl) -lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 86. The compound of any of Claims 75-79 characterized in that R4 is hydrogen, -C (0) R9 or -S (0) 2R9; wherein R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl.- 87. The compound of any of claims 75-79 characterized in that R4 is alkyl, alkenyl "or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo. , haloalkoxy, nitro, -0R9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, -C (NR9) N (R9) 2, -C (0) SR9, -C (S) SR9, -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S ( 0) tN (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (O) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (0) R10, -N (R9 ) C (0) OR10, -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, ~ N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), - 0C (0) R10, -0C (NR9) R10, -0C (S) R10, -0C (0) 0R10, -0C (NR9) OR10, -OC (S) OR10, -0C (0) SR9, -OC (0) N (R9) 2, -0C (NR9) N (R9) 2, -0C (S) N (R9) 2, -CÍOJ-R ^ -CÍOJR9, -C (0) -R11-C (S ) R9, -C (0) -R1X-C (NR9) R9, -C (0) -R1X-C (0) OR9, -C (0) -R -C (S) OR9, | -C (0) -R1: L-C (NR9) OR9, -C (0) -R1X-C (0) N (R9) 2, -C (0) -R -C (S) N (R9) 2, -C (0) -R11-C (NR9) N ( R9) 2, -C (0) -Ru-C (0) SR9, -C (0) -R1X-C (S) SR9 and -C (0) -R11-C (NR9) SR9; or R 4 is cycloalkylalkyl, heterocyclylalkyl, aralkyl, or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, cycloalkylalkyl optionally substituted, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9 , -R8-SR9, -R8-S (O) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N ( R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8- S (O) tN (R9) N (R9) 2 (where t -es 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) ) C (O) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8- OC (NR9) R10, -R8-OC '(S) R10, -R8-OC (O) OR10, -R8-OC (NR9) OR10, '-R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (O) N (R9) 2, -R8-OC (NR9) N ( R9) 2, -R8-OC (S) N (R9) 2, -R8-C (O) -Rn-C (O) R9, -R8-C (0) -R13"-C (S) R9, -R8-C (0) -R -C (NR9) R9, -R8-C (0) -R1: LC (0) 0R9, -R8-C (0) -R -C (S) OR9, -R8 -C (0) -RX1-C (NR9) OR9, -R8-C (0) -Rai-C (0) N (R9) 2, -R8-C (0) -R ^ -C (S) N (R9) 2, -R8-C (O) -R1; LC (NR9) N (R9) 2, -R8 ~ C (0) -Ru-C (0) SR9, -R8-C (0) -RX1-C (S) SR9 and -R8-C (0) -Ru-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 88. The compound of Claim 87 characterized in that said compound is: 5- ((E) -3,3-Dimethyl-but-l-enyl) -1,4-dimethyl-lH-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 89. The compound of the formula (IV); characterized in that: R1 and R2 are each independently hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heterocycle, optionally substituted heterocycloalkyl, -0R9, -SR9, -N (R9) 2, -C (0) OR9 or -C (0) N (R9) 2; R4 is hydrogen; or R4 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, haloalkyl, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, -C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, - C (NR 9) OR 9, -C (0) N (R 9) 2, -C (S) N (R 9) 2, -C (NR 9) N (R 9) 2, -C (0) SR 9, -C (S ) SR9, -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is | 1 or 2), -N (R9) C (O) R10, -N (R9) C (0) OR10, -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N (R9) C (0) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (0) tR10 (where t is 1 or 2), -OC (0) R10, -OC (NR9) R10, -OC (S) R10, -OC (0) OR10, -OC ( NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (0) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2 , -C (O) -R ^ -C (O) R9, -C (0) -Rn-C (S) R9, -C (0) -Rn-C (NR9) R9, -C (0) - Ru-C (0) 0R9, -C (0) -Ru-C (S) OR 9, -C (0) -R 11 -C (NR 9) OR 9, -C (0) -R -C (0) N (R 9) 2, -C (0) -R ^ -C (S) N (R9) -C (O) -R- (NR9) N (R9) 2, -C (0) -R11-C (0) SR9, - C (0) -R11-C (S) SR9 and -C (O) -R- (NR9) SR9; or R 4 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, heteroaralkenyl optionally substituted, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0 ) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (0) N (R9) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-N ( R9) C (0) R10, -R8 ~ N (R9) C (0) 0R10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, ~ R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8- N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8-0C (0) R10, -R8-OC (NR9 ) R10, ~ R8-0C (S) R10, -R8-0C (0) OR10, -R8-OC (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-0C (S) N (R9) 2, -R8-C (0) -R1: LC (0) R9, -R8-C (0) -R -C (S) R9, -R8-C (0) -Ru-C (NR9) R9, -R8-C (0) -RX1-C (0) OR9, -R8 -C (0) -R11-C (S) OR9, -R8-C (0) -R11-C (NR9) OR9, -R8-C (0) -R ^ -C (0) N (R9) 2, -R8-C (0) -R ^ -C (S) N (R9) 2, -R8-C (0) -RX1-C (NR9) N (R9) 2, -R8-C (0) -R1, LC (0) SR9, -R8-C (0) -R -C (S) SR9 and -R8-C (0) -R1: LC (NR9) SR9; R6 is hydrogen or optionally substituted alkyl; each R7 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted with one or more substituents selected from the group consisting of nitro, halo, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, | -OR14, -SR14 , -S (0) tR15 (where t is 1 or 2), -N (R14) 2, -CN, -C (0) R14, -C (S) R14, -C (NR14) R14, -C ( 0) 0R14, -C (S) 0R14, -C (NR14) 0R14, -C (0) N (R14) 2,. -C (S) N (R1) 2, -C (NR14) N (R14) 2, -C (0) SR14, -C (S) SR14, -C (NR14) SR14, -S (0) t0R14 ( where t is 1 or 2), -S (0) tN (R14) 2 (where t is 1 or 2), -S (0) tN (R14) N (R14) 2 (where "t is 1 or 2) , -S (0) tN (R14) N = C (R1) 2, -S (0) tN (R14) C (0) R15, -N (R14) C (O) R15, -N (R14) C (0) OR15, -N (R1) C (0) SR15, -N (R14) C (NR14) SR15, -N (R14) C (S) SR15, -N (R1) C (0) N (R14) 2, -N (R14) C (NR14) N (R14) 2, -N (R14) C (S) N (R14) 2, -N (R14) S (0) tR15 (where t is 1 or 2), -OC (0) R15, -0C (NR14) R15, -OC (S) R15, -OC (0) OR15, -OC ( NR14) OR15, -OC (S) OR15, -OC (0) SR14, -QC (0) N (R14) 2, -OC (NR14) N (R1) 2, -OC (S) N (R14) 2 , -C (O) -R16-C (O) R14, -C (0) -R16-C (S) R14 -C (O) -R16-C (NR14) R14, -C (0) -R16- C (0) OR14, -C (0) -R16-C (S) OR14, -C (O) -R16-C (NR14) OR14, -C (0) -R16-C (0) N (R14) 2, -C (0 ) -R16-C (S) N (R14) 2i -C (O) -R16C (NR14) N (R14) 2, -C (0) -R16-C (0) SR14, -C (O) -R16 -C (S) SR14 and -C (O) -R16-C (NR14) SR14; or each R7 is cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, dioxo, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl , optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R1J-OR14, -R13-SR, -R -S (0) t (where t is 1 or 2), -R13-N (R1) 2, -R13-CN, -R13-C (0) R14, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0 ) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, -R13-C (S) N (R14) 2, -R13- C (NR1) N (R1) 2, -R13-C (0) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R13-S (0) t0R14 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is io 2), -R13-S (0) tN (R14) N (R14) 2 (where t is 1 or 2), - R13-S (0) tN (R14) N = C (R14) 2, -R13-S (0) tN (R14) C (0) R15, -R13-N (R14) C (0) R15, -R13 -N (R14) C (0) OR15, -R13-N (R14) C (0) SR15, -R13-N (R14) C (NR14) SR15, -R13-N (R14) C (S) SR15, -R13-N (R14) C (0) N (R14) 2, -R13-N (R14) C (NR14) N (R14) 2, -R13- N (R1) C (S) N (R14) 2, -R13-N (R14) S (0) tR15. (Where t is 1 or 2), -R13-0C (0) R15, -R13-0C ( NR14) R15, -R13-0C (S) R15, -R13-0C (0) OR15, -R13-0C (NR14) OR15, -R13-0C (S) OR15, -R13-0C (0) SR14, - R13-OC (0) N (R14) 2, -R13-OC (NR14) N (R14) 2, -R13-OC (S) N (R1) 2, -R13-C (0) -R16-C ( 0) R14, -R13-C (0) -R16-C (S) R14, -R13-C (0) -R16-C (NR14) R14, -R13C (0) -R16-C (0) OR14, -R13-C (0) -R16-C (S) OR14, -R13-C (0) -R16-C (NR14) OR14, -R13-C (0) -R16-C (0) N (R14) 2, -R13-C (0) -R16-C (S) N (R14) 2, -R13-C (0) -R16C (NR14) N (R14) 2, -R13-C (0) -R16-C (0) SR14, -R13-C (0) -R16-C (S) SR14 and -R13-C (0) -R16-C (NR14) SR14; wherein each R 8 and R 13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl ", optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R1s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; wherein each R11 and R16 are independently an optionally substituted branched or simple alkylene chain or an optionally substituted straight or branched alkenylene chain; and R32 is independently hydrogen, halo, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. 90. The compound of Claim 89 characterized in that: R1 and R2 are each independently cyano, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; R32 is hydrogen or halo; R 4 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C (S) R9, - R8 ~ C (NR9) R9, -R8-C (0) OR9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) ) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8- S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -Rs-S ( 0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (0) R10, -Ra! -N (R9) C (0) 0R10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, -R6 -N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8! -N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) tR10 (where t is 1 or 2), -R8 '-0C (0) R10, -R8-OC (NR9) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8! -0C (NR9) OR10, -Rf 3-0C (S) OR10, -R8-OC (0) SR9, -R8-OC (0) N (R9) 2, -R £ '-OC (NR9) N (R9) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R1X-C (0) R9, -R £ '-C (0) -R ^ -CISJR9, -R8-C (0) -R1: L-C (NR9) R9, -R8-C (0) -R1: L-C (0) OR9, -R £ l-C (0) -R 11 -C (S) OR 9, -R 8 -C (0) -Ru-C (NR 9) OR 9, -RE LC (0) -R -C (0) N (Rs) 2, -R8-C (0) -Rn-C (S) N (R9) 2, -R £ '-C (0) -R1X-C (NR9) N (R9) 2 f -R8-C (0) -Rai-C (0) SR9, -R8-C (0) -RX1-C ( S) SR9 and -R8-C (O) -R1X-C (NR9) SR9; R6 is hydrogen; R7 is aryl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R13-OR14, -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (0) R1, -R13-C (S) R14, -R13-C (NR14) R14, -R13-C (0) OR14, -R13-C (S) OR14, -R13-C (NR14) OR14, -R13-C (0) N (R14) 2, -R13-C (S) N (R14) ) 2, -R13-C (NR14) N (R14) 2, -R13-C (O) SR14, -R13-C (S) SR14, -R13-C (NR14) SR14, -R 13-S (O) t0R14 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (O) tN (R14) N ( R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) N = C (R1) 2, -R13-S (O) tN (R14) C (O) R15 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR1) N (R14) 2 (where t is 1 or 2) and -R13-N (R14) S (0) tR15 (where t is 1 or 2); wherein each R 8 and R 13 are independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; R14 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl or heteroaralkyl optionally substituted; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 and R 15 are independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted or optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain; and as a simple isomer, a mixture of isomers, or as a racemic mixture of isomers; or as a solvate or polymorph; or as a prodrug; or as a pharmaceutically acceptable salt thereof. 91. The compound of any of Claims 89-90 characterized in that R7 is cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each is substituted by R26 and optionally substituted by R25; characterized in that: R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkenyl, -R13-OR14; -R13-SR14, -R13-S (0) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C ( 0) OR14, -R13-C (0) N (R14) 2, -R13-S (O) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R1) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where t is 1 or 2), -R13-N (R14) C (O) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R15-C (0) R1, -R13-C (0) -R16-C (S) R14 and -R13-C ( 0) -R16-C (0) N (R14) 2; R26 is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R1 s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 92. The compound of Claim 90 characterized in that R7 is: characterized in that: m is 0 to 1; R25 is selected from the group consisting of halo, nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkenyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heteroaryl, -R13-OR14; -R13-SR14, -R13-S (O) tR15 (where t is 1 or 2), -R13-N (R14) 2, -R13-CN, -R13-C (O) R14, -R13-C ( O) OR14, -R13-C (O) N (R14) 2, -R13-S (0) tN (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (0) R15, (where t is 1 or 2), -R13-S (0) tN (R14) C (0) N (R14) 2 (where t is 1 or 2), -R13-S (0) tN (R14) C (NR14) N (R14) 2 (where "t is 1 or 2), -R13-N (R14) C (0) R15, -R13-N (R14) S (0) tR15 (where t is 1 or 2), -R13-C (0) -R16-C (0) R14, -R13-C (0) -R16-C (S) R14 and -R13-C (0) -R16-C ( 0) N (R14) 2, and R26 is selected from the group consisting of -R13 ~ C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R13 is independently selected from the group consisting of a direct bond 'or an optionally substituted branched or simple alkylene chain; wherein each R14 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally-substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl; and wherein each R16 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 93. The compound of Claim 92 characterized in that R26 is in the para position. 94. The compound of Claim 89 characterized in that R7 is alkyl, alkenyl or alkynyl, wherein each is substituted by substituent R and optionally substituted by substituent R25 characterized in that: R25 is selected from the group consisting of halo, optionally substituted alkyl, -N (R1 ) 2 and -OR14; and R26 is selected from the group consisting of -C (0) R14, -S (0) tR15 (where t is 1 or 2), -S (O) tN (R14) 2 (where t is 1 or 2) and -S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, aryl. optionally substituted, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl. 95. The compound of Claim 89 characterized in that R7 is cycloalkylalkyl, heterocyclylalkyl, aralkyl or heteroaralkyl, wherein each is substituted by R26 and optionally substituted by R25 characterized in that: R25 is selected from the group consisting of halo, optionally substituted alkyl, -R13-N (R14) 2 and -R13-OR14; and R26, is selected from the group consisting of -R13-C (0) R14, -R13-S (0) tR15 (where t is 1 or 2), -R13-S (0) tN (R14) 2 (where t is 1 or 2) and -R13-S (0) tN (R14) C (0) R15 (where t is 1 or 2); wherein each R 13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted single or branched alkenylene chain; wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R14s, together with the atom to which they are attached, form optionally substituted heterocycle; and wherein each R15 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl. 96. It is comprised of any of Claims 90-95 characterized in that R25 is selected from the group consisting of halo, optionally substituted alkyl, optionally substituted cycloalkyl, -R13-OR14, -R13-SR14, and -R13-N (R14) 2; wherein each R13 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; and wherein each R14 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R14s, together with the atom to which they are attached, form optionally substituted heterocycle. 97. The compound of any of Claims 90-95 characterized in that R1 and R2 are each independently selected from the group consisting of cyano, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 98. The compound of Claim 97 characterized in that R1 and R2 are each independently alkyl or haloalkyl. 99. The compound of Claim 97 characterized in that R1 and R2 are alkyl or phenyl. 100. The compound of any of Claims 97-99 characterized in that R 4 is cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, heteroaralkyl optionally substituted, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8- C (0) R9, -R8-C (S) R9, -R8-C (NR9) R9, -R8-C (0) OR9v -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) 2, -R8-C (S) N (R9) 2, '-R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C ( NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (O) tN (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN (R9) C (0 ) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -R8-N (R9) C (O) R10, -R8-N (R9) C (0) OR10, -R8-N (R9) C (O) SR10, -R8-N (R9) C (NR9) SR10, -R8-N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) 2, -R8-N (R9) C (S) N (R9) 2, -R8-N (R9) S (O) tR10 (where t is 1 or 2), -R8-OC (0) R10, -R8- OC (NR9) R10, -R8-OC (S) R10, -R8-OC (O) OR10, -R8-OC (NR9) OR10, -R8-OC (S) OR10, -R8-OC (O) SR9, -R8-OC (O) N (R9) 2, -R8-OC (NR9) N (R9) ) 2, -R8-OC (S) N (R9) 2, -R8-C (0) -R -C (0) R9, -R8-C (0) -Rn-C (S) R9, -R8-C (0) -Ru-C (NR9) R9, -R8-C (0) -R11-C (0) 0R9, -R8 -C (0) -Ru-C (S) OR9, -R8-C (0) -R1: LC (NR9) OR9, -R8-C (0) -Rn-C (0) N (R9) 2r -R8-C (0) -R- (S) N (R9) 2, -R8-C (0) -R11-C (NR9) N (R9) 2, -R8-C (0) -R1: LC (0) SR9, -R8-C (0) -R1: LC (S) SR9 and -R8-C (O) -R1 : LC (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroachalkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or a branched or single alkenylene chain Optionally substituted. 101. He . composed of any of the Claims 100 characterized in that R4 is: characterized in that: n is 0 to 4; R18 is halo, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted aralkenyl; and R19 is haloalkyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, -R8-OR9 or -R8-C (0) N (R9) 2; where R8 is a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; and wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, heteroaryl optionally substituted and optionally substituted heteroaralkyl; or where two R9s, together with the atom to which they are attached, form optionally substituted heterocycle. 102. The compound of Claim 101 characterized in that said compound is 3,5-dimethyl-4- (2-trifluoromethyl-phenyl) -lH-pyrrole-2-carboxylic acid (4-methanesulfonyl-phenyl) -amide. 103. The compound of any of Claims 100 characterized in that R 4 is optionally substituted naphthyl. 104. The compound of any of Claims 97-99 characterized in that R4 is hydrogen, -C (0) R9o -S (0) 2R9; wherein R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl. 105. The compound of any of Claims 97-99 characterized in that R4 is alkyl, alkenyl or alkynyl, wherein each is optionally substituted by one or more substituents. selected from the group consisting of halo, haloalkoxy, nitro, -OR9, -SR9, -S (0) tR10 (where t is 1 or 2), -N (R9) 2, -CN, -C (0) R9, - C (S) R9, -C (NR9) R9, -C (0) OR9, -C (S) OR9, -C (NR9) OR9, -C (0) N (R9) 2, -C (S) N (R9) 2, | -C (NR9) N (R9) 2, -C (0) SR9, -C (S) SR9, -C (NR9) SR9, -S (0) tOR9 (where t is 1 or 2), -S (0) tN (R9) 2 (where t is 1 or 2), -S (O) tN (R9) N (R9) 2 (where t is 1 or 2), -S (0 ) tN (R9) N = C (R9) 2, -S (0) tN (R9) C (0) R10 (where t is 1 or 2), -S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (O) tN (R9) C (NR9) N (R9) 2 (where t is 1 or 2), -N (R9) C (0 ) R10, -N (R9) C (0) 0R10, -N (R9) C (0) SR10, -N (R9) C (NR9) SR10, -N (R9) C (S) SR10, -N ( R9) C (O) N (R9) 2, -N (R9) C (NR9) N (R9) 2, -N (R9) C (S) N (R9) 2, -N (R9) S (O) tR10 (where t is? Or 2), - 0C (0) R10, -OC (NR9) R10, -OC (S) R10, -0C (0) 0R10, -0C (NR9) OR10, -OC (S) OR10, -OC (0) SR9, -OC (O) N (R9) 2, -OC (NR9) N (R9) 2, -OC (S) N (R9) 2, -CÍO-R ^ -CÍOJR, -C (0) -R11-C (S) ) R9, -C (O) -R11-C (NR9) R9, -C (0) -Ru-C (0) OR9, -C (0) -R11-C (S) OR9, -C (O) -R1X-C (NR9) OR9, -C (O) -R ^ -C (O) N (R9) 2, -C (O) -R- (S) N (R9) 2, -C (O) -Ru-C (NR9) N (R9) 2, -C (0) -R -C (0) SR9, -C (0) -R- (S) SR9 and -C (O) -R- (NR9) SR9; or R 4 is heterocyclylalkyl, aralkyl, or heteroaralkyl, wherein each is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkoxy, nitro, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl optionally substituted cycloalkenyl, optionally substituted cycloalkenylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heteroaralkenyl, -R8-OR9, -R8-SR9, -R8-S (0) tR10 (where t is 1 or 2), -R8-N (R9) 2, -R8-CN, -R8-C (0) R9, -R8-C ( S) R9, -R8-C (NR9) R9, -R8-C (0) 0R9, -R8-C (S) OR9, -R8-C (NR9) OR9, -R8-C (O) N (R9) ) 2, -R8-C (S) N (R9) 2, -R8-C (NR9) N (R9) 2, -R8-C (0) SR9, -R8-C (S) SR9, -R8-C (NR9) SR9, -R8-S (0) tOR9 (where t is 1 or 2), -R8-S (0) tN (R9) 2 (where t is 1 or 2), -R8- S (0) tN (R9) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) N = C (R9) 2, -R8-S (0) tN ( R9) C (0) R10 (where t is 1 or 2), -R8-S (0) tN (R9) C (0) N (R9) 2 (where t is 1 or 2), -R8-S (0) tN (R9) C (NR9) N (R9) 2 (where "t is 1 or 2), -R8-N (R9) C (0) R10, -R8-N (R9) C (0) 0R10, -R8-N (R9) C (0) SR10, -R8-N (R9) C (NR9) SR10, ~ R8 ~ N (R9) C (S) SR10, -R8-N (R9) C (0) N (R9) 2, -R8-N (R9) C (NR9) N (R9) ¿, -R8- N (R9) C (S) N (R9) 2, -R8-N (R9) S (0) t 10 (where t is 1 or 2), -R8-0C (0) R10, -R8-OC ( NR9) R10, -R8-OC (S) R10, -R8-OC (0) OR10, -R8-0C (NR9) OR10, -R8-0C (S) OR10, -R8-0C (0) SR9, -R8-0C (0) N (R9) 2, -R8-0C (NR9) N (R9) ) 2, -R8-0C (S) N (R9) 2, -R8-C (0) -R ^ -C (0) R9, -R8-C (0) -R13-C (S) R9, -R8-C (0) -R1X-C (NR9) R9, -R8-C (0) -R1X-C (0) OR9, - R8-C (0) -R11-C (S) OR9, -R8-C (0) -R- (NR9) OR9, -R8-C (0) -Ru-C (0) N (R9) 2, · -R8-C (0) -Rn-C (S) N (R9) 2, -R8-C (0) -R11-C (NR9) N (R9) 2, ~ R8 ~ C (0) -R ^ -C (0) SR9, -R8-C (0) -R1: L-C (S) SR9y -R8-C (0) -R1; L-C (NR9) SR9; wherein each R8 is independently a direct bond, an optionally substituted branched or simple alkylene chain, or an optionally substituted branched or simple alkenylene chain; wherein each R9 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, -heteroaryl optionally substituted and optionally substituted heteroaralkyl; or wherein two R9s, together with the atom to which they are attached, form optionally substituted heterocycle; wherein each R 10 is independently selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycle, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and wherein each R 11 is independently an optionally substituted branched or simple alkylene chain or an optionally substituted single or branched alkenylene chain. 106. A method for the treatment of a disease, a mediated disorder, or otherwise, affected by one or more spheroidal nuclear receptors, or in which the steroid nuclear receptor activity is involved, comprising: administering a pharmacologically active composition comprising a pharmaceutically acceptable compound or derivative thereof as set forth in any of claims 1-105, for a patient in need of such treatment. 107. The method of claim 106, characterized in that said disease is associated with an excess or shortage of receptor activity or endogenous regulators of said steroid receptor activity in said patient. 108. The method of claim 106, characterized in that the disease or disorder is related to cancer. 109. The method of claim 106, characterized in that the disease or disorder is related to infertility. 110. The method of claim 106, characterized in that the disease or disorder is related to one or more metabolic syndromes. 111. The method of claim 106, characterized in that the disease or disorder is related to bone or cartilage dysfunction. 112. The method of claim 106, characterized in that the disease or disorder is related to immune dysfunction. 113. The method of claim 106, characterized in that the disease or disorder is related to cognitive dysfunction. 114. The method of claim 106, characterized in that the disease or disorder is related to high blood pressure. 115. The method of claim 106 characterized in that the disease or disorder is related to heart disease. 115. The method of claim 106, characterized in that the disease or disorder is related to kidney disease. 116. The method of claim 106, characterized in that the disease or disorder is related to fibrosis. 117. The method of claim 106, characterized in that the disease or disorder is related to epidermal dysfunction. 118. The method of claim 106, characterized in that the disease or disorder is related to muscle wasting. 119. The method of claim 106, characterized in that said spheroidal nuclear receptor is the mineralocorticoid receptor. 120. A pharmaceutical composition comprising a compound of any of claims 1-105, and a pharmaceutically acceptable excipient. 121. The pharmaceutical composition of claim 120, further comprises one or more additional active ingredients. 122. The pharmaceutical composition of the claim characterized in that said one or more additional active ingredients are selected from the group consisting of ACE inhibitors, Angiotensin II bloggers, anticoagulants, anti-carcinogenic agents, anti-arrhythmic agents, anti-inflammatory agents, beta-blockers, calcium channel antagonists. , lipid modulating agents, cytokine antagonists, digital medicines, diuretics, endothelin blockers, vasodilators, immune suppressors and glucose-lowering agents. 123. A method for modulating the activity of one or more spheroidal nuclear receptors in a cell, tissue or organism, comprising administering a compound as set forth in any of claims 1-105 to said cell, tissue or organism. 124. The method of claim 123, characterized in that said one or more spheroidal receptors include a mineralocorticoid receptor.